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Abstract 
 
The causative agents of Tuberculosis (Tb), Mycobacterium tuberculosis and 
Mycobacterium bovis, subvert a number of host immune mechanisms to promote 
persistence of infection in the human host. Infection with these immunoevasive 
pathogens is estimated to cause 1.8 million deaths per year. The only Tb vaccine 
currently available is an attenuated form of M. bovis, called bacille Calmette Guérin 
(BCG), and its efficacy is highly variable. Thus, development of more effective vaccine 
strategies for Tb is of significant importance. 
Host-derived natural CD4+CD25+ T regulatory cells (Tregs) suppress host 
immune responses and prevent autoimmunity. However, Tregs can also interfere with 
protective immune responses against chronic infections or with the protective efficacy 
of vaccines. There is speculation that mycobacteria exploit the suppressive activity of 
Tregs to permit persistence in the host and that Treg activity also diminishes the 
protective efficacy of the BCG vaccine. 
Therefore, to explore the role of Tregs in anti-mycobacterial immunity, I first 
optimised a protocol to inactivate Tregs in vivo in a murine model, through 
administration of anti-CD25 monoclonal antibody. In addition, I developed a novel 
plasmid DNA replicon vaccine against Tb to aid with the assessment of the effect of 
Tregs on Tb vaccines. 
I hypothesised that inactivating Tregs in vivo prior to mycobacterial infection 
would enhance acute immune responses that are thought to be protective under current 
dogma and thereby enhance bacterial clearance. Enhanced immune responses were 
observed but, contrary to the hypothesis, inactivation of Tregs did not alter bacterial 
numbers in the lung.  
I also hypothesised that inactivating Tregs in vivo prior to live BCG or DNA 
vaccination would enhance primary and secondary immune responses that are thought 
to be protective against Tb infection and thereby enhance the protective efficacies of the 
vaccines. Enhanced vaccine-induced immune responses and accelerated secondary 
immune responses were observed for the BCG vaccine. However, Treg inactivation did 
not alter the protective efficacy of the BCG vaccine, and preliminary data suggests Treg 
 iii 
inactivation may in fact decrease the protective efficacy of one plasmid DNA vaccine 
tested. 
In summary, this thesis illustrates that inactivating natural Tregs does not 
enhance protection from mycobacterial infection. This implies that inactivation of 
natural Tregs cannot be used in a therapeutic setting to enhance treatment or vaccination 
approaches for Tb. More importantly, Treg inactivation enhances immune responses 
that current dogma regard as protective against Tb infection, but does not 
correspondingly enhance protection. As a result of this disparity, this thesis questions 
the validity of measures that are commonly used as immune correlates of protection for 
Tb vaccine design. Ultimately, the development of more accurate immune correlates of 
protection for Tb will permit targeted design of more effective Tb vaccination 
strategies. 
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Mycobacterium tuberculosis, the causative agent of Tuberculosis (Tb) in humans, has 
long been associated with disease in its human host. Mycobacterial deoxyribose nucleic 
acid (DNA) has been found in numerous mummified human remains, dating back 
several thousand years in Egypt and South America [1-4]. Co-evolution of M. 
tuberculosis with its human host has led to a complex disease process manifest in the 
immune response to Tb.  
The human immune system is a carefully orchestrated interplay of cells and 
hormones that detect and control or eliminate danger to the health of the host. The 
immune system has evolved to combine broad activation signals with highly specific 
recognition of antigens. Processing of these activation signals and presentation of 
specific epitopes by the innate arm of the immune system and antigen presenting cells 
(APCs) activates the adaptive arm, which has more targeted antigen-specific actions. It 
is vital to understand how this initial immune response unfolds after exposure to a 
specific pathogen in order to design effective immunotherapies or diagnostics for the 
resulting disease.  
Importantly, if the immune system encounters a certain pathogen for a second 
time, it can exhibit immunological memory. This second encounter with a pathogen 
results in an immune response that is faster or larger and more effective at controlling or 
eradicating the pathogen than the initial encounter. Immunological memory forms the 
basis of vaccination, and vaccine design relies on understanding how an effective 
secondary response can be induced to a specific pathogen. 
Unfortunately, the immune response to Tb is so complex that a satisfactory 
model of primary and secondary immune responses has not yet been developed. M. 
tuberculosis has evolved strategies to evade the immune response ranging from hiding 
or disguising itself to actually hijacking the cellular machinery of the infected host to 
actively shut the immune response down. This makes it challenging to formulate a 
general model of the primary immune response. Vaccine design for Tb has also been a 
challenge, as it is not understood which aspects of a primary immune response lead to a 
successful, protective secondary immune response.  
The development of a new vaccine to combat Tb is of real importance as Tb is 
one of the top three infectious killers, alongside human immunodeficiency virus (HIV) 
and malaria. Tb killed an estimated 1.6 million people and newly infected 8.8 million 
people worldwide in 2005 [5]. While death and incidence rates seem to have stabilised 
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worldwide, the total number of cases continue to grow in areas such as Africa, Eastern 
Mediterranean and South-East Asia.  
The overall goal of my thesis was to evaluate the role of natural T regulatory 
cells (Tregs) in the primary immune response to mycobacterial infection and their 
impact on development of protective memory immunity induced by vaccination. 
Through this, I was able to suggest refinements of current models for protective primary 
and secondary immune responses against Tb, and deeper understanding of this area will 
facilitate the generation of a more effective vaccine to combat Tb.  
Natural Tregs are a subset of lymphocytes that can suppress effector immune 
mechanisms, such as proliferation and cytokine production by other lymphocytes 
(section 1.4.2). Given the ability of natural Tregs to suppress immune mechanisms and 
the immunoevasive nature of mycobacteria (section 1.2.5), it has been widely 
hypothesised that Tregs are exploited by mycobacteria to suppress the host immune 
response. Therefore, I sought to evaluate whether natural Tregs suppress the immune 
response during mycobacterial infection in an in vivo murine model. Additionally, since 
natural Tregs can inhibit lymphocyte activation or cytokine production, and these 
factors are important for optimal development of immunological memory (section 
1.3.2.3), activation of natural Tregs during vaccination could diminish Tb vaccine 
efficacy. Therefore, I used several Tb vaccines, including a novel DNA replicon vaccine 
developed during the course of this project, to investigate whether inactivating natural 
Tregs during vaccination would enhance the development of protective memory against 
Tb. 
 In this chapter, I review M. tuberculosis the organism (section 1.1), the primary 
and secondary immune responses to mycobacteria and mechanisms by which 
mycobacteria manipulate these responses (section 1.2). In addition, an overview of 
current models of immunological memory and strategies for vaccine design is included 
(section 1.3). Finally, as my thesis focuses on the role of Tregs, a review of the subtypes 
of these cells and their mechanisms of induction and action is presented (section 1.4). 
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1.1 Mycobacteria 
 
M. tuberculosis is a very resilient, niche-evolved pathogen. It is a 2-5 µm long rod-
shaped Actinobacterium belonging to the genus Mycobacterium. The genus has 
traditionally been divided into rapid growers such a Mycobacterium smegmatis or 
Mycobacterium flavescens, which form colonies on solid media in less than 7 days, or 
slow growers such as Mycobacterium bovis, Mycobacterium avium and M. tuberculosis, 
which take longer than 7 days [6]. Within the slow-growing mycobacteria, M. 
tuberculosis is part of the M. tuberculosis complex (MTBC), a group of organisms so 
closely related that they are defined as subspecies of the same species. The MTBC 
consists of M. tuberculosis, Mycobacterium africanum, Mycobacterium canetti, M. 
bovis and Mycobacterium microti. It is noteworthy that while these organisms are 
highly related at a genetic level, they are remarkably different in terms of host range and 
pathogenicity. For example, M. bovis has a broad mammalian host range while M. 
microti is almost exclusively a rodent pathogen. 
Mycobacteria possess a highly specialised cell wall, which allows them to 
survive within the host and remain viable for a period in the environment outside of a 
host. The cell wall contains some peptidoglycan, which is a feature of gram-positive 
bacteria, but mycobacteria are genetically more related to gram-negative bacteria [7]. 
However, their cell wall is so unique that they cannot be classified gram-positive or 
negative. The most striking feature of the cell wall is its high proportion of lipids. These 
lipids are largely made up of mycolic acids, which make up to 50-60 % of the dry 
weight of the cell wall. The strong hydrophobicity of the lipid layer in the mycobacterial 
cell wall means that mycobacteria are classified as acid-fast, due to their ability to retain 
basic dyes upon acid or heat treatment. The classical stain for mycobacteria is the Ziehl-
Neelsen stain, whereby mycobacteria stain bright red/pink against surrounding tissue 
after a carbol-fuchsin stain followed by destain with acid-alcohol, although there are 
several variations on this technique [8].  
As a slow-growing mycobacterial species, the replication time for M. 
tuberculosis is around 14-24 hours in vitro [9, 10] and 20-28 hours in vivo in murine 
models [11]. M. tuberculosis is a facultative intracellular pathogen as it can survive and 
replicate within host cells, most notably the alveolar macrophage, which is the resident 
phagocytic cell in the lung. While M. tuberculosis replicates optimally at the interface 
of the liquid media or the host tissue and air [10], it can also persist in anaerobic 
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conditions. For example, as a pulmonary Tb infection progresses, mycobacteria are 
contained within fibrotic structures known as granulomas. The inside of a granuloma is 
believed to be highly hypoxic as the granuloma tissue is not supported by a blood 
supply [12]. During this period of anaerobic survival within the granuloma, M. 
tuberculosis enters a growth phase known as latency, which is addressed in section 
1.2.4. 
Currently genomes have been sequenced for a number of mycobacteria 
including laboratory strains and clinical isolates of M. tuberculosis [13, 14], an isolate 
of M. bovis [15] and the Pasteur strain of the attenuated vaccine, M. bovis bacille 
Calmette Guerin (BCG) [16]. Comparisons of the regions of difference between sub-
species and strains has revealed how different clinical isolates of M. tuberculosis are 
and how similar sub-species of the MTBC are, considering marked differences in host 
tropism and pathogenicity (reviewed in [17]).  
 
1.2 The immune response to mycobacteria 
 
1.2.1 A general outline of the immune response 
 
The human immune system has evolved to control pathogens such as M. tuberculosis. 
Pathogens possess two features essential to initiate and direct an immune response: 
pathogen associated molecular patterns (PAMPs) and antigens. PAMPs are molecules 
commonly found in viruses or bacteria, and allow the host to distinguish between cells 
that are host-derived and cells that are foreign [18]. Antigens are typically proteins that 
are pathogen-specific and enable the immune system to target one particular pathogen. 
As a result, PAMPs function to activate the immune response in a generic way, while 
antigens supply a target to direct the response against a specific pathogen. 
An immune response to a pathogen progresses in two phases; the innate and 
adaptive phases. Upon infection, PAMPs from a pathogen initially interact with pattern 
recognition receptors (PRRs) on leukocytes and non-lymphoid cells in the infection site 
[18]. They induce the release of hormones known as chemokines and cytokines, which 
enhance recruitment of more leukocytes and activate specific functions of those 
leukocytes respectively. This initial inflammation at the infection site is known as the 
innate immune response. Essential cells recruited for the innate immune response 
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include natural killer (NK) cells, eosinophils, basophils and mast cells, but also 
phagocytic cells, such as macrophages, neutrophils and dendritic cells (DCs). 
Phagocytosis is the process whereby extracellular components including large 
molecules can be taken up and contained within a vacuole called a phagosome. During 
an infection, entire microbes are phagocytosed and some phagocytic cells are equipped 
with anti-microbial functions to control growth or destroy the microbe within the 
phagosome.  
A key activity of DCs is to initiate the adaptive phase of the immune response. 
When DCs engulf a pathogen two things occur. Firstly, PAMPs interact with PRRs and 
convey a danger signal to that DC, activating it and enabling it to migrate out of 
inflamed tissue to the local draining lymph node [18]. Secondly, DCs process antigens 
derived from the engulfed pathogen and load peptides from them onto molecules 
encoded by the major-histocompatibility complex (MHC) locus (reviewed in [19]). 
Once an activated DC is in the lymph node, it is a very effective APC, displaying 
antigen loaded onto MHC molecules to lymphocytes. There are three main types of 
MHC known as class I (MHC I), class II (MHC II) and the MHC I-like CD1 molecule 
[20], which interact with and activate lymphocytes, that are respectively CD8+, CD4+ 
and NK T cells, through their T cell receptors (TCRs). CD8+ and CD4+ T cells have 
what is known as variant TCR, since somatic recombination in the region of their 
genome that encodes their TCR during development results in individual lymphocytes 
that each express a unique TCR. Most NK T cells have a semi-invariant TCR, 
composed of an invariant α-chain paired with a β-chain from a restricted reportiore. 
This semi-invariant TCR can recognise microbial glycolipid antigens loaded onto CD1.  
When lymphocytes recognise their cognate antigen presented by an activated 
DC, they begin to proliferate and activate their effector functions. CD8+ T cells secrete 
cytokines and can be cytotoxic upon encountering pathogen-infected cells. CD4+ T cells 
primarily exert their effects through cytokine secretion, and can be divided into subsets 
depending on their cytokine profile. The most well-known of these divisions is the T 
helper (Th) 1 / Th2 division [21]. Th1 cells produce interferon (IFN)-γ and tumour 
necrosis factor (TNF)-α and promote macrophage anti-microbial activation, whereas 
Th2 cells produce interleukin (IL)-4, IL-5 and IL-13 and promote antibody production 
by B cells. After proliferation and activation in the lymph node, lymphocytes enter the 
circulation and are recruited into the infection site by chemokine signals produced by 
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the innate immune response. These lymphocytes direct their effector functions against 
the pathogen and control the infection. 
In this way the innate and adaptive arms of the immune response allow a rapid 
but generic innate response to control the pathogen until a more directed but delayed 
adaptive response can be initiated to control, and ideally eradicate, an infection. 
 
1.2.2 Infection with M. tuberculosis 
 
The most common form of disease caused by M. tuberculosis is pulmonary Tb, since 
the host is infected primarily by inhalation of aerosolised droplets containing the 
bacterium. From the lung, the infection can disseminate to almost any other organ.  
Tb infection induces local inflammation that contains the infection, which is 
known as a granuloma (section 1.2.4). Symptoms of Tb include night-sweats, tiredness 
and a persistent cough. The sputum that a patient produces from this cough eventually 
contains blood, as the integrity of the granuloma and lung degrade. The cough 
aerosolises bacilli present in the lung, enabling the transmission of infection to other 
individuals. As the inflammation consolidates lung tissue, the affected lung tissue is not 
able to function and perform efficient oxygen exchange. Death typically results when 
consolidated lung tissue can no longer support the oxygen requirements of the patient or 
infection has caused complications, such as pleural effusion.  
Once a person is exposed to aerosolised M. tuberculosis, there are several 
different outcomes possible, reviewed in [22] (Fig. 1.1).  
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Figure 1.1: Possible outcomes after exposure to aerosolised M. tuberculosis 
After exposure to aerosolised M. tuberculosis, several outcomes are possible. An exposed 
individual may: 1) eliminate the pathogen resulting in a sterile cure, 2) control the infection 
within a granuloma resulting in latent Tb, 3) become infected and progress rapidly to exhibit 
symptoms of active Tb, 4) progress from latent to active Tb when the granuloma in the lung 
breaks down. 5) During active Tb infection, inflammation in the lung, loss of integrity of the 
granuloma and coughing enables M. tuberculosis to become aerosolised and facilitates transfer 
of infection between individuals. 
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Some individuals exposed to M. tuberculosis do not develop reactivity to M. 
tuberculosis antigens, as determined by the Mantoux skin test. The immune response in 
these individuals may have efficiently destroyed the bacterium, presumably using innate 
mechanisms of the immune response (addressed in section 1.2.3.4). Of the individuals 
that are exposed, 10-30% become infected and reactive in the Mantoux test. Of these 
infected individuals, 90% spend years without displaying clinical symptoms of active 
disease. This group is deemed to have a chronic or latent Tb infection, and it has been 
estimated that the lifetime risk of developing active Tb is approximately 12% in these 
individuals [23]. Latent infection can reactivate spontaneously in later life or in 
situations of lowered immunocompetence. The remaining 10% of infected individuals 
progress quickly from the initial exposure to display clinical symptoms of Tb, termed as 
active Tb. Individuals that progress directly to active Tb are unable to control the initial 
infection and are thought to possess characteristics that make them susceptible to M. 
tuberculosis infection. Therefore, within the human population, there is a spectrum of 
susceptibilities to M. tuberculosis infection and the susceptibility of an individual is a 
product of genetics, environment, health and stresses or a combination of these factors. 
 
1.2.3 The primary immune response to M. tuberculosis 
 
1.2.3.1 Containing infection with the innate immune response 
 
Upon inhalation of M. tuberculosis, the bacteria are phagocytosed, predominantly by 
the alveolar macrophage. The alveolar macrophage is a lung resident phagocytic cell 
and is paradoxically both the preferred habitat of the mycobacteria and the first line of 
host defence against bacterial lung infections. Uptake of mycobacteria by alveolar 
macrophages is facilitated by a number of molecules including cholesterol [24] and 
mannose receptors that recognise the mannose-rich cell wall of the mycobacteria [25].  
DCs and macrophages can both phagocytose mycobacteria, but each fulfils 
different functions after phagocytosis. DCs actively migrate to the draining lymph node 
and are particularly effective at producing IL-12 and presenting antigen, initiating the 
Th1 immune response and priming CD4+ and CD8+ T cells [26]. Macrophages once 
activated by IFN-γ, are very effective at eliminating mycobacteria, whereas DCs cannot 
kill the invading organisms even after IFN-γ activation [27]. Therefore, while clearly 
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necessary to initiate the adaptive immune response against Tb, DCs may act as a 
reservoir for the mycobacterial growth and contribute to dissemination of infection 
though DC migration to the lymph node [27], in contrast to macrophages that possess 
the cellular machinery to control Tb infection.  
PAMPs from invading mycobacteria interact with PRRs such as the toll-like 
receptors (TLRs) on host cells. Presumably early events such as signalling through 
TLRs are important for control of the infection, as mice deficient in MyD88, a central 
molecule involved in signal transduction from TLRs, succumb quickly to infection [28, 
29]. A number of TLRs are considered vital for optimal control of mycobacterial 
infection, including TLR2, TLR4 and TLR9 [30]. Interaction with TLRs on phagocytic 
cells leads to activation of DCs and partial activation of anti-microbial activity in 
alveolar macrophages. TLR signalling also results in the release of pro-inflammatory 
cytokines such as IL-1, tumour necrosis factor (TNF)-α and most importantly IL-12 
[31, 32] as well as chemokines, which initiate a site of inflammation to promote influx 
of monocytes, neutrophils and NK cells and later activated lymphocytes.  
IL-12 produced by DCs is important for control of mycobacterial infection. IL-
12 is a heterodimeric cytokine composed of two subunits: p40 (shared with IL-23) and 
p35 (exclusive to IL-12), which together make active IL-12 p70. IL-12p40 and IL-
12p35 gene-disrupted (-/-) mice exhibit defective immune responses and reduced 
protection to mycobacteria [33, 34]. The importance of IL-12 in mice is mirrored by 
human studies in which patients with mutations in the IL-12 receptor gene are highly 
susceptible to mycobacterial infection [35]. In the local lung environment early during 
infection IL-12 acts on NK cells [36] and even back on the macrophage [37, 38] to 
induce IFN-γ production. Thus, IL-12 production by DCs in the draining lymph node 
creates an environment that promotes Th1 development. 
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1.2.3.2 The adaptive immune response  
 
The adaptive immune response, initiated upon antigen presentation in the lymph node, 
is essential for the control of mycobacterial infection. Antigens presented on MHC I to 
CD8+ T cells are typically derived from cytosolic protein transported into the 
endoplasmic reticulum (ER) where they are loaded onto MHC I and exported to the cell 
surface for presentation (reviewed in [19]) (Fig. 1.2). Antigens presented on MHC II to 
CD4+ T cells are typically derived from phagocytosed protein processed through the 
endocytic pathway (reviewed in [19]) (Fig. 1.2). Since mycobacteria are phagocytosed, 
it is uncertain how mycobacterial antigen in the phagosome can access the MHC I 
pathway to activate CD8+ T cells but several mechanisms have been proposed. MHC I 
presentation in vitro [39] and activation of CD8+ T cells in vivo [40] can be efficiently 
induced when phagocytic cells engulf apoptotic vesicles containing mycobacterial 
antigen. It is thought these apoptotic bodies access the MHC I pathway through what 
has been called the detour pathway [41] and cross-presentation or cross-priming 
(reviewed in [42]). Alternatively, mycobacteria or their antigen may enter the cytoplasm 
of chronically infected cells and thus, following proteasomal degradation, be loaded 
onto MHC I in the ER and exported to the cell surface [43, 44]. Although the exact 
mechanisms that mediate presentation of mycobacterial antigens on MHC I remain 
uncertain, it is established that M. tuberculosis infection results in activation of CD8+ T 
cells. 
Within the adaptive immune response, αβ CD4+ and CD8+ T cells are essential 
for control of mycobacterial infection. This was first demonstrated in depletion studies 
with monoclonal antibodies (mAbs) [45, 46] and was further validated by observing M. 
tuberculosis infection in gene-disrupted murine models. In wild-type (WT) mice, 
bacterial numbers increase steadily in the lung until around 3-4 weeks after infection, 
when they stabilise and remain constant for an extended period of time. Bacteriostasis 
in the lungs coincides with the influx of large numbers of CD4+ and CD8+ T cells to the 
lung [47]. In αβ TCR -/- mice, which lack CD4+ T cells, CD8+ T cells or NK T cells, 
and MHC class II -/- mice, which do not have CD4+ T cells, lung bacterial numbers 
increase rapidly after Tb infection and the infection is quickly lethal [48-50]. Therefore, 
it is clear that CD4+ T cells are vital for control of mycobacterial infection.  
The contribution of CD8+ T cells to protection against Tb infection is less 
defined. In MHC class I -/- mice, which lack MHC Ia for presentation to CD8+ T cells 
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and CD1 for NK T cells, lung bacterial numbers progress to ~1 log10 higher than wild-
type mice by week 5 after infection but eventually stabilise [49]. In Transporter-
associated-with-antigen-processing -/- mice, that lack the ability to load cytosolic 
antigen on MHC I, lung bacterial numbers also progress to ~1 log10 higher than wild-
type mice and stabilise but this leads to earlier lethality [49, 51].  
Other studies have tried to extricate the contribution by CD8+ T cells to 
protection against Tb infection from other MHC I-dependent cells by following M. 
tuberculosis infection in β-2 microglobulin (β-2m) -/-, CD8 -/- or MHC Ia -/- mice. β-
2m -/- mice cannot form MHC Ia, which presents antigen to CD8+ T cells. MHC Ia -/- 
mice do not express MHC Ia and also cannot present antigen to CD8+ T cells. CD8 -/- 
mice lack CD8+ T cells. All of these mice exhibit increased lung bacterial numbers and 
accelerated lethality compared to WT mice; however lung bacterial numbers and the 
rates of lethality are higher in β-2m -/- mice compared to MHC Ia -/- or CD8 -/- mice 
[52-54]. Increased disease severity in β-2m -/- mice may be due to a defect in iron 
metabolism caused by β-2m deficiency, which inhibits innate immune mechanisms 
[55]. In conclusion, CD8+ T cells clearly have a role in controlling the infectious burden 
but the degree to which they control bacterial growth has not yet been determined. 
CD1-restricted T cells and NK T cells are also activated during the course of 
mycobacterial infection through presentation of glycolipids in the context of CD1. The 
mycobacterial cell wall is rich in glycolypids, such as phosphatidylinositol mannoside 
(PIM) or lipo-arabinomannan (LAM). PIM can be presented on CD1d to activate both 
human and murine NK T cells [56] and LAM can be presented on CD1b to activate 
human αβ CD1-restricted T cells [57]. The importance of CD1-restricted T cells and 
NK T cells is unresolved. CD1d -/- mice, which do not have NK T cells, have a similar 
progression of infection to WT mice [51]. However, the murine model may not be 
appropriate to evaluate the impact of CD1-restricted responses on Tb infection 
(reviewed in [58]). Mice only express the Group 2 CD1 isoform CD1d that presents 
glycolipid to NK T cells, whereas humans also express the Group 1 CD1 isoforms 
CD1a, CD1b and CD1c that present glycolipid to CD1-restricted T cells. Therefore, 
humans can present a wider range of mycobacterial glycolipids to CD1-restricted T 
cells than mice, and murine models may underestimate control of bacterial numbers by 
CD1-restricted responses during Tb infection. 
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A further lymphocyte population, known as γδ T cells, utilise a γδ-chain TCR 
and can recognise a diverse range of antigens (protein and non-protein), particularly 
with phosphate residues as recognition sites. γδ T cells are activated by mycobacterial 
stimulation [59] but γδ T cell -/- mice do not differ from WT mice in terms of tissue 
bacterial numbers [49], although they do exhibit altered granuloma formation [60]. This 
altered granuloma formation may account for increased pathology and tissue bacterial 
numbers observed in γδ T cell -/- mice compared to WT mice after high dose 
intravenous infection [61]. However, γδ T cells make up only 2-3 % of peripheral blood 
mononuclear cells (PBMCs) in mice but make up 7% of PBMCs in humans [62, 63]. 
Thus, the smaller proportion of γδ T cells in mice may lead to an underestimation of 
their role in anti-mycobacterial immunity in humans.  
In summary, CD4+ T cells are integral for control of mycobacterial infection in 
the lung, although CD8+ T cells also contribute to this control. NK T cells and γδ T cells 
may contribute to control of Tb infection in humans but this will be difficult to 
accurately model in mice. While the effect of these lymphocytes on protection from 
primary mycobacterial infection has been explored using in vivo murine models, the 
effect of Tregs on protection from mycobacterial infection had not been assessed at the 
outset of this thesis. Tregs are capable of suppressing effector mechanisms of the 
lymphocyte subsets described above (section 1.4.2). A major question for this thesis 
was whether Tregs suppress effector mechanisms of CD4+ and CD8+ T cells during 
mycobacterial infection and thereby inhibited control of mycobacterial infection. 
 
1.2.3.3 Th1 development 
 
The main function of CD4+ T cells is to provide help for other lymphocytes, primarily 
by producing cytokines. When CD4+ T cells are activated by TCR triggering in the 
presence of IL-2 and IL-12, they proliferate and differentiate into CD4+ Th1 effector 
cells. The presence of certain cytokines such as IFN-γ further augments this 
development while Th2 cytokines such as IL-4 can inhibit development [21]. Therefore, 
the cytokine millieu during intial TCR triggering is critical for predicting whether a Th1 
response will develop. During early mycobacterial infection, activated DCs produce IL-
12 (section 1.2.3.1), and can produce IL-2 and IFN-γ. Production of IL-2 by DCs is 
even enhanced upon incubation with mycobacteria-infected neutrophils [496]. Other 
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leukocytes such as NK cells [36], NK T cells [56, 57], macrophages [37, 38] and γδ T 
cells [59] can also produce IFN-γ during early mycobacterial infection. Therefore, 
several cell types can contribute to the cytokine millieu during early mycobacterial 
infection and ensure preferential development of the Th1 immune response that is 
regarded as protective against Tb. 
CD4+ Th1 effector cells are characterised by activation of STAT1 and STAT4 
and expression of the transcription factor, Tbet (reviewed in [497]). This programs the 
CD4+ Th1 effector cell to produce effector cytokines such as IFN-γ and TNF-α.  
IFN-γ is a key cytokine that mediates control of mycobacterial infection. IFN-γ -
/- mice are incapable of controlling Tb infection, and bacterial numbers in the lung 
climb exponentially until premature death of the mice between 30 and 60 days after 
infection [49, 64-66]. These results are mirrored in humans studies, since individuals 
known to be highly susceptible to mycobacterial infection were found to have mutations 
in the IFN-γ receptor gene [67, 68]. While these findings demonstrate that IFN-γ 
production is important in mycobacterial infection, they do not indicate which cell must 
produce the cytokine.  
IFN-γ can be produced by several different leukocytes, such as infected 
macrophages [38], NK  cells [69], NK T cells [70], CD8+ T cells [71] and CD4+ T cells 
[72]. IFN-γ production by cells of the innate immune system such as NK cells could 
initiate conditions conducive for later Th1 development. Deficiencies in IFN-γ 
production by cells of the innate immune response could contribute to the observed high 
bacterial burdens in IFN-γ -/- mice. Indeed NK cell activity during M. tuberculosis 
infection is affected by IFN-γ gene disruption, along with the cytolytic activity of CD8+ 
T cells and cytokine production by CD4+ T cells [66].   
However IFN-γ production by CD4+ T cells early during infection is widely 
regarded as necessary for optimal protection from Tb infection. Cellular infiltrate to the 
lung has been followed after infection in strains of mice that are deemed susceptible or 
resistant to M. tuberculosis infection [47]. The early appearance of IFN-γ producing 
CD4+ and CD8+ T cells in the lungs of resistant mice correlated with lower tissue 
bacterial numbers and increased survival after infection compared to susceptible mice 
[47]. In addition, MHC II -/- mice or CD4 -/- mice that have no CD4+ T cells, have 
transiently decreased levels of IFN-γ relative to WT mice two weeks after 
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mycobacterial infection, but quickly reach similar levels of IFN-γ production in the lung 
by the onset of the adaptive response at week 4 [50]. In the absence of CD4+ T cells, 
IFN-γ is produced predominantly by CD8+ T cells during the adaptive response and, 
despite similar levels of IFN-γ production by week 4 after infection, these mice 
succumb rapidly to infection. This study has been used to suggest that IFN-γ produced 
by CD4+ T cells is key for control of mycobacterial infections. If CD4+ T cells 
recognise and interact with infected macrophages, it is hypothesised that CD4+ T cells 
would deliver IFN-γ in a targeted, more effective fashion to the infected cell compared 
to other IFN-γ-producing leukocytes. However, there are alternative hypotheses. The 
transient deficiency in IFN-γ at 2 weeks may affect the protective outcome of infection. 
Alternatively, CD4+ T cells may play a role in protection from Tb infection that is 
independent of IFN-γ production. Therefore, it remains unresolved which cellular subset 
produces protective IFN-γ. 
Another key cytokine for protection against mycobacterial infection is TNF-α. 
TNF-α is produced by a number of different types of cell during infection, including 
macrophages, DCs, CD4+ and CD8+ T cells. Studies in both TNF-α receptor -/- mice or 
mice treated with TNF-α neutralising antibody demonstrated that a loss or deficiency in 
TNF-α signalling during the course of mycobacterial infection led to higher bacterial 
numbers in the lung, extensive necrosis of tissue due to lack of granuloma organisation 
and a rapidly lethal infection compared to WT mice [73]. Administration of TNF-α 
neutralising antibody after the onset of chronic infection led to granuloma instability 
and re-activation of infection [74]. Human cases again confirm the importance of TNF-
α. Rheumatoid arthritis patients can be treated with anti-TNF-α antibodies, such as 
infliximab, to minimise arthritis-associated inflammation. Patients that were latently 
infected with Tb, were found to develop active Tb after anti-TNF-α treatment [75]. 
Therefore, TNF-α is regarded as essential for formation and retention of the granuloma 
structure, enabling containment of mycobacterial infection. 
 
1.2.3.4 Immunomodulation of the immune response by cytokines 
 
Apart from the classical Th1 cytokines, IFN-γ and TNF-α, other cytokines can have 
immunomodulatory roles during mycobacterial infection. 
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IL-17 is a recently characterised cytokine whose role in mycobacterial infection 
is not yet well defined. IL-17 is a pro-inflammatory cytokine that promotes the 
recruitment of neutrophils by inducing CXC chemokine production and cytokine 
production, such as IL-6, IL-8 and TNF-α by macrophages [76, 77]. IL-17 is produced 
predominantly by Th17 differentiated CD4+ T cells, although γδ T cells also produce 
IL-17 during mycobacterial infection [78]. Th17 differentiation is promoted during 
CD4+ T cell activation by the presence of TGF-β and IL-6 and Th17 lymphocytes are 
maintained by IL-23 signalling [79-81]. IL-23 has been shown to be responsible for 
some protection and control of mycobacterial infection, using plasmid-mediated 
expression of IL-23 in the lung of murine models [82, 83]. Furthermore, mice deficient 
in the IL-12p40 subunit, shared by IL-12 and IL-23, have more severe disease compared 
to mice deficient in the IL-12p35 subunit, which is used solely by IL-12 [33]. While IL-
17 and IL-23 may contribute to protection in a primary response, it has also been 
suggested that IL-17+CD4+ T cells accelerate recruitment of IFN-γ+CD4+ T cells to the 
lung upon secondary challenge and thereby mediate protective memory against Tb [84].  
IL-6 has an important role early during the anti-mycobacterial immune response 
to promote inflammation. IL-6 -/- mice infected with M. tuberculosis by aerosol exhibit 
early increases in lung bacterial numbers and decreased IFN-γ production from lung and 
spleen-derived leukocytes prior to the onset of adaptive immunity [85]. After the onset 
of the adaptive response, lung bacterial numbers stabilise in IL-6 -/- mice but remain  
~1 log10 higher than in WT mice. This suggests that IL-6 production contributes to early 
control of M. tuberculosis infection, but does not impact on chronic infection.  
IL-27 is a member of the IL-6/IL-12 family of cytokines and is released by 
APCs. Recently, it has emerged that IL-27 suppresses the development of Tregs and 
Th17 CD4+ T cells, favouring Th1 CD4+ effector T cell development [86]. M. 
tuberculosis infection of IL-27 receptor -/- mice leads to lower lung bacterial numbers 
compared to WT mice, despite both possessing similar numbers of IFN-γ+CD4+ T cells 
in the lung [87]. However, the amount of IFN-γ produced by an individual CD4+ T cell 
is decreased in IL-27 receptor -/- mice. The decrease in IFN-γ production is 
hypothesised to promote survival of effector IFN-γ+CD4+ T cells, as IFN-γ production 
can enhance activation induced cell death (AICD) in CD4+ T cells [88] and lead to 
apoptosis of effector CD4+ T cells after BCG infection [89, 90]. 
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There may also be roles for Th2 cytokines, such as IL-4, during M. tuberculosis 
infection. IL-4 -/- mice on a C57BL/6 background infected with M. tuberculosis by 
aerosol exhibited similar bacterial numbers in the lung, spleen and liver to WT 
C57BL/6 mice, during both the acute and chronic phases of infection [85, 91]. 
However, IL-4 -/- mice display increased IFN-γ production from splenocytes and 
increased IFN-γ and TNF-α mRNA expression in the lung up to 4 weeks after infection 
[85]. An increase in IFN-γ in the absence of IL-4 may be anticipated given that IL-4 
negatively regulates IFN-γ production, but it is important to note here that increased 
IFN-γ production did not correlate with a decrease in tissue bacterial numbers. Finally, 
IL-10 and transforming growth factor (TGF)-β are cytokines that are regarded as being 
anti-inflammatory. It is proposed that production of IL-10 or TGF-β can initiate 
reactivation of Tb infection (section 1.2.4). 
In conclusion, several cytokines contribute to protection at different stages of 
mycobacterial infection. IL-12 is vital early after infection, as may be IL-23. IFN-γ is 
essential for bacteriostasis, TNF-α is necessary for granuloma formation and 
containment of infection and IL-17 may mediate protective memory. Other cytokines 
such as IL-6, IL-27 and IL-4 may modulate the immune response to infection. Several 
different cell types are capable of producing each of these cytokines but specific cell 
subsets may need to produce the cytokine for it to effectively reach the target, the Tb-
infected macrophage. Thus, once CD4+ and CD8+ T cells are activated and capable of 
producing cytokines, they can migrate into the inflamed tissue and interact with the 
infected macrophage, resulting in control of mycobacterial growth. Since Tregs can 
suppress cytokine production by other leukocyte subsets (section 1.4.2), I hypothesised 
that Tregs might suppress production of protective cytokines during mycobacterial 
infection. Inhibition of cytokine production that is necessary for control of primary 
mycobacterial infection could enhance survival of mycobacteria within the host.  
 
1.2.3.5 Effector mechanisms of anti-mycobacterial immunity 
 
There are several mechanisms by which infected macrophages control or eliminate 
mycobacterial infection (Fig. 1.2). Firstly, fusion of a phagosome containing microbes 
with a lysosome results in degradation of the microbes and facilitates further processing 
of the microbial components in the endocytic pathway and eventual presentation of 
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antigen on MHC II. This process begins with phagocytosis and the creation of the 
phagosome in the cytosol. The phagosome can fuse directly with the lysosome or 
mature through interactions with endosomes that sequentially alter the protein contents 
of the phagosome before fusion with the lysosome [92, 93]. The lysosome contains a 
host of hydrolytic enzymes, which function optimally at acidic pH, and the lysosome is 
maintained at pH 4.5-5.0 by ATP-dependent proton pumps in the lysosomal membrane 
[94, 95]. The hydrolytic enzymes are capable of degrading microbes contained within 
the phago-lysosome [96] through either enzymatic attack or the damaging effects of 
high pH and this constitutes a vital bacteriocidal function of macrophages. 
If mycobacteria escape phago-lysosomal fusion (outlined in 1.2.5), IFN-γ and 
TNF-α signalling to the infected macrophage activates alternative bacteriocidal 
mechanisms, including autophagy and reactive oxygen and nitrogen species production.  
Autophagy is a process whereby a cell can degrade entire organelles in 
structures similar to lysosomes. The antigen contained in the organelle may enter the 
endocytic pathway and thereby the MHC II processing pathway. In mycobacteria-
infected macrophages, phagosomes containing mycobacteria can enter the autophagic 
pathway [97, 98]. Autophagy has been induced in mycobacteria-infected cells by 
starvation or IFN-γ treatment and it decreases bacterial numbers in macrophage in vitro 
cultures [97]. Mycobacterial antigen can access MHC II on macrophages following 
autophagy of mycobacteria-infected phagosomes but whether this process also occurs in 
DCs in vivo is yet to be explored. 
Reactive oxygen intermediates (ROI) are produced by macrophages in response 
to IFN-γ and TNF-α activation [99]. In vitro evidence suggests ROI production does not 
inhibit M. tuberculosis growth [100-102]. However, ROI production in in vitro 
activated macrophages has been demonstrated to kill M. microti [103] and mice 
deficient in ROI production exhibit early transient defects in control of pulmonary M. 
tuberculosis infection [99, 104].  
Reactive nitrogen intermediates (RNI) are also produced by macrophages in 
response to IFN-γ signalling [100, 102, 105, 106] and this production is augmented by 
TNF-α signalling [107]. The cytokine signalling induces production of inducible nitric 
oxide synthase (NOS2), which uses L-arginine as the substrate for RNI production 
including nitric oxide. RNI production has been demonstrated to inhibit M. tuberculosis 
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growth in vitro [100, 102, 106] and in murine models [108]. Alveolar macrophages 
from human Tb patients have increased levels of NOS2 mRNA expression and 
increased staining with NOS2-reactive mAb [109, 110]. Thus, RNI production is 
regarded as the most important mycobacteriocidal function of the cytokine-activated 
alveolar macrophage and the protective effects of IFN-γ and TNF-α production by 
CD4+ T cells are thought to be due primarily to their ability to activate RNI production 
by the macrophage.  
Infected macrophages can also be eliminated through cytotoxic lymphocyte 
(CTL) activity. Cytotoxicity can be mediated either by ligation of CD95 (Fas) on target 
cells to CD95 ligand (FasL) on the cytolytic cell or by exocytosis of cytolytic granules 
containing molecules, such as granzyme B, granulysin and perforin. Apoptosis or lysis 
of mycobacteria-infected cells can transfer mycobacteria from macrophages where 
phago-lysosomal fusion or RNI production has been inhibited to new phagocytic cells, 
which could be comparatively more proficient at eliminating the mycobacteria [111] or 
facilitating antigen presentation [40]. Molecules released by CTLs and the process of 
apoptosis may also have a direct effect on the viability of the mycobacteria.  
Cytotoxic activity is regarded as the principal activity of the activated CD8+ T 
cells, although other leukocytes can also be cytotoxic against infected macrophages or 
mycobacteria, including: neutrophils [112], NK cells [113], NK T cells [114], γδ T cells 
[115] and activated CD4+ T cells [116]. CD8+ T cells have two key effector functions: 
cytokine production and cytotoxicity. CD8+ T cells migrate into infected lung tissue and 
produce IFN-γ and TNF-α [71, 117], which can contribute to activation of macrophage 
bacteriocidal functions outlined above. However, the unique activity of CTLs and CD8+ 
T cells is that they can directly lyse and kill target cells. This results in the death of the 
entire mycobacteria-infected macrophage and can also kill the mycobacteria 
themselves.  
The expression of FasL, granulysin and perforin is upregulated by both CD4+ 
and CD8+ T cells stimulated with M. tuberculosis [118]. While Fas-FasL signalling and 
granule exocytosis both induce apoptosis of mycobacteria-infected cells [116, 118], 
granule exocytosis has the more dramatic effect on mycobacterial viability. Granule 
exocytosis is utilised predominantly by CD8+ T cells as compared to other CTLs [116, 
118, 119]. Perforin, granzyme B and granulysin are contained within these granules. 
The course of acute Tb infection is similar in perforin -/- and granzyme B -/- mice to 
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WT mice [120, 121], although perforin -/- mice do not contain the chronic phase of Tb 
infection as well as WT mice, resulting in a slow but steady increase in lung bacterial 
numbers [120, 121]. Granulysin released by cytotoxic lymphocytes has been shown to 
directly kill extracellular mycobacteria [119, 122]. To kill intracellular mycobacteria, 
granulysin requires the presence of perforin, presumably to access intracellular 
compartments containing mycobacteria [119, 122].  
The method by which granulysin kills mycobacteria is not certain. Mycobacteria 
that have been incubated with granulysin develop a distorted cell surface with numerous 
protrusions observed by electron scanning microscopy [122] and resulting changes in 
membrane permeability may impact on their viability [123]. The effects of granulysin 
on extracellular mycobacteria and infected macrophages in vitro are well documented 
but the role of granulysin in vivo in humans is unknown. Currently we lack tools to 
analyse the role of granulysin in vivo, as mice lack a granulysin homolog and granulysin 
-/- mice cannot be generated [124]. 
In summary, many effector mechanisms control growth or elimination of 
mycobacteria phagocytosed by the macrophage. These include: phago-lysosomal fusion 
in the macrophage, autophagy, cytokine signalling to macrophages to activate ROI or 
RNI production and cytotoxic mechanisms. While there are many host effector immune 
mechanisms that can control mycobacterial infection, mycobacteria have also developed 
many mechanisms to evade the host immune response (section 1.2.5).
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Figure 1.2: Effector mechanisms of the immune response during Tb infection 
1) Mycobacteria are phagocytosed by the macrophage and contained within a phagosome. 2) 
The phagosome can fuse with a lysosome degrading the mycobacteria contained or 3) the 
mycobacteria can evade phago-lysosomal fusion. 4) If the mycobacteria are degraded, the 
antigens are processed through the endocytic pathway and loaded onto MHC II, exported to the 
cell surface and 5) presented to activated CD4+ T cells. 6) Activated CD4+ T cells will release 
IFN-γ and TNF-α that signal to the infected macrophage and 7) induce production of ROI and 
RNI to eliminate mycobacteria within stalled phagosomes. 8) Mycobacterial antigen could be 
cross-presented on MHC I if it escapes the phagosome and enters the cytosol. 9) This antigen 
can be processed and loaded onto MHC I in the ER 10) before being exported to the cell surface 
and presented to activated CD8+ T cells. 11) Activated CD8+ T cells release IFN-γ and TNF-α, 
as well as cytolytic granules containing perforin and granulysin. 12) The contents of the 
cytolytic granules can have direct cytotoxic effects on mycobacteria contained within the 
phagosome.  
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1.2.4 Latent infection and the granuloma 
 
In the murine model of Tb, the acute phase of the infection is characterised by an 
exponential mycobacterial growth phase in the lung. This initial infectious insult is 
contained by the innate and adaptive immune responses and, from weeks 3-4 after 
infection, there is no net increase in bacterial numbers in the lung, resulting in a stable, 
chronic Tb infection [49]. This stabilisation in bacterial numbers is also thought to 
occur in humans exposed to Tb, in situations where the initial immune response is 
sufficient to control the infection and contain it within infected macrophages but not 
eradicate it, resulting in latent Tb. In the mouse, activated CD4+ and CD8+ T cells arrive 
in the lung at the same time as bacterial numbers stabilise, suggesting that these 
lymphocytes are capable of inducing bacteriostasis. It is interesting to note that although 
there is a slight reduction in bacterial numbers after the influx of CD4+ and CD8+ T 
cells, many bacteria persist, resulting in chronic infection [47]. When chronic or latent 
infection is established, an equilibrium is reached between the mycobacterial bacilli and 
the host. The vital structure for this equilibrium is the granuloma. 
A granuloma is an immunological structure, comprising many leukocytes and 
non-haematopoietic cells, which forms to contain pathogen-infected cells. If the 
formation of the granuloma is prevented, as in ICAM-1 -/- mice that lack a key 
adhesion molecule, lung bacterial numbers stabilise but the mice suffer significant 
dissemination and pathology [125]. Therefore, granuloma formation is critical for 
physically containing the bacteria. However, once a granuloma has formed, it is in fact a 
dynamic structure. Studies in a murine model suggest that leukocytes migrate in and out 
of the granuloma, and structures similar to secondary lymphoid tissue and follicles form 
around its periphery [126]. Furthermore, following super-infection in a zebrafish model, 
mycobacteria-infected macrophages from outside the granuloma will home 
preferentially to an existing structure [127]. This suggests that mycobacterial infection 
of a macrophage induces phenotypic changes in that macrophage that facilitate its 
localisation to forming or pre-formed granulomas.  
Granuloma formation is co-ordinated by chemokines and cytokine signalling. 
By comparing chemokine gene expression profiles in WT and TNF-α -/- mice, TNF-α 
has been shown to co-ordinate chemokine expression by CD11b+ macrophages after M. 
tuberculosis infection, early during granuloma formation and later for maintenance of 
the granuloma during chronic infection [128]. In addition, administration of TNF-α 
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neutralising antibody to chronically M. tuberculosis infected mice led to loss of 
granuloma structure and increased bacterial numbers in the lung [74].  
The primary cell type believed to be important for production of TNF-α is the 
CD4+ T cell. Depletion of CD4+ T cells in chronically Tb infected mice leads to loss of 
granuloma integrity [129] and CD4+ T cells are the predominant lymphocyte subset 
within the murine granuloma [130]. CD8+ T cells are also important for granuloma 
maintenance. CD8 -/- mice or mice deficient in CD8+ T cell effector molecules, such as 
perforin and Fas/FasL, initially control bacterial numbers in the lung at similar levels to 
WT mice [131]. After the onset of adaptive immunity, the rate of increase of bacterial 
numbers in the lungs of CD8, perforin and Fas or FasL -/- mice is reduced, but unlike in 
WT mice, bacterial numbers do not stabilise. CD8+ T cells accumulate in the granuloma 
tissue more slowly than CD4+ T cells [130] and CD8+ T cells switch from primarily 
producing IFN-γ during the acute phase to displaying cytotoxic activity during the 
chronic phase of infection [132]. Therefore, the current model suggests CD4+ T cells 
maintain granuloma integrity, while CD8+ T cells function to control the number of 
mycobacteria within the granuloma and thereby contribute to containment of infection 
during latency.  
Factors that are detrimental to granuloma integrity can lead to reactivation. A 
number of stresses that undermine the immune response can contribute to reactivation, 
such as malnutrition, physical and mental stress, aging, immunosuppressive treatments 
and HIV infection [133]. An imbalance in key immune system mediators, such as IL-10 
and TGF-β, may also contribute. For example, transgenic mice on a C57BL/6 
background were engineered to express IL-10 under the IL-2 promoter. When these 
mice were infected with M. tuberculosis, they over-expressed IL-10 [134]. This caused 
no difference in lung bacterial numbers between transgenic and WT mice during the 
acute phase of infection but differences became apparent during the chronic phase of the 
infection. Unlike WT mice, lung bacterial numbers did not stabilise in the transgenic 
mice but continued to increase. Since the murine model is not regarded as a good model 
of latent Tb (outlined in section 1.2.7), it is problematic to translate these results of 
increased bacterial numbers in the lung in the mouse during a chronic infection into an 
analogous human disease outcome. However, human patients with active Tb exhibit 
elevated serum IL-10 levels compared to subjects lacking symptoms that have been 
exposed to individuals with active Tb [135] and it is hypothesised that IL-10 promotes 
reactivation of Tb infection.  
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TGF-β may also inhibit T cell responses during Tb infection. TGF-β production 
from human monocytes can be induced by stimulation with either M. tuberculosis [136] 
or mycobacterial components such as LAM [137].  In addition, in vitro culture of 
PBMCs from patients who have active Tb, with neutralising antibody or natural 
inhibitors of TGF-β enhances IFN-γ production [138]. Thus, there is speculation that 
TGF-β is produced and suppresses T cell effector mechanisms during active Tb 
infection; but this has not been assessed using an in vivo model. 
The granuloma environment induces changes in the mycobacteria. Within the 
granuloma, there are lymphocytes producing cytokines, such as IFN-γ and TNF-α, as 
well as CTLs. As a result, macrophages containing mycobacteria become highly 
activated, anti-microbial and produce RNI. Furthermore, the conditions at the centre of 
the human Tb granuloma become hypoxic and toxic to both host cells and mycobacteria 
[12]. It is thought that due to these conditions, mycobacteria alter their metabolism and 
enter a dormancy phase by inducing expression of a number of mycobacterial genes. 
The best characterised of these are the genes controlled by the response regulator DosR 
(Rv3133c), comprising the DosR regulon. The 48 genes in the regulon are 
transcriptionally upregulated in vitro in response to hypoxia or RNI products [139]. 
Many of these genes are also upregulated in M. tuberculosis isolated from IFN-γ-treated 
macrophages [140] and chronically infected murine lung tissue [141] suggesting that the 
genes are involved in mycobacterial survival after the onset of adaptive immunity in 
vivo. The most well-known gene of the DosR regulon is hspX (Rv2031c), which 
encodes the dominant protein in stationary phase cultures of M. tuberculosis, the 16 kDa 
alpha-crystallin homologue (Acr) [142]. Inhibition of Acr production does not affect 
growth on media or infectivity but hspX deficient M. tuberculosis strains do not survive 
in murine or human macrophages in vitro [142]. Therefore, it is thought that genes of 
the DosR regulon, such as hspX, are essential for survival in host macrophages after the 
onset of adaptive immunity. 
 
1.2.5 Suppression of the immune response 
 
During the long history of co-evolution between humans and mycobacteria, humans 
have evolved effector immune mechanisms to combat the intracellular infection; 
however, mycobacteria have evolved ways to evade or disrupt these mechanisms.  
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Latency induces changes in mycobacteria that not only permit survival but also 
promote immunoevasion. The altered state of metabolism induced by latency changes 
the antigen expression profile [143]. Some immunogenic mycobacterial proteins such as 
the 6 kDa early secreted antigenic target (ESAT-6) are highly expressed during active 
growth [144], but not during latency. Conversely, production of other proteins, such as 
Acr, are upregulated during latency [142]. Individuals with latent Tb infection mount T 
cell responses against Acr [145] but responses to Acr are lower than responses to 
antigens present during active growth in murine models [146]. Therefore, altering 
antigen expression during different metabolic stages can allow mycobacteria to evade 
the immune response. 
Mycobacteria can also impair the immune response in several ways, including 
inhibition of: phago-lysosomal function, ROI and RNI production, macrophage 
activation and antigen presentation.  
Phago-lysosomal function can be inhibited in macrophages infected with 
mycobacteria and this inhibition could be mediated in a number of ways. Fusion of the 
phagosome with the lysosome has been shown to be inhibited, since phagosomes 
containing live, viable mycobacteria are inhibited from fusing with lysosomes [147-
149]. However, phagosomes containing mycobacteria are capable of fusing with other 
endosomes, which suggests they are dynamic, fusion-competent structures that are 
selectively prevented from fusing with lysosomal compartments [149, 150]. A host 
protein found in lymphoid and myeloid cells called tryptophan aspartate-containing coat 
(TACO) protein has been recently identified, and may inhibit fusion. TACO relocalises 
within cells to associate with phagosomal membranes containing live mycobacteria and 
is retained for prolonged periods [151, 152]. Phago-lysosomal function may also be 
inhibited by interference with the acidity of the compartments. The lysosome contains 
hydrolytic enzymes, which require a low, acidic pH for optimal function. Acidification 
is mediated by ATP-dependent proton pumps, but mycobacteria-infected phagosomes 
can exclude these proton pumps, preventing acidification [153-155]. Mycobacteria can 
also produce ammonia, which has been proposed to increase the phago-lysosomal pH 
[156]. 
Mycobacteria are also able to prevent damage caused by ROI and RNI produced 
by infected macrophages. Mycobacterial products such as LAMs and 
phenolicglycolipid-1 can act as free-radical scavengers and mitigate oxidative damage 
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[157, 158]. M. tuberculosis possesses the genes noxR1, noxR3 and ahpC that can 
provide resistance to nitrosative and oxidative stress [159-161]. Furthermore, M. 
tuberculosis expresses a methionine sulfoxide reductase, which catalyses the reduction 
of methionine sulfoxide formed from the reaction of ONOO- and methionine residues in 
mycobacterial proteins and can repair damage caused by RNI [162]. 
For maximal anti-mycobacterial function, infected macrophages require IFN-γ 
signalling and mycobacterial infection can also interfere with this process. Human 
macrophages infected with M. tuberculosis are refractory to the effects of IFN-γ 
signalling and, since M. tuberculosis co-infection prevents the macrophage from killing 
Toxoplasma gondii, it is thought to be due to a generalised defect in macrophage 
function [163]. It is proposed that mycobacterial cell wall products such as the 19 kDa 
lipoprotein [164] prevent interaction of signal transducer and activator of transcription 
(STAT)1, cyclic AMP response element-binding protein and p300, which are 
downstream mediators of IFN-γ signalling [163]. This defect prevents effective IFN-γ-
induced gene expression, demonstrating that mycobacteria can interfere with even the 
most integral host mechanisms for their elimination.  
Finally, as intracellular pathogens, mycobacteria live inside macrophages or 
DCs and the immune system must detect mycobacterial antigens displayed on the 
surface of macrophages to effectively eliminate the mycobacteria that they contain. 
Ideally mycobacterial antigens would be displayed on MHC II to encourage IFN-γ 
production by activated CD4+ T cells and facilitate full activation of the macrophage. 
However macrophages infected with mycobacteria can down-regulate MHC II surface 
expression. Infected macrophages can sequester MHC II and prevent efficient antigen 
processing by preventing the arrival of MHC II into endosomes and phago-lysosomes 
containing mycobacterial antigen [165]. Furthermore, IFN-γ signalling to macrophages 
leads to upregulation of MHC II expression, but mycobacterial infection suppresses 
expression of IFN-γ induced genes, including MHC II [164]. Macrophages infected 
with mycobacteria have decreased expression of the locus encoding MHC II and 
thereby decreased protein production [166]. Thus, mycobacteria interfere with MHC II 
expression and loading in infected macrophages and can result in sub-optimal targeting 
by activated CD4+ T cells. 
To conclude, mycobacteria have developed a number of different ways of 
evading the immune response: changing their antigen profile, preventing phago-
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lysosome fusion, reducing free radicals from ROI and RNI production, inhibiting IFN-γ 
activation of macrophages and preventing optimal antigen presentation. Due to the wide 
array of evasive tactics largely directed at the infected macrophage, it is conceivable 
that mycobacteria may have mechanisms for manipulating or suppressing other cells of 
the immune response, such as activation of Tregs and their suppressive mechanisms. 
 
1.2.6 The secondary immune response 
 
A secondary immune response to mycobacteria occurs either in the situation where an 
individual is vaccinated with the BCG vaccine (section 1.3.4), or if they have had a Tb 
infection and have been treated with antibiotics, and are then exposed to a 
mycobacterial challenge. The traditional view of a secondary immune response to 
challenge is that the response is either accelerated, increased in magnitude or it 
possesses an enhanced quality essential for improved control of infection compared to a 
primary immune response. Thereby, the infectious challenge can be more effectively 
controlled or eliminated, resulting in less severe disease in the host. However, the 
mechanism by which a secondary immune response is more effective than a primary 
immune response for controlling Tb infection is undefined. 
A strong Th1 cell-mediated immune response during primary challenge is vital 
for containment of primary Tb infection. Since IFN-γ production by CD4+ T cells is 
important for a protective primary immune response, Tb vaccines have largely aimed to 
induce strong CD4+IFN-γ+ T cell responses, in the belief that this would lead to a larger 
pool of Tb-specific memory CD4+ T cells. However, this approach does not guarantee a 
more effective vaccine, as vaccinations that induce strong CD4+IFN-γ+ T cell responses 
do not consistently result in enhanced protection from Tb infection [167]. This may be 
indicative of the fact that inducing strong CD4+IFN-γ+ T cell responses contradicts the 
current model of CD4+ Th1 memory induction, outlined in section 1.3.2.4. 
While it remains difficult to define aspects of the primary immune response that 
correlate with enhanced secondary immune responses to Tb, some components of the 
immune system have been shown to be vital for protective memory. Transfer of spleen-
derived T cells from mice vaccinated intravenously with BCG into naïve animals 
protected recipients against Tb or BCG infection to a similar degree as BCG vaccination 
[168], illustrating that T cells mediate protection against Tb after BCG vaccination. 
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CD4+ T cell depleted splenocytes transferred from BCG infected animals into naïve 
recipients do not protect as well against M. tuberculosis infection when compared to 
total or even CD8+ T cell depleted splenocytes [169].  In addition, adoptive transfer of 
purified CD4+ or CD8+ T cells from BCG vaccinated mice into naïve recipients 
demonstrated that CD4+ T cell transfer resulted in reduced bacterial burden in the lung 
and spleen after BCG challenge, while CD8+ T cell transfer reduced burden only in the 
spleen [170]. These results indicate that the CD4+ T cell population is vital for the 
reduced bacterial numbers found in the lung of vaccinated compared to naïve animals, 
whereas CD8+ T cells can inhibit dissemination of the secondary infection to other 
tissues. 
It has not been widely explored how CD4+ and CD8+ T cells mediate their 
effects during a secondary immune response and their mechanisms might not parallel 
the behaviour of these populations during a primary immune response. As previously 
mentioned, a critical cytokine for the anti-mycobacterial primary immune response is 
IFN-γ but the amount of IFN-γ induced following vaccination does not correlate with 
protection against secondary mycobacterial challenge [167]. However, the appearance 
of IFN-γ+CD4+ T cells in the lung correlates with the onset of bacteriostasis during a 
primary mycobacterial infection [47], and the earlier appearance of IFN-γ+CD4+ T cells 
correlates with the earlier onset of bacteriostasis in vaccinated compared to naïve mice 
after mycobacterial challenge [171]. Therefore, it has been suggested that the earlier 
appearance of IFN-γ+CD4+ T cells in the lung is responsible for the reduced bacterial 
numbers in the lung observed in BCG vaccinated compared to naïve mice. Building on 
this model of mycobacterial immunity using peptide vaccinated mice, the arrival of IL-
17+CD4+ T cells in the lung during the secondary immune response precedes the 
appearance of IFN-γ+CD4+ T cells [84]. The arrival of IL-17+CD4+ T cells correlates 
with the upregulation of chemokine transcription in the lung and depletion of IL-17 
reduced the accumulation of IFN-γ+CD4+ T cells. Thus, the current model for the 
mechanism of protection during a secondary immune response suggests that an 
accelerated appearance in the lung of IL-17+CD4+ T cells induces chemokine 
production, providing an environment that encourages the earlier influx of IFN-γ+CD4+ 
T cells. 
 While there exists an obvious role for IFN-γ+CD4+ T cells in induction of 
bacteriostasis in the lung, the question that remains is whether this is the only 
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mechanism that facilitates vaccine-mediated protection. Naive and BCG vaccinated 
IFN-γ -/- mice both succumb to M. tuberculosis infection quickly and display higher 
bacterial burdens compared to WT naïve and BCG vaccinated mice, demonstrating the 
importance of IFN-γ in both primary and secondary immune responses [172]. However, 
when IFN-γ -/- mice were vaccinated with BCG, the vaccinated mice had a significantly 
longer survival time compared to naïve IFN-γ -/- mice [172]. IFN-γ -/- BCG vaccinated 
mice also displayed lung bacterial numbers ~1 log10 lower than naïve IFN-γ -/- mice 
after the first 20 days of infection and exhibited diminished lung pathology [172].  
Interestingly, when the CD4+ T cell population was depleted in IFN-γ -/- BCG 
vaccinated mice, their survival time reverts to that of IFN-γ -/- naive mice, as does their 
lung pathology [172]. The collective observations from this study indicates that BCG 
vaccination can confer a measure of protection to vaccinated mice that is independent of 
IFN-γ mediated mechanisms but is mediated by CD4+ T cells. As a result, alternative 
mechanisms of protection for Tb immunity are being proposed (reviewed in [173]) and 
the concordance of several of these mechanisms with my findings will be discussed in 
chapter 6. 
Although the roles of IFN-γ, CD4+ and CD8+ T cells during secondary 
protective immune responses are have been investigated, the impact of Tregs on the 
development of protective memory against Tb had not been assessed prior to this thesis. 
Tregs can suppress proliferation and cytokine production by CD4+ and CD8+ T cells 
(section 1.4.2). Proliferation and production of certain cytokines are essential for 
optimal T cell memory development (sections 1.3.2.2 and 1.3.2.3). Thus, Tregs could 
suppress the development of protective memory against Tb during vaccination and this 
possibility is explored in my thesis. 
 
1.2.7 Animal models of Tb 
 
Animal models have contributed significantly to our understanding of pathogenesis, 
immunology and host-bacilli interactions during Tb infection. Several different animals 
can be used as models of Tb due to their susceptibility to M. tuberculosis or related 
mycobacterial infections, such as M. bovis and M. marinum. Each model has advantages 
and disadvantages that must be considered. Tb is a complex disease in humans, with 
resistant and susceptible individuals and multiple stages of disease that can affect a 
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variety of tissues. Some animal models are better suited to model specific aspects of 
disease than others. 
The mouse is the most widely used model of Tb infection. Mice are easily 
housed and their genome is well characterised. There are also a wide variety of 
immunological tools, such as murine-directed antibodies and gene-deficient strains of 
mice, which can be utilised when working with murine models. Mice can be infected in 
a number of ways but a low-dose infection of ~50 colony forming units (CFU) of M. 
tuberculosis by aerosol is regarded as the most physiologically relevant to human Tb 
infection (reviewed in [22, 174]). Using this approach, lung bacterial numbers increase 
slowly but in a log linear fashion until 3-4 weeks after infection, when the lung bacterial 
numbers stabilise, coinciding with the influx of activated T cells into the lung. 
Thereafter lung bacterial numbers remain high at ~106 CFU but relatively stable until 
mice succumb to infection. Although bacterial numbers in the lung stabilise, lung 
pathology does progress. Discrete lung lesions that correspond to the implantation sites 
of the aerosolised M. tuberculosis accumulate and consist of infected macrophage and 
lymphocytic infiltrate with some fibrosis evident at later stages. The survival times of 
mice differ according to strain. C57BL/6 and BALB/c mice survive on average to 250 
days post infection and are termed resistant to infection, while DBA/2, C3H, CBA and 
129Sv mice survive on average to 100 days post infection and are termed susceptible 
[175].  
Dissemination of mycobacteria from the lung of infected mice occurs through 
the lymph and blood to the lymph node and other tissues such as the liver and spleen. 
This occurs prior to the onset of adaptive immunity, typically around 1-2 weeks after 
infection [176] and bacterial numbers in these tissues increase until the influx of 
activated T cells at 3-4 weeks after infection when bacterial numbers stabilise. After 
stabilisation of bacterial numbers, the chronic phase of Tb infection ensues. 
The chronic phase of Tb infection in the murine model is not regarded as an 
accurate representation of human latent infection, since murine lung lesion structure 
does not replicate that of the human granuloma. Human granulomas are highly 
structured with infected macrophages surrounded by activated lymphocytes and 
fibroblasts enclosing the structure, and progress to become necrotic in the centre 
(reviewed in [177]. Murine lung lesions do not exhibit the same organised structure, 
possibly as lung architecture of a mouse is much smaller than that of humans [178]. 
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Murine lung lesions also do not exhibit the same degree of central necrosis, possibly as 
the centres of murine lung lesions do not reach the extreme oxidative stress levels 
observed in human granuloma tissue due to the smaller size of murine lesions [12]. In 
addition, bacterial numbers in the murine lung after the onset of stationary phase is a lot 
higher than bacterial numbers observed in human tissue (reviewed in [179]).  
 Despite these differences, mice are a useful model for Tb vaccination. 
Subcutaneous (s.c.) BCG vaccination of mice results in Th1 immune responses against 
mycobacterial antigens. After an aerosol M. tuberculosis challenge, a ~1 log10 decrease 
in lung bacterial numbers is observed in BCG vaccinated mice compared to naïve 
controls [22]. This ~1 log10 decrease is regarded in pre-clinical vaccine trials to be the 
gold standard level of protection, against which novel vaccines are easily compared 
[180, 181].  
BCG can also be used to model Tb infection. When administered to mice 
intranasally (i.n.), BCG initiates a pulmonary mycobacterial infection with recruitment 
to the lung of cellular subsets similar to those observed during pulmonary M. 
tuberculosis infection, including IFN-γ producing CD4+ T cells [182, 183]. Since BCG 
does not cause significant disease in immunocompetent humans, this model permits 
analysis of pulmonary mycobacterial infection in physical containment level (PC)-2 
conditions and parallels may be drawn with virulent M. tuberculosis infection. Similar 
to M. tuberculosis infection, early growth of BCG is observed in the lung, followed by 
dissemination to other tissues, and upon the onset of adaptive immunity bacterial 
numbers in tissues stabilise [182, 183]. However, unlike M. tuberculosis infection, the 
tissue bacteria numbers then slowly decline [182, 183].  
Other small animal models of Tb infection include the guinea pig and rabbit 
infection models. Both models exhibit similar kinetics of bacterial growth to the murine 
model after low-dose aerosol infection [184, 185]. By contrast to the murine model, 
both models exhibit lung pathology more representative of human Tb with tissue 
necrosis [185, 186]. Guinea pig and rabbit models share the limitations that they are 
larger and more difficult to house than mice and reagents available for immunological 
analysis are limited. 
More recently, other animal models of mycobacterial infection have been 
developed, such as the non-human primate model and fish or amphibian models. The 
strength of the non-human primate model is its ability to model the onset and 
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progression of latent infection [187], which cannot be as faithfully represented with 
other animal models, but there are significant costs associated with housing the non-
human primate model. M. marinum is a natural pathogen of fish and amphibians that 
induces granuloma formation, and infection of zebrafish embryos with fluorescently 
labelled M. marinum can be used to visualise mycobacteria within a living host [127]. 
While the M. marinum zebrafish model enables visualisation of mycobacteria in vivo, 
there are vast differences between immune systems of zebrafish embryos and adult 
humans, and data should be interpreted with this in mind. 
 As outlined above, there are a number of different animal models for Tb 
infection available and one should consider their advantages and disadvantages when 
designing experiments. This thesis focuses on characterising the acute phase of the 
immune response to infection and vaccination rather than the latent phase of infection, 
which makes the well defined and well resourced murine model of Tb ideal. 
Furthermore, the BCG i.n. infection model was used to enable immunological analyses 
within a PC-2 facility, but some immunological findings and protection data were also 
obtained using virulent M. tuberculosis or M. bovis infections. 
 
1.3 Vaccination 
 
1.3.1 The principles of vaccination 
 
The idea of using small doses of a whole or part of a pathogen to prevent full infection 
with the virulent organism is an old one (reviewed in [188]); evidence exists in ancient 
Chinese and Indian literature for the use of variolation to prevent smallpox, and more 
recently in history, Edward Jenner observed that cowpox infection prevented smallpox 
infection. However, all utilise the same basic principle of immunology: immunological 
memory, which will be discussed below.  
There are several broad concerns to consider when designing vaccines to prevent 
infection. Firstly, the vaccine must be safe to administer. Vaccines are given to a range 
of different people, from healthy adults through to the immunocompromised, the elderly 
or the very young, whose immune systems may be underdeveloped or impaired. A 
vaccine must induce protective immunity without resulting in immunopathology or 
infection. Secondly the vaccine must induce the correct type of immune response, 
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targeted for the specific pathogen. Just as there are different types of primary immune 
response, there are different types of secondary immune responses and targeting an 
aberrant immune response for that pathogen could lead to more severe disease in 
vaccinated individuals [189]. Designing a vaccine to induce the optimal immune 
response to prevent disease caused by a specific pathogen is known as rational design. 
The rational design approach is at the interface of vaccinology and immunology, 
where researchers endeavour to use the principles of immunology to enhance vaccine 
design. Traditionally, vaccine design has used an empirical approach, in which a 
vaccine was created and tested for protection against infection and detailed prior 
knowledge of the protective immune response to the pathogen was not essential. The 
empirical approach has worked for many pathogens but as the understanding of 
different types of immune responses advanced, it emerged that classical vaccine designs 
typically induce strong antibody responses. Antibody responses can control 
extracellular bacterial infections and some viral and protozoal infections.  
By contrast, classical vaccine designs have not resulted in successful vaccines 
for infections including HIV, malaria and Tb (reviewed in [190]). It has emerged that 
cell-mediated responses are needed to control or eradicate these infections. Thus, it is 
unsurprising that classical vaccine designs are ineffective for these infections and there 
is a push to understand more about the induction of cell-mediated immunity to enable 
rational vaccine design. However, large gaps remain between vaccinology and 
immunology, as the most desirable primary and secondary immune responses for 
protective immunity against these infections are not well defined. Therefore, while 
rational design is desirable for infections like HIV malaria and Tb, it is not wholly 
attainable until the protective immune response for these infections is better understood. 
 
1.3.2 Immunological memory models 
 
Immunological memory denotes the enhancement or acceleration of secondary immune 
responses compared to that induced by the initial pathogen encounter and the response 
is antigen specific rather than a generalised heightened responsiveness of the immune 
system. Cells that mediate memory immune responses are termed memory 
lymphocytes, which are long-lived, antigen-specific B or T cells. Memory lymphocytes 
develop from naïve lymphocytes after an initial encounter with their specific antigen 
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during the primary immune response. They become memory lymphocytes that can 
persist long-term and, upon secondary stimulation with their cognate antigen, their 
response is typically quantitatively and/or qualitatively enhanced compared to the 
primary response. The process of memory development differs between B and T cells 
and there are also memory subsets within these two populations. For vaccinology, it is 
key to determine how the optimal memory B or T cell is generated to prevent disease 
caused by a target pathogen. 
 
1.3.2.1 Humoral memory 
 
B cell memory is also referred to as humoral immunity, which encompasses the 
memory B lymphocytes and some CD4+ Th2 cells. Memory B lymphocytes include 
both quiescent memory B cells located in secondary lymphoid tissue and long-lived 
plasma cells located in the bone marrow. Primary antigenic stimulation is delivered 
through the B cell receptor and, with CD4+ T cell help in the form of cytokine 
production and co-stimulatory signals, promotes B cell survival and immunoglobulin 
(Ig) class switching and the establishment of plasma and memory B cell populations 
early during a primary immune response (reviewed in [191]). Plasma cells continue to 
produce high-affinity antibody that is released into circulation, and quiescent memory B 
cells produce high-affinity antibody after secondary antigenic stimulation, (reviewed in 
[192]). Therefore the key mediator of humoral memory is high-affinity serum antibody, 
first from the plasma cell and then from the activated memory B cell. Antibody-
mediated immunity is particularly effective at controlling extracellular bacterial 
infections and viral infections before they enter their target host cell or after lysis.  
 
1.3.2.2 Cell-mediated memory 
 
Cell-mediated memory encompasses CD4+ and CD8+ T cells and their effector 
mechanisms, including cytokine production and cytotoxicity. T cell memory is more 
complex than B cell memory to define, as there are several T cell subsets with different 
proposed models of memory development. Even within these defined subsets, there is 
significant heterogeneity in terms of surface and functional marker expression, cellular 
location and survival requirements.  
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Memory T cell subpopulations have been proposed on the basis of proliferation 
[193] or by division into fast and slow responder subsets based on their capacity to 
initiate effector mechanisms after antigenic stimulation [194]. These subpopulations 
have recently been refined by studies relating memory T cell subsets to their location. A 
study by Sallusto, et al. of human memory cells, defined as CD45RAlo and CD45ROhi, 
demonstrated differential cell surface expression of CCR7 within the memory 
population in both CD4+ and CD8+ T cells [195]. CCR7 is a chemokine receptor that 
promotes lymphocyte homing to and retention within the lymph node. CCR7− memory 
T cells were predominantly found in peripheral tissues and circulation, whereas CCR7+ 
memory T cells were predominantly found in lymphoid tissue. CCR7− memory T cells 
were termed effector memory T cells (TEM), as this subset was able to rapidly 
upregulate effector mechanisms such as IFN-γ production upon stimulation. CCR7+ 
memory T cells were termed central memory T cells (TCM) due to their location in 
lymphoid tissue. TCM were less effective at rapid cytokine production but proliferated 
more readily than TEM and could differentiate into TEM upon polyclonal stimulation. 
Memory T cells were also demonstrated to differentially express CD62L [195]. CD62L 
is also a lymph node homing marker and TCM were found to be predominantly CD62Lhi, 
while TEM were CD62Llo.  
Subsequent to this study, it has emerged that the TCM/TEM distinction may not 
hold true in all situations. Memory T cell populations defined by CCR7 expression, as 
suggested by Sallusto, et al., have been shown to exhibit the distinct proliferative 
capacities and to localise to distinct tissue locations in other studies. However, a 
distinction between the populations in terms of effector responses has not always been 
apparent [196-198]. Differentiation of memory T cell subsets based on CD62L 
expression has also not translated into differences in effector responses in other studies 
[63, 199]. Therefore while the TCM/TEM distinction based on CCR7 or CD62L 
expression may assist in delineating probable location and proliferative capacity of 
memory T cells, replicable markers of memory T cell effector capacity remain to be 
identified.  
 
1.3.2.3 Factors mediating the development and maintenance of memory T cells  
 
There are several basic factors that mediate development of a memory T cell 
population, although requirements for these can differ between CD8+ and CD4+ T cell 
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populations. Key factors for the development or maintenance of memory T cells include 
signalling from the γc chain family of cytokines and TCR signalling at various stages of 
memory development. The γc chain family of cytokines all use the common γ chain as 
part of their receptor for cell signalling. Cytokines from this family that have been 
shown to enhance memory T cell development include IL-2, IL-7 and IL-15.  
For efficient memory induction, there is an established role for early IL-2 
signalling. IL-2 is predominantly secreted by CD4+ T cells and IL-2 signalling during 
priming has been shown to be important for development of both CD4+ and CD8+ 
memory T cells. Effective IL-2 signalling to naïve CD4+ T cells undergoing initial 
expansion promotes their long-term survival, presumably inducing upregulation of the 
IL-7 receptor α chain [200, 201]. IL-2 signalling to CD8+ T cells during priming may 
only slightly affect the number of effector or memory CD8+ T cells but is essential to 
develop memory cells capable of expanding upon secondary stimulation [202].  
It has also been shown that CD4+ T cells promote the development of CD8+ 
memory T cells [203]. It was suggested that this was due to the capacity of CD4+ T cells 
to secrete IL-2 during priming, but it appears that CD4+ T cells also enhance 
maintenance of CD8+ memory T cells [204].  
IL-7 and IL-15 also have established roles in the maintenance of memory T cells 
in vivo. IL-7 is secreted constantly by fibroblasts and its availability is thought to be 
controlled by its consumption rather than production. Thereby, the constant amount of 
IL-7 maintains a fixed population size for memory T cells. For CD4+ effector T cells, 
upregulation of the IL-7 receptor α chain correlates with their transition into a memory 
cell population [201] and CD4+ memory T cells do not persist in IL-7 -/- mice [205]. 
Thus, IL-7 is important for optimal transition and maintenance of CD4+ memory T 
cells.  
TCR signalling also promotes survival of CD4+ memory T cells [205] and IL-7 
and TCR signalling can synergise for the optimal survival conditions of CD4+ memory 
T cells. For CD8+ memory T cells, TCR signalling does not appear to be as important, 
as transfer of CD8+ memory T cells into MHCI -/- mice does not affect the ability of the 
cells to persist [206]. Instead, maintenance of CD8+ memory T cells is dependent on IL-
7 and IL-15 signalling [207-209].  
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Therefore, the γc chain family of cytokines and TCR signalling play roles in 
CD4+ and CD8+ memory T cell development and maintenance. CD4+ memory T cells 
require IL-7 and TCR signalling and CD8+ memory T cells require IL-15 but TCR 
signalling is not as essential. Both CD4+ and CD8+ memory T cells require early IL-2 
signalling for optimal memory development, but this leads to subtly different outcomes 
for each population. Tregs can affect proliferation and cytokine production, particularly 
IL-2 production by effector T cells (section 1.4.2). Therefore, it is possible that Treg-
mediated suppression could impede the efficient development of immunological 
memory. 
 
1.3.2.4 Models of memory T cell differentiation 
 
Two models of memory differentiation have been used to explain memory T cell 
development: the sequential or linear differentiation model and the branched 
differentiation model, as described in Fig. 1.3 [210].  
Some evidence has been used to argue in favour of the sequential model for 
memory development. It was found that effector T cells generated in vitro or in vivo and 
transferred into a naïve host can confer memory and naïve T cells must divide a number 
of times before they can form a memory population [211-214]. These studies have been 
used to suggest that memory differentiation progresses from a naïve T cell, to an 
effector T cell defined as a cell that has proliferated, to a memory T cell. However, the 
definition of an effector T cell as a T cell that has proliferated is too simplistic. 
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Figure 1.3: The Linear and Branched Models of Memory T Cell Development. 
A) The linear model suggests progression from an individual naïve T cell, which upon antigenic 
stimulation, proliferates to become an effector T cell, then finally to a memory T cell. Within 
the memory T cell population, progression from TCM to TEM cells and vice versa has been 
suggested. B) The branched differentiation model suggests progression from an individual naïve 
T cell to an effector T cell, with several differentiation stages. During effector T cell 
differentiation, activated T cells may branch off and establish memory cell populations. It is 
possible that TCM and TEM cell populations are established from discrete stages along this 
course. However, in the branched differentiation model, the effector T cell is a state of terminal 
differentiation and the effector T cell population is destined to die and not contribute to 
protective memory. This figure is based on figures in Farber, et al. [217]. 
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Proliferated T cells do not necessarily acquire full effector functions including 
cytokine production and cytotoxicity. After a primary antigenic stimulation, cells 
proliferate and can acquire effector capabilities but a spectrum of cells displaying these 
different capabilities is induced. For example, if naïve CD8+ T cells are activated in 
vitro with their cognate antigen and high-level IL-2, they proliferate and develop into 
full effectors that demonstrate cytokine production and cytotoxicity [215]. In contrast, if 
naïve CD8+ T cells are activated in vitro with their cognate antigen and IL-15 or low-
level IL-2, they proliferate and produce cytokines but do not acquire cytotoxicity and 
are thereby not full CD8+ effector T cells [215]. T cells that are not full effectors can 
also be generated in vivo. Administration of heat-killed Listeria monocytogenes leads to 
expansion of antigen-specific CD8+ T cells but cells do not acquire cytokine production 
or cytotoxic [216]. The point along this differentiation pathway at which cells also 
acquire the capability to become memory cells is not clear, although some stimulation 
and proliferation is clearly necessary. 
Broad models of T cell memory such as the sequential or branched models of 
memory cell development can be helpful, but there is no clearly defined path for T cell 
memory induction on an individual cell basis.  After TCR stimulation there is 
heterogeneity within the effector T cell population in terms of division cycles 
undergone and effector function. It is not known which cells within the heterogeneous 
population persist and contribute to protective immunity. Furthermore, the applicability 
of basic models of memory differentiation differs between CD8+, CD4+Th1 and Th2 
cells and possibly other T cell subsets. For CD8+ T cells, the initial burst size, or 
number of activated antigen-specific CD8+ T cells during a primary immune response, 
corresponds to the magnitude of the memory responses [218]. It is therefore conceivable 
that within a larger total effector cell population, there are more cells destined to 
become memory cells, leading to a bigger memory response. These results have been 
used to suggest the linear model of memory differentiation is more suited for CD8+ T 
cells. 
By contrast, the ability of CD4+ effector T cells to become memory cells 
depends on the cytokines they produce. A study using sorted TCR transgenic CD4+ T 
cells specific for a model antigen has demonstrated that IFN-γ+CD4+ T cells do not 
contribute to memory development [219]. IFN-γ+CD4+ and IFN-γ−CD4+ populations 
sorted from short-term Th1-promoting in vitro cultures of TCR transgenic T cells were 
transferred into naïve congenic mice and tracked in vivo long-term. IFN-γ+CD4+ T cells 
Chapter 1 - General Introduction 
 
40 
quickly disappeared but IFN-γ−CD4+ T cells persisted and produced IFN-γ upon 
secondary restimulation. It is therefore believed that IFN-γ+CD4+ T cells do not persist 
long-term after primary challenge. IFN-γ expression confers an enhanced susceptibility 
to AICD, as has been demonstrated for Th1 cells compared to Th2 cells [88, 220]. In 
addition, IFN-γ production has been shown to lead to apoptosis of effector CD4+ T cells 
after BCG infection [89, 90]. This has led to a branched model of memory CD4+ Th1 
cell differentiation [221]. In this model, antigenic stimulation leads to proliferation and 
activation of naïve CD4+ T cells. If T cells differentiate to the point that they express 
IFN-γ, they die during contraction of the primary immune response and do not 
contribute to memory populations. However, activated IFN-γ−CD4+ T cells can establish 
long-lived memory populations, producing IFN-γ upon subsequent challenge and it is 
proposed that these cells mediate immunological memory and protection from 
subsequent infections.  
This model of CD4+ Th1 memory is particularly relevant for Tb vaccine 
development, since it is thought that natural immunity for Tb relies on CD4+ Th1 
memory. Previously, many Tb vaccine approaches have sought to increase the number 
of IFN-γ+ CD4+ T cells after vaccination but it has been demonstrated that increased 
IFN-γ production during a primary immune response does not correlate with protection 
induced by Tb vaccination [167]. An essential gap in our current knowledge is an 
immunological marker from the primary immune response that correlates with 
protection from Tb infection upon secondary challenge. The branched model of Th1 
memory differentiation suggests that a correlate of protection for Tb may be found 
within the IFN-γ−CD4+ T cell population and that, if either the induction or subsequent 
function of the IFN-γ−CD4+ T cell population is enhanced, Tb vaccine strategies can be 
improved. 
 
1.3.3 Types of vaccination 
 
When designing a vaccine, one must consider the key components required to 
successfully initiate an immune response. An adjuvant must be included, to provide 
danger signals to activate APCs, such as PAMPs. An antigen must also be included, to 
direct an adaptive immune response against the target pathogen. A vaccine can contain 
a single antigen from a pathogen that has immunodominant antigens. When a broader 
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response is necessary, a mixture of several antigens or the entire killed or weakened 
pathogen can be used. There are several different types of vaccines: live, inactivated or 
subunit vaccines (either protein or DNA). 
With live vaccines, recipients are vaccinated with a live organism that does not 
cause disease, as it has been altered to remove virulence but retain immunogenicity. 
Some of the first available vaccines were live, attenuated vaccines and attenuation was 
initially achieved by culturing virulent strains for long periods (reviewed in [188]), 
during which the organisms lost or mutated genomic material not essential for in vitro 
survival, including virulence factors. Attenuation of virulent organisms through in vitro 
culture, or more recently targeted mutation of candidate virulence genes, has been 
widely used to develop bacterial and viral vaccines. The advantage of live, attenuated 
vaccines is that they simultaneously deliver many different antigens for the pathogen 
with a spectrum of PAMPs and can induce something close to natural protective 
immunity. Furthermore, some live vaccines persist for a period of time and, if 
maintenance of natural immunity requires antigen persistence, immunity can be 
maintained for a prolonged period of time. However, there are safety concerns with live 
vaccines. Attenuated strains could revert to a virulent phenotype by point mutation 
reversion in virulence genes or acquisition of genetic material from co-infections with 
other related organisms. Furthermore, in susceptible or immunocompromised 
individuals, even attenuated pathogens can result in a productive infection, such as BCG 
lymphadenitis, which is the most common complication of BCG vaccination [222].  
Due to these safety issues, inactivated vaccines were developed, whereby 
pathogens were inactivated or killed before being used to vaccinate an individual. 
Common approaches for pathogen inactivation include heat treatment or treatment with 
chemicals such as formaldehyde, acetone or phenol [223]. The inactivated pathogens 
again deliver antigen and PAMPs in one physically associated unit but are often less 
effective than live vaccination [224]. This may because the treatments alter the integrity 
and conformation of pathogen antigens or, since inactivation kills the pathogen, it may 
prevent secretion or production of an antigen or PAMP essential for immunogenicity. 
Safety of inactivated vaccines is not guaranteed as inconsistent validation of pathogen 
inactivation has lead to scenarios where vaccine batches have been released and used 
when not fully inactivated [225]. 
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To further refine vaccines, subunit approaches have been used. Subunit vaccines 
are purified immunogenic components from the pathogen administered in conjunction 
with a formulated adjuvant. The antigen is usually an immunodominant protein from the 
pathogen, which may be purified from cultures of that pathogen [226] or produced by 
recombinant bacteria [227]. Adjuvants can be formulated to ensure localised, gradual 
delivery of the antigen and PAMPs, called the depot effect. Subunit vaccines are 
regarded as safer than live or inactivated vaccines but are typically less immunogenic, 
require repeated administration and careful choice of the antigen and adjuvant. The 
adjuvant must ensure effective activation of DCs and the selected antigen must be 
immunogenic, if not immunodominant. For some pathogens, there are no 
immunodominant antigens or  they may produce different antigens or antigenic variants 
at different periods of their life-cycle [228] or infection [142, 144], so the breadth of 
antigens delivered by subunit vaccination may be limiting compared to a live vaccine.  
A key characteristic of protein-based subunit vaccines is that they induce strong 
antibody responses; however, many intracellular infections require cell-mediated 
immune mechanisms for their control. Thus, researchers have endeavoured to develop 
subunit vaccines for intracellular infections that target the MHC I processing pathway 
and induce CTLs. In 1990, it was shown that intramuscular (i.m.) injection of plasmid 
DNA in saline resulted in transfection of the surrounding myocytes [229]. This was a 
significant finding for gene therapy but it was subsequently found that this process 
resulted in an immune response, as antibodies directed against protein from transfected 
genes were induced [230]. The definitive step came when it was shown that transfection 
also induced CTLs directed against protein expressed by the plasmid DNA, and this 
conferred protective immunity against a target pathogen [231]. As a result the process 
of DNA vaccination, as outlined in Fig. 1.4, was born. 
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Figure 1.4: The Process of DNA Vaccination 
1) Genomic material encoding an antigen from a pathogen (green) is cloned into a DNA vector 
(black). 2) This construct is transformed into bacteria 3) before being propagated and purified. 
4) Purified DNA plasmids are injected into an individual. 5) The DNA plasmid transfects cells 
surrounding the injection site by endocytosis or receptor-mediated uptake of nucleic acid and 
translocates to the nucleus of the target cell by undefined mechanisms. 6) The antigen is 
expressed using the molecular machinery of the transfected cell 7) and the antigen is presented 
to specific T cells and initiates an immune response in the vaccinated individual. It is unknown 
currently which cell must be transfected to facilitate antigen presentation. Non-lymphoid cells 
surrounding the injection site (such as myocytes shown above) are transfected and may transfer 
antigen to APCs [241] or present antigen themselves [239]. Alternatively, APCs resident in the 
tissue may be directly transfected and thereby mediate antigen presentation [242]. 
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DNA vaccination has several advantages compared to other approaches 
(reviewed in [232, 233]). While direct injection of naked DNA encoding an antigen fails 
to induce antibody titres comparable to protein antigen and adjuvant co-administration, 
DNA vaccination can induce robust cell-mediated responses. In addition, specialised 
delivery methods such as gene-gun administration can be used to enhance antibody 
titres. Purified DNA plasmids can be efficiently manufactured and do not require 
refrigerated storage in contrast to many live or subunit vaccines, which improves the 
prospects of using these vaccines in the field. Antigens chosen can be well defined and 
manipulated to remove any toxic regions, making DNA vaccines very safe, even for 
immunocompromised patients. However, the mechanisms by which DNA vaccines 
access MHC I and II processing pathways and induce cell-mediated and humoral 
immunity remain to be defined [234-240]. 
For Tb vaccines, researchers have pursued vaccine designs that induce CD4+ 
Th1 immunity, since IFN-γ production and CD4+ T cells are important for protection 
from primary Tb infection (section 1.2.3) and are assumed to be important for 
protection from secondary Tb challenge (section 1.2.6). Live BCG vaccination has had 
some success for combating Tb (section 1.3.4). However, the focus of Tb vaccine 
research is beginning to shift from inducing IFN-γ producing CD4+ T cells, as it 
becomes increasingly clear that it can not be assumed that IFN-γ producing CD4+ T 
cells are the sole cellular subset responsible for protective memory against Tb. Other 
live vaccines have been developed to target Tb and are currently in pre-clinical trials 
(section 1.3.4). Several of these enhance CD8+ T cell activation compared to BCG 
vaccination and have shown comparable or increased protective efficacy [180, 181]. 
The induction of CD8+ T cell memory is a promising target for Tb vaccine design and 
DNA vaccines provide a method to induce CD8+ T cell responses. Therefore, during the 
course of this thesis, a novel DNA replicon vaccine was created to induce CD8+ T cell 
memory and tested for protective efficacy. 
It must be remembered that many factors need to be considered for vaccine 
design to induce the optimal type of immunity for a pathogen. Further ways of 
optimising vaccines will be addressed in chapter 4 but include: optimisation of antigen, 
adjuvant, immunogenicity, route and method of administration, and promotion of long-
term immunity. Vaccine approaches have largely been developed empirically so the 
exact mechanisms governing their interactions with the immune system are yet to be 
fully defined. A deeper understanding of how different factors enhance or impede 
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memory development will enable vaccinology to advance and develop truly rational 
vaccine design approaches. 
1.3.4 Vaccination against Tuberculosis 
 
The only commercially available vaccine for Tb is BCG, a live attenuated strain of M. 
bovis. BCG was first developed by Calmette and Guérin by passaging a virulent M. 
bovis strain isolated from a bovine mastitis sample 230 times through glycerinated bile 
potato medium, resulting in gene deletions and duplication and attenuation. BCG was 
first given to a human in 1921 (reviewed in [243]) and BCG has become since then the 
most widely administered vaccine globally.  
Unfortunately, the effectiveness of BCG is inconsistent. BCG can effectively 
prevent forms of childhood Tb involving dissemination [244], probably due to its ability 
to control blood-borne bacilli [245]. However, a meta-analysis of literature estimates the 
effectiveness of the BCG vaccine in adults to be 50% [246]. The effectiveness varies 
substantially between studies included in the meta-analysis, ranging from 80% to no 
protection. Additionally, in some studies the effectiveness of BCG wanes over time 
[247], whereas in others similar levels of protection have been observed up to 60 years 
after vaccination [248]. 
There are several possible explanations for the variation in effectiveness 
between different BCG vaccinated populations. There are multiple substrains of BCG in 
use, due to passaging in different laboratories, which have diverged genetically and 
immunogenically from one another (reviewed in [243]). Different BCG substrains can 
confer different levels of protection against Tb [249]. Variation may also be a result of 
host genetics, with genetic elements prevalent in different populations contributing to 
the variable protection afforded by BCG. Moreover, the virulence of different strains of 
M. tuberculosis can vary and the virulence of the strain of M. tuberculosis endemic to a 
population could affect the effectiveness of the BCG vaccine.  
Finally, there may be environmental factors that affect the effectiveness of the 
BCG vaccine. Populations that exhibit low BCG effectiveness are commonly in 
developing countries, which have greater exposure to helminth infections and 
environmental mycobacteria than populations in developed countries. Helminth 
infection at the time of BCG vaccination is hypothesised to result in either 
immunosuppression of the BCG immune response or skew the response to an 
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unprotective Th2 profile [250]. Similar hypotheses have been suggested for the 
interaction between environmental mycobacteria and BCG vaccination [251]. BCG may 
be subject to immunosuppression if environmental mycobacteria have tolerised or 
skewed the immune response for antigens that are cross-reactive with BCG. Suboptimal 
APC priming after exposure to environmental mycobacteria [252] could result in Treg 
induction (section 1.4.3), or could prime a Th2 instead of Th1 immune response to 
conserved mycobacterial antigens, resulting in an unprotective immune response to Tb 
[252]. Alternatively, exposure to environmental mycobacteria may prime an immune 
response that reacts robustly to the BCG but clears the bacillus before it can establish 
protective immunity against Tb [253]. 
Since BCG fails to consistently protect against Tb, significant effort has been 
directed towards developing new vaccine strategies against Tb. At least twelve vaccines 
are moving towards or currently in clinical trials (reviewed in [254]). These include: 
• A SecA2 deletional mutant of M. tuberculosis. SecA2 encodes a 
component of a virulence-associated secretion system that secretes 
superoxide dismutase A. Deletion attenuates the pathogen but promotes 
apoptosis of infected macrophages in vitro, enhancing CD8+ T cells 
priming in vivo and making it more protective than BCG in mouse and 
guinea pig models [181].  
• Recombinant BCG that expresses the listeriolysin O protein from 
Listeria monocytogenes. The listeriolysin O protein forms pores in the 
phagosomal membrane, giving mycobacterial protein access to the MHC 
I processing pathway, permitting strong CD8+ T cell priming [180]. This 
vaccine exhibited better protection against virulent M. tuberculosis than 
the BCG vaccine in a murine model [180]. 
• A modified vaccinia virus Ankara (MVA) viral vector containing 
Antigen 85A, a mycobacterial antigen (MVA-85A) [255]. 
Administration of this construct can boost mycobacterial antigen-specific 
immune responses in subjects primed with the BCG vaccine, and 
boosting is not affected by the time elapsed between priming and 
boosting [256].  
Therefore, a variety of new vaccine strategies are being developed for Tb. While all 
possess a rational immunological basis, truly rational vaccine design for Tb is not 
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feasible due to gaps in knowledge between Tb immunology, protective immunity and 
vaccinology. 
A final consideration is that neither BCG vaccination nor prior M. tuberculosis 
infection treated with antibiotics enables the host to eliminate the infection, however 
they enable earlier control of the infection [257]. Since natural immunity against Tb 
infection does not eliminate infection, we must question whether natural immunity is 
what we want to replicate through Tb vaccination. 
 
1.4 T regulatory cells 
 
1.4.1 The re-discovery of T regulatory cells 
 
The concept of a lymphocyte that suppresses other lymphocytes was first proposed in 
the early 1970s [258, 259]. These cells were known as suppressor T cells but an 
inability to identify factors that mediated their mechanism of action or clone the cells 
themselves led to the demise of this area of research [260]. However, in the mid-1990s 
this concept was revived [261] and has led to a plethora of research on suppressive T 
cells, now known as Tregs.  
The key observation that implied the existence of a suppressive T cell subset 
was that murine neonates thymectomised before day 3 post-birth developed symptoms 
of autoimmunity, while neonates thymectomised after this time point did not develop 
these complications [262, 263]. It was hypothesised that a distinct T cell subset leaving 
the thymus around day 3 post-birth was responsible for suppressing the immune 
response and preventing autoimmunity. Subsequently, cell surface markers for this T 
cell subset were identified, initially relying on CD4 [262], CD25 [261] and CD45RA 
[264]. Now many more markers, both on the cell surface and inside the cell are used to 
define the different subsets of Tregs. The first type of Treg defined in 1995 [261] is now 
known as the natural or intrinsic Treg, described in section 1.4.2, and the natural Treg 
subset is a major focus of this thesis. In addition, there are other suppressive T cells in 
the periphery that are induced in certain conditions and are collectively known as 
induced or adaptive Tregs, outlined in section 1.4.3. 
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1.4.2 Natural T regulatory cells 
 
1.4.2.1 Mechanism of development 
 
Two models have been suggested for selection of natural Tregs in the thymus. 
Developing thymocytes undergo both positive and negative selection (reviewed in 
[265]). Positive selection ensures that the specific TCR on a thymocyte can engage 
MHC/self-peptide complex and deliver a survival signal. If this signal is not received, 
the thymocyte dies of neglect. Negative selection ensures that the affinity of the 
interaction with MHC/self-peptide complex is not too high. If thymocytes with a very 
high affinity TCR for MHC/self-peptide complex escaped the thymus, they could be 
auto-reactive and initiate autoimmunity in the periphery. Thymocytes with very high 
affinity TCRs are deleted due to negative selection. Therefore, thymocytes with low 
affinity TCRs for MHC/self-peptide complex survive to emerge as single positive CD4 
or CD8 T cells.    
It was initially hypothesised that natural Tregs are selected using MHC and TCR 
signals similar to other T cells, but using different signalling thresholds [266, 267]. It 
was thought that natural Tregs develop from thymocytes with TCRs of intermediate 
affinity for the MHC II/self-peptide complex. A higher TCR signal compared to 
conventional T cells was thought to trigger the development of the Treg suppressive 
phenotype. 
 However, a more recent model suggests that thymocytes require a specific signal 
to commit to the Treg lineage, either from an unidentified invariant signal or selection 
on an unconventional TCR ligand [268]. The precise mechanism of natural Treg 
selection in the thymus is undefined, as are the antigen-presenting cell subsets required 
for their selection, but it is important to note that while natural Tregs may use self-
peptide for selection [269], Tregs in the periphery possess a diverse TCR repertoire 
[266]. 
 
1.4.2.2 Cell surface markers 
 
Natural Tregs emerge from the thymus as CD4+ T cells (Fig. 1.5) of which the majority 
express high levels of CD25 [261], CD152 [270] and glucocorticoid induced TNF 
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receptor (GITR) [271] but low CD127 [272, 273] on the cell surface. Natural Tregs 
acquire CD25 expression at the CD4 single positive stage of thymocyte development 
[274]. After TCR engagement, Tregs can either act in the lymphoid tissue to inhibit 
effector T cell development or in the periphery at the site of inflammation. A sub-
population of Tregs express CCR7 and these inhibit proliferation in the lymph nodes 
draining the site of inflammation [275]. Another sub-population of Tregs express high 
levels of adhesion molecules, such as CD103, and chemokine receptors, such as CCR5, 
and these promote extravasation and homing of Tregs to inflammation sites [276]. By 
virtue of the fact that natural Tregs are likely to be selected for a higher affinity for a 
self-peptide/MHC complex in the thymus, they should again encounter this self-
peptide/MHC complex in the periphery, and are thought to undergo continual low-level 
TCR stimulation. This may explain why many cell surface markers for Tregs are also 
markers of T cell activation, giving Tregs a semi-activated phenotype, even in naïve 
mice. 
 
1.4.2.3 Intracellular markers 
 
A significant hindrance for the study of natural Tregs was the lack of a marker specific 
for Tregs. While the majority of Tregs express CD25, GITR or CD152 in a naïve 
mouse, expression of these markers does not correlate totally with suppressive activity. 
Furthermore, identifying Tregs during an active immune response was exceedingly 
problematic, as naïve T cells upregulate activation markers once activated, leading to 
confusion between activated T cells and Tregs. Therefore, the recent identification of 
forkhead box P3 transcription factor (Foxp3), otherwise known as scurfin, as a highly 
specific marker for the suppressive Treg phenotype was a significant advance. Foxp3 is 
selectively produced in CD4+CD25+ T cells [277, 278], and its effects in vivo are 
illustrated in both a natural mouse Foxp3 mutant, the scurfy mouse, and a human 
condition affecting Foxp3 called immune dysregulation, polyendocrinopathy, 
enteropathy, X-linked syndrome (IPEX). Both the scurfy mouse and IPEX patients 
exhibit autoimmunity, immune dysregulation and a deficiency in Tregs [279, 280].  
Foxp3 expression correlates very specifically with the Treg suppressive 
phenotype, and it has been postulated to be the “master regulator” of the suppressive 
phenotype [281, 282]. There is considerable homology of the Foxp3 gene across 
species, which suggests conserved function [281]. The gene is located on the X 
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chromosome, which leads to disease in the event of Foxp3 deficiency in hemizygous 
males and in homozygous, but not heterozygous, females [283]. It has been 
demonstrated with chromatin immunoprecipitation and mouse genome array tiling that 
there are binding regions for Foxp3 in approximately 700 genes [284]. When compared 
to mRNA microarray data [285], only 10% of the genes whose expression is altered in 
Tregs bind directly to Foxp3, suggesting Foxp3 initiates a genetic program in Tregs, 
which may be carried out by other transcription factors. There is evidence that Foxp3 
can act both as a repressor and as an activator and this may depend on histone 
modifications around its binding site [284, 286]. Furthermore, it has become apparent 
that Foxp3 interacts with other transcription factors such as NFAT and NF-κB [287] 
and can override the Th17-promoting effect of RORγt [288]. An internal balance 
between the amounts of these transcription factors is thought to regulate the 
programming of an individual cell and whether it becomes an effector T cell or a Treg. 
 
1.4.2.4 Mechanism of action 
 
Several mechanisms of action have been suggested for natural Tregs (Fig. 1.5), but it is 
known that natural Tregs need TCR stimulation [289, 290] and IL-2 signalling [291] to 
activate their suppressive mechanisms. Once activated, CD4+CD25+ T cells can 
suppress proliferation of CD4+ [289] and CD8+ [292] responder T cells in vitro and, 
once stimulated with their specific antigen, they can suppress in an antigen-non-specific 
manner. In vitro, the failure of the responder population to proliferate correlates with a 
decrease in IL-2 transcription and thereafter production by responder T cells [289, 291]. 
IL-2 feeds an autocrine loop necessary for maximal proliferation and full activation of 
responder T cell effector mechanisms, such as cytokine production and CTL activity. 
Furthermore, cell populations dependent on full activation of responder T cells are also 
affected by Treg suppression, such as B cells [293, 294], macrophages and NK T cells 
[295, 296].  
 The mechanism by which natural Tregs inhibit IL-2 production in responder 
cells, and whether IL-2 inhibition acts alone or in concert with other mechanisms to 
result in suppression, is not understood. A number of Treg suppressive mechanisms 
have been characterised, and each predominate in different in vitro and in vivo 
scenarios. It is known that responder T cells and Tregs need to be in close proximity to 
each other for suppression to occur in vitro [290]. However, whether this extends to in 
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vivo conditions and whether Tregs act through APCs interacting with responders T cells 
or directly on responder T cells, is uncertain. Thus, proposed mechanisms of Treg 
suppression are divided into indirect or direct mechanisms. 
 Models of indirect Treg suppression suggest the APC mediates suppression by 
Tregs of the responder T cells. One indirect model suggests that a Treg will direct an 
APC presenting antigen to downregulate co-stimulatory signals [297]. Subsequent 
antigen presentation by that APC to responder T cells would result in inefficient 
responder T cell activation and failure to induce IL-2 production and proliferation. 
However, it is possible that Tregs simply use APCs as a platform to bring them in close 
proximity to responder T cells undergoing TCR stimulation. As a result, Treg 
suppressive mechanisms would be enhanced by the presence of APC but Tregs would 
act on responder T cells through direct mechanisms.  
Models of direct Treg suppression mechanisms refer to a direct interaction 
between the Treg and the responder T cell. In an APC-free system, using peptide loaded 
onto MHC I tetramers to initiate CD8+ T cell activation, the addition of CD4+CD25+ 
Tregs still suppressed CD8+ T cell proliferation and cytokine production [292]. 
Therefore, in in vitro cultures, Tregs can signal to and suppress responder T cells 
directly. 
Many effector molecules have been postulated to mediate the indirect and direct 
suppressive mechanisms of Tregs.  
CD25 is the alpha chain of the high affinity IL-2 receptor and is expressed at 
high levels on natural Tregs. Tregs need IL-2 from responder T cells early after TCR 
signalling to activate the Treg suppressive function and, in the periphery, IL-2 is 
required for the homeostasis of Tregs [298, 299]. High CD25 expression may give 
Tregs a competitive advantage over responder T cells for IL-2, which could be 
responsible for the suppressive phenotype of Tregs. It has recently been demonstrated in 
vitro that uptake of IL-2 by Tregs can suppress CD4+ responder T cells by depriving 
them of IL-2 early during proliferation, resulting in apoptosis of the responder cells 
[300].  
CD152 is also expressed at high levels on natural Tregs and has also been 
implicated in the suppressive activity of Treg. CD152 is expressed late after activation 
on T cells and binds to CD80 and CD86 on APCs. Binding of CD152 and CD80 or 
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CD86 initiates reverse signalling, delivering negative signals to the APC and the T cell. 
This negative signalling ordinarily suppresses proliferation and as CD152 is upregulated 
on T cells late after activation, it is thought to prevent over-activation of the immune 
response (reviewed in [301]). Administration of anti-CD152 mAb or its Fab fragment 
inhibits Treg-mediated suppression in vitro [302] and administration of anti-CD152 
mAb contributes to autoimmunity in vivo [270]. However, it is contentious as to how 
anti-CD152 mAbs act in vivo (reviewed in [303]). They may cross-link CD152 on the 
Treg and deliver a negative signal to inhibit suppressive mechanisms of Tregs. Anti-
CD152 mAbs could also bind to and block CD152 on Tregs, preventing it from binding 
to CD80 and CD86 on APCs and thereby preventing Tregs from delivering a 
suppressive signal to the APCs.  
Tregs also express and secrete cytokines that can mediate suppression, such as 
IL-10 and TGF-β. In vitro studies using neutralising antibodies against IL-10 or TGF-β 
or Tregs from IL-10-deficient mice, demonstrate that Tregs can still efficiently suppress 
CD4+ CD25- T cell proliferation in the absence of these soluble factors [289]. However, 
while soluble cytokine may not be vital for Treg suppression in vitro, membrane-bound 
cytokine could mediate the effects of Tregs. Tregs stain extracellularly with anti-TGF-β 
polyclonal antibody after in vitro activation and high concentrations of anti-TGF-β 
neutralising antibody can inhibit suppression of CD4+ CD25- responder T cells [304]. 
These observations suggest that Tregs express membrane-bound TGF-β in its inactive 
form and, upon encounter with the target T cell, membrane-bound TGF-β is converted 
to active TGF-β at the immunological synapse. Only high amounts of neutralising 
antibody could penetrate the synapse between the Treg and the target cell, explaining 
the dose-dependent affects of TGF-β neutralising antibody.  
There is confusion about the importance of cytokines for suppression by Tregs 
in vitro, but many in vivo models indicate that IL-10 and TGF-β are critical. In the well-
characterised murine Leishmania major infection model, administration of IL-10 
neutralising antibody abrogates Treg suppression [305]. In a murine model of type I 
diabetes, expression of a dominant negative TGF-β receptor on responder CD8+ T cells 
meant these lymphocytes could no longer be suppressed by Tregs expressing TGF-β, 
leading to disease progression [286, 306].  
Finally, Tregs can develop cytolytic activity in some situations and inhibit 
immune responses by directly killing responder lymphocytes or APCs. Human CD4+ 
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CD25+ Tregs activated with anti-CD3 and anti-CD46 mAbs, expressed high levels of 
granzyme A and human induced Tregs expressed high levels of granzyme B [307]. Both 
types of Treg were effective at killing a range of leukocytes in vitro through a perforin-
dependent mechanism. Supporting the human studies, murine natural Tregs upregulate 
granzyme B after activation and Tregs from granzyme-B-deficient mice are not 
suppressive [308], although, in contrast to human studies, Tregs from perforin-deficient 
mice retain their suppressive activity [308]. Thus, Tregs can mediate suppression 
through cytolytic activity, but it remains uncertain what the target cells of cytolysis are 
(the APC or the responder T cells), and which molecules mediate these effects in vivo 
[309]. 
Overall, there are several proposed mechanisms of suppression for Tregs. There 
is variation between in vitro and in vivo models of suppression but different 
mechanisms may be important in different states of disease or infection. Therefore, 
there may be a combination of several suppressive mechanisms that result in the local or 
systemic environment of suppression in vivo. Of particular interest for my study is 
whether natural Treg mechanisms are activated and if natural Tregs exert their 
suppressive effects during mycobacterial infection or during vaccination against Tb.  
 
1.4.3 Induced T regulatory cells 
 
T cells with suppressive abilities can also arise in the periphery from conventional T 
cells and these induced or adaptive Tregs are important for immune control during 
certain infections. There are several types of induced Treg and there are also several 
mechanisms of induction proposed that are outlined below, but all need an initial TCR 
signal. If TCR triggering is optimal and co-stimulatory signals are effectively induced 
on APCs this results in normal effector T cell development. However, if TCR triggering 
is sub-optimal or co-stimulatory signals are lacking then induced Tregs can develop. It 
is interesting to note that natural Tregs can promote the induction of Tregs. Natural 
Tregs can affect the co-stimulatory capacity of APCs and so can cause sub-optimal 
responder T cell activation [297]. Furthermore, natural Tregs produce cytokines, such as 
IL-10 and TGF-β, that can induce Foxp3 expression and/or a suppressive Treg 
phenotype, as discussed below.  
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1.4.3.1 Low-dose antigen induced Tregs 
 
Low amounts of antigen can induce Foxp3 expression in CD4+ T cells and these cells 
become functional suppressors (Fig. 1.5). Delivery of low amounts of antigen to DCs by 
coupling antigen to an anti-DEC205 mAb led to development of CD4+Foxp3+ T cells, 
whose suppressive function was dependent on TGF-β [310]. Low-dose antigen 
induction of Tregs is also relevant to in vivo autoimmunity models, where tolerance is 
induced by low-dose antigen exposure [311]. Therefore, a subset of inducible Tregs can 
arise in situations of low-dose antigen. 
 
1.4.3.2 IL-10 induced Tregs 
 
Tregs that develop in the presence of IL-10 are termed Tr1 cells (Fig. 1.5). These cells 
were initially generated by a combination of vitamin D, antigen and 
immunosuppressants [312]. It was subsequently demonstrated that, if IL-10 is present 
during TCR triggering of CD4+ T cells, then Tregs develop that produce large amounts 
of IL-10, as well as other cytokines such as TGF-β, IFN-γ and IL-5 [313]. Some 
suppression by Tr1 cells is likely to be mediated by IL-10 production but they may also 
utilise IL-10-independent mechanisms [314]. Unlike other induced Treg populations, 
homogeneous populations of Tr1 cells generated in vitro and in vivo do not produce 
Foxp3 [314]. IL-10-induced Tregs have been shown to develop during the course of 
some infections. For example, in Bordetella pertussis infection, the filamentous 
haemagglutinin antigen induces IL-10 production by DCs and macrophages but inhibits 
IL-12 production, leading to development of IL-10 producing antigen-specific Tr1 cells 
[315]. Therefore, IL-10-induced Tr1 cells may arise under specific conditions during 
infection. 
 
1.4.3.3 TGF-β  induced Tregs 
 
Another induced Treg subtype develops in the presence of TGF-β and is termed Th3 
(Fig. 1.5). If TGF-β is present during TCR signalling, CD25 and Foxp3 production can 
be induced in CD4+CD25− T cells [316]. These cells are highly suppressive and have 
increased cell-surface expression of CD25 and CD152. Studies of human T cells 
differentiated in these conditions indicate that suppression is contact dependent [317]. 
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However, the presence of TGF-β during CD4+ T cell TCR triggering does not guarantee 
induction of a Treg. In vitro studies have demonstrated that the suppressive Treg 
phenotype is induced in the presence of TGF-β and IL-2, which results in Foxp3 
expression [79, 318, 319]. However, the inflammatory Th17 phenotype can develop in 
the presence of TGF-β and IL-6, and is stabilised by IL-23 signalling [79, 80]. Within 
the same cell there can be induction of Foxp3 and RORγt, the transcription factor 
responsible for the Th17 phenotype [288]. Therefore, in vivo where IL-2, TGF-β and 
IL-6 are all present during TCR signalling, for example in the mucosa, a diverse 
spectrum of cellular phenotypes can develop, ranging from the induced Treg through to 
the Th17 phenotype.  
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Figure 1.5: Schematic outlining Treg subsets and mechanisms of action. 
Natural CD4+CD25+ Tregs are derived directly from the thymus and suppress by cell-contact 
dependent, cytokine dependent or cytotoxic mechanisms. Induced Tregs arise in the periphery 
after antigen presentation to naïve CD4+ T cells in sub-optimal conditions. The subtypes of 
induced Tregs are: low-dose antigen induced Tregs that typically suppress through TGF-β; Tr-1 
Tregs that are induced by the presence of IL-10 during antigen presentation and typically 
suppress through IL-10; and Th3 Tregs that are induced by the presence of TGF-β during 
antigen presentation and typically suppress by cell-contact or cytokine dependent mechanisms. 
If antigen presentation is optimal, activated effector T cells develop. 
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1.4.4 Non-CD4+ T regulatory cells 
 
In addition to CD4+ Tregs there are other subsets of lymphocytes that exhibit 
suppressive phenotypes. These have similar mechanisms of induction and suppression 
to CD4+ Tregs. 
Suppressive CD8+ T cells have been found in several models. In a murine model 
of autoimmunity, transfer of CD8+ T cells from recovered mice protects recipient mice 
from autoimmunity [320]. Protection was mediated by CD8+ T cells that recognised 
self-peptide presented on auto-reactive CD4+ T cells and either directly killed auto-
reactive cells or suppress their activation by cytokine production [320]. Furthermore, 
antigen-presentation in vitro by IL-10-secreting plasmacytoid DCs induced a 
suppressive phenotype in CD8+ T cells, similar to the Tr1 subtype of CD4+ Tregs [321]. 
CD4−CD8− T cells can also exhibit suppressive qualities. Human CD4−CD8− T 
cells can be highly suppressive and cytotoxic to syngeneic T cells bearing the same 
TCR [322]. The origin of CD4−CD8− T cells is uncertain but it has been recently 
demonstrated that CD4+ T cells can convert to highly suppressive, cytotoxic CD4−CD8− 
T cells during the course of CD4+ T cell activation and differentiation [323]. 
 
1.4.5 Suppressing the suppressors 
 
Tregs mediate a feedback loop on the immune response. Once activated, they prevent 
immune responses against self-antigen from accelerating into autoimmunity and 
responses against foreign antigen from becoming excessive and causing 
immunopathology. Sometimes Tregs need to be controlled to enable an appropriate 
immune response to develop, so immune mechanisms exist that suppress the 
suppressive functions of Tregs. 
Signalling through TLRs on APCs or Tregs can inhibit activation of Tregs or 
their suppressive functions. Ligation of TLRs on APCs induces secretion of cytokines 
[324, 325] that render responder T cells resistant to the suppressive effects of Tregs. 
TLR ligation on Tregs themselves can abrogate their suppressive functions. Addition of 
TLR2 ligand to Treg cultures promoted Treg expansion but abrogated their suppressive 
function [326] and knock-down of TLR8 expression on human CD4+CD25+ Tregs 
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resulted in increased suppressive function [327]. However, TLR ligation on Tregs can 
also promote suppressive functions. Addition of the TLR4 ligand, lipopolysaccharide 
(LPS), enhanced Treg activation and suppression function [328]. TLR signalling and 
activation of the APC can also upregulate co-stimulatory signal molecules such as 
GITR ligand (GITRL) and signalling through the GITR/GITL pathway can inhibit Treg 
activity (outlined in section 3.1). Therefore TLR signalling to Tregs modulates their 
function, either enhancing or inhibiting Treg activity. 
 In summary, there are several types of Tregs with different but overlapping 
phenotypes and mechanisms of action (Fig. 1.5). The role of a particular subset or 
subsets of Tregs varies depending on the environment during the induction and 
maintenance of an immune response [329]. Therefore, a number of factors contribute to 
either activating or suppressing Tregs subsets at various points during an immune 
response.  
 
1.5 Aims 
 
The broad aim of this thesis is to examine mechanisms of immune control exerted by M. 
tuberculosis. This thesis focuses on the role of Tregs, specifically natural CD4+CD25+ 
Tregs, and whether these cells have been exploited by M. tuberculosis as an 
immunoevasive tactic.  
As will be discussed in Chapter 3, Tregs have been shown in other chronic 
infections to suppress immune responses and immunopathology but promote pathogen 
survival [305, 315, 330-335]. There has been much speculation that Tregs similarly 
enable pathogen persistence during Tb infection.  
Furthermore, Tregs have also been shown to inhibit vaccine-induced immune 
responses and reduce protective efficacy of vaccines [336-339]. Since there is no 
consistent vaccine against Tb, it is also speculated that Tregs reduce Tb vaccine efficacy 
and improved vaccine strategies against Tb are of the upmost importance, as will be 
outlined in Chapters 4 and 5. Thus, the aims of this thesis can be summarised as 
follows: 
1. To develop a protocol to target and inactivate Tregs in vivo in a murine model of 
mycobacterial infection or vaccination against Tb. 
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2. To evaluate whether Treg inactivation prior to mycobacterial infection, using the 
protocol defined in Aim 1: 
• Enhances the acute immune response 
• Decreases tissue bacterial numbers 
• Increases tissue pathology 
3. To develop a novel DNA vaccine for Tb called pKUN85A, and perform 
preliminary testing to evaluate vaccine efficacy.  
4. To evaluate whether Treg inactivation prior to vaccination against Tb, using 
several vaccines including pKUN85A: 
• Enhances the primary immune response to vaccination 
• Enhances the secondary immune response to infectious challenge 
• Enhances vaccine protective efficacy against infectious challenge 
5. To create a model to examine the role of Tregs during vaccination against Tb. 
When these studies were commenced, the role of Tregs during mycobacterial immunity 
had not been explored using an in vivo model. It was widely speculated that modulation 
of Treg activity during mycobacterial infection or vaccination could be used to enhance 
the efficacy of therapies and vaccines directed against Tb. Therefore, these studies 
formally examine an issue that has invited much interest; does Treg-mediated 
immunosuppression aid immunoevasion by Tb or inhibit the efficacy of vaccines 
directed against Tb?
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2.1 Mice 
 
Inbred C57BL/6 mice were bred and housed in a conventional animal facility at the 
Malaghan Institute of Medical Research Biomedical Research Unit, Wellington, New 
Zealand. Mice infected with M. tuberculosis or M. bovis were housed at the Animal 
Containment Facility, AgResearch Wallaceville, Upper Hutt, New Zealand. All animal 
experimental protocols used in this thesis were approved by the Victoria University of 
Wellington Animal Ethics Committee and the AgResearch Wallaceville Animal Ethics 
Committee. At the commencement of each experiment, mice were aged between 6 and 
12 weeks and mice within each experiment were age- and sex-matched. 
 
2.2 Antibody preparation and in vivo treatments 
 
2.2.1 Antibody production 
 
B cell hybridoma clones were cultured to produce mAbs in-house. The clones PC61, 
DTA-1 and 5F-1 were cultured to produce mAbs for Treg modulation and the clones 
2.4G2, 2C11 and 37.51 were cultured to produce mAbs for lymphocyte restimulation or 
staining for flow cytometry.  
One mL aliquots of the cell-lines at 2 x106 cells/mL were stored in Freezing 
Media (Appendix 8.3) in liquid nitrogen before being rapidly defrosted with 10 mL of 
37 ˚C 10 % complete Iscove’s Modified Dulbecco’s Medium (cIMDM) (Appendix 8.3) 
and grown in a FalconTM T25 tissue culture flask (BD Biosciences Labware, Bedford, 
MA, USA) until confluent. Cells were re-plated with 5 % cIMDM (Appendix 8.3) in 
several FalconTM T75 tissue culture flasks (BD Biosciences Labware) and cells were 
expanded to acquire at least 3 x107 cells.  
The 3 x107 cells were used to seed a CELLine CL1000 flask (INTEGRA 
Biosciences AG, Chur, Switzerland). The CL1000 flask consists of an upper 
compartment and a lower compartment separated by a 10 kDa semi-permeable 
membrane, which allows exchange of metabolic waste while retaining the mAb within 
the lower compartment. A silicon membrane on the bottom of the lower compartment 
permits gas exchange. Cells were suspended in 15 mL of 20 % cIMDM (Appendix 8.3) 
in the lower compartment of the flask. The upper compartment of the flask was filled 
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with 500 mL of 1 % cIMDM (Appendix 8.3). Every 2-4 days, the cells were harvested 
from the lower compartment and viable cells were counted by trypan blue exclusion 
(section 2.4.1). After viable cell counts were determined, 5 x107 cells were removed, 
volume was adjusted to 15 mL with 20 % cIMDM and these cells were used to re-seed 
the lower compartment of the flask. The 1 % cIMDM in the upper compartment was 
also replaced and the flask was incubated at 37 ˚C with 5 % CO2. 
The remaining suspension of cells in media from the lower compartment was 
centrifuged at 800 x g for 15 min to pellet cells and debris. The supernatant, containing 
mAb secreted by the hybridoma, was harvested and kept either at 4 ˚C for short-term 
storage or at -20 ˚C for long-term storage, until sufficient supernatant had been 
harvested for purification of antibodies. 
 
2.2.2 Antibody purification 
 
Once approximately 100 mL or more of supernatant had been harvested, the supernatant 
was subjected to low-pressure chromatography for mAb purification. Supernatant was 
prepared for purification by centrifuging again at 4000 x g at 4 ˚C for 30 min followed 
by filtration through a Serum 0.2 µm Acrodisc filter (Pall Life Sciences, Pall Corp., 
Cornwall, UK) to remove residual cell debris. A 5 mL Hi-TrapTM Protein G HP 
sepharose column (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) was used to 
bind antibodies and these were stored in 20 % ethanol (BDH, Poole, UK) when not in 
use. BioLogic low-pressure chromatography apparatus with a BioFrac Fraction 
Collector and LP Data View Software (all from BioRad, Hercules, CA, USA) were used 
for purification. The flow rate was set at 1.5 mL/min and the column was initially 
washed with 20 % ethanol for 10 minutes (min), followed by degassed, distilled (d)H20 
for 10 min. The UV spectrophotometer was zeroed and degassed dH20 was run for a 
further 5 min to establish a baseline zero reading. The column was washed with 
Purification Wash Buffer (Appendix 8.3) for 20 min to equilibrate the pH of the column 
to 8.0. After equilibration, supernatant was run through the column to bind the mAb to 
the column. The column was washed with purification wash buffer to remove other 
proteins present in the supernatant until absorbance readings returned to baseline. The 
antibody was eluted into 1.5 mL fractions by passing Purification Elution Buffer 
(Appendix 8.3) at pH 2.7 through the column. The 1.5 mL fractions were treated with 
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37.5 µL of Neutralisation/Stabilisation Buffer (Appendix 8.3) at pH 9.0 to neutralise the 
pH of the solution containing the mAb. 
Fractions containing mAb were identified by UV spectrophotometry at 280 nm 
and pooled fractions were dialysed in 1 L of phosphate buffered saline (PBS) (Appendix 
8.3) using a Slide-A-Lyzer 10 kDa dialysis cassette (Pierce, Rockford, IL, USA). PBS 
was changed once and the dialysed solution containing mAb was filtered using a Serum 
0.2 µm Acrodisc filter to sterilise. One mL aliquots of mAb were prepared and stored at 
-80 ˚C until use. Final mAb concentration was determined using 1:10 dilutions of 
dialysed, filtered solution with UV spectrophotometry at 280 nm and the equation 
[340]: 
Protein (mg/mL) = A280 x 0.74 (for Rat IgG) x dilution factor (10) 
 
2.2.3 In vivo antibody administration 
 
To assess the effect of Treg inactivation on acute mycobacterial infection or 
vaccination, mice received 100 µg of anti-CD25 mAb (clone PC61) in 200 µl of PBS by 
intraperitoneal (i.p.) injection to inactivate Tregs. Control mice received 100 µg of rat 
IgG (Sigma-Aldrich, St Louis, MO, USA) in 200 µl of PBS by i.p. injection. 
Inactivation was confirmed by assessing the proportion of CD4+CD25+ lymphocytes in 
peripheral blood samples by flow cytometry two days after antibody administration (see 
sections 2.4.1 and 2.4.3), unless otherwise stated. 
To assess the effect of Treg inactivation or modulation of GITR/GITRL 
signaling on chronic mycobacterial infection, mice were administered mAbs in 200 µl 
of PBS by i.p. injection at weeks 6 and 8 after infection. Mice received doses of either 
500 µg of rat IgG (Sigma-Aldrich), 100 µg of anti-CD25 mAb (clone PC61), 500 µg of 
anti-GITR (clone DTA-1), 500 µg of anti-GITRL (clone 5F-1) or both 100 µg of anti-
CD25 mAb (clone PC61) and 500 µg of anti-GITR (clone DTA-1). 
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2.3 Infections and vaccinations 
 
2.3.1 BCG intranasal infection 
 
M. bovis BCG Pasteur strain 1173P2 stocks were prepared by growing BCG in Tween 
Albumin Broth (Appendix 8.3). Logarithmically growing BCG cultures were harvested 
and pooled. Cultures were centrifuged at 5000 x g for 30 min at 4 ˚C and washed twice 
in PBS/0.05% Tween 80 (Appendix 8.3) before being resuspended in PBS/0.05% 
Tween 80. Aliquots were prepared and frozen at – 80 ˚C for future use. One aliquot was 
defrosted and ten-fold serial dilutions were plated onto Middlebrook 7H11 agar 
(Appendix 8.3) to determine CFU/mL. Colonies were counted after 2-3 weeks of 
incubation at 37 ˚C. Undiluted aliquots were also plated on blood agar and incubated for 
5 days at 37 ˚C to confirm that the batch of BCG was free from other bacterial 
contaminants. 
To prepare BCG for infections, an aliquot of M. bovis BCG Pasteur strain 
1173P2 was thawed at 4 ˚C. BCG was sonicated 3 times for 30 seconds (sec) using an 
Ultrasonic Sonicator (Unisonics Pty. Ltd., Sydney, Australia) with 1 min rests between 
sonications on ice, before dilution in PBS. To facilitate i.n. BCG infection, mice were 
anaesthetised with an i.p. injection of 1x anaesthetic (Appendix 8.3) using a dose of 2.6 
mg of xylazine and 87 mg of ketamine per kg of body weight. Anaesthetised mice were 
placed on their backs and challenged with a 50 µl inoculum containing 1 x 104 CFU of 
BCG, which was slowly pipetted onto their noses and inhaled.  
 
2.3.2 M. tuberculosis and M. bovis aerosol infections 
 
M. tuberculosis Erdman strain (originally from Prof Ian M. Orme, Colorado State 
University, CO, USA) and the M. bovis WAg201 strain [341] were grown from a low-
passage seed lot in Tween Albumin Broth [342] to early mid-log phase. Cultures were 
divided into aliquots and frozen at -70°C, until use. To infect mice by low-dose aerosol 
exposure, diluted thawed stock was administered using a Madison chamber aerosol 
generation device (University of Wisconsin, Madison, WI, USA) calibrated to deliver 
approximately 50 bacteria into the lungs. Aerosol infections, maintenance and 
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manipulation of infected mice were performed under strict isolation conditions in the 
AgResearch Wallaceville Biohazard Facility.    
 
2.3.3 BCG vaccination 
 
To vaccinate mice with BCG, an aliquot of M. bovis BCG Pasteur strain 1173P2 was 
thawed at 4 ˚C. BCG was sonicated 3 times for 30 sec using an Ultrasonic Sonicator 
with 1 min rests between sonications on ice before dilution in PBS. Mice were 
vaccinated s.c. on the left flank with 200 µl PBS containing 1 x 106 CFU of BCG. 
 
2.3.4 DNA vaccinations 
 
To vaccinate mice with pcDNA-85A, purified plasmid (section 2.6.12) was prepared in 
PBS to deliver a 100 µg dose of plasmid in 100 µL. To vaccinate mice with pKUN85A, 
purified plasmid from section 2.6.12 was prepared in PBS to deliver the indicated dose 
of plasmid in 100 µL. For experiments in chapter 4, 100, 25, 10 or 5 µg doses of 
pKUN85A were used but, for experiments in chapter 5, just a 25 µg dose of pKUN85A 
was used. Control mice were vaccinated with 100 µg of pKUNrep6 prepared as 
indicated in section 2.6.12, resuspended in 100 µL of PBS. DNA vaccines were 
delivered i.m. to the gluteal muscles of the hind limb, with approximately 50 µL of the 
total dose administered to each hind limb of the mouse. 
 
2.4 Immunological techniques 
 
2.4.1 Tissue preparation 
 
Tissues were harvested from animals at indicated times. If mice were euthanised for 
tissue harvest, this was performed primarily by cervical dislocation. If mediastinal 
lymph nodes were to be harvested, mice were euthanised by lethal anaesthetic so as to 
preserve the architecture of the pleural cavity and facilitate recovery of these lymph 
nodes. Mice were euthanised through lethal anaesthesia by i.p. administration of 1x 
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anaesthetic using a dose of 10.4 mg of xylazine and 348 mg of ketamine per kg of body 
weight. 
 
2.4.1.1 Blood 
 
Blood was harvested from ear marked mice by warming them for approximately 5 min 
under a heat lamp before restraining mice and gently cutting across the tail vein on the 
dorsal side of the tail with a sterile scalpel blade. Approximately 10 drops of blood were 
collected directly into a 1 mL aliquot of chilled Alsevers Solution (Appendix 8.3).  
Pressure was applied to the cut site and, once blood-flow was stemmed, mice were 
returned to their cages. 
 The blood samples were stored on ice until samples could be processed. Samples 
were centrifuged at 400 x g for 10 min at 4 ˚C, supernatants removed and pellets were 
washed with 3 mL of 5% cIMDM. Red blood cells were then lysed by resuspending 
pellets in 3 mL of room temperature ACT Lysis Buffer (Appendix 8.3) and incubating 
for 8 min. Samples were topped up with 10 mL of 5% cIMDM and centrifuged at 400 x 
g for 10 min at 4 ˚C. Pellets were resuspended in 200 µL of Flow Cytometry Buffer  
(Appendix 8.3) and transferred into 96-well plate format for antibody staining described 
in section 2.4.3 in preparation for flow cytometric analysis. 
 
2.4.1.2 Spleen and lymph nodes 
 
Spleens and inguinal, mediastinal or popliteal lymph nodes were harvested from 
euthanised mice with minimal attached adipose tissue, placed in chilled 5% cIMDM and 
stored on ice until samples could be processed. 
Spleens and lymph nodes were placed on FalconTM 70 µm Cell Strainers (BD 
Biosciences Labware) moistened with 5% cIMDM and cells were released by gently 
disrupting the tissues with the sterile plunger from a 2 mL syringe (BD Biosciences 
Labware). Lymph nodes from the same treatment groups were pooled at this stage as 
noted to allow sufficient cell numbers for further immunological analyses. Filters were 
washed with 15 mL of 5% cIMDM to wash cells through into 50 mL FalconTM tubes 
(BD Biosciences Labware) and tubes were centrifuged to pellet cells. 
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Lymph node cells were resuspended in 1 mL of chilled 5% cIMDM before being 
counted as described below and used in immunological analyses. Spleen cells were 
resuspended in 3 mL of room temperature ACT Lysis Buffer and incubated for 8 min to 
lyse red blood cells. Spleen samples were then topped up with 10 mL of 5% cIMDM to 
inhibit further lysis and centrifuged at 400 x g for 10 min at 4 ˚C. Spleen pellets were 
resuspended in 5 mL of chilled 5% cIMDM and filtered through FalconTM 70 µm Cell 
Strainers into 50 mL FalconTM tubes before being counted as described below and used 
in immunological analyses. 
 
2.4.1.3 Lung 
 
Lungs were harvested from euthanised mice, placed in chilled 5% cIMDM and stored 
on ice until samples could be processed. 
Lung samples were digested with collagenase to release cells. Lung tissue was 
cut into small pieces with sterile dissection scissors, placed in one well of a sterile 6 
well plate (BD Biosciences Labware) and incubated with 5 mL of freshly made Lung 
Digestion Media (Appendix 8.3) at 37 ˚C for 60 min. After incubation, cells were 
dissociated by drawing the solution up and down a sterile transfer pipette (SAMCO, San 
Fernando, CA, USA) several times. The solution was filtered through FalconTM 70 µm 
Cell Strainers into 50 mL FalconTM tubes. Lung tissue that remained in the filter was 
gently disrupted with a sterile plunger from a 2 mL syringe before the filter was washed 
with 15 mL of 5% cIMDM. 
Cells were pelleted by centrifugation at 400 x g for 10 min at 4 ˚C and 
resuspended in 15 mL of 5% cIMDM. After resuspension, 10 mL of 70% Percoll 
(Appendix 8.3) was carefully layered beneath the cell suspension to create a clear 
interface. Samples were centrifuged at 836 x g for 20 min at 4 ˚C with minimal 
deceleration and the lymphocyte fraction accumulated at the interface. Approximately 
7-10 mL containing the lymphocyte fraction was harvested from this interface and 
washed with 20 mL of 5% cIMDM. The pelleted cells were resuspended in 10 mL of 
5% cIMDM and filtered through FalconTM 70 µm Cell Strainers into 50 mL FalconTM 
tubes, before being counted as described below and used in immunological analyses. 
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2.4.1.4 Viable cell counts 
 
Viable lymphocyte counts were determined for tissues from naïve, BCG vaccinated and 
BCG infected mice by trypan blue exclusion. Aliquots of lymphocyte preparations from 
tissues were diluted initially at 1:10 in 0.4 % Trypan Blue stain (Gibco BRL) and 10 µL 
of the dilutions was applied to the side of a cell on an AC1000 Improved Neubauer 
counting chamber (Hawksley, Lancing, UK). Counting chamber cells were analysed by 
light microscopy and lymphocytes that excluded the dye were counted as viable. The 
number of lymphocytes per mL was determined by the equation: 
 
Lymphocytes per mL= (Viable count per cell / 4) x dilution factor x 104 
 
Since trypan blue exclusion requires analysis of slides outside of a Class II biological 
safety cabinet, spleen lymphocyte counts were determined for M. tuberculosis infected 
mice through approximation based on spleen weight. As the basis for approximation, 
naïve mice were culled their spleens were weighed, processed as described above and 
viable lymphocyte counts were performed by trypan blue exclusion. These cell counts 
were plotted against spleen weights and the equation for the resulting function was used 
to estimate viable lymphocyte count by spleen weight in M. tuberculosis infected mice 
(Fig. 2.1). 
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Figure 2.1: Plot of spleen weight against viable lymphocyte count from spleen cell 
preparations. 
Spleens were harvested from naïve mice and weight was determined. Spleens were 
subsequently processed and viable lymphocyte counts were determined by trypan blue 
exclusion. Viable lymphocyte counts were plotted against spleen weight and the linear 
regression analysis was performed. The equation of the resulting line of best fit was used to 
estimate viable lymphocyte counts from spleen weight during processing of M. tuberculosis 
infected spleens. 
 
2.4.2 In vitro lymphocyte restimulation 
 
After counting, lymphocyte preparations were restimulated for further immunological 
analyses, such as flow cytometry, [3H] thymidine proliferation assays or IFN-γ enzyme-
linked immuno-sorbent assays (ELISAs). 
 For flow cytometric analysis of cytokine production, cells were restimulated 
with anti-CD28 mAb (to provide co-stimulation) and mycobacterial antigen as 
indicated, or anti-CD28 mAb and anti-CD3 mAb (as a polyclonal stimulus) for a 
positive control. Anti-CD28 mAb (clone 37.51) was prepared in-house and used at 2 
µg/ml. Anti-CD3 mAb (clone 2C11) was also prepared in-house and used at 2 µg/ml. 
Mycobacterial antigens used included M. bovis culture filtrate protein (CFP, gifted by 
AgResearch Wallaceville, Upper Hutt, New Zealand) used at 10 µg/ml or purified 
antigen 85A (Ag85A, provided by Assoc Prof John T. Belilse and Dr Karen M. Dobos, 
Colorado State University, CO, USA) used at 10 µg/ml. Cells were plated at 1 x 106 
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cells per well in 150 µL in round-bottomed 96-well plates (BD Biosciences Labware) 
with 5 % cIMDM containing either anti-CD28 mAb/mycobacterial antigen or anti-
CD28 mAb/anti-CD3 mAb. Cells were incubated for approximately 16 hours before the 
addition of monensin at 20 nM for 4 hours to inhibit export of cytokine. Cells were then 
stained for flow cytometry to assess cell surface molecule expression (section 2.4.3.2) 
and cytokine production (section 2.4.3.3). 
For [3H] thymidine proliferation assays and IFN-γ ELISAs, cells were 
restimulated with either mycobacterial antigen (CFP or Ag85A, 10 µg/ml), anti-CD3 
mAb (clone 2C11, 2 µg/ml) as a positive control, or left unstimulated as a negative 
control. Cells were plated at 1 x 106 cells per well in 150 µL in flat-bottomed 96-well 
plates (BD Biosciences Labware) with 5 % cIMDM containing either mycobacterial 
antigen, anti-CD3 mAb or nothing. Samples were plated in triplicate and incubated as 
indicated in section 2.4.4 for proliferation or incubated for 72 hours before being 
prepared for storage for the IFN-γ ELISA. The 96-well plates were frozen at – 20 ˚C 
until use of the supernatants in the IFN-γ ELISA (section 2.4.5.1).  
Cells harvested after M. tuberculosis infection were plated at 2 x 106 cells per 
well in 2 mL in flat-bottomed 24-well plates (BD Biosciences Labware) with 5 % 
cIMDM containing either CFP (10 µg/ml), anti-CD3 mAb (clone 2C11, 2 µg/ml) or 
nothing. Cells were incubated for 72 hours before supernatants were harvested. 
Supernatants were filtered using low-protein binding 0.2 µm Acrodisc filters (Pall Life 
Sciences) to sterilise samples and aliquots were frozen at – 20 ˚C until use of the 
supernatants in the IFN-γ ELISA (section 2.4.5.1). Supernatant samples pre- and post-
filtration were also plated on Middlebrooks 7H11 agar and incubated for up to 5 weeks 
to confirm supernatant sterility. 
 
2.4.3 Flow cytometry 
 
Samples were prepared in round-bottom 96-well plates (BD Biosciences Labware) and 
centrifugations were performed at 400 x g for 10 min at 4 ˚C. Samples were kept on ice 
and protected from light throughout staining. 
After staining, described below, cells were prepared for flow cytometric analysis 
by washing them washed twice and then resuspending them in 200 µL of chilled Flow 
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Cytometry Buffer (Appendix 8.3). Samples were filtered through gauze into Titertube® 
Microtubes (BioRad) and stored on ice until analysis on a BD FACSortTM or BD 
FACSCaliburTM flow cytometer using BD CellQuestTM Pro software (all from BD 
Biosciences, San Jose, CA, USA). The antibodies used were all pre-titrated to an 
optimal concentration for staining, to maximise separation between populations and 
minimise background staining. 
For each restimulation condition and each tissue, non-stained and single-stained 
samples were also prepared. Single-stained samples were prepared with anti-CD4-FITC 
(clone GK1.5), anti-CD4-PE (clone GK1.5) anti-CD4-PerCP (clone RM4-5) and anti-
CD4-APC (clone RM4-5), (all from BD Biosciences Pharmingen, San Diego, CA, 
USA), which were all used 0.05 µg per 100 µL stain volume and prepared in the same 
way as the samples of interest. Non-stained samples were used to adjust the voltage 
settings and single-stained samples were used to adjust compensation settings. 
Three types of flow cytometric analysis were performed in this thesis: 
1. Screening of peripheral blood samples (section 2.4.1.1) for CD4+CD25+ 
lymphocytes after PC61 treatment prior to mycobacterial infection or 
vaccination (section 2.4.3.1).  
2. Analysis of in vitro restimulated samples from the spleen, lung or lymph 
nodes (sections 2.4.1 and 2.4.2) for IL-2 and IFN-γ production by CD4+ 
and CD8+ lymphocytes (sections 2.4.3.2 and 2.4.3.4). 
3. Analysis of unstimulated samples from the spleen, lung or blood (section 
2.4.1) for Foxp3 and CD25 expression by CD4+ lymphocytes (sections 
2.4.3.3 and 2.4.3.5). 
 
2.4.3.1 Staining after PC61 treatment 
 
To evaluate the efficacy of CD25+ Treg inactivation following PC61 treatment, 
lymphocytes from peripheral blood samples were stained with anti-CD25-FITC (clone 
7D4) and anti-CD4-PerCP (clone RM4-5) (both from BD Biosciences Pharmingen). 
The 7D4 clone of anti-CD25 mAb recognises a different epitope within the CD25 
protein from the epitope recognized by the PC61 clone [343, 344], and therefore 
should detect any CD25-expressing cells in mice that had been treated with PC61. 
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Prepared blood samples were plated in 200 µL into round-bottom 96-well plates, 
centrifuged and then washed with 200 µL of Flow Cytometry Buffer. Cells were then 
resuspended with 50 µL of Flow Cytometry Buffer containing 1 µg of purified anti-
CD16/CD32 (clone 2.4G2) and incubated for 15 min. Anti-CD16/CD32 binds to and 
blocks the FcγIII/II receptors to prevent antibody binding to these receptors and thus 
non-specific staining. After incubation 1 µg of anti-CD25-FITC and 0.05 µg of anti-
CD4-PerCP in 50 µL of Flow Cytometry Buffer was added and samples were incubated 
for 30 min.  
Cells were prepared for flow cytometry as described above and a minimum of 
40,000 events were collected in the lymphocyte gate. FlowJo Version 4.5 was used for 
data analysis. 
 
2.4.3.2 Cell surface staining for assessment of cytokine production 
 
In vitro restimulated lymphocytes from the spleen, the lymph node or lung, were first 
stained for cell surface molecules with anti-CD8-FITC (clone 53-6.7) and anti-CD4-
PerCP (clone RM4-5)  (both from BD Biosciences Pharmingen) before being fixed for 
intracellular cytokine staining.   
Restimulated samples were centrifuged and then washed with 200 µL of Flow 
Cytometry Buffer. Cells were then resuspended with 50 µL of Flow Cytometry Buffer 
containing 1 µg of purified anti-CD16/CD32 (clone 2.4G2) and incubated for 15 min. 
After incubation 0.125 µg of anti-CD8-FITC and 0.05 µg of anti-CD4-PerCP in 50 µL 
of Flow Cytometry Buffer was added and samples were incubated for 30 min in the 
dark. 
Cells were pelleted and then washed in 200 µL of PBS before being fixed with 
100 µL of 4% paraformaldehyde (Appendix 8.3) for 10 min at room temperature. After 
incubation, 100 µL of PBS was added and cells were pelleted, washed in 200 µL of 
PBS and then used for intracellular cytokine staining (section 2.4.3.4). 
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2.4.3.3 Cell surface staining for assessment of Foxp3 expression  
 
Unstimulated lymphocytes isolated from the spleen, the lymph node or blood, were first 
stained for cell surface molecules with anti-CD25-FITC (clone 7D4) and anti-CD4-
PerCP (clone RM4-5)  (both from BD Biosciences Pharmingen) before being fixed for 
Foxp3 staining.   
Samples were centrifuged and then washed with 200 µL of Flow Cytometry 
Buffer. Cells were then resuspended with 50 µL of Flow Cytometry Buffer containing 1 
µg of purified anti-CD16/CD32 (clone 2.4G2) and incubated for 15 min. After 
incubation, 1 µg of anti-CD25-FITC and 0.05 µg of anti-CD4-PerCP in 50 µL of Flow 
Cytometry Buffer was added and samples were incubated for 30 min in the dark. 
Cells were fixed prior to Foxp3 staining (section 2.4.3.5) using Fix/Perm Buffer 
composed of 1 part Fix/Perm Concentrate and 3 parts Fix/Perm Diluent (both from 
eBioscience Inc., San Diego, Ca, USA). Cells were pelleted and then washed twice in 
200 µL of PBS before being resuspended in 200 µL of Fix/Perm Buffer and incubated 
overnight at 4 ˚C. Cells were pelleted, and washed twice with 200 µL of PBS, then used 
in the Foxp3 staining protocol (section 2.4.3.5). 
 
2.4.3.4 Intracellular cytokine staining 
 
Fixed cells were permeabilised for intracellular staining by incubation with 200 µL of 
Saponin Buffer (Appendix 8.3) for 30 minutes. Cells were pelleted and resuspended in 
100 µL of Saponin Buffer containing either 0.1 µg each of anti-IL-2-PE (clone JES6-
5H4) and anti-IFN-γ-APC (clone XMG1.2), or 0.1 µg each of rat IgG2b-PE and rat 
IgG1-APC as isotype controls (all from BD Biosciences Pharmingen). Cells were 
incubated with antibodies for 30 min before being washed twice with 200 µL of 
Saponin Buffer and prepared for flow cytometric analysis as described above. A 
minimum of 100 000 events were collected from the lymphocyte gate for each sample. 
Background staining (isotype control) was subtracted from cytokine (IL-2 or IFN-γ) 
staining. FlowJo Version 4.5 was used for data analysis.  
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2.4.3.5 Foxp3 staining 
 
Fixed cells were permeabilised for Foxp3 staining by washing cells twice with 200 µL 
of 1x Permeabilisation Buffer (eBioscience Inc.). Cells were pelleted and resuspended 
in 100 µL of 1x Permeabilisation Buffer containing either 0.1 µg of anti-Foxp3-PE 
(clone FJK-16s) (eBioscience Inc.) or 0.1 µg of rat IgG2a-PE (BD Biosciences 
Pharmingen) as an isotype control. Cells were incubated with antibodies for 45 min 
before being washed twice with 200 µL of 1x Permeabilisation Buffer and being 
prepared for flow cytometric analysis as described above. A minimum of 100 000 
events were collected from the lymphocyte gate for each sample. Background staining 
(isotype control) was subtracted from Foxp3 staining. FlowJo Version 4.5 was used for 
data analysis.  
 
2.4.4 Tritiated [3H] thymidine incorporation assay 
 
After plating (section 2.4.2), cells were incubated at 37˚C for 60 hours for antigen 
stimulated or unstimulated cells, or 24 hours for anti-CD3 stimulated cells. Cells were 
observed under the inverted microscope to ensure lymphocytes were undergoing 
activation and proliferation at the times indicated above. To each well, 10 µL of 0.5 
mCi [3H] thymidine  (GE Healthcare) diluted in 5% cIMDM was added at either 60 or 
24 hours as indicated above. Cells were incubated for a further 12 hours and frozen at -
20 ˚C until they were harvested. 
 Cells from defrosted plates were harvested onto printed glass fiber filtermats 
(Wallac, Turku, Finland) using the Harvester 96® (Tomtec Inc., Hamden, CT, USA). 
Each filtermat was thoroughly dried in a microwave oven and sealed in a sample bag 
with 5 mL of Betaplate Scint Fluid (both from Wallac). Scintillation from the content of 
each well was assessed using a 1450 MicroBeta Plus liquid scintillation counter and 
MicroBeta Windows software (both from Wallac). The triplicate cultures for each 
sample were averaged to give a measurement of counts per minute (CPM) for each 
sample. 
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2.4.5 ELISAs 
 
2.4.5.1 IFN-γ  ELISA of cell culture supernatants 
 
Culture plates (section 2.4.2) were thawed, cell debris was pelleted by centrifugation at 
600 x g for 15 min and supernatants were used immediately in the BD OptEIA Mouse 
IFN-γ assay kit (BD Biosciences Pharmingen).  
Nunc-ImmunoTM 96 MicrowellTM plates (Nunc A/S, Roskilde, Denmark) were 
incubated overnight at 4 ˚C with 100 µL of anti-mouse IFN-γ capture antibody (BD 
Biosciences Pharmingen) diluted 1:250 in ELISA Coating Buffer (Appendix 8.3). Wells 
were washed 4 times with ELISA Wash Buffer (Appendix 8.3) and incubated with 200 
µL of ELISA Assay Diluent (Appendix 8.3) for 60 min to block non-specific protein 
binding.  
While the plates were blocking, the supernatant samples were prepared. 
Unstimulated cultures were prepared at neat and 1:10 dilutions, antigen (CFP or 
Ag85A) stimulated cultures were prepared at neat and 1:20 dilutions and anti-CD3 
stimulated cultures were prepared at 1:40 and 1:200 dilutions. After blocking, plates 
were washed 4 times with ELISA Wash Buffer, 100 µL of the appropriate samples or a 
two-fold serial dilution of the recombinant IFN-γ standard (BD Biosciences 
Pharmingen) were added to wells. Plates were sealed and incubated for 2 hours at room 
temperature then washed 4 times with ELISA Wash Buffer. Plates were incubated for 
60 min at room temperature with 100 µL of ELISA Assay Diluent containing 
biotinylated anti-mouse IFN-γ detection antibody diluted 1:250 and avidin-horseradish 
peroxidase (HRP) conjugate enzyme reagent diluted 1:250 (both BD Biosciences 
Pharmingen). Plates were washed 6 times with ELISA Wash Buffer and 100 µL of 
freshly prepared, room temperature TMB Substrate Reagent (BD Biosciences 
Pharmingen) was added.  
Plates were incubated until a clear gradient of colour was observed across the 
recombinant IFN-γ standard dilutions, at which point 50 µL of ELISA Stop Solution 
(Appendix 8.3) was added. After stopping the reactions, the absorbance of each well 
was read at 450 nm and converted to absorbance values to amount of IFN-γ in pg/mL 
using the standard curve plotted from the recombinant IFN-γ standard dilutions. The 
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limit of detection was 32.5 pg/mL. The triplicate cultures for each sample were 
averaged to give a mean measurement of IFN-γ production for each sample. 
 
2.4.5.2 Anti-CD25 (clone PC61) ELISA of murine serum 
 
To detect PC61 mAb in murine serum after i.p. administration, a sandwich ELISA to 
detect rat IgG in murine sera was attempted based on a protocol outlined in Loughry, et 
al. [345]. This assay ineffective as the detection limit was higher than the concentration 
of PC61 in the serum of a mouse that had just received 100 µg of the antibody. 
Therefore, a more sensitive ELISA was used to evaluate PC61 presence in murine sera 
based on a method described in Cao, et al. [346].  
  Mice were administered 100 µg of PC61 i.p. and bled at days 3, 10, 14 and 21 
after treatment. Mice were also bled immediately prior to PC61 treatment to establish a 
baseline measurement. Sera were harvested and stored at 4 ˚C until use. 
Nunc-ImmunoTM 96 MicrowellTM plates (Nunc A/S) were incubated with 12.5 
ng per well of recombinant mouse IL-2Rα (CD25) (R&D Systems Inc., Minneapolis, 
MN, USA) in 50 µL ELISA Coating Buffer. Wells were washed 5 times with ELISA 
Wash Buffer and incubated with 200 µL of ELISA Assay Diluent for 60 min at room 
temperature to block non-specific protein binding. After incubation, sera samples were 
prepared as a five-fold serial dilution from neat to 1:31250 and the PC61 standard was 
prepared as a 1:2 serial dilution from 100 ng/mL to 0.05 ng/mL. Wells were washed 5 
times with ELISA Wash Buffer and 50 µL of sera sample dilutions or PC61 standard 
dilutions were added to wells and incubated at room temperature for 2 hours. Sera 
samples were plated in duplicate at each dilution. Wells were washed 5 times with 
ELISA Wash Buffer and 50 µL of biotinylated anti-Rat IgG1 Fc domain mAb (clone 
RG11/39.4) (BD Biosciences Pharmingen) at 4 µg/mL diluted in ELISA Assay Diluent 
was added to wells and plates were incubated at room temperature for 60 min. Wells 
were washed 5 times with ELISA Wash Buffer and 50 µL of avidin-HRP conjugate 
enzyme reagent diluted 1:250 (BD Biosciences Pharmingen) was added to wells and 
plates were incubated at room temperature for 60 min. Plates were washed 10 times 
with ELISA Wash Buffer and 100 µL of freshly prepared, room temperature TMB 
Substrate Reagent (BD Biosciences Pharmingen) was added.  
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Plates were incubated in the dark at room temperature until a clear gradient of 
colour was observed across PC61 standard dilutions, at which point 50 µL of ELISA 
Stop Solution was added. After stopping the reactions, the absorbance of each well was 
read at 450 nm. Absorbance values were converted to the amount of PC61 in ng/mL 
serum using the standard curve plotted from the standard dilutions. The concentration 
was then used to estimate the amount of PC61 in circulation per mouse, assuming a 
total serum volume in a 30 g 8 week old mouse of approximately 0.945 mL, given an 
estimated total plasma volume of 3.15 mL per 100 g body weight [347]. The limit of 
detection was 0.014 µg/mouse. The mean of duplicate dilutions for each sample was 
used to determine the average amount of circulating PC61 per mouse at each time point 
assessed. 
 
2.5 Microbiological and histological techniques 
 
2.5.1 Determination of BCG bacterial load 
 
Lung or spleen samples were mechanically homogenised in 3 ml of PBS/Tween80 0.5% 
(Appendix 8.3) using an Ultra Turrax T25 Disperser (IKA Works, Selangor, Malaysia) 
and a freshly autoclaved S25N-8G dispersing tool (IKA Works). The dispersing tool 
was cleaned with PBS/Tween80 between samples, and sterilised with 70 % ethanol and 
rinsed with PBS/Tween80 between groups. Homogenised samples were used to make 
five 10-fold dilutions and 3 x 10 µL of each dilution was plated on Middlebrooks 7H11 
agar supplemented for BCG. Plates were incubated at 37˚C for 2-3 weeks before 
colonies were counted. The limit of detection for this assay was 100 CFU per organ. 
Spleen samples or lung samples early after infection that did not result in colonies were 
assigned a value of 90 CFU (just below the detection limit), rather than zero, to prevent 
exaggerating statistical differences between treatment groups.  
 
2.5.2 Determination of M. tuberculosis and M. bovis bacterial load 
 
Lung or spleen samples were mechanically homogenised in 3 ml of PBS/ Tween80 
0.5% using a Seward Stomacher 80 (Seward, Norfolk, UK). Homogenised samples 
were used to make five or two 10-fold dilutions for lungs or spleens respectively. Three 
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volumes of 10 µL for each dilution and the neat homogenate were plated on 
Middlebrooks 7H11 agar supplemented for either M. bovis or M. tuberculosis. Plates 
were incubated at 37˚C for 2-3 weeks before colonies were counted. The limit of 
detection for this assay was 100 CFU per organ. Spleen samples or lung samples early 
after infection that did not result in colonies were assigned a value of 90 CFU (just 
below the detection limit), rather than zero, to prevent exaggerating statistical 
differences between treatment groups. 
 
2.5.3 Assessment of histopathology 
 
The lower left lobe of the lung was inflated and fixed with 10% phosphate-buffered 
formalin (Sigma-Aldrich). After fixation, samples were embedded in paraffin, sectioned 
and stained with haematoxylin and eosin through the Pathology Department, Wellington 
School of Medicine, University of Otago. Samples were analysed by light microscopy 
by pathologist Professor Brett Delahunt, Department of Pathology, Wellington School 
of Medicine. Individual lung sections were graded for degree and extent of 
inflammation, and composite scores for inflammation or numbers of lung lesions per 
sample were used to evaluate the statistical significance of differences between 
treatment groups.  
 
2.6 Molecular biology techniques 
 
2.6.1 Ag85A polymerase chain reaction (PCR) 
 
PCR primers 5’Ag85A and 3’Ag85A (Sigma-Genosys, Castle Hill, Australia) 
(Appendix 8.1) were designed to amplify the Ag85A gene, using the pcDNA3-85A 
plasmid (Fig. 4.3.A) as template DNA.  
PCR amplification was performed using the AccuPrime Pfx PCR system 
(Invitrogen). PCR reactions were prepared on ice in PCR Strip Tubes (Axygen 
Scientific, Union City, CA, USA) and run in an iCycler Thermal Cycler (BioRad). The 
optimal annealing temperature (TA) was determined to be 68 ˚C by a temperature 
gradient PCR ranging from 66-70 ˚C. A suitable Mg2+ concentration was determined to 
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be 1 mM after performing PCRs ranging from 1-5 mM Mg2+. Individual 25 µL 
reactions were composed of reagents detailed in Table 2.1 and run using the PCR 
conditions detailed in Table 2.2.  PCR products were visualised by agarose gel 
electrophoresis (section 2.6.10). 
 To prepare enough Ag85A PCR product for cloning, fifteen 25 µL reactions 
were run and pooled before PCR product was purified with the UltraCleanTM PCR 
Clean-Up Kit (MO BIO, Carlsbad, CA, USA) (section 2.6.9) and quantified (section 
2.6.8).  
 
Table 2.1: Reagents used for Ag85A PCR 
Reagent Volume Added 
per Reaction 
Stock 
Concentration 
Final 
Concentration 
10x AccuPrime Pfx Reaction Mix  2.5 µL  10x 1x 
5’ Ag85A primer  0.5 µL  20 µM 0.4 µM 
3’ Ag85A primer  0.5 µL  20 µM 0.4 µM 
AccuPrime Pfx DNA polymerase 0.2 µL 2.5 U/µL 0.1 U/µL 
pcDNA3-85A template DNA 1 µL 10 pg/µL 0.4 pg/µL 
DNAase/RNAase free H20 20.3 µL   
10x AccuPrime Pfx Reaction Mix contains MgSO4 and dNTPs that, when the mix is diluted, 
reach final concentrations of 1 mM and 0.3 mM respectively. 
 
Table 2.2: PCR cycles used for Ag85A PCR 
Type of cycle Temperature Time Number of cycles 
Initial denaturation  95 ˚C  2 min 1 
Denaturation  95 ˚C 15 sec 
Annealing  68 ˚C  30 sec 
Extension 72 ˚C 60 sec 
 
30x 
Final Extension 72 ˚C 7 min 1 
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2.6.2 MluI restriction digests 
 
To create digested Ag85A stock for ligation, twelve 20 µL restriction digest reactions as 
detailed in Table 2.3 were performed. MluI restriction enzyme and H buffer (Roche 
Diagnostics GmbH, Mannheim, Germany) were used in the reactions. Digests were 
incubated at 37 ˚C for 3 hours before being purified using the UltraCleanTM PCR Clean-
Up Kit (section 2.6.9). 
 
Table 2.3: Reaction conditions for MluI digestion of Ag85A PCR product 
Reagent Volume 
Added per 
Reaction 
Stock 
Concentration 
Final 
Concentration 
Purified Ag85A PCR 
product 
17 µL 87.93 ng/µL 74.74 ng/µL 
10x SuRE/Cut H buffer 2 µL 10x 1x 
MluI  1 µL 10 U/µL 0.5 U/µL 
Total reaction volume 20 µL   
 
To create the digested pKUNrep6 (Fig. 4.3.B) stock for ligation, ten 20 µL restriction 
digest reactions as detailed in Table 2.4 were performed. MluI restriction enzyme and H 
buffer were used in the reactions. One reaction was also run with 1 µL of 
DNAase/RNAase free H20 substituted for the 1 µL of MluI to provide the undigested 
pKUNrep6 ligation control. Digest reactions and controls were incubated at 37 ˚C for 3 
hours before undergoing dephosphorylation (section 2.6.3).  
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Table 2.4: Reaction conditions for MluI digestion of pKUNrep6 
Reagent Volume 
Added per 
Reaction 
Stock 
Concentration 
Final 
Concentration 
pKUNrep6 DNA 15 µL 167.01 ng/µL 125.25 ng/µL 
10x SuRE/Cut H buffer 2 µL 10x 1x 
MluI 1 µL 10 U/µL 0.5 U/µL 
DNAase/RNAase free 
H20 
2 µL   
Total reaction volume 20 µL   
 
 
2.6.3 Dephosphorylation 
 
After a 3 hour incubation for MluI digestion of pKUNrep6, 17.5 U of calf intestinal 
alkaline phosphotase (CIAP) (Stratgene, La Jolla, CA, USA) in 1 µL was added to 9 of 
the digest reactions. One tube was not treated with CIAP to provide a phosphorylated, 
digested pKUNrep6 ligation control. Dephosphorylation reactions and controls were 
incubated at 37 ˚C for 60 min before being purified using the UltraCleanTM PCR Clean-
Up Kit (section 2.6.9). 
 
2.6.4 Ligation 
 
After the pKUNrep6 vector and Ag85A insert were prepared (sections 2.6.1-2.6.3), they 
were quantified (section 2.6.8) and ligated together using T4 DNA ligase (Invitrogen). 
To ensure a suitable ratio of pKUNrep6 vector to Ag85A insert in each reaction, pmol 
ends of both pKUNrep6 and Ag85A were determined using the following equation 
[340], where the number of base pairs (bp) for pKUNrep6 was 13481 bp and for Ag85A 
was 989 bp: 
pmol ends of dsDNA =               2 x 106 x (amount in µg of dsDNA)   
                                                   
                                               (Number of bp in dsDNA molecule) x 660 
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Ligation reactions were prepared on ice in PCR Strip Tubes and run at 14 ˚C 
overnight in an iCycler Thermal Cycler. Ligation reactions are detailed in Table 2.5.  
 
Table 2.5: Ligation Reactions and Controls 
Ratio of Insert 
to Vector 
Insert 
(Ag85A) 
Vector 
(pKUNrep6) 
T4 DNA  
Ligase 
5 x T4 DNA 
Ligase 
Buffer 
DNAase/ 
RNAase free 
H20 
Experimental ligations 
1:2 60 ƒmol 120 ƒmol 1 µL 4 µL Up to 20 µL 
1:1 60 ƒmol 60 ƒmol 1 µL 4 µL Up to 20 µL 
3:1 180 ƒmol 60 ƒmol 1 µL 4 µL Up to 20 µL 
5:1 300 ƒmol 60 ƒmol 1 µL 4 µL Up to 20 µL 
10:1 600 ƒmol 60 ƒmol 1 µL 4 µL Up to 20 µL 
Ligation controls 
0:1- no ligase 0 ƒmol 60 ƒmol 0 µL 4 µL Up to 20 µL 
0:1- using 
phosphorylated 
pKUNrep6 
0 ƒmol 60 ƒmol 1 µL 
 
4 µL Up to 20 µL 
0:1- ligase 0 ƒmol 60 ƒmol 1 µL 4 µL Up to 20 µL 
1:1- no ligase 60 ƒmol 60 ƒmol 0 µL 4 µL Up to 20 µL 
0:1- using 
undigested 
pKUNrep6 
0 ƒmol 60 ƒmol 0 µL 4 µL Up to 20 µL 
 
Ligation controls were also included to validate the experimental ligation reactions 
(Table 2.5). The ligation control with 0:1 ratio and no ligase could indicate either if 
digestion has not been complete or if dephosphorylation has not been successful and the 
plasmid has religated, although a sample of digested, dephosphorylated pKUNrep6 was 
visualised on an agarose gel prior to ligation to confirm linear conformation. The 0:1 
ratio with ligase using the phosphorylated vector would validate that the digested 
pKUNrep6 vector can be religated and enzymatic digestion has not damaged the vector 
ends. The 0:1 ratio with ligase would validate that the digested and dephosphorylated 
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pKUNrep6 vector can be religated and dephosphorylation has not damaged vector ends. 
The 1:1 ratio without ligase would give a baseline for comparison to experimental 
ligations, in case there was low-level religation of pKUNrep6 or undigested pKUNrep6 
in the vector DNA. The inclusion of undigested pKUNrep6 could indicate if the ligation 
reaction itself affects the integrity of the vector DNA but also provides a positive 
control to confirm the vector DNA confers antibiotic resistance to E coli after 
transformation. 
 
2.6.5 Transformations 
 
Transformations were performed using chemically competent MAX Efficiency® 
DH5aTM Escherichia coli (Invitrogen). Fifty µL of E. coli was thawed on wet ice for 
each transformation reaction and dispensed into pre-chilled eppendorf tubes. For 
transformations with intact pKUNrep6 DNA, 1 µL of DNA at 200 ng/µL was added to 
the thawed E. coli. For transformations using ligation reactions from section 2.6.4, 7.5 
µL of the ligation reaction was added to the thawed E coli. For transformation controls, 
one transformation reaction was left without the addition of plasmid as a negative 
control and one transformation reaction received 2.5 µl of pUC19 at 10 pg/µL as a 
positive control. After addition of DNA, transformation reactions were gently tapped, 
left on ice for 30 min and then heat-shocked by placing in a 42 ˚C waterbath for 45 sec. 
Reactions were placed on ice for 2 min before the addition of 0.45 mL of SOC media 
(Invitrogen), then incubated, shaking at 225 revolutions per minute (rpm) at 37 ˚C, for 
60 min in an InnovaTM 4200 Incubator (New Brunswick Scientific, Edison, NJ, USA).  
After incubation, 50 µL of transformation reaction was plated onto Luria Broth 
supplemented agar plates containing ampicillin (LB Amp+ agar plates) (Appendix 8.3) 
and incubated overnight at 37 ˚C. Both pKUNrep6 and pUC19 contain ampicillin 
resistance genes and colonies that grow contain the desired plasmids. Individual 
colonies were selected from transformant plates, streaked out onto a second plate and 
incubated overnight at 37 ˚C. An individual colony from the second plate was chosen, 
streaked out onto a master plate and incubated overnight at 37 ˚C. A colony from this 
transformant master plate was inoculated into 6 mL of LB Amp+ liquid culture 
(Appendix 8.3) and incubated overnight at 37 ˚C. One mL of this liquid culture was 
used to make Glycerol Stocks (Appendix 8.3) and the other 5 mL was used in the 
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Qiagen Miniprep Plasmid protocol (section 2.6.11) to provide a plasmid DNA sample. 
The transformants were then screened for the insertion of the Ag85A gene into their 
plasmids by orientation PCR (section 2.6.6), orientation restriction digest (section 2.6.7) 
and sequencing. 
 
2.6.6 Orientation PCR 
 
PCR primers 5’CS and 3’ Mid (Sigma-Genosys)(Appendix 8.1) were designed to 
amplify the sequence spanning the pKUNrep6 vector DNA into the 5’ region of the 
Ag85A gene (Fig. 4.7).  
Template DNA for each transformant was acquired by inoculating a colony from 
the transformant master plate into a 20 µL aliquot of DNAase/RNAase free H20. These 
aliquots were heated to 95 ˚C for 2-5 min, cell debris was pelleted by centrifuging at 
16000 x g for 2 min. Supernatants containing the plasmid released by cell lysis were 
transferred to fresh tubes. PCR amplification was performed using the Expand High 
FidelityPLUS PCR system (Roche Diagnostics GmbH). PCR reactions were prepared on 
ice in PCR Strip Tubes and run in an iCycler Thermal Cycler. Reactions were run with 
pKUNrep6 as template DNA or H20 instead of template DNA for negative controls, and 
pKUN85AOF (Fig. 4.3 C) as template DNA for a positive control. Reagents for 
individual 25 µL reactions are detailed in Table 2.6. Reactions were run using the 
conditions detailed in Table 2.7 before being visualised by agarose gel electrophoresis 
(section 2.6.10). 
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Table 2.6: Reagents used for Orientation PCR 
Reagent Volume Added 
per Reaction 
Stock 
Concentration 
Final 
Concentration 
5 x Expand High FidelityPLUS 
Reaction Buffer  
5 µL  5x 1x 
MgCl2 solution 2.5 µL 25 mM  2.5 mM 
dNTPs 1 µL 10 mM 400 µM 
5’ CS primer  3.125 µL  3.2 µM 0.4 µM 
3’ Mid primer  3.125 µL  3.2 µM 0.4 µM 
Expand High FidelityPLUS DNA 
polymerase 
0.25 µL 10 U/µL 0.1 U/µL 
Boiled E. coli template DNA or 
Control template DNA 
2 µL Variable or                                  
10 ng/µL 
Variable or                            
0.8 pg/µL 
DNAase/RNAase free H20 8 µL   
Total reaction volume 25 µL   
 
Table 2.7: PCR cycles used for Orientation PCR 
Type of cycle Temperature Time Number of cycles 
Initial denaturation  95 ˚C  2 min 1 
Denaturation  95 ˚C 15 sec 
Annealing  59 ˚C  30 sec 
Extension 72 ˚C 60 sec 
 
30x 
Final Extension 72 ˚C 7 min 1 
 
2.6.7 Orientation digest 
 
Orientation restriction digest reactions were performed as detailed in Table 2.8, using 
plasmid DNA prepared from transformants (section 2.6.11) and KspI and XbaI 
restriction enzymes and L buffer (Roche Diagnostics GmbH). pKUNrep6 was used as a 
negative control, and pKUN85AOF as a positive control. Digest reactions and controls 
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were incubated at 37 ˚C for 60 min before being visualised by agarose gel 
electrophoresis (section 2.6.10). 
 
Table 2.8: Reaction conditions for KspI and XbaI orientation digestion of pKUN85A 
Reagent Volume 
Added per 
Reaction 
Stock 
Concentration 
Final 
Concentration 
Template DNA 5 µL 40-400 ng/µL 2-20 ng/µL 
10x SuRE/Cut L buffer 2 µL 10x 1x 
KspI 0.2 µL 10 U/µL 0.1 U/µL 
XbaI 0.2 µL 10 U/µL 0.1 U/µL 
DNAase/RNAase free 
H20 
12.6 µL   
Total reaction volume 20 µL   
 
 
2.6.8 PicoGreen DNA quantitation 
 
Purified DNA samples, including PCR products, restriction digest products and E. coli 
plasmid extractions, were quantified using the Quant-iTTM PicoGreen® dsDNA Assay 
Kit (Invitrogen Molecular Probes, Eugene, Oregon, USA). To each well of a 96-well 
FluoroNuncTM plate (NUNC A/S), 1 µL of DNA to be quantified was added to 99 µl of 
DNAase/RNAase free H20 and 100 µL of a 1:200 dilution of PicoGreen reagent. 
Samples were incubated for 5 minutes in the dark and then quantified by measuring 
fluorescence intensity, with excitation at 480 nm and emission at 520 nm in the 
FLUOstar Optima microplate multi-detection reader (BMG Labtech GmbH, Offenburg, 
Germany). Fluorescence was measure in triplicate and amount of DNA was calculated 
by comparison with a standard curve ranging from 0.5-200 ng/µL created using 
bacteriophage lambda DNA supplied with the Quant-iTTM PicoGreen® dsDNA Assay 
Kit (Invitrogen Molecular Probes). 
 
Chapter 2 - Methods 
 
87 
2.6.9 PCR and digest product purification 
 
PCR and digests products were purified using the UltraCleanTM PCR Clean-Up Kit 
(MO BIO). Five volumes of SpinBind buffer, containing guanidine hydrochloride and 
isopropanol, were added to the pooled PCR or digest product, mixed and transferred to 
a filter unit. Filter units were centrifuged at 12000 x g for 30 sec to bind DNA in the 
solution to the filter and filtered solution was discarded. The bound DNA was washed 
twice with 300 µL of SpinClean buffer, containing ethanol, and filtered solution was 
discarded. Empty filter units were centrifuged at 16000 x g for 60 sec to remove any 
traces of SpinClean buffer. Fifty µL of DNAase/RNAase free H20 was added to the 
filter, left for 1 min and centrifuged at 16000 x g for 60 sec into a fresh eppendorf tube 
to elute the DNA. 
 
2.6.10 Agarose gel electrophoresis 
 
Agarose gel electrophoresis was used to analyse the size and integrity of PCR and 
digest products. Typically 1-10 µL of product was mixed at a 5:1 ratio of product : 
Loading Buffer (Appendix 8.3) and loaded onto the agarose gel. The gels used were 
either 2% or 1.5% for the Ag85A PCR product and orientation PCR products or 0.8% 
for pKUNrep6 and pKUN85A digest products (Appendix 8.3). Typically 4 µL of a 
DNA ladder (High Mass DNA Ladder, Low Mass DNA Ladder or 100 bp Ladder as 
appropriate for the anticipated fragment size, all from Invitrogen) was loaded to 
calculate the size of PCR or digest products. Samples were run at 80-100 V for 1-2 
hours to ensure bands of interest were separated. Gels were stained with ethidium 
bromide in dH20 (500 ng/mL) for 30 min and destained in dH20 for 10-15 min. Gels 
were visualised using a TFX-35M UV transilluminator (Gibco BRL, Gaithersburg, MD, 
USA) and the Kodak Digital Science Electrophoresis Documentation and Analysis 
System 120 (Eastman Kodak Co., Windsor, CO, USA) and fragment size was estimated 
using the Kodak Digital Science 1D program (Eastman Kodak Co.) 
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2.6.11 Qiagen Plasmid Mini-prep protocol 
 
Plasmid was amplified and purified for cloning, orientation digests and sequencing 
using the Qiagen Plasmid Mini-prep kit (Qiagen GmbH). E. coli containing the target 
plasmids were inoculated into 5 mL of LB Amp+ liquid cultures (Appendix 8.3) and 
grown for 16 hours, shaking at 225 rpm at 37 ˚C in an InnovaTM 4200 Incubator. The 
liquid cultures were centrifuged at 600 x g for 8 min to pellet the E. coli and pellets 
were frozen overnight.  
Pellets were thawed and resuspended in 0.5 mL of Buffer P1 (50 mM Tris-HCl, 
pH 8.0; 10mM EDTA; 100 µg/mL). A further 0.5 mL of Buffer P2 (200 M NaOH; 1 % 
SDS) was added and samples were inverted 6 times to lyse the cells. After incubation at 
room-temperature for 5 min, 0.5 mL of Buffer P3 was added, samples were inverted 6 
times and incubated on ice for 5 min to precipitate protein. Samples were centrifuged at 
4600 x g for 10 min to pellet protein precipitate and genomic DNA, and supernatants 
containing the plasmid DNA were applied to an equilibrated Qiagen-tip 20. The 
Qiagen-tip 20 was washed four times with 1 mL of Buffer QC before DNA was eluted 
from the Qiagen-tip 20 into a fresh 15 mL tube with 0.8 mL of Buffer QF. DNA was 
precipitated with 0.56 mL of room-temperature isopropanol (BDH) before being 
pelleted by centrifugation at 4600 x g for 60 min. The supernatant was decanted and the 
DNA pellet was washed with 1 mL of 70% ethanol (BDH) to remove excess salts and 
isopropanol. The DNA pellet was dried overnight and redissolved in 50 µL of 
DNAase/RNAase free H20, typically yielding from 2-20 µg of plasmid DNA per 
reaction. 
 
2.6.12 Qiagen Plasmid Endotoxin-Free Mega-prep protocol 
 
Plasmid was amplified and purified for protein expression and vaccination studies using 
the Qiagen Plasmid Mega-prep Endotoxin-free kit (Qiagen GmbH). E. coli containing 
the pKUN85A plasmid were inoculated into a 10 mL starter LB Amp+ liquid culture 
(Appendix 8.3) and grown for 8 hours, shaking at 225 rpm at 37 ˚C in an InnovaTM 4200 
Incubator. This starter culture was inoculated into 2 L of LB Amp+ liquid culture and 
grown for 16 hours, shaking at 225 rpm at 37 ˚C in an InnovaTM 4200 Incubator. The 
liquid culture was pelleted by centrifugation at 600 x g for 15 min and pellets were 
frozen overnight.  
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The pellet was thawed and resuspended in 55 mL of Buffer P1 (50 mM Tris-
HCl, pH 8.0; 10mM EDTA; 100 µg/mL) in a 1 L Schott bottle. A further 55 mL of 
Buffer P2 (200 M NaOH, 1 % SDS) was added and the suspension was inverted 10 
times to lyse the cells. After incubation at room temperature for 5 min, 55 mL of 4˚C 
Buffer P3 (3.0 M potassium acetate, pH 5.5) was added to precipitate protein. The 
suspension was poured into a QIAfilter Mega Cartridge and left to incubate for 10 min. 
The suspension was filtered to remove protein precipitate and genomic DNA and the 
filtrate was treated with 3.75 mL of ER buffer (isopropanol; polyethylene glycol octyl 
phenyl ether) to remove endotoxin. The suspension was applied to an equilibrated 
Qiagen-tip 2500. The Qiagen-tip 2500 was washed with 200 mL of Buffer QC (1.0 M 
NaCl; 50 mM MOPS, pH 7.0; 15% isopropanol). DNA was eluted from the Qiagen-tip 
2500 with 35 mL of Buffer QF (1.6 M NaCl; 50 mM MOPS, pH 7.0; 15% isopropanol). 
DNA was precipitated with 24.5 mL of room-temperature isopropanol before being 
pelleted by centrifugation at 4600 x g for 60 min. The supernatant was decanted and the 
DNA pellet was washed with 5 mL of 70% ethanol to remove excess salts and 
isopropanol. The DNA pellet was dried overnight and redissolved in 500 µL of 
DNAase/RNAase free H20, typically yielding from 0.7-1.5 mg of plasmid DNA per 
reaction. 
 
2.7 Detection of protein expression  
 
2.7.1 Transfection of the NIH-3T3 cell-line 
 
The NIH-3T3 cells are a continuous adherent murine fibroblast-derived cell-line [348]. 
They were selected to be target cells for transfection with pKUN85A to model protein 
expression from the construct in mammalian cells. NIH-3T3 cells were plated at 5 x 104 
cells/mL in 5% cIMDM with 2 mL per well in 6-well flat-bottom plates (BD 
Biosciences Labware) and incubated for 24 hours at 37 ˚C with 5% CO2. After 24 
hours, supernatant was aspirated and 1 mL of incomplete Iscove’s Modified Dulbecco’s 
Medium (iIMDM) (Appendix 8.3) was added per well.  
Transfection mixtures were made up for each plate. The mixture contained 564 
µL of iIMDM, 36 µl of room temperature FuGene 6 Transfection Reagent (Roche 
Diagnostics GmbH) and 15 µg of a target DNA in a 5-50 µL volume. The FuGene 
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Transfection Reagent was added directly to the iIMDM followed by the target DNA. 
Control mixtures containing FuGene or DNA only were included to test for toxic effects 
of the FuGene reagent or the target DNA respectively. A control mixture with only 
iIMDM was also included. The DNA plasmids used in transfection mixtures were 
pKUNrep6, pKUN85AOF, pcDNA3-85A and pKUN85A. One 6-well plate was used 
for each transfection mixture and, for each well in the 6-well plate, 100 µL of 
transfection mixture was gently pipetted in a dropwise circular pattern onto cells before 
the plates were returned to the incubator for 5 hours. After 5 hours, 1 mL of 10% 
cIMDM was added per well and cells were returned to the incubator for 72 hours. 
Transfected cells were then lysed and cell lysates were used for immunoprecipitation of 
the target proteins, NS-1 and Ag85A (section 2.7.2). 
 
2.7.2 Lysis of NIH-3T3 cells and immunoprecipitation of target 
proteins 
 
After 72 hours of incubation, cell culture supernatants were harvested and individual 
wells in the 6-well plate were pooled. Cells were also harvested by treatment of each 
well with 300µL of Gibco Trypsin-EDTA (Invitrogen) and wells were washed out with 
2 mL of 5% cIMDM then pooled for each 6-well plate. Cells were pelleted by 
centrifugation at 400 x g for 8 min and washed three times with 2 mL of PBS. The cell 
pellets were resuspended in 300 µL of Lysis Buffer (Appendix 8.3) and incubated at 
4˚C for 15 min. Insoluble material was pelleted by centrifugation at 12000 x g for 10 
min at 4 ˚C and solubilised material in 250 µL of the supernatants was transferred to 
fresh tubes for immunoprecipitation. 
 To the 250 µL of cell lysates, 50 µl of anti-mouse IgG beads (eBiosciences Inc.) 
was added, incubated at 4 ˚C for 30 min and centrifuged at 12000 x g for 3 min at 4 ˚C 
to pre-clear the cell lysate. Supernatants were transferred to fresh tubes and primary 
antibodies were added that corresponded to primary antibodies to be used for the 
immunodetection in section 2.15. For NS-1 blots, 25 µL of anti-NS-1 antibody was 
added and for Ag85A blots 50 µL of anti-Ag85A antibody was added. Cell lysates were 
incubated at 4 ˚C for 60 min before 50 µl of anti-mouse IgG beads (eBiosciences Inc.) 
was added. The cell lysates and beads were incubated at 4 ˚C for 60 min while gently 
rotating and centrifuged at 12000 x g for 1 min at 4 ˚C to immunoprecipitate the target 
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protein with the pelleted beads. Pellets were washed twice with 300 µL of Lysis Buffer 
and frozen until bead pellets were used for sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE), Western transfer and immunodetection of NS-1 or 
Ag85A (section 2.7.3). 
 
2.7.3 SDS-PAGE, Western transfer and immunoblotting 
 
Bead pellets were thawed and 4 µl of Sample Reducing Dye, 10 µl of LDS Loading 
Buffer and 26 µL of 1x MOPS Buffer (all from Invitrogen) were added to prepare the 
samples for electrophoresis. Samples were heated to 95 ˚C for 10 min, to denature anti-
mouse IgG antibodies and release the immunoprecipitated protein into solution, and 
centrifuged at 12000 x g for 3 min to pellet the beads. Twenty µL of the sample was 
loaded per well onto a 4-12% Bis-Tris gel (Invitrogen). Seven µL of the MultiMark 
multi-coloured standard 1x (Invitrogen) was also loaded onto the gel to estimate protein 
molecular weight. The gel was run using the X-Cell Sure-LockTM Electrophoresis Cell 
System (Invitrogen), with 1x MOPS Running Buffer (Invitrogen) in the outer reservoir 
and 1x MOPS Running Buffer and Antioxidant (Invitrogen) in the inner reservoir. The 
gel was run at 200 V for 50 min, equilibrated in 1x Western Transfer Buffer (Appendix 
8.3).  
The gel was then assembled into the X-Cell IITM Blot Module (Invitrogen) and 
transferred onto a nitrocellulose membrane (BioRad). The Western transfer was run 
using 1x Western Transfer Buffer at 100V for 75 min. After transfer, protein was 
visualised on the nitrocellulose membrane by brief incubation with 0.5% Ponceau-S 
solution (Sigma-Aldrich) followed by destain in water, to ensure effective transfer of 
protein and even loading of samples. 
The membrane was blocked by incubation in 15 mL of Western Blocking 
Solution (Appendix 8.3) for 60 min at room temperature while gently rocking. Blocking 
solution was rinsed off the membrane with Tris Buffered Saline (TBS) (Appendix 8.3) 
and 5 mL of primary antibody diluted in TBS was added. For NS-1 blots, the 
supernatant containing anti-NS-1 antibody was used at a 1:50 dilution. For Ag85A 
blots, the supernatant containing anti-Ag85A antibody was used neat. The membrane 
was incubated in primary antibody overnight at 4 ˚C on a rocker, then washed five times 
with 15 mL of TBS for 5 min. Five mL of secondary anti-native mouse IgG-HRP 
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antibody (eBiosciences Inc.) diluted in TBS was added. For NS-1 blots and Ag85A 
blots, the secondary anti-native mouse IgG-HRP antibody was used at a 1:1000 dilution. 
Proteins bands were detected with addition of 2 mL of SuperSignal® West Pico 
ChemiLuminescent substrate (Pierce) and exposure of the membrane to Kodak 
EKTASCAN B/RA film (Eastman Kodak Co.). Film was exposed from 1 min to 8 
hours depending of the sensitivity of the assay and developed in a Kodak X-OMAT 
1000 processor (Eastman Kodak Co.). 
 
2.8 Statistical analysis 
 
Normal distribution of variation within in vivo experimental groups was not assumed 
and therefore statistical significance between treatment groups or between experimental 
time points was determined by the non-parametric two-tailed Mann-Whitney test. 
Differences that gave p values ≤ 0.05 were considered statistically significant. For flow 
cytometric, [3H] thymidine proliferation, ELISA and pathology scoring data, graphs 
represent mean ± the standard error of the mean (SEM). For data assessing bacterial 
numbers in the tissues, graphs represent geometric mean ± the standard error of the 
geometric mean (GEM).
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3.1 Introduction 
 
M. tuberculosis has evolved numerous ways to subvert the immune response and 
promote its survival in the infected host (section 1.2.5). A further way to escape host 
immune responses, exploited by many infectious organisms, is to enhance of Treg 
function in the infected host [305, 334, 335, 349]. Therefore, I chose to investigate 
whether M. tuberculosis also exploits the host natural Treg population to suppress the 
immune response and thereby enhance survival of M. tuberculosis in the infected host. 
 
3.1.1 Tools for in vivo study of Tregs 
 
Before it could be examined whether natural Tregs suppressed the host immune 
response to M. tuberculosis infection, a protocol for manipulating natural Treg activity 
in vivo had to be selected and optimised. Natural Tregs, conventionally defined as 
CD4+CD25+ T cells in a naïve mouse [261], can be functionally inactivated in vivo by 
the administration of anti-CD25 mAbs [350]. Two anti-CD25 mAbs from different 
clones have been used in vivo: PC61 and 7D4. PC61 is a rat anti-mouse CD25 IgG1 
antibody and 7D4 is a rat anti-mouse CD25 IgM antibody. Each mAb targets distinct 
epitopes on CD25 [343, 344]. Different doses of both antibodies have been used in 
different studies, ranging from 125 µg to 1 mg per mouse [333, 351, 352]. In vivo 
administration of either antibody has been shown to decrease the number of 
CD4+CD25+ T cells in peripheral blood and tissues as detected by flow cytometry, and 
promote autoimmune disease [350].  
Both PC61 and 7D4 were initially regarded as depleting antibodies, but recent 
studies suggest that 7D4 predominantly inactivates rather than depletes Tregs [353]. 
The mechanism of action of PC61 seems to be a combination of depleting and 
inactivating Tregs [352] and the implications of these studies on the results presented in 
this chapter will be addressed in the discussion. CD25 is also transiently upregulated on 
activated T cells [354] and it has been suggested that anti-CD25 mAbs administered 
during an active immune response could also target recently activated CD4+CD25+ 
effector T cells for depletion or inactivation.  
GITR is another cell surface marker upregulated on both Tregs and activated 
effector T cells and GITR, with its ligand GITRL, are thought to play a key role in 
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modulating Treg activity [355]. The current model of GITR/GITRL signalling suggests 
that when GITRL on an APC interacts with GITR on a responder T cell, it delivers a co-
stimulatory signal to the responder T cell that promotes proliferation and makes it 
initially refractory to the suppressive effects of Tregs [356].  
Two antibodies are used to modulate the GITR/GITRL signalling pathway: 
DTA-1 and 5F-1. DTA-1 is a rat anti-mouse GITR antibody and when used in vitro, it 
abrogates the ability of CD4+CD25+ Tregs to suppress the proliferation of naïve 
CD4+CD25− T cells upon TCR stimulation [357]. Therefore, DTA-1 is thought to be an 
agonistic antibody that signals through GITR to make responder T cells refractory to the 
suppressive effects of Tregs [355]. 5F-1 is an anti-GITRL antibody and when used in 
vitro, it enhances suppression of CD4+CD25- T cells by CD4+CD25+ Tregs [356]. Thus, 
5F-1 is thought to be an antagonistic antibody that binds to GITRL on APCs and 
prevents it from signalling through GITR on responder T cells [355]. 
Therefore, tools like anti-CD25, -GITR and -GITRL mAbs can be used to 
identify and in some cases manipulate Tregs in vivo. However, there are some 
limitations inherent in their use and these limitations will be outlined and discussed 
during the course of this chapter. 
 
3.1.2 T regulatory cells and infections 
 
The survival of many infectious organisms in the host can improve as a result of natural 
Treg action [305, 330, 333, 334]. Antibody-mediated inactivation of Tregs, or 
interference with their proposed mechanisms of action, can impact greatly on the degree 
of tissue damage, pathogen load and the development of immunological memory. 
Infection of mice with L. major was the first well-defined example of Treg involvement 
in the maintenance of a chronic infection [305].  
L. major is a protozoal organism that establishes an intracellular infection of 
macrophages in the skin. While the infection in C57BL/6 mice is controlled by a Th1 
immune response, the protozoa are not entirely eliminated. CD4+CD25+ Tregs are 
present in these chronic skin lesions and are essential to suppress the local immune 
response and permit pathogen persistence [305]. In addition, a proposed Treg 
suppressive mechanism is the secretion of IL-10, and blockade of the IL-10 receptor 
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enhanced the immune response, resulting in complete clearance of L. major from the 
site of infection [305, 358]. However, while it has been shown that CD4+CD25+Foxp3+ 
Tregs are found in L. major lesions and can produce IL-10 [305, 359], the bulk of IL-10 
is produced by CD4+CD25−Foxp3− effector T cells that may co-produce cytokines such 
as IFN-γ [360, 361]. Therefore, the current model for Treg involvement in L. major 
infection is that CD4+CD25+Foxp3+ Tregs located in the lesion suppress the effector 
immune response by directing CD4+CD25−Foxp3− effector T cells to produce IL-10. 
Prolonged or increased disease as a result of Treg activity has also been 
demonstrated for other infectious agents including Plasmodium berghei [333], 
Plasmodium yoelii [334], Litomosoides sigmodontis [330], and hepatitis C virus [349]. 
Treatment with anti-CD25 mAbs prior to infection can result in increased 
immunopathology in some models [331, 362] but can also result in increased pathogen 
clearance [330, 333, 334]. CD4+CD25+Foxp3+ Treg activity is often associated with 
chronic infections and it has been hypothesised that chronic infectious agents in 
particular can promote Treg activation, thereby hijacking this host immune mechanism 
to suppress the immune response and permit long-term immunoevasion.  
Immunosuppression mediated by Tregs can increase pathogen load during 
infection, but it can also benefit the host by preventing over-activation of effector 
immune mechanisms and immunopathology [331, 332]. Helicobacter pylori infection 
can cause chronic gastritis and natural Tregs have been shown to prevent the 
development of this pathology in a murine model [332]. Athymic nude mice were 
reconstituted with total lymphocytes from C57BL/6 or lymphocytes depleted of CD25+ 
cells, and then infected with H. pylori. Mice that received lymphocytes depleted of 
natural CD4+CD25+ Tregs had increased IFN-γ responses to H. pylori antigens and 
reduced H. pylori colonisation of the gut compared to mice that received total 
lymphocytes. However, the mice that received lymphocytes depleted of natural 
CD4+CD25+ Tregs also had earlier onset and enhanced severity of gastritis compared to 
mice that received total lymphocytes. Enhanced immunopathology with depletion of 
Tregs has been observed with other infections such as ocular lesion formation in herpes 
simplex virus (HSV)-1 infection [331].  
Therefore, suppression by Tregs during an infection can be detrimental to the 
host by increasing pathogen load, and beneficial to the pathogen by permitting its 
persistence. However, suppression by Tregs during an infection can also benefit the host 
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by preventing either over-activation of the immune response or suppressing a persistent 
immune response, both of which could cause host tissue immunopathology. 
 
3.1.3 T regulatory cells and Tuberculosis 
 
During early studies of suppressor T cells, it was observed that PBMCs from human 
subjects that were incubated with BCG in vitro acquired a suppressive phenotype [363]. 
These cells were CD4+, sensitive to irradiation and their suppressive phenotype enabled 
them to inhibit proliferation of fresh PBMCs from human subjects corresponding with a 
decrease in IL-2 production [363, 364]. Subsequently, the concept of suppressor T cells 
became unfavoured; as did the idea that a suppressive lymphocyte subset could regulate 
immune responses to mycobacteria. 
However, more recent studies of human Tb patients suggest that a suppressive 
lymphocyte subset could inhibit the immune response during M. tuberculosis infection. 
A Cambodian study revealed a subset of chronically infected patients who were 
unresponsive to the Mantoux skin test [365]. Lymphocytes from these patients 
proliferated poorly in response to in vitro stimulation with mycobacterial antigen, and 
had decreased levels of IL-2 and enhanced IL-10 secretion. Since Tregs can secrete IL-
10 and inhibit lymphocyte proliferation, these observations are consistent with the 
proposed mechanism and effects of Tregs. Furthermore, studies have demonstrated that 
patients with active M. tuberculosis infections have increased proportions of 
CD4+CD25+ [366, 367] and CD4+CD25+Foxp3+ Tregs [368-371] in their PBMCs and 
disease sites compared to uninfected and, in some studies, latently infected individuals. 
Depletion of CD25+ lymphocytes from PBMC samples prior to in vitro restimulation 
with mycobacterial antigen led to increased IFN-γ production [366, 367, 372]. 
However, the addition of IL-10 or TGF-β neutralising antibodies to in vitro 
restimulations did not affect IFN-γ production [372]. This suggests that a CD25+ 
leukocyte population is responsible for suppression of IFN-γ production during active 
Tb infection via IL-10- and soluble TGF-β-independent mechanisms. 
If Tregs suppressed the immune response during active Tb infection, it had been 
speculated that depletion of Tregs in vivo would relieve this suppression and result in 
better control or resolution of the infection [373]. Human Tb studies demonstrated 
increased IFN-γ production in vitro by PBMCs depleted of CD25+ leukocytes, but the 
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effect of Tregs in vivo on bacterial numbers in tissue had not been explored. 
Additionally, excess IFN-γ production can be damaging and enhanced IFN-γ production 
in the absence of Tregs could enhance lung pathology. Therefore, it was unresolved as 
to whether the increased numbers of Tregs observed in PBMCs of Tb patients affected 
outcomes of Tb infection, such as bacterial numbers in the lung or tissue pathology. In 
order to address these questions, I employed in vivo PC61 mAb treatment to inactivate 
Tregs in a murine model prior to mycobacterial infection and evaluated the ensuing 
immune responses and protection from infection. 
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3.2 Aims 
 
The results presented in this chapter aimed to assess whether natural Tregs inhibit the 
acute response to mycobacterial infection and facilitate mycobacterial survival.  
Given the impact of Tregs during other infections, I hypothesised that 
inactivation of CD4+CD25+ Tregs prior to mycobacterial infection would increase the 
acute immune response and decrease bacterial numbers in the tissues, but could cause 
increased immunopathology in the lung. 
To test this hypothesis, CD4+CD25+ Tregs were inactivated in the C57BL/6 
murine model of Tb infection through administration of the anti-CD25 mAb (PC61) 
prior to infection with mycobacteria. Thereafter, the immune response and outcomes of 
infection, such as bacterial numbers in tissues and lung pathology, were assessed. My 
main objectives were to: 
• Optimise and characterise in vivo inactivation of CD4+CD25+ Tregs by 
administration of PC61. 
• Characterise the acute immune response to mycobacterial infection after 
inactivation of CD4+CD25+ Tregs. 
• Characterise the outcomes of mycobacterial infection after inactivation of 
CD4+CD25+ Tregs, such as tissue bacterial numbers and lung pathology. 
These outcomes were assessed using several mycobacterial infections: BCG, M. bovis 
and M. tuberculosis. Modulation of Treg activity during the chronic phase of infection 
was also explored, as Tregs are particularly relevant in other chronic infections for 
promoting pathogen persistence. 
Results from this chapter were published as the first assessment of 
immunosuppression by natural Tregs in an in vivo model of Tb [374]. 
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3.3 Results 
 
3.3.1 Treg inactivation in the lung and other tissues 
 
In order to set up an in vivo model assessing natural Treg-mediated suppression during 
mycobacterial infection, an appropriate dose of the anti-CD25 mAb, PC61, was chosen. 
Published studies have used 1 mg [351], 200 µg [352] and 125 µg [333] doses of PC61 
per mouse.  A lower 100 µg dose of PC61 per mouse had been used to inactivate Tregs 
in vivo (personal communication, R.S. McHugh) and was found to be sufficient to 
inactivate Tregs (Figs. 3.1-3.4). This lower dose of PC61 was selected with the aim of 
minimising persistence of the antibody in vivo, to minimise any effect of PC61 on 
activated effector T cells that could transiently express CD25 [354] after mycobacterial 
infection. 
Before it could be assessed whether natural Tregs suppress immune responses 
and bacterial clearance during mycobacterial infection, the process of inactivating Tregs 
prior to infection had to be validated. The route of administration of PC61 needed to be 
optimised and Treg inactivation had to be assessed in lymphoid and non-lymphoid 
tissues. 
 Two routes of administration for PC61 antibody were compared to determine 
how to most effectively inactivate CD4+CD25+ Tregs in the lung tissue, since the lung 
is the primary site of mycobacterial infection. Administration of PC61 i.p. is routinely 
used because the antibody enters the lymphatics and venous drainage, enabling broad 
distribution through multiple tissues. Administration of PC61 i.n. would deliver the 
antibody directly to the lung tissue, which is the primary site of pulmonary 
mycobacterial infection.  
To determine the most effective route of administration, PC61 was administered 
i.p., i.n. or both i.p. and i.n. CD4+CD25+Foxp3+ Treg presence in the lung tissue was 
evaluated by flow cytometry two days later (Fig. 3.1 A). When lymphocytes were 
stained for CD25 expression in preparation for flow cytometry, the anti-CD25 mAb 
clone 7D4 was used. The 7D4 clone recognises a different epitope within the CD25 
protein to the epitope that PC61 recognises [343, 344] and thereby should minimise 
epitope masking when labeling cells from mice treated with PC61. 
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Figure 3.1: Optimisation of the route of PC61 administration  
Mice were treated with either PBS, 100 µg of PC61 in 200 µL of PBS i.p., 100 µg of PC61 in 
50 µL of PBS i.n., or 50 µg of PC61 in 200 µL of PBS i.p. as well as 50 µg of PC61 in 50 µL of 
PBS i.n. Two days later, lung lymphocytes were isolated and CD4+CD25+Foxp3+ T cells were 
identified by flow cytometry. A) Sample flow cytometry plots showing lymphocyte gating, CD4 
gating and CD25 (using anti-CD25 mAb clone 7D4) and Foxp3 staining of CD4+ gated 
lymphocytes from lungs of mice treated with PBS or PC61 i.p. B) Number of 
CD4+CD25+Foxp3+ T cells in the lung after the different PC61 administration routes. Bars 
represent mean values ± SEM. Five animals were analysed per treatment group. Results 
represent one experiment. 
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All routes of administration resulted in significant but similar reductions in the average 
number of CD4+CD25+Foxp3+ Tregs in the lung (Fig 3.1 B). However, i.n. 
administration of PC61 increased the variation in CD4+CD25+ Foxp3+ Treg numbers in 
the lung as detectable by flow cytometry (Fig 3.1 B). The cause of variation was not 
assessed but could be due to loss of antibody during i.n. administration, as some 
antibody solution could enter the oesophagus rather than the trachea and the lung. 
Regardless of the cause of variation associated with i.n. PC61 administration, i.p. 
administration was chosen as the most consistent way to inactivate natural Tregs in vivo 
in the lung. 
While i.p. administration of PC61 was found to effectively reduce numbers of 
CD4+CD25+Foxp3+ Tregs in the lung, the ability of PC61 to inactivate CD4+CD25+ 
Tregs across different tissues remained to be assessed. Mice were treated with either 
PC61 or control rat IgG antibody and percentages of Tregs were evaluated in several 
tissues by flow cytometry 3 days later. The percentages of Tregs were compared in the 
blood, the spleen to represent lymphoid tissue and the lung to represent a peripheral 
tissue and the primary site of mycobacterial infection (Fig. 3.2).  
The percentage of CD4+ lymphocytes that were CD25+ was significantly 
reduced in all tissues in PC61 treated mice compared to control treated mice: a 74% 
reduction in the blood, a 70% reduction in the spleen and a 61% reduction in the lung 
(Fig. 3.2 A). The presence of Foxp3+ lymphocytes was also evaluated by flow 
cytometry. The percentage of CD4+ lymphocytes that were CD25+ and Foxp3+ was also 
significantly reduced in all tissues in PC61 treated mice compared to control treated 
mice: an 89% reduction in the blood, a 91% reduction in the spleen and a 93% reduction 
in the lung. The reduction in CD4+CD25+Foxp3+ lymphocytes was more pronounced 
than for total CD4+CD25+ lymphocytes, suggesting that PC61 targets the Foxp3+ Treg 
subset more effectively within the CD4+CD25+ population (Fig. 3.2 B). Unsurprisingly, 
since PC61 targets the CD25 surface molecule, there was no significant difference in 
the percentage of CD4+ lymphocytes that were CD25− and Foxp3+ in any tissue 
analysed (Fig. 3.2 C). Of note, CD4+CD25−Foxp3+ lymphocytes made up a higher 
proportion of the CD4+ lymphocyte population in tissues such as the spleen or lung than 
in the blood (Fig. 3.2 C) and it is important to note that these cells, which possess Treg 
function [282], were still present after PC61 treatment.
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Figure 3.2: Treg inactivation in the blood, spleen and lung after PC61 treatment 
Mice were treated with PBS (filled bars) or 100 µg of PC61 (open bars) i.p. Three days later, 
lymphocytes were isolated from the peripheral blood, spleen and lung, counted and stained for 
CD4, CD25 (using anti-CD25 mAb clone 7D4) and Foxp3. Samples were analysed by flow 
cytometry for the percentage of CD4+ lymphocytes that were A) CD25+, B) CD25+Foxp3+ and 
C) CD25−Foxp3+. Bars represent mean values ± SEM. Five animals were analysed per 
treatment group. Results are representative of two replicate experiments. Treatment groups were 
compared using the two-tailed Mann Whitney test; NS indicates p > 0.05, ** indicates p ≤ 0.01. 
Results are representative of two replicate experiments. 
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3.3.2 Repopulation by Tregs after PC61 administration 
 
After PC61 treatment, CD4+CD25+Foxp3+ lymphocytes as detected by flow cytometry 
are dramatically reduced. However, CD4+CD25+ Foxp3+ Tregs eventually repopulate 
the periphery, either after homeostatic proliferation, expression of CD25 by 
CD4+CD25−Foxp3+ Tregs or after reconstitution from the thymus. To assess the effect 
of Tregs on mycobacterial infection, CD4+CD25+ Tregs had to remain inactivated after 
PC61 treatment during the course of the infection. Therefore, Treg repopulation in the 
periphery after PC61 treatment was followed.  
Mice were treated with either PC61 or control rat IgG antibody and peripheral 
blood samples were analysed for the presence of CD4+CD25+ Tregs by flow cytometry 
up to day 56 after initial antibody treatment. Foxp3 was not assessed, as an anti-Foxp3 
mAb for flow cytometry was not commercially available at the time these experiments 
were conducted. The mean percentage of CD4+ lymphocytes that were CD25+ was 
significantly reduced in peripheral blood samples for up to 29 days after PC61 treatment 
(Fig. 3.3 A). From day 23 after PC61 treatment, some mice within the PC61 treated 
group exhibited higher percentages of Tregs compared to earlier time points, such as 
day 5 after PC61 treatment (Fig. 3.3 B/C). This led to increased variation in percentages 
of Tregs within the PC61 treated group from day 23 (Fig. 3.3 A) and indicated that mice 
began repopulation of the Treg lymphocyte compartment from around day 23 after 
PC61 treatment. 
 Since Treg repopulation of the periphery may be altered by homeostatic cues, 
such as cytokine release during an active immune response, Treg repopulation in 
peripheral blood during mycobacterial infection was also followed.  
Mice were treated with PC61 or control rat IgG antibody and infected with BCG 
i.n. 3 days later. Peripheral blood samples were taken up to 56 days after treatment and 
samples were analysed for the presence of CD4+CD25+ lymphocytes by flow 
cytometry. The mean percentage of CD4+ lymphocytes that were CD25+ was 
significantly reduced in peripheral blood samples for up to 29 days after PC61 treatment 
compared to control treated mice (Fig. 3.3 A). Similar to Treg repopulation observed in 
the naïve mouse, mice within the PC61 treated group infected with BCG began to 
exhibit increased variation from day 23 after treatment (Fig. 3.3 A/B/C), indicating that 
Treg repopulation also began in these mice around day 23.
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Figure 3.3: Treg repopulation in peripheral blood of naïve or mycobacteria-infected mice 
Groups of mice were administered either 100 µg of rat IgG (filled symbols) or 100 µg of PC61 
(empty symbols) i.p. In addition, groups of mice were either mock infected with PBS (squares) 
or infected with BCG (circles) i.n. three days (dashed line) after antibody treatment. Treg 
repopulation of peripheral blood was followed up to day 56. Peripheral blood samples were 
analysed for the presence of CD4+CD25+ lymphocytes by flow cytometry. For surface staining 
of CD25, the anti-CD25 mAb clone 7D4 was used. A) CD4+CD25+ repopulation in peripheral 
blood. Symbols represent mean values ± SEM. CD4+CD25+ lymphocytes were significantly 
reduced in PC61 treated mice compared to control treated mice until day 29 after PC61 
treatment in both infected and uninfected mice. Scatter plots of the percent of CD4+ 
lymphocytes that were CD25+ at B) day 5 and C) day 23 after PC61 treatment. Symbols 
represent percentages from individual mice and lines represent mean values for each treatment 
group. Five animals were analysed per treatment group at each time point. Treatment groups 
were compared using the two-tailed Mann Whitney test; ** indicates p ≤ 0.01. Results represent 
one experiment.
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In the previous experiments, Treg repopulation was monitored in the peripheral blood 
but Treg repopulation may be different in the periphery, as Tregs could be recruited into 
sites of active inflammation. In order to address this issue, mice were treated with PC61 
or control rat IgG antibody and infected 3 days later with BCG i.n. (Fig. 3.4 A) or M. 
tuberculosis by aerosol (Fig. 3.4 B). Lung lymphocytes were analysed for the presence 
of CD4+CD25+Foxp3+ lymphocytes during early infection by flow cytometry. Numbers 
of CD4+CD25+Foxp3+ lymphocytes were significantly reduced in the lung in PC61 
treated mice compared to control treated mice up to day 24 after antibody treatment for 
BCG infection (Fig. 3.4 A) and day 17 after antibody treatment for M. tuberculosis 
infection (Fig. 3.4 B). 
 At the outset of these experiments, a low dose of PC61 mAb was chosen in 
order to effectively inactivate Tregs but minimise antibody persistence in vivo. There 
was speculation that, if anti-CD25 mAbs persist in vivo, they could interfere with 
effector T cell responses, as recently activated effector T cells transiently upregulate 
CD25 [354]. The persistence of PC61 in vivo after a 100 µg dose had not been 
documented.  
To assess the persistence of the PC61 mAb in circulation in vivo, mice were 
treated with PC61 and serum was harvested immediately prior to PC61 treatment and at 
days 3, 10, 14, and 21 after treatment. Serum was tested by ELISA to assess the serum 
concentration of PC61 and this was used to estimate the total amount of PC61 per 
mouse in circulation at each time point. Mice were treated with a 100 µg dose of PC61 
mAb and the limit of detection for the ELISA was equivalent to 0.014 µg of PC61 per 
mouse. At day 3 after PC61 treatment, the mean amount of PC61 detected per mouse 
was 13.4 µg (Fig. 3.5). By day 10, this had dropped to 5 µg per mouse and by days 14 
and 21 the amount of PC61 per mouse was very low and usually below the limit of 
detection for the ELISA (Fig. 3.5). Therefore, after a 100 µg dose of PC61, the antibody 
was detectable in circulation up to day 10 after administration but was generally 
undetectable by day 14 after administration. PC61 could potentially affect activation of 
effector T cells up to 14 days after PC61 administration and the implications of this for 
the results presented in this thesis are outlined in section 3.4.3. 
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Figure 3.4: Treg repopulation in the lung after mycobacterial infection 
Mice were administered 100 µg of rat IgG (filled circles) or 100 µg of PC61 (empty circles) i.p. 
and infected i.n. with BCG or infected with M. tuberculosis by aerosol three days (dashed line) 
after antibody treatment. Lung lymphocytes were isolated and analysed for the presence of 
CD4+CD25+Foxp3+ lymphocytes by flow cytometry and Treg influx to the lungs was followed. 
Surface staining for CD25 used the anti-CD25 mAb clone 7D4. The number of 
CD4+CD25+Foxp3+ lymphocytes in the lung during A) BCG infection or B) M. tuberculosis 
infection. Symbols represent mean values ± SEM, and some symbols obscure error bars. Four to 
five animals were analysed per treatment group at each time point. Treatment groups were 
compared using the two-tailed Mann Whitney test and there were significant differences at all 
time points; ** indicates p ≤ 0.01. Results represent single experiements. 
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Figure 3.5: Persistence of PC61 mAb in circulation 
Mice were administered 100 µg of PC61 i.p. and serum was harvested immediately prior to 
treatment, and at days 3, 10, 14 and 21 after PC61 administration. Serum was then used in an 
ELISA to assess the amount of PC61 per mouse after antibody treatment.  The limit of detection 
for this assay was 0.014 µg per mouse. Sera collected from mice prior to PC61 treatment were 
below this limit of detection. Symbols represent mean values ± SEM. Five to ten animals were 
analysed at each time point. Results are representative of one experiment. 
 
 
In conclusion, Tregs repopulated the periphery from day 23 after PC61 treatment, 
regardless of whether or not there was a concurrent mycobacterial infection. The acute 
phase of the immune response to mycobacterial infection in the C57BL/6 murine model 
extends up to 28 days after infection (section 1.2.7). CD4+CD25+ Tregs were reduced as 
a result of PC61 treatment for this period of time and reduced in both the peripheral 
blood and the lung. Therefore, this model can be used to successfully reduce 
CD4+CD25+ Treg numbers during acute mycobacterial infection, when initial cellular 
proliferation occurs in the draining lymphoid tissue and cytokine producing 
lymphocytes initially migrate to affected tissues. However, it is important to note that 
after PC61 treatment, antibody can persist in circulation for up to 14 days and the effect 
of PC61 on an active immune response is not well defined. 
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3.3.3 Treg influx to the lung after mycobacterial infection 
 
Tregs can mediate suppression of other leukocytes in the draining lymph node, by 
suppressing proliferation and lymphocyte activation, or in peripheral tissues, by 
suppressing cytokine production and other effector cell functions. Therefore, 
lymphocyte populations in the lung during mycobacterial infection were evaluated to 
monitor Treg numbers and determine their proportion relative to total CD4+ T cells. 
 Mice were infected with BCG i.n. or M. tuberculosis by aerosol and lung 
lymphocytes were analysed for the presence of CD4+CD25+Foxp3+ Tregs and total 
CD4+ lymphocytes over the early course of infection. During both BCG and M. 
tuberculosis pulmonary infections, the number of CD4+CD25+Foxp3+ Tregs increased 
significantly in the lung over the early course of mycobacterial infection compared to 
immediately prior to infection (Fig. 3.6). This increase occurred in parallel with an 
accumulation of total CD4+ lymphocytes during both BCG infection (Fig. 3.6 A) and M. 
tuberculosis infection (Fig. 3.6 B).  
This illustrated that CD4+CD25+Foxp3+ Tregs accumulated in mycobacteria-
infected lungs but suggests Tregs accumulated with similar kinetics to total CD4+ T 
cells and were present in the lung at the same time as other CD4+ T cells.  
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Figure 3.6: Comparison of Treg and total CD4+ T cell influx to the lung tissue after 
mycobacterial infection 
Mice were infected A) i.n. with BCG or B) by aerosol with M. tuberculosis three days after 
treatment with rat IgG. Lung lymphocytes were isolated and analysed for the presence of 
CD4+CD25+Foxp3+ lymphocytes (black circles) and total CD4+ lymphocytes (grey circles) by 
flow cytometry. Symbols represent mean values ± SEM, and some symbols obscure error bars. 
Four to five animals were analysed per treatment group at each time point.  Numbers of 
CD4+CD25+Foxp3+ lymphocytes at time points indicated were compared to day 0, immediately 
prior to infection, using the two-tailed Mann Whitney test; * indicates p ≤ 0.05, ** indicates p ≤ 
0.01. Results represent single experiments. 
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3.3.4 Design of experimental methodology 
 
The results outlined above demonstrate that PC61 treatment effectively inactivates 
natural Tregs in the peripheral blood, lymphoid tissue and peripheral tissue, and that 
repopulation in the blood and peripheral tissues does not begin until around day 23 after 
PC61 treatment, even in the presence of an active infection. Based on the results 
outlined above, an experimental protocol was designed to evaluate whether natural 
CD4+CD25+ Tregs suppress the acute phase of the immune response to mycobacterial 
infection, resulting in increased tissue bacterial numbers but diminished tissue 
pathology (Fig. 3.7).  
Mice were administered PC61 i.p. and, two days later, peripheral blood samples 
were taken to confirm inactivation of Tregs (Fig. 3.7 A). Surface staining for CD25 
expression in these samples used the anti-CD25 mAb clone 7D4. Treg inactivation, as 
assessed by flow cytometry, was consistent in all mice that were administered PC61 
across all experiments (data not shown). The following day, mice were infected with 
mycobacteria to initiate a pulmonary infection and samples were taken during the 
course of the infection to assess immune responses, tissue bacterial numbers and 
pulmonary inflammation (Fig. 3.7 B).  
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Figure 3.7: Experimental outline for testing whether natural Tregs suppress the acute 
phase of mycobacterial infection 
A) Mice were treated with 100 µg of rat IgG or 100 µg of PC61 i.p. and two days later a 
peripheral blood sample was taken and assessed by flow cytometry for the presence of 
CD4+CD25+ lymphocytes. The following day, mice were infected either with BCG i.n. or by 
aerosol with M. bovis or M. tuberculosis. B) At 7, 14 and 28 days after BCG infection or 44 
days after M. bovis or M. tuberculosis infection, the immune response was evaluated by flow 
cytometry and/or ELISA, and lung bacterial numbers and pulmonary inflammation were 
evaluated. Black mice represent when Tregs were present, grey mice represent when mice were 
being tested for the presence of Tregs and white mice represent when Tregs were significantly 
reduced compared to control mice. 
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3.3.5 Natural Tregs and the immune response to primary 
mycobacterial infection  
 
Inactivation of Tregs prior to other infections has resulted in increases in effector 
lymphocyte proliferation and cytokine production in response to antigen stimulus [330, 
333, 375]. Therefore, it was hypothesised that inactivation of Tregs prior to a 
mycobacterial infection in vivo, using the approach outlined in Fig. 3.7, would enhance 
the ensuing immune response. Since IFN-γ is important for protection against primary 
mycobacterial infection [64, 65, 376], IFN-γ production was assessed by ELISA during 
the course of BCG infection.  
At day 14 after infection, PC61 treated mice displayed a trend for increased 
antigen-driven IFN-γ production compared to control mice, although this difference was 
not statistically significant (Fig 3.8 A/B). IFN-γ production was comparable between 
PC61 treated and control mice by day 28 after infection (Fig 3.8 A), by which time 
Tregs had begun to repopulate the periphery (Fig 3.3 A). IFN-γ production was also 
evaluated at day 14 after M. tuberculosis infection (Fig 3.8 C), although modified 
restimulation conditions were used. Fewer cells were plated per volume of media, 
resulting in a lower overall cytokine production compared to samples assessed in Fig. 
3.8 A/B. However, PC61 treated mice again displayed a trend for increased antigen-
driven IFN-γ production after M. tuberculosis infection compared to control mice, 
similar to BCG infection but again not statistically significant (Fig 3.8 C).  
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Figure 3.8: ELISA analysis of IFN-γ  production during mycobacterial infection  
Mice were administered rat IgG (filled circles) or PC61 antibody (empty circles) i.p., 3 days 
before mycobacterial infection (dashed line) with either BCG or M. tuberculosis. At day 7, 14 
or 28 after infection, splenocytes were harvested and restimulated with CFP before supernatants 
were used in ELISAs to assess IFN-γ production. A) Time course of IFN-γ production after 
BCG infection. B) The amount of IFN-γ in supernatants from splenocytes of rat IgG treated and 
PC61 treated mice at day 14 after BCG infection. C) The amount of IFN-γ in supernatants from 
splenocytes of rat IgG treated and PC61 treated mice at day 14 after M. tuberculosis infection.  
Symbols in A) represent mean values ± SEM and symbols in B) and C) represent individual 
values and black lines represent mean values. The limit of detection for this assay was 32.5 
pg/mL. Four to five animals were analysed per treatment group at each time point. Treatment 
groups were compared using the two-tailed Mann Whitney test; NS indicates p > 0.05. Results 
for BCG infection are representative of two replicate experiments, while results for M. 
tuberculosis infection represent a single experiment. 
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Total IFN-γ production was increased at day 14 after infection, but to determine which 
lymphocyte population contributed to the increase, cytokine production was assessed by 
flow cytometry. Lymphocytes from the spleen (Fig. 3.9) and lung (Fig. 3.10) were 
harvested at day 14 after BCG infection, restimulated with CFP in vitro overnight and 
analysed by flow cytometry for IFN-γ or IL-2 production. In the spleen, the percentage 
of CD4+ lymphocytes producing IFN-γ and the percentage of total lymphocytes 
producing IL-2 were significantly increased in mice treated with PC61 compared to 
control mice (Fig. 3.9 B/C).  A significant increase in IFN-γ was not observed in the 
lung (data not shown), although, the percentage of CD4+ lymphocytes from the lung 
producing IL-2 was significantly higher in PC61 treated mice than in control mice (Fig. 
3.9 B).  
CD8+ lymphocytes also produce cytokines in the lung following mycobacterial 
lung infection [71]. Although cytokine production by CD8+ lung-resident lymphocytes 
was detected, there was no statistically significant difference in the percentages 
producing IFN-γ or IL-2 from mice treated with PC61, compared to control mice (data 
not shown). Together, these data illustrate that antibody-mediated Treg inactivation 
induced a modest increase in the proportion of CD4+ lymphocytes producing cytokines 
known to be protective in a mycobacterial infection [64, 65, 376, 377].  
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Figure 3.9: IFN-γ  and IL-2 production by splenocytes after mycobacterial infection 
Mice were treated with rat IgG or PC61 and infected with BCG 3 days later. At 14 days after 
infection, spleens were harvested and isolated splenocytes were stimulated with CFP overnight 
before being assessed for cytokine production by flow cytometry. A) Representative flow 
cytometry plots of lymphocyte gating, CD4 gating and isotype or IFN-γ/IL-2 staining for 
restimulated splenocytes from rat IgG treated and PC61 treated mice. B) Percentage of CD4+ 
lymphocytes producing IFN-γ. C) Percentage of total lymphocytes producing IL-2. Symbols 
represent values for individual mice and black lines indicate mean values; 8 animals were 
analysed per treatment group. Results are representative of two replicate experiments. 
Treatment groups were compared using the two-tailed Mann Whitney test; ** indicates p ≤ 
0.01, *** indicates p ≤ 0.001. Results are representative of two replicate experiments. 
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Figure 3.10: IFN-γ  and IL-2 production by lung lymphocytes after mycobacterial infection 
Mice were treated with rat IgG or PC61 and infected with BCG 3 days later. At 14 days after 
infection, lungs were harvested and isolated lymphocytes were stimulated with CFP overnight 
before being assessed for cytokine production by flow cytometry. A) Representative flow 
cytometry plots of lymphocyte gating, CD4 gating and isotype or IFN-γ/IL-2 staining for 
restimulated lung lymphocytes from rat IgG treated and PC61 treated mice. B) Percentage of 
CD4+ lymphocytes producing IL-2. Symbols represent values for individual mice and black 
lines indicate mean values; 4 animals were analysed per treatment group. Results are 
representative of two replicate experiments. Treatment groups were compared using the two-
tailed Mann Whitney test; * indicates p ≤ 0.05. Results are representative of two replicate 
experiments. 
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3.3.6 Lung bacterial numbers and inflammation during BCG or M. 
tuberculosis infection 
 
Inactivation of CD4+CD25+ Tregs modestly enhanced antigen-driven cytokine 
production during the acute immune response to mycobacterial infection. Studies in 
murine models of other infections have shown that pre-treatment with anti-CD25 mAbs 
can enhance the immune response and reduce pathogen burden on the host [330, 333, 
334]. Therefore, it was hypothesised that inactivation of Tregs during mycobacterial 
infection would reduce the number of bacteria in infected tissues. 
To assess this, mice were treated with either PC61 or control rat IgG followed 
by infection with either BCG or M. tuberculosis (Fig. 3.7). Since BCG bacterial 
numbers in the lung stabilise earlier than virulent M. tuberculosis, lung bacterial 
numbers in BCG infected mice were assessed at days 7, 14 and 28 (Fig. 3.11 A), while 
lung bacterial numbers were assessed in M. tuberculosis infected mice at days 7, 14 and 
44 (Fig. 3.11 B). In contrast to other infection models [330, 333, 334], bacterial 
numbers in the lungs were comparable between PC61 treated and rat IgG treated mice 
after both BCG and M. tuberculosis infections (Fig. 3.11 A/B). This suggests that 
CD4+CD25+ Treg inactivation did not affect bacterial growth or clearance after BCG or 
M. tuberculosis infection. 
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Figure 3.11: Lung bacterial numbers after BCG or M. tuberculosis infection 
Mice were administered rat IgG (filled circles) or PC61 (empty circles) i.p., and 3 days later 
were infected A) with BCG i.n. or B) by aerosol with M. tuberculosis. Bacterial numbers in the 
lung tissue homogenates were determined during the course of the infections. Symbols 
represent geometric mean values ± GEM, and some symbols obscure error bars. The limit of 
detection for this assay at 2 log10 CFU is indicated by the dotted lines. Five animals were 
analysed per treatment group at each time point. Treatment groups were compared using the 
two-tailed Mann Whitney test; no significant differences were observed. Results for BCG 
infection are representative of two replicate experiments, while results for M. tuberculosis 
infection represent a single experiment. 
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In other infection models, CD4+CD25+ Treg inactivation has enhanced infection-
induced pathology [331, 332]. Although the modestly enhanced immune response 
observed after Treg inactivation did not enhance clearance of the mycobacteria, it was 
possible that it could exacerbate inflammation in the lung and pathology associated with 
Tb.  
In order to address this, mice were treated with either PC61 or control rat IgG 
followed by infection with either BCG or M. tuberculosis. Lung samples were collected 
over the course of the infections and the tissue was prepared for histological analysis. A 
similar degree of moderate granulomatous inflammation, with predominantly interstitial 
infiltrating lymphoid cells and epithelial histocytes, was observed in both PC61 treated 
and rat IgG treated mice at day 28 after BCG infection and day 44 after M. tuberculosis 
infection (Fig. 3.12 A). When inflammation was graded, composite pathology scores 
(with scores ranging from 0 (least severe) to 5 (most severe)) for both BCG and M. 
tuberculosis infections were low and averaged below 2 for PC61 and rat IgG treatment 
groups at all times assessed. 
Thus, distinct from studies using CD4+CD25+ Treg inactivation prior to other 
infections, CD4+CD25+ Treg inactivation prior to infection with either BCG or M. 
tuberculosis did not affect either the bacterial numbers in the lung or the degree of 
disease-associated lung pathology that developed. 
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Figure 3.12: Pulmonary inflammation after BCG or M. tuberculosis infection 
Mice were administered either control rat IgG antibody (filled circles) or PC61 (empty circles) 
i.p., and three days later were infected i.n. with BCG or by aerosol with M. tuberculosis. Lung 
tissue samples were taken in parallel with lung samples taken for Fig. 3.11, fixed, sectioned 
and stained with haematoxylin and eosin before being graded for pulmonary inflammation. 
Sections from lungs taken on day 28 after BCG infection or on day 44 after M. tuberculosis 
infection are shown. One micrograph, representative of sections from five animals, is shown for 
each treatment group. All micrographs were taken at 40x magnification; scale bars, 100 µm. 
Results for BCG infection are representative of two replicate experiments, while results for M. 
tuberculosis infection represent a single experiment. 
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3.3.7 Lung bacterial numbers and inflammation during M. bovis 
infection 
 
M. bovis is another member of the MTBC and it is the causative agent of bovine Tb. 
New Zealand has relatively high rates of M. bovis infection in cattle and livestock, 
which compromise products such as dairy and beef (reviewed in [378]). Improved 
understanding of the regulation of the immune response to M. bovis infection could 
facilitate the development of improved therapies and vaccines to manage bovine Tb. It 
is possible that suppression by Tregs could promote pathogen persistence during M. 
bovis infection and this point can also be explored using the murine model (Fig. 3.7), 
since M. bovis infection also causes disease in mice. It was anticipated that, similar to 
results obtained with M. tuberculosis and BCG infection, CD4+CD25+ Treg inactivation 
prior to M. bovis infection would not affect either the bacterial numbers in the lung or 
the degree of disease-associated lung pathology. 
To validate this, bacterial numbers were assessed in the lung after either PC61 or 
control rat IgG treatment followed M. bovis infection, and lung samples were collected 
in parallel for histological analysis. Lung bacterial numbers were evaluated at days 7, 14 
and 44 after infection and were comparable between PC61 treated and control treated 
mice up to day 44 after infection (Fig. 3.13 A). There were no obvious differences in 
pulmonary inflammation early after M. bovis infection but there was a dramatic 
difference between PC61 treated and control mice at day 44 after infection. Lungs of 
control mice exhibited moderate to severe granulomatous lesions, which were 
multifocal and coalescing, with involvement of airways and evidence of some necrosis 
(Fig. 3.14 A). In comparison, lungs of PC61 treated mice exhibited diminished 
inflammation, with mild granulomatous lesions that were multifocal but not coalescing, 
with no airway involvement and no necrosis (Fig. 3.14 A). Median composite lung 
pathology scores revealed a significantly diminished level of inflammation in the lung 
at day 44 after infection in PC61 treated compared to control mice (Fig. 3.14 B). 
To further define when differences in inflammation due to PC61 treatment arose 
and whether they affected dissemination of the infection, bacterial load and pulmonary 
inflammation around day 44 was examined more closely. Bacterial numbers in the lungs 
were comparable between PC61 treated and control mice at days 38, 48 and 60 after M. 
bovis infection (Fig. 3.13 B), demonstrating that alterations in pulmonary inflammation 
were not preceded or followed by alterations in lung bacterial numbers. Bacterial 
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numbers in the spleens were also comparable between PC61 treated and control mice 
(Fig. 3.13 C), demonstrating that the altered inflammation in the lung did not affect 
dissemination of infection to other tissues.  PC61 treated mice had a slightly lower 
median composite lung pathology score than control mice at day 38, but this difference 
was not significant and lung pathology scores were comparable between PC61 treated 
and control mice at days 48 and 60 (Fig. 3.14 C). 
In summary, inactivation of CD4+CD25+ Tregs prior to M. bovis infection may 
result in a different outcome to those observed with BCG and M. tuberculosis 
infections. Although Treg inactivation prior to infection did not affect bacterial numbers 
in the lung for any of the mycobacterial infections tested in this thesis, it significantly 
diminished pulmonary inflammation induced by M. bovis infection in the murine model 
at day 44 after infection. During subsequent experiments, slightly diminished 
pulmonary inflammation was also observed in PC61 treated compared to control mice 
at day 38 after M. bovis infection. Therefore, further analysis of the effect of Treg 
inactivation on pulmonary inflammation after M. bovis infection is required to 
determine if this is a real effect and the implications of this are discussed in section 
3.4.4.  
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Figure 3.13: Tissue bacterial numbers after M. bovis infection 
Mice were administered either control rat IgG antibody (filled circles) or PC61 (empty circles) 
i.p., and 3 days later were infected by aerosol with M. bovis. Bacterial numbers in the lung and 
spleen homogenates were determined during the course of the infection. Bacterial numbers were 
determined from days 7-44 and, in a separate experiment, from days 38-60. A) Bacterial 
numbers in the lung for days 7-44 after infection. B) Bacterial numbers in the lung for days 38-
60 after infection. C) Bacterial numbers in the spleen for days 38-60 after infection. Symbols 
represent geometric mean values ± GEM, and some symbols obscure error bars. The limit of 
detection for this assay at 2 log10 CFU is indicated by the dotted lines. Four to five animals were 
analysed per time point. Treatment groups were compared using the two-tailed Mann Whitney 
test; no significant differences were observed. Results represent single experiments. 
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Figure 3.14: Pulmonary inflammation after M. bovis infection 
Mice were administered either rat IgG (filled circles) or PC61 (empty circles) i.p., and 3 days 
later were infected by aerosol with M. bovis. Lung tissue samples were taken in parallel with 
samples taken for Fig. 3.12, fixed, sectioned and stained with haematoxylin and eosin before 
being graded for pulmonary inflammation. Inflammation was assessed from days 7-44 and, in a 
separate experiment, days 38-60. A) Sections from lungs taken on day 44 after M. bovis 
infection. One micrograph, representative of sections from five animals, is shown for each 
treatment group. Both micrographs were originally taken at 10x magnification. B) Composite 
pathology scores for lung samples taken at days 7-44 after M. bovis infection. C) Composite 
pathology scores for lung samples taken at days 38-60 after M. bovis infection. Scores ranged 
from 0 (least severe) to 5 (most severe). Symbols represent individual values and median values 
are indicated by the horizontal black line (although some symbols obscure this line). Four to 
five animals were analysed per treatment group at each time point. Treatment groups were 
compared using the two-tailed Mann Whitney test; NS indicates p > 0.05, ** indicates p ≤ 0.01. 
Results represent single experiments. 
 Chapter 3 – Tregs and Primary Infection  
 
126 
3.3.8 Tregs during the chronic phase of mycobacterial infection 
 
Tregs are hypothesised to promote pathogen persistence in chronic infections, and 
modulation of Treg activity during a chronic infection can impact on disease outcomes 
[330]. Although inactivation of Tregs prior to mycobacterial infection did not affect 
bacterial numbers in the lung during the acute phase of infection, it was hypothesised 
that natural Tregs suppress bacterial clearance during chronic Tb infection. If that were 
the case, abrogation of Treg-mediated suppression in chronically infected mice by either 
DTA-1 or PC61 treatment could decrease bacterial numbers in the lung. Conversely, it 
was hypothesised that enhancement of Treg-mediated suppression by 5F-1 treatment 
could increase bacterial numbers in the lung. 
Mice were infected with M. tuberculosis for 6 weeks to permit lung bacterial 
numbers to stabilise and lung lesions containing CD4+ effector T cells and Tregs to 
develop. At weeks 6 and 8 after infection, groups of mice received either PBS or rat IgG 
as negative controls, or PC61 alone, DTA-1 alone, 5F-1 alone or a combination of PC61 
and DTA-1. At week 10, lung samples were taken for assessment of pathology and 
evaluation of bacterial numbers. There were no significant differences between 
treatment groups for either pulmonary inflammation (data not shown) or bacterial 
numbers (Fig. 3.15) in the lung. Therefore, modulation of Treg activity with PC61, 
DTA-1 or 5F-1 mAbs during the chronic phase of M. tuberculosis infection did not 
result in significant changes in lung bacterial numbers or disease-associated pathology 
in the C57BL/6 model. 
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Figure 3.15: Impact of Treg modulation on chronic M. tuberculosis infection 
Mice were infected with M. tuberculosis for 6 weeks and, at weeks 6 and 8, mice were 
administered Treg-modulating mAbs i.p. Groups received PBS or rat IgG control antibody as 
negative controls (black bars), PC61 (anti-CD25) alone, DTA-1 (anti-GITR) alone, or a 
combination of PC61 and DTA-1 as mAbs hypothesised to inhibit Treg activity (striped bars), 
or 5F-1 (anti-GITRL) alone as an mAb hypothesised to enhance Treg activity (hatched bar). At 
week 10 after infection, lung samples were harvested for determination of lung bacterial 
numbers. Bars represent geometric mean values ± GEM. Three to five animals were analysed 
per treatment group. Treatment groups were compared to the PBS treated group using the two-
tailed Mann Whitney test; no significant differences were observed. Results represent one 
experiment. 
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3.4 Discussion 
 
In this chapter, I aimed to assess whether natural CD4+CD25+ Tregs suppressed the 
acute response to mycobacterial infection. To achieve this, methodology using PC61 
treatment to target CD4+CD25+ Tregs, outlined in Fig. 3.7, was developed to inactivate 
Tregs in vivo and limitations of that approach were identified.  
I hypothesised that PC61 treatment prior to mycobacterial infection would 
enhance the immune response to infection and correspondingly decrease bacterial 
numbers in the tissues, but also lead to enhanced immunopathology in the lung. When 
these parameters were evaluated, PC61 treatment prior to infection did correlate with 
modest increase in IFN-γ and IL-2 production after infection. For BCG and M. 
tuberculosis infections, lung bacterial numbers and pulmonary inflammation during the 
acute phase of the infection was unaffected by PC61 treatment. For M. bovis infection, 
PC61 treatment may correlate with diminished pulmonary inflammation around day 44 
after infection, although PC61 treatment did not alter lung bacterial numbers. Therefore, 
although natural CD4+CD25+ Tregs suppressed the immune response during 
mycobacterial infection, they did not impact on measures of protection, such as 
pathogen clearance or lung pathology after BCG or M. tuberculosis infection, but may 
enhance lung pathology after M. bovis infection.  
The lack of effect on lung bacterial numbers in this study contrasts with the 
increased pathogen clearance observed after treatments that interfere with Treg function 
prior to, and during other infections [305, 330, 333, 334]. Although many pathogens 
exploit natural Tregs to suppress the immune response to their advantage, it is 
interesting that a similar role for natural Tregs in mycobacterial infection is not apparent 
from these results.  This study focussed solely on the role of natural Tregs, as defined 
by CD25 expression, during early mycobacterial infection. It remains undetermined 
whether other subgroups of Tregs mediate immunosuppression during early 
mycobacterial infection and whether natural or induced Tregs suppress immune 
responses and enable pathogen persistence during later stages of M. tuberculosis 
infection. 
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3.4.1 PC61 treatment and its limitations 
 
While PC61 has been widely used to inactivate Tregs in vivo, this chapter illustrates an 
important limitation of this approach. A sub-population of CD4+CD25−Foxp3+ Tregs 
were not affected by PC61 treatment and, although many studies define CD4+CD25+ 
lymphocytes in a naïve mouse as natural Tregs, the marker that correlates best with the 
suppressive phenotype of Tregs is Foxp3. A CD4+CD25loFoxp3+ population has been 
observed in naïve transgenic mice that express Foxp3 as a fusion protein with green 
fluorescent protein (GFP) [282]. In these mice, the CD25loFoxp3+ population has 
increased expression of genes that encode proteins characteristically produced by Tregs, 
including GITR, IL-10 and CD152 [282], and possess the Treg suppressive phenotype 
[282], similar to CD25hiFoxp3+ Tregs. 
However, CD25hiFoxp3+ Tregs differ from CD25loFoxp3+ Tregs, as the latter 
have increased expression of inducible T-cell co-stimulator precursor, chemokine 
receptors and β1-integrin, which are associated with the ability to enter tissue [282]. 
CD25loFoxp3+ Tregs are found at low levels in the peripheral blood but make up a 
larger proportion of the total Foxp3+ lymphocyte population in tissues such as spleen 
and lung [282].  Thus, it is suggested that the CD25loFoxp3+population may have a 
tissue-homing/effector phenotype [282].  
In this chapter, the percentage of CD4+ lymphocytes that were CD25− and 
Foxp3+ was unaffected by PC61 treatment in all tissues analysed (Fig 3.2 C). The lung 
and spleen also had a higher percentage of resident CD4+CD25−Foxp3+ lymphocytes 
than the blood (Fig 3.2 C). Mice were infected with mycobacteria by aerosol or i.n. 
infection, since aerosol exposure is the most common way to contract an M. 
tuberculosis infection. Therefore, the CD4+CD25−Foxp3+ population, a significant Treg 
subset in the lung that persists despite PC61 treatment, could suppress local immune 
responses during a pulmonary mycobacterial infection. This possibility remains to be 
evaluated as novel techniques are developed for exploring the role of CD4+CD25−
Foxp3+ Tregs. 
Recently, there has been considerable controversy about the mechanism of 
action of PC61 when it is administered in vivo. The anti-CD25 mAbs, 7D4 and PC61, 
had been thought to deplete Tregs in vivo. However, a recent report suggested that 
administration of 7D4 caused functional inactivation, rather than depletion of the 
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CD4+CD25+ Treg population, by downregulating or inducing shedding of CD25 from 
the surface of Tregs [353]. It was suggested that PC61 acts similarly in vivo to 7D4, but 
this was indirectly implied through analysis of Foxp3 mRNA transcript rather than 
expression of Foxp3 protein. A recent report followed the kinetics of CD25 and Foxp3 
protein expression in vivo after PC61 treatment in CD4+ T cells [352]. This showed that, 
while CD4+CD25+ Foxp3+ Tregs can shed CD25 early after PC61 treatment and become 
CD4+CD25−Foxp3+ T cells, cells with a naïve CD69lo phenotype are subsequently 
depleted [352]. The authors suggested that depletion could be due to lack of IL-2 
signalling as a homeostatic survival signal [352]. Therefore, in vivo administration of 
PC61 depletes a subset of naïve Tregs and converts Tregs possessing a more activated 
phenotype into a CD25−Foxp3+ population that is functionally inactivated, possibly due 
to the lack of IL-2 receptor alpha chain. Notably, a significant increase in the percentage 
of CD4+CD25−Foxp3+ T cells was not observed at day 3 after PC61 treatment in the 
blood, spleen or lungs (Fig. 5.2 C), supporting the suggestion that at least a substantial 
population of Tregs are depleted by day 3 after PC61 treatment. Notwithstanding 
current debate over the mechanism of action for PC61, the ability of PC61 to inhibit 
Treg activity in vivo is well-documented [333, 350-352] and PC61 is referred to as 
inactivating, rather than depleting, Tregs in this thesis.  
A further point of contention is whether Tregs repopulate the periphery after 
PC61 treatment more rapidly during active immune responses due to altered 
homeostatic signals compared to naïve animals. In a study by Couper, et al., Tregs 
began to repopulate the periphery from 14 days after PC61 treatment but malarial 
infection subsequent to PC61 treatment slightly accelerated CD4+CD25+ Treg 
repopulation of the periphery compared to a naïve mouse [379]. In this thesis, 
repopulation of the periphery by CD4+CD25+ Tregs was not evident until 23 days after 
PC61 treatment for both naïve and mycobacteria infected animals (Fig. 3.3).  The PC61 
mAb used in this study was prepared in-house and, there may be differences in the 
production, stability and function in vivo of the antibody between the two studies. The 
study by Couper, et al. also used a higher dose of PC61 than was used in this thesis, but 
it is interesting that the two models display different effects of active infection on Treg 
repopulation. The difference could imply that malarial infection induces stronger Treg 
homeostatic or expansion signals compared to a mycobacterial infection. 
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3.4.2 Induction of Tregs during Tb infection 
 
According to current dogma, conditions during mycobacterial infection are favourable 
for the development of induced Tregs. Antigen presentation to naïve CD4+CD25− T 
cells in conditions of low-dose antigen, high IL-10 or high TGF-β is sufficient for 
conversion of naive T cells to a Treg suppressive phenotype, as outlined in section 
1.4.3. IL-10 not only promotes the induction of Tregs but some induced Treg subsets 
also produce IL-10 as a mechanism of immunosuppression. Human Tb patients 
unresponsive to the purified protein derivative skin test, exhibit increased IL-10 
production from their PBMCs when cultured in vitro with mycobacterial antigens [365]. 
Murine studies also point to the importance of IL-10 during infection with M. 
tuberculosis, as IL-10 mRNA synthesis is induced in the lung in WT mice infected by 
aerosol [380]. Although IL-10 -/- mice do not display increased resistance to BCG 
infection [381] or M. tuberculosis infection [91], mice expressing increased levels of 
IL-10 have a higher rate of disease reactivation during later stages of infection 
compared to control mice [134]. These previous studies in humans and murine models 
have shown that IL-10 is produced during periods of antigen presentation in a M. 
tuberculosis infection and increased amounts of IL-10 correspond to increased 
reactivation of disease. IL-10 production during the course of mycobacterial infection 
was not assessed in this thesis, but, given evidence that induced Tregs may be involved 
in M. tuberculosis infection and contribute to reactivation of latent disease, this warrants 
further investigation.  
 
3.4.3 Suppression by Tregs during chronic Tb infection 
 
Immunosuppression mediated by Tregs during chronic infection has been previously 
reported. During the chronic stages of filarial infection with L. sigmodontis, combined 
treatment with PC61 and DTA-1 caused a significant decrease in filarial load [330]. 
This study suggests that during a chronic infection there is an equilibrium between 
effector lymphocytes and natural Tregs and interference with this to enhance effector 
lymphocyte function can improve pathogen clearance. However, it is difficult to analyse 
and manipulate natural Tregs during an active infection.  
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Dissecting the role of Tregs during active infection is limited by the tools 
available. The use of in vivo administration of PC61 as a technique to target Tregs 
during an active immune response has been controversial. PC61 could theoretically also 
target recently activated CD4+ effector T cells, which transiently upregulate CD25 after 
TCR stimulation [354]. Despite this, PC61 has been administered during active immune 
responses and was found to enhance these responses [330, 339], suggesting it does not 
inhibit effector T cells but targets Tregs preferentially. Results presented in this thesis 
also suggest that the presence of PC61 does not significantly inhibit effector immune 
responses. PC61 was shown to persist in circulation up to 14 days after administration 
(Fig. 3.5). In the protocol outlined in Fig. 3.7, PC61 would persist in circulation during 
the first week of mycobacterial infection. However, this does not inhibit the immune 
response, since IFN-γ production is the same after the first week of mycobacterial 
infection and is enhanced after the second week in PC61 treated compared to control 
treated mice (Fig. 3.8).  
Despite potential complications inherent in using CD25 and GITR to target 
Tregs, PC61, DTA-1 and 5F-1 mAbs were used in this chapter to modulate the activity 
of Tregs during the chronic phase of a mycobacterial infection. In contrast to L. 
sigmodontis infection, combined treatment with PC61 and DTA-1 did not affect 
bacterial numbers in the lung (Fig. 3.15), implying that inhibiting Treg activity during 
the chronic phase of mycobacterial infection might not promote pathogen clearance. 
Treatment with 5F-1 also did not affect bacterial numbers in the lung (Fig. 3.15), 
implying that enhancing Treg activity during the chronic phase might not promote 
pathogen persistence.  
The DTA-1 and 5F-1 mAbs target the GITR/GITRL signalling pathway. L. 
sigmodontis lesion sites accumulate large numbers of GITR+ effector T cells and Tregs 
[330], implying that the GITR/GITRL signalling pathway is important in L. sigmodontis 
infection. GITR expression has been observed on CD4+CD25+Foxp3+ Tregs in the 
PBMCs of patients with active Tb infection [371] and Tregs of this phenotype can be 
expanded from patients with latent Tb infection [370]. However, the accumulation of 
GITR+ effector T cells and Tregs in lung lesions has not been assessed in a murine Tb 
model. It is unknown if the GITR/GITRL signalling pathway plays a significant role in 
regulating Treg activity during mycobacterial infection, but these preliminary results 
indicate that the pathway does not. However, Treg subsets or mechanisms unaffected by 
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the GITR/GITRL signalling pathway may promote mycobacterial persistence during the 
chronic phase of M. tuberculosis infection. 
 
3.4.4 Immunopathology during M. bovis infection 
 
PC61 treatment prior to M. bovis infection caused a significant reduction in pulmonary 
inflammation around day 44 after infection (Fig. 3.14 A/B), which was not observed 
with PC61 treatment prior to BCG or M. tuberculosis infections (Fig. 3.12). Subsequent 
experiments exhibited a similar trend at day 38 after M. bovis infection, but this was not 
statistically significant and further analysis is required (Fig. 3.14 C). M. bovis infection 
causes more extensive inflammation in mice than BCG or M. tuberculosis infections 
[382], thus any reduction in lung pathology that may be mediated by PC61 treatment 
could be restricted to infections with more extensive inflammation.  
A decrease in lung pathology with inactivation of Tregs was not anticipated; it 
was hypothesised that inactivation of Tregs would increase IFN-γ production and 
thereby increase lung pathology. The reduction in pathology observed with M. bovis 
infection appears to be transient and could reflect a pro-inflammatory mechanism 
present during M. bovis infection that may be amplified by Tregs as they repopulate the 
periphery. Natural Tregs can produce TGF-β and induction of the highly inflammatory 
Th-17 cell is dependent on the presence of TGF-β and IL-6 during TCR stimulation 
[79]. Therefore, removal of natural Tregs may remove a source of TGF-β that Th-17 
cells use to differentiate during the initial stages of a M. bovis infection, thus preventing 
Th-17 cell-mediated immunopathology. Future studies aim to evaluate the composition 
of the M. bovis granuloma. Samples of M. bovis infected lung with or without PC61 
treatment over the course of infection have been prepared and stored. These will be used 
in immunohistochemical analysis to evaluate granuloma composition and the presence 
of T cells producing cytokines, including IFN-γ, IL-10, TGF-β and IL-17. 
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3.4.5 Subsequent published studies 
 
Recently, two studies were published that also investigated the role of Tregs in a murine 
model of Tb infection and used approaches that did not inactivate Tregs by 
administration of anti-CD25 mAbs. 
The first study by Kursar, et al. reconstituted recombinase activating gene 1 
(Rag1) -/- mice with sorted CD4+CD25− T cells alone, sorted CD4+CD25+ T cells alone 
or a mix of sorted CD4+CD25+ and CD4+CD25− T cells [383]. The reconstituted mice 
and WT C57BL/6 mice were then infected with M. tuberculosis by aerosol and bacterial 
numbers in tissues were evaluated at day 30 post-infection. Mice that had received 
CD4+CD25− T cells alone had significantly lower bacterial numbers in the lung and 
spleen than mice that had received CD4+CD25+ T cells. The enhanced protection 
observed in CD4+CD25− T cell reconstituted mice did not correlate with increased 
numbers of IFN-γ+CD4+ T cells or changes in other mediators of mycobacterial 
immunity. Therefore, the mechanism for reduction of bacterial numbers in the absence 
of CD4+CD25+ Tregs in this model is undefined. 
However, this study has limitations inherent in its design. Firstly, a control 
group of Rag 1 -/- mice reconstituted with total CD4+ T cells was not included. Total 
CD4+ T cells would have contained a more physiologically relevant proportion of Tregs 
than the mixture of CD4+CD25+ and CD4+CD25− T cells that was used. Normally, 
CD4+CD25+ Tregs are present in the periphery at a 1:10 to 1:20 ratio to CD4+CD25− T 
cells. In the study of Kursar, et al. Tregs were transferred at a 1:2 ratio and were present 
at a 1:1 ratio by day 30 after infection. Thus, Tregs comprised an unphysiologically 
high proportion of CD4+ T cells in mice that received the mixture of CD4+CD25+ and 
CD4+CD25− T cells. Mice that received this mixture were used as a baseline to 
approximate the WT phenotype but, due to the high proportion of Tregs, may have 
actually approximated a phenotype when Tregs are unphysiologically and perhaps 
pathologically high. 
Similar to the experimental approach used in this chapter, the methodology used 
by Kursar, et al. did not eliminate CD4+CD25−Foxp3+ Tregs. Additionally, by day 30 
after infection, all groups of reconstituted mice had comparable numbers of 
CD4+Foxp3+ Tregs, suggesting there is a homeostatic mechanism in reconstituted mice 
that promotes Treg expansion in mice that received CD4+CD25− T cells.   
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Finally, it appears that values for tissues with undetectable CFUs were recorded 
as zero rather than a value at or just below the detection limit. If these CFU values were 
recorded as zero, rather than at the detection limit, this would have amplified the 
statistical significance of the decrease in bacterial numbers between mice that received 
CD4+CD25− T cells alone and mice that received CD4+CD25+ and CD4+CD25− T cells.  
The second study by Scott-Browne, et al., used mixed bone marrow chimeras in 
combination with antibody depletion to eliminate Foxp3+ Tregs in vivo [384]. Chimeras 
were created containing Thy1.1+ Foxp3+/+ and Thy1.2+ Foxp3+/+ bone marrow, or 
Thy1.1+ Foxp3+/+ and Thy1.2+ Foxp3-/- bone marrow. Chimeric mice were treated 
with anti-Thy1.1 depleting mAb, infected with M. tuberculosis and treated with anti-
Thy1.1 mAb weekly to maintain depletion of Thy1.1+ leukocytes during the infection. 
Thereby, Thy1.1+ Foxp3+/+:Thy1.2+ Foxp3+/+ chimeric mice possessed Tregs while 
Thy1.1+ Foxp3+/+:Thy1.2+ Foxp3-/- chimeric mice were depleted of total Foxp3+ Tregs 
during mycobacterial infection.  
This elegant methodology enabled assessment of suppression by both 
CD4+CD25+Foxp3+ and CD4+CD25−Foxp3+ Treg populations during mycobacterial 
infection. A significant decrease in lung bacterial numbers was observed in Treg 
depleted chimeric mice compared to chimeric mice that possessed Tregs. In addition, 
this study demonstrated that IFN-γ production in response to polyclonal restimulation 
was amplified in Treg depleted chimeric mice, although there was no significant 
increase in the antigen-specific response to a peptide from ESAT-6. In agreement with 
our study (Fig. 3.6), Scott-Browne, et al. also demonstrated parallel accumulation of 
CD4+Foxp3+ Tregs and CD4+ effector T cells in the lungs after mycobacterial infection 
[384].  
However, methodology employed by Scott-Browne, et al. was complicated by 
several factors that were acknowledged and explored by the authors. The efficacy of 
Thy1.1 depletion waned over time and in Thy1.1+ Foxp3+/+:Thy1.2+ Foxp3-/- chimeric 
mice there was significant expansion of Tregs. As a result, all groups of chimeric mice 
possessed comparable numbers of CD4+Foxp3+ Tregs by day 30 after infection [384]. 
Furthermore, the chimeric Treg deficient mice displayed signs of autoimmunity, 
characterised by robust and generalised immune activation [384]. A complete 
deficiency of Tregs can provoke autoimmunity as evidenced by the scurfy mouse model 
and by athymic mice reconstituted with CD4+CD25− T cells [261, 280]. As a result, it is 
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not surprising that the chimeric Treg deficient animals exhibited a degree of 
autoimmunity [384]. From these data, it is not possible to separate the impact of 
autoimmunity on mycobacterial growth from the effect of heightened mycobacteria-
specific responses on bacterial growth. The generalised immune activity induced in the 
chimeric Treg deficient mice could contribute to a decrease in bacterial numbers in 
tissues during mycobacterial infection. 
Finally, the study evaluated antigen-specific responses by restimulating with one 
peptide from ESAT-6 that contained a known CD4+ T cell epitope [384]. While this 
effectively highlights antigen-specific immune responses to that epitope, it limits the 
ability of the study to detect the overall effect of Treg depletion on antigen-driven 
immune responses. Infection with M. tuberculosis does not result in an immune 
response to a single immunodominant epitope and there is no single immunodominant 
protein [385]. Responses to various mycobacterial peptides and proteins can be very 
different. Furthermore, the degree of overlap between the TCR repertoires of effector 
CD4+ T cells and Tregs directed against non-self peptides has not been resolved, 
although some overlap is apparent with self-peptides [386]. The selected CD4+ T cell 
epitope from ESAT-6 may restimulate CD4 effector T cells, but it may not engage a 
TCR within the Treg repertoire. Therefore, it would have been valuable to evaluate 
immune responses not only to the ESAT-6 peptide but also to other peptides, if not 
entire proteins or mixed mycobacterial protein preparations. 
By contrast to these two studies, the results presented in this chapter correlate 
inactivation of Tregs with an increase in mycobacteria-specific cytokine production 
(Figs. 3.8-3.10). Other studies have used polyclonal stimulation and not observed any 
differences in cytokine production [383] or observed an enhanced polyclonal response 
with no enhancement of mycobacterial peptide-specific cytokine production [384]. 
However, the methodology used in this chapter, which targeted CD4+CD25+ but not 
CD4+CD25−Foxp3+ Tregs, did not result in reduced bacterial numbers in the tissues 
following mycobacterial infection (Figs. 3.11/3.13), while the other studies exhibited 
significant reductions [383, 384]. The methodology used by Kursar, et al. and Scott-
Browne, et al. resulted in more profound differences in proportions of CD4+CD25+ 
Tregs and CD4+Foxp3+ Tregs respectively, relative to the total CD4+ T cell population. 
This could account for the differences in bacterial numbers observed. The more 
profound depletion of Tregs, and in particular the ability to deplete total CD4+Foxp3+ 
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Tregs in the study by Scott-Browne, et al., is a significant advantage over the 
limitations of in vivo PC61 administration used to inactivate CD25+ Tregs. 
However, interpretation of the studies by Kursar, et al. and Scott-Browne, et al. 
is complicated by the fact that they induced more profound differences in proportions or 
numbers of Tregs than in vivo PC61 administration. The profound differences in Treg 
numbers and ratios might not reflect fluctuations in Tregs that occur during natural 
mycobacterial infection, and the physiological relevance of these studies is unknown. 
Furthermore, a complete lack of Tregs can induce generalised immune activation and 
autoimmunity, as was pointed out by Scott-Browne, et al. As a result, it is difficult to 
control for the effect of generalised immune activation and the resulting cytokine and 
chemokine milieu on bacterial numbers. Either mycobacteria-specific responses or 
generalised responses could result in the observed decreases in bacterial numbers.  
In summary, several studies, including mine, have explored the role of Tregs in 
M. tuberculosis infection using different murine models that possess different 
advantages and disadvantages. To date, it is still unclear whether natural Tregs allow 
mycobacterial infections to take hold and persist within the murine models, let alone 
during human Tb, under normal physiological conditions. As more tools are developed 
for manipulation of Treg subsets in vivo (section 6.2.6), more extensive assessment of 
Treg suppression during mycobacterial infection will be possible. 
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3.5 Summary 
 
The work presented in this chapter demonstrates that inactivation of CD4+CD25+ Tregs 
with PC61 treatment prior to mycobacterial infection resulted in modest increases in 
cytokine production but did not affect bacterial numbers in the lungs after BCG, M. 
tuberculosis or M. bovis infection. This suggests that CD4+CD25+ Tregs mildly 
suppress immune responses induced by mycobacterial infection, but do not suppress 
immune responses to the point where pathogen clearance is inhibited. This outcome 
contrasts with other published studies where inactivation of Tregs in infection models 
can enhance both immune responses and pathogen clearance. This implies that 
mycobacteria are not as sensitive to the effects of Treg inactivation as other infectious 
agents that have been tested. 
Preliminary studies suggest that PC61 treatment prior to M. bovis infection may 
result in a transient reduction in pulmonary inflammation around day 44 after infection. 
This could indicate that Tregs contribute to the increased severity of pathology that is 
observed during M. bovis infection compared to other mycobacterial infections in the 
murine model. CD4+CD25+ Treg activity was also experimentally modulated during the 
chronic phase of infection but neither enhancement nor inhibition of Treg activity 
significantly affected lung bacterial numbers or pathology.  
This study illustrates that, despite modestly enhancing acute immune responses 
to mycobacterial infection, inactivation of CD4+CD25+ Tregs did not affect bacterial 
numbers during the acute phase of a virulent mycobacterial infection. It must be noted 
that this does not entirely preclude a role for Tregs during mycobacterial infection. Treg 
suppression during chronic infection and the effect of CD4+CD25−Foxp3+ and induced 
Treg subsets during mycobacterial infection remain exciting possibilities that can be 
explored, as novel tools for in vivo Treg manipulation are developed.
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Chapter 4: Construction of a novel plasmid DNA 
replicon vaccine against Tb 
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4.1 Introduction 
 
The efficacy of the BCG vaccine is highly variable (section 1.3.4) and as a result there 
is a considerable drive to develop new vaccines against Tb. Although many candidate 
Tb vaccines induce cell-mediated immunity with both CD4+ and CD8+ T cell activation, 
many researchers have focussed primarily on enhancing CD4+ Th1 immunity (section 
1.2.6). However, the contribution of CD8+ T cells to vaccination against Tb is just 
beginning to be explored (section 1.2.6) and DNA vaccination offers a promising way 
to induce CD8+ T cell-mediated immunity. 
 
4.1.1 DNA plasmid vaccination for Tb: Pros and Cons 
 
DNA plasmid vaccination can establish effective humoral and cell-mediated immunity 
[230, 231], making it an attractive approach for preventing infections such as Tb. 
Plasmid constructs encoding mycobacterial antigens have been used as DNA plasmid 
vaccines against Tb predominantly in murine models, inducing both humoral responses 
and cell-mediated responses and resulting in a level of protection comparable to BCG 
[387, 388]. For protection against Tb, DNA plasmid vaccines should be administered 
i.m. rather than by gene-gun bombardment, as gene-gun administration favours humoral 
rather than cellular immunity [389]. DNA plasmid vaccination can also broaden the 
epitopic repertoire against the target antigen as compared to the repertoire induced for 
the same antigen by BCG vaccination [390]. 
 A significant problem facing DNA plasmid vaccination in general is that DNA 
plasmid vaccination of humans and non-human primates has not resulted in the levels of 
protection seen in murine models (reviewed in [232]). Immunogenicity can be enhanced 
by modulation of one or more factors, such as codon optimisation, optimising CpG 
motifs, using immunological adjuvants or incorporating DNA vaccines into prime-boost 
approaches. These strategies will be further described in section 4.4.4. Even so, the 
immunogenicity of DNA vaccines is poor when translated into humans. This may be 
due to the fact that this technique has been optimised for murine models, but not 
humans with respect to dose amount, dose volume, site of administration and method of 
delivery. In addition to the observed variation in immunogenicity across species, direct 
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scaling of DNA plasmid vaccine dosage from a 25 g mouse into a 75 kg human means a 
3000-fold increase in the amount of DNA required. This is challenging for vaccine 
manufacture and administration, and may complicate the transition of DNA plasmid 
vaccines into human trials [391]. Reducing the required dose of DNA, as well as 
optimising immunogenicity, will be vital for the successful translation of DNA plasmid 
vaccination from murine models into humans. 
 
4.1.2 Plasmid DNA replicons 
 
To minimise some of the limitations of conventional DNA plasmid vaccines, plasmid 
DNA replicons have been developed. Plasmid DNA replicons encode the target antigen 
as well as a ribonucleic acid (RNA) replicase gene, which enhances vaccine 
immunogenicity, often at lower doses than conventional DNA plasmids [392]. The 
RNA replicases used in DNA replicons are derived from single-stranded, positive-sense 
strand (+str) RNA viruses that require an RNA replicase to replicate their genome in 
infected cells. Most DNA replicon vectors used for vaccination have been derived from 
two families of viruses: alphaviruses, such as the Semliki Forest virus [393] and Sindbis 
virus [394], and flaviviruses, such as the Yellow Fever virus [395] and Kunjin virus 
[396]. 
Plasmid DNA replicons exhibit increased immunogenicity at lower doses than 
conventional plasmids. It was originally hypothesised that, since RNA replicase can 
amplify the amount of mRNA encoding the target antigen, the amount of target antigen 
produced is also amplified. It is difficult to compare antigen expression between 
conventional DNA plasmids and plasmid DNA replicons in vivo but it is unlikely that 
increased antigen expression alone accounts for the pronounced increase in 
immunogenicity observed with plasmid DNA replicons [392, 397].  
The formation of double-stranded (ds) RNA has also been proposed to enhance 
the immunogenicity of plasmid DNA replicons [397]. The amplification of +str RNA 
by an RNA replicase requires that +str RNA serves as a template for negative-sense 
strand (–str) RNA synthesis, and during this process dsRNA is formed (Fig. 4.1). In a 
eukaryotic cell, dsRNA is typically only present during viral infections and thereby 
dsRNA acts as a PAMP.  The interaction of dsRNA with several PRRs initiates 
signalling through several pathways, outlined in Fig. 4.1. The PRRs include TLR3, 
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retinoic acid inducible gene-I (RIG-1) and protein kinase receptor (PKR) (Fig. 4.1). 
These signalling pathways are responsible for inhibition of protein synthesis in virally 
infected cells, as well as initiation of inflammation through type I IFN release, 
promoting the development of a robust immune response (Fig. 4.1).  
Type I interferon production also has the effect of activating the RNase L 
enzyme. Once activated, RNase L can degrade RNA within the cell but it can also 
initiate caspase-dependent apoptosis. The initiation of the RNase L pathway has been 
shown to be vital for cell-mediated immunity after vaccination with plasmid DNA 
replicons, as a deficiency in RNase L [397, 398] or type I IFNs [399] can abrogate 
vaccine efficacy in murine models. Collectively, the current model is that plasmid DNA 
replicons cause type I interferon production, which activates the immune response, but 
also results in inhibition of protein synthesis, degradation of RNA and apoptosis of the 
transfected cell (Fig. 4.1).  
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Figure 4.1: Proposed mechanism of action for plasmid DNA replicons 
1) Like conventional DNA plasmids, plasmid DNA replicons are taken up by the host cell and 
presumably translocate to the nucleus. 2) In the nucleus, polycistronic +str messenger RNA 
(mRNA) is transcribed and transported to the cytosol. 3) In the cytosol, the +str mRNA is 
translated into both the target antigen and the RNA replicase. 4) The RNA replicase can bind 
the +str mRNA and use it as a template to replicate -str mRNA and subsequently more +str 
mRNA [400]. 5) The newly formed dsRNA can interact with a number of different PRRs. 
Extracellular and endosomal dsRNA binds to TLR3, which is present on cell membranes, and 
initiates a danger signal cascade that leads to type I IFN production and, in APCs, this also leads 
to upregulation of activation markers [401]. Cytoplasmic dsRNA binds RIG-I present in the 
cytosol, which activates interferon regulatory factor-3 and NF-κB, resulting in type I interferon 
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production [402]. Cytoplasmic dsRNA can also bind to cytoplasmic PKR [403, 404]. Binding of 
dsRNA or even IFN signalling activates PKR and leads to the phosphorylation and inhibition of 
eukaryotic translation initiation factor 2 (reviewed in [405]). 6) PKR activation inhibits protein 
expression, which may explain why vastly increased antigen expression is not observed after 
DNA replicon administration despite amplification of the mRNA encoding the target antigen. 
Overall, transfection of a cell with a plasmid DNA replicon results in type I IFN production, 
which acts as danger signal to initiate the immune response, but also eventual apoptosis of the 
host cell. 
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4.1.3 Apoptosis and DNA vaccine immunogenicity 
 
Minimising apoptosis of DNA-transfected cells can enhance the efficacy of DNA 
vaccines. Co-administration of the Bcl-xL anti-apoptotic gene on a conventional 
plasmid DNA vaccine resulted in enhanced anti-tumour responses [406], showing that 
inhibiting apoptosis can enhance DNA vaccination. Apoptosis is thought to diminish 
DNA vaccine efficacy by reducing the amount of antigen expressed, reducing the 
window of time during which antigen is expressed or by removing transfected APCs 
that would otherwise present antigen. 
On the other hand, minimising apoptosis of DNA-transfected cells can decrease 
DNA vaccine immunogenicity. Plasmid DNA replicons are typically cytopathic and 
interference with apoptosis of transfected cells can diminish the immunogenicity of 
plasmid DNA replicon vaccines. Co-administration of the Bcl-xL anti-apoptotic gene on 
a cytopathic plasmid DNA replicon reduced protection by the vaccine against a tumour 
challenge [407]. The current rationale for this is that large number of apoptotic 
transfected cells expressing the target antigen and releasing type I IFNs result in a 
localised inflammatory environment at the vaccination site [408]. APCs attracted into 
this environment would phagocytose large amounts of apoptotic debris containing target 
antigen, resulting in efficient distribution of antigen to APCs and increased antigen 
presentation [408]. Therefore, apoptosis is regarded as a mechanism that enhances 
efficacy of cytopathic plasmid DNA replicon vaccines. 
Non-cytopathic plasmid DNA replicons are also available, such as the Kunjin-
based plasmid DNA replicons. Kunjin-based plasmid DNA replicons can replicate 
mRNA transcripts and express protein encoded on the replicon in vitro and in vivo for 
prolonged periods of time, as the Kunjin RNA replicase possesses intrinsic anti-
apoptotic activity [396, 409]. The non-structural (NS) proteins expressed by Kunjin-
based plasmid DNA replicons inhibit both IFN-α/β and IFN-γ signalling, presumably 
by preventing phosphorylation of STAT1 and STAT2, which mediate IFN signalling in 
the transfected cell [410]. Decreased IFN signalling means the transfected cell is less 
likely to undergo apoptosis. 
Vaccination with Kunjin-based plasmid DNA replicons has been shown to 
confer protective immunity in tumour and infectious challenge murine models at lower 
doses compared with conventional plasmids [411-413]. Kunjin-based plasmid DNA 
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replicons have been shown to induce strong CD8+ T cell responses with IFN-γ 
production and cytolytic activity [411, 414], presumably due to production of antigen in 
the cytosol that would effectively access the MHC I presentation pathway. Therefore, 
Kunjin-based plasmid DNA replicons are immunogenic, particularly for CD8+ T cells, 
and require lower doses than conventional plasmid DNA vaccines to induce equivalent 
responses. Due to their non-cytopathic nature, Kunjin-based plasmid DNA replicons are 
thought to produce antigen for longer periods in vivo than cytopathic plasmid DNA 
replicons. 
 
4.1.4 Antigen 85A 
 
The Antigen 85 (Ag85) complex comprises 3 highly related proteins [415, 416] Ag85A, 
B and C, which are encoded by separate genes, fbpA, fbpB and fbpC, in the genome of 
M. tuberculosis [417-419]. Ag85 complex gene homologs are present in other 
mycobacteria including M. bovis BCG, M. bovis and M. leprae [417-420], suggesting a 
fundamental role for this complex in mycobacterial physiology. Ag85 complex proteins 
are the major secreted proteins in mycobacterial liquid cultures but they are also thought 
to associate transiently with the cell wall of mycobacteria (Fig. 4.2). The proteins share 
a fibronectin-binding capacity, which suggests they may be necessary for complement 
receptor phagocytosis of M. tuberculosis [421, 422]. Their major function appears to be 
as mycolyl-transferases, to mediate the production of the glycolipids α, α’-trehalose 
dimycolate and α, α’-trehalose monomycolate [423]. Blocking mycolyl-transferase 
activity inhibited growth of Mycobacterium aurum A+, a surrogate organism used for 
M. tuberculosis drug testing, but did not inhibit growth of E. coli on solid media [423]. 
Therefore, Ag85A, B and C are attractive anti-mycobacterial drug targets [423]. These 
glycolipids form a pseudo-lipid bilayer with mycolic acids (Fig. 4.2) and regulate 
mycobacterial cell wall permeability. Thus, Ag85 complex proteins are critical for the 
final stages of mycobacterial cell wall biogenesis and can be exposed on outer surface 
of the mycobacterial cell wall.
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Figure 4.2: Schematic view of the composition of the mycobacterial cell wall 
This schematic, based on a figure in McNeil, et al. [424], demonstrates several key features of 
the mycobacterial cell wall from slow-growing mycobacteria; the presence of a thin layer of 
peptidoglycan that is covalently bound to a layer of arabinogalactan via a phosphodiester linker, 
LAM covalently bound to the cell membrane, the presence of large amounts of mycolic acid 
bound to arabinogalactan and glycolipids intercalating with the mycolic acid on the surface to 
form a “pseudo-lipid bilayer” (reviewed in [425]). 
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Since Ag85 complex proteins are present on the cell wall and secreted from 
mycobacteria in large amounts, they are also prime antigenic targets for the immune 
response and have been reported to be highly immunogenic. Initial studies showed that 
Ag85 complex proteins could be used for in vitro restimulation to induce proliferation 
and IFN-γ secretion in splenocytes from BCG-vaccinated mice [426] and in PBMCs 
from BCG-vaccinated or M. tuberculosis-infected human subjects [427, 428]. 
Subsequently, components of the Ag85 complex have been further characterised for use 
in vaccination.  
The Th1 epitopes in Ag85A, B and C have been mapped in seven strains of 
BCG-infected mice [429], M. tuberculosis-infected BALB/c and C57BL/6 mice [430] 
as well as in Mantoux test positive and M. tuberculosis-infected human subjects [431]. 
Despite significant homology between the proteins, there appears to be distinct regions 
within each of these proteins that induce strong T cell responses [430]. Ag85A and B 
proteins both generate strong Th1 responses and CTL responses when they are 
incorporated into conventional DNA plasmids and used in murine vaccination models 
[387, 432]. In contrast, Ag85C incorporated into a DNA plasmid vaccine does not 
generate effective Th1 and CTL responses [432] and, as a result, most vaccine 
approaches have utilised Ag85A and Ag85B as candidate Tb antigens.  
Proteins from the Ag85 complex have also been incorporated into cytopathic 
plasmid DNA replicon vaccines. The Ag85A gene was incorporated into a cytopathic 
plasmid DNA replicon encoding a Sindbis-derived RNA replicase [433]. Vaccination of 
BALB/c mice with this construct conferred a 0.77 log10 reduction in lung bacterial 
numbers after virulent M. tuberculosis challenge and this protection was maintained 
long-term. The Ag85B gene has also been incorporated into a Sindbis-derived plasmid 
DNA replicon and conferred significant protection against M. tuberculosis infection 
[398]. However, a protein from the Ag85 complex has not yet been used in a non-
cytopathic DNA replicon system. Thus, the aim of this chapter was to develop a novel 
non-cytopathic plasmid DNA replicon, encoding Ag85A, which I hypothesised would 
result in long-term expression of antigen in a highly immunogenic construct and strong 
induction of CD8+ T cell responses. 
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4.2 Aims 
 
In this chapter, I aimed to develop and test a novel DNA replicon vaccine against Tb 
infection. This novel construct would express Ag85A as the target antigen and also 
express RNA replicase from the Kunjin virus, resulting in the first non-cytopathic 
plasmid DNA replicon vaccine directed against Tb.  
I hypothesised that pKUN85A would induce cell-mediated immunity with 
strong CD8+ T cell responses, which would control infection in the lung and mitigate 
dissemination to other organs. I anticipated that protection from Tb infection would be 
conferred by pKUN85A at lower doses than conventional DNA vaccines. My main 
objectives were to: 
 Clone Ag85A into a Kunjin-based vector called pKUNrep6, resulting in a novel 
plasmid DNA replicon vaccine called pKUN85A. 
 Test pKUN85A for Ag85A protein expression in a mammalian cell line. 
 Evaluate pKUN85A for immunogenicity in the C57BL/6 murine model. 
 Evaluate protection afforded by pKUN85A against Tb infection, dissemination 
of infection and infection-induced pathology in the C57BL/6 murine model.  
 
Furthermore, as Kunjin-based vectors are non-cytopathic, pKUN85A should express 
protein in vivo for a longer period of time compared to cytopathic plasmid DNA 
replicons. If antigen persistence is required for maintenance of mycobacterial immunity, 
then protection conferred by pKUN85A will be relatively long-lived.  
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4.3 Results 
 
4.3.1 Designing the cloning strategy 
 
The first step towards developing the novel DNA replicon vaccine, pKUN85A, was to 
design a strategy for cloning the Ag85A gene into the cloning site of the pKUNrep6 
vector. The Ag85A coding sequence was to be amplified from a construct encoding the 
Ag85A gene called pcDNA3-85A (Fig. 4.3 A), which has been used as a conventional 
plasmid DNA vaccine against Tb [433]. The Ag85A gene was then cloned into the MluI 
cloning site of the pKUNrep6 DNA vector (Fig. 4.3 B). The pKUNrep6 DNA vector 
was supplied by Dr Alex Khromykh, University of Queensland, Brisbane, Australia. 
The sequence cloned into the MluI cloning site of pKUNrep6 must be in-frame 
with the open reading frame (ORF) surrounding the cloning site. This ORF stretches 
from just after the cytomegalovirus (CMV) EI promoter to the end of NS-5, resulting in 
a polycistronic mRNA.  In transfected cells, this polycistronic mRNA is translated into 
a polypeptide containing foot and mouth disease virus (FMDV) autoprotease domains 
either side of the cloning site (Fig. 4.4). The autoproteolytic action of the FMDV 
domains releases the peptide sequence encoded between them, releasing target antigens 
cloned into this site. Downstream of the cloning site on the same polypeptide are 
regions for the Kunjin NS proteins: NS-1, NS-2A, NS-2B, NS-3, NS-4A, NS-4B and 
NS-5 (Fig. 4.4). The Kunjin NS proteins form a complex that functions as the RNA 
replicase of the Kunjin virus [434, 435]. The cloning cassette in pKUNrep6 contains 
only the MluI restriction site. Therefore, the Ag85A gene must be cloned into the MluI 
cloning site of pKUNrep6, in-frame with the surrounding ORF, to ensure effective 
transcription and translation both of Ag85A and the NS proteins of the Kunjin RNA 
replicase. 
A cloning strategy (Fig. 4.5) was developed to clone the Ag85A gene into the 
MluI site of pKUNrep6, creating the new plasmid pKUN85A (Fig. 4.3 D). The Ag85A 
coding sequence was amplified by PCR using primers with 5’ends that incorporated 
MluI restriction sites at either end of the PCR product (Table 4.1).  
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Figure 4.3: Plasmid diagrams for pcDNA3-85A, pKUNrep6, pKUN85AOF and pKUN85A 
Plasmid features include CMV EI promoter regions (dark blue), Ag85A (orange), NS-1 (yellow), 
the other Kunjin NS genes NS-2A, NS-2B, NS-3, NS-4A, NS-4B and NS-5 in sequence (green), 
MluI restriction sites (red), foot and mouth disease virus autoprotease domains (purple), 
polyadenylation (PolyA) sites (light pink) and the ORFs running from start to termination 
codons (black arrows). Total bp size of the plasmids is indicated and the first bp is designated 
by the black notch at the top of the plasmid. A) The pcDNA3-85A plasmid containing Ag85A in 
an ORF running from 932 to 1975 bp. B) The pKUNrep6 vector with the MluI cloning site at 
4239 bp and the ORF spanning the MluI site, NS-1 and the other NS genes from 4090 to 12330 
bp. C) The pKUN85AOF construct with Ag85A inserted into the MluI site out of frame. Ag85A 
insertion introduces a premature stop codon at 4242 bp, which truncates the ORF so it only 
spans from 4090 to 4242 bp and prevents translation of NS-1 and the other NS genes. D) The 
pKUN85A construct with Ag85A inserted into the MluI site in the correct orientation and in-
frame with the surrounding ORF. This creates a large ORF spanning from 4090 to 13314 bp 
that includes Ag85A, NS-1 and the other NS genes.
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Figure 4.4: Schematic diagram of the translated product from pKUN85A 
The pKUN85A ORF (outlined in Fig. 4.3 D) encodes the peptides outlined above. The 
translated ORF is a 3075 amino acid (aa) polypeptide containing the Ag85A peptide and the 
Kunjin virus NS peptides NS-1, NS-2A, NS-2B, NS-3, NS-4A, NS-4B and NS-5. The Ag85A 
peptide is bordered by FMDV 2A auto-protease domains, which mediate the release of the 
Ag85A peptide from the polypeptide. Other proteolytic domains between the NS peptides 
mediate the release of these peptides and permit formation of the Kunjin RNA replicase. The 
released 339 aa peptide encoding Ag85A does not contain the full-length Ag85A protein but it 
contains the regions of Ag85A that encode epitopes, which induce strong cytokine production in 
BCG vaccinated or M. tuberculosis infected BALB/c and C57BL/6 mice. 
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Figure 4.5: The cloning strategy for the creation of pKUN85A 
1) pKUNrep6 is amplified by transformation into E. coli. 2) E. coli are propagated and 
pKUNrep6 plasmid stock is purified by plasmid mini-prep. 3) pKUNrep6 is digested with MluI, 
dephosphorylated with CIAP, purified and quantified in preparation for ligation. 4) The Ag85A 
gene is PCR amplified from pcDNA3-85A, which introduces MluI restriction sites to either end 
of the product, and the product is purified. 5) The Ag85A PCR product is digested with MluI, 
purified and quantified in preparation for ligation. 6) The Ag85A PCR product and pKUNrep6 
are ligated using T4 DNA ligase, creating pKUN85A. 7) E. coli are transformed with ligation 
reactions and transformants are screened for the presence of intact pKUN85A with orientation 
PCRs, orientation digests and DNA sequencing. 8) A transformant containing pKUN85A is 
selected, propagated and used for vaccine production. 
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The positioning of the primers, called 5’ Ag85A and 3’ Ag85A, and MluI 
restriction sites relative to the Ag85A gene (Table 4.1) was chosen to ensure that after 
cloning, the Ag85A coding sequence would be in-frame with the ORF that extends over 
the cloning site (Fig. 4.4). The sequence was also selected to avoid incorporating start or 
stop codons. One complication that arose during primer design was that the 3’ end of 
the Ag85A gene is rich in guanine (G) and cytosine (C) bases rather than adenine (A) 
and thymine (T) bases, making design of primers to target this region difficult. High GC 
content in a PCR primer increases the melting temperature of the primer and prolonged 
periods at higher heat decreases the efficacy of the DNA polymerase used in the PCR 
reaction. Therefore, while the 5’ primer includes the first codon after the Ag85A start 
codon, the 3’ primer truncates the end of Ag85A, as it was designed to bind to a less 
GC-rich sequence. However, the sequence amplified by the primers retains regions of 
the Ag85A protein that have been reported to be immunogenic in BALB/c and C57BL/6 
mice (Fig. 4.4) [430].  
 
Table 4.1: Ag85A PCR primer design 
5’ Ag85A primer: GCGACGCGTTGCAGCTTGTTGACAGGGTTCG 
GC content (%) 61.29 
Projected secondary structure Weak 
Projected primer dimer None 
 
3’ Ag85A primer: GATACGCGTGACCCAGTGCCCGTTGCAGG 
GC content (%) 65.52 
Projected secondary structure Weak 
Projected primer dimer None 
Bases underlined indicate MluI restriction enzyme sites and bases in bold indicated sequence 
coding for Ag85A. Three filler bases were added 5’ of the MluI restriction site to promote 
efficient enzyme scanning and digestion. 
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A second primer pair was designed to clone the Ag85A gene into pKUNrep6 out of 
frame, creating the second plasmid pKUN85AOF (Fig. 4.3 C). The primers, called 5’ 
Ag85A2 and 3’ Ag85A2 (Appendix 8.1), were designed to incorporate MluI restriction 
sites at either end of the Ag85A gene and facilitate insertion of the gene into the MluI 
site using the cloning strategy described above. However, in this construct, the Ag85A 
coding sequence is out of frame with the ORF spanning the cloning site and the cloned 
section incorporates a stop codon to prematurely terminate transcription (Fig. 4.3 C).  
Thus, the pKUN85AOF plasmid possesses the Ag85A coding sequence in the 
correct site and orientation but does not express either Ag85A or the Kunjin RNA 
replicase. The pKUN85AOF plasmid was used as a positive control for orientation 
PCRs and digests and a negative control for protein expression studies. The pKUNrep6 
plasmid expresses only Kunjin RNA replicase and was used as a negative control for 
orientation PCR and digests and a positive control for Kunjin RNA replicase protein 
expression studies. 
 
4.3.2 Preparation of Ag85A PCR product and pKUNrep6 vector DNA 
 
Using pcDNA3-85A as template DNA, a PCR reaction to amplify the Ag85A gene was 
optimised and conditions are outlined in section 2.6.1. To amplify the Ag85A gene, PCR 
reactions used the high-fidelity AccuPrime Pfx PCR system, which has several features 
that ensure purity of the Ag85A PCR product. AccuPrime Pfx PCR system uses Pfx 
DNA polymerase to amplify the target sequence, which has intrinsic proofreading 
activity to minimise the risk of incorporating mutations into the amplified sequence. 
Anti-Pfx antibodies are also included, to prevent non-specific activity of Pfx at low 
temperatures, as are accessory proteins, to prevent mispriming during PCR 
amplification. Following PCR amplification of the Ag85A gene, a ~990 bp PCR product 
was observed (Fig. 4.6 A), which was purified and quantified in preparation for cloning 
(sections 2.6.8 and 2.6.9). 
The pKUNrep6 vector was also prepared for cloning. DH5α E. coli were 
transformed with pKUNrep6 plasmid (section 2.6.5), and a transformant containing the 
pKUNrep6 plasmid was selected and used to propagate the plasmid.  The pKUNrep6 
DNA was purified and quantified (sections 2.6.8 and 2.6.9) and MluI digestion and 
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dephosphorylation of the pKUNrep6 vector were optimised in preparation for cloning 
(Fig. 4.6 B). Conditions are outlined in sections 2.6.2 and 2.6.3. 
 
 
 
 
 
 
Figure 4.6: Preparation of Ag85A PCR product and pKUNrep6 for cloning 
A) Ten µL of Ag85A PCR products and 1 µl of the purified Ag85A PCR product were run on a 
1.5 % agarose gel at 80 V for 1 hour. Four µL of the 100 bp DNA ladder (Invitrogen) was run to 
estimate PCR product size. PCR product size was estimated at approximately 990 bp, which 
corresponds with the expected size of 996 bp. B) Three µL of pKUNrep6 digest products were 
run on a 0.8 % agarose gel at 100 V for 1 hour. Four µL of the High Mass DNA ladder 
(Invitrogen) was run to estimate digest product size. Undigested pKUNrep6 ran as two bands at 
approximately 12000-13000 bp, which represents plasmid DNA in the open circle format, and a 
faster band at approximately 8800 bp, which represents more compact supercoiled plasmid 
DNA. Both digested and digested/dephosphorylated pKUNrep6 products ran as one band that 
was estimated at 12000-13000 bp, which corresponds with the expected size of linear 
pKUNrep6 at 13481 bp. Figures are representative of two replicate experiments.  
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4.3.3 Cloning Ag85A into pKUNrep6 
 
After the Ag85A PCR product and the pKUNrep6 vector had been prepared, they were 
used in the cloning strategy outlined in Fig. 4.5 (described in sections 2.6.2 to 2.6.5). 
The Ag85A PCR product and the pKUNrep6 vector were digested with MluI. Digested, 
linearised pKUNrep6 was also treated with CIAP. This removes the 5’ phosphate group 
from the DNA backbone of the linearised vector, and prevents the digested ends of the 
vector from religating prior to ligase treatment.  
The digested stocks of the Ag85A gene and pKUNrep6 were purified, quantified 
and ligated. Ligation reactions were incubated overnight and then transformed into E. 
coli. Transformation reactions were plated onto LB Amp+ agar plates, as the pKUNrep6 
vector contains an ampicillin resistance gene, to screen for transformants and resulting 
colonies were counted (data not shown). Positive controls were included, such as E. coli 
transformed with undigested pKUNrep6 DNA or pUC19 plasmid DNA, which also 
contains an ampicillin resistance gene, and these resulted in a large number of colonies.  
A negative control for transformation was also included, which was E. coli that were 
left untransformed, and this did not yield any colonies. E. coli transformed with target 
ligation reactions yielded colonies and these were screened for the insertion of the 
Ag85A gene into pKUNrep6 and orientation of the gene.  
  
4.3.4 Screening of transformants for pKUN85A 
 
Transformants were screened to check for the presence and orientation of the Ag85A 
insert in three ways: orientation PCR, orientation restriction digest and sequencing.  
Colonies on transformant master plates were used for the orientation PCR 
(section 2.6.6), using the primer pair 5’ CS and 3’ Mid (Appendix 8.1). This primer pair 
is designed to amplify the sequence extending from within the pKUNrep6 vector 
upstream of the cloning site into the middle of Ag85A, resulting in an 852 bp PCR 
product if the gene has inserted correctly (Fig. 4.7 A). Three transformants containing 
the vector with the Ag85A gene inserted in the correct orientation were identified using 
the orientation PCR: numbers 33, 37 and 42 (Fig. 4.7 B).  
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 The orientation PCR is a rapid way to assess the orientation of the Ag85A insert 
but a restriction digest was performed to confirm these results. DNA samples were 
prepared from transformants 33, 37 and 42 (section 2.6.11) and used in an orientation 
restriction digest (section 2.6.7). The orientation restriction digest used the restriction 
enzymes XbaI and KspI (Fig. 4.8 A). Digestion of the projected plasmids with these 
enzymes results in fragments of 8802, 5196 and 467 bp if Ag85A is inserted in the 
incorrect orientation but fragments of 8064, 5196 and 1205 bp if Ag85A is inserted in 
the correct orientation (Fig. 4.8 B). All three transformants identified in the orientation 
PCR had bands at 8064, 5196 and 1205 bp after restriction digest, confirming that the 
Ag85A gene had inserted in the correct orientation. 
 Transformants 33, 37 and 42 contained the vector with the Ag85A insert in the 
correct orientation, as indicated by orientation PCR and orientation digest. These 
transformants were then sequenced using the Alan Wilson Centre Sequencing Service, 
Massey University, Palmerston North, New Zealand. Four primer sites were chosen to 
sequence the region spanning the cloning site in both the forward and reverse directions 
(Appendix 8.1 and 8.2). The projected construct sequence was constructed using Vector 
NTI Software (Invitrogen). A compiled sequence acquired for each transformant sample 
was compared to the projected construct sequence (Appendix 8.2) using the bl2seq 
Basic Local Alignment Search Tool, which is available on the National Center for 
Biotechnology Information website 
(http://www.ncbi.nlm.nih.gov/BLAST/bl2seq/wblast2.cgi). Sequence comparison 
confirmed that transformants 33 (data not shown), 37 (Appendix 8.2) and 42 (data not 
shown) all contained the Ag85A gene, without mutations, and that insertion was in-
frame with the ORF spanning the cloning site. Therefore, transformants 33, 37 and 42 
would all have been suitable for vaccine propagation, but transformant number 37 was 
chosen and used as the master transformant for pKUN85A (Appendix 8.2). Large liquid 
cultures of transformant number 37 were prepared and the pKUN85A plasmid was 
purified using endotoxin removal solution and endotoxin free buffers (section 2.6.12). 
Purified pKUN85A plasmid was used in protein expression, immunogenicity and 
protection assays. 
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Figure 4.7: Orientation PCR of transformants 
A) Transformants were screened for the presence and orientation of the Ag85A insert initially by 
orientation PCR, using the PCR primers 5’ CS and 3’ Mid. If the Ag85A gene had inserted in 
the correct orientation, an 852 bp PCR product was observed. If the Ag85A gene had not 
inserted or had inserted in the wrong orientation, there was no product. B) Ten µl of orientation 
PCR products were run on an agarose gel (1.5 %) at 100 V for 1 hour. Four µL of the 100 bp 
DNA ladder (Invitrogen) was run to estimate PCR product size. Orientation PCR product size 
was estimated at approximately 900 bp, which corresponds with the expected size of 852 bp. 
PCR products were observed in the pKUN85AOF positive control and three transformants; 
colony numbers 33, 37 and 42. Orientation PCRs were performed once to screen transformant 
colonies and results were confirmed using orientation digests and sequencing. 
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Figure 4.8: Sample orientation digest for transformants 
A) Transformants were also screened for the presence and orientation of the Ag85A insert by an 
orientation digest using the restriction enzymes XbaI and KspI. B) Three µl of sample 
orientation digest products from pKUN85A transformants were run on a 1 % agarose gel at 100 
V for 2 hours to ensure optimal separation of larger fragments. Four µL of the 100 bp DNA 
ladder (Invitrogen) and four µL of the High Mass DNA ladder (Invitrogen) were run to estimate 
digest fragment size. If the Ag85A gene inserted in the correct orientation, 8064, 5196 and 1205 
bp fragments were observed. If the Ag85A gene inserted in the wrong orientation, 8802, 5196 
and 497 bp fragments were observed. Orientation digests were performed on miniprep DNA 
from transformants previously identified by orientation PCRs and results were confirmed using 
sequencing. 
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4.3.5 Expression of Ag85A and NS-1 protein from pKUN85A 
 
The Ag85A gene had inserted into pKUNrep6, as predicted; however protein expression 
from the pKUN85A plasmid had to be tested in transfected mammalian cells to confirm 
that pKUN85A expressed the Ag85A protein and the Kunjin RNA replicase NS 
proteins. To analyse Ag85A and NS-1 protein expression, pKUN85A was transfected 
into the murine fibroblast cell-line NIH-3T3 (section 2.7.1). Seventy-two hours after 
transfection, supernatants and cells were harvested and lysed, and cell lysates were 
immunoprecipitated to enrich for either the Ag85A protein or the NS-1 protein (section 
2.7.2). These immunoprecipitated cell lysates were then used in SDS-PAGE gel 
electrophoresis, Western transfer and immunodetection of protein expression (section 
2.7.3). Antibody pairs used for immunodetection targeted either the Ag85A or the NS-1 
protein and detection was optimised using dot blots.  
The mouse anti-Ag85A primary antibody (clone 32.15) is not commercially 
available, and cell culture supernatant containing the antibody was sourced from Dr 
Kris Huygen, Institut Pasteur, Brussels, Belgium [429]. Supernatant containing the 
mouse anti-Ag85A primary antibody was used undiluted and anti-native mouse IgG-
HRP secondary antibody was used at a 1:1000 dilution for detection of Ag85A. A 
specific band for Ag85A should resolve on a Western blot at ~32 kDa, but all cell 
lysates displayed a non-specific band at ~12 kDa, including negative controls and the 
positive control containing purified Ag85A protein (data not shown). This indicated that 
the anti-Ag85A antibody (clone 32.15) was not specific for Ag85A or was not sufficient 
to detect Ag85A in our assay. 
The mouse anti-NS-1 primary antibody is also not commercially available, and 
cell culture supernatant containing the antibody was sourced from Dr Alex Khromykh 
and Dr Rob Hall, University of Queensland, Brisbane, Australia. Supernatant containing 
the mouse anti-NS-1 primary antibody was used at a 1:50 dilution and anti-native 
mouse IgG-HRP secondary antibody was used at a 1:1000 dilution for detection of NS-
1, and these concentrations resulted in a specific band on a Western blot. Ponceau-S 
staining of the blots indicated that loading of the immunoprecipitated cell lysates was 
consistent in terms of the total amount of protein applied (Fig. 4.9 A).  
The predicted size of NS-1 is 39-41 kDa. After immunodetection, there was a 
clear band in this region for the positive control, which was cell lysate from pKUNrep6 
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transfected cells (Fig. 4.9 B). The pKUN85AOF construct has the Ag85A gene inserted 
out of frame with the ORF spanning the cloning site and introduces a premature stop 
codon (Fig. 4.3 C). This construct should not produce Ag85A protein and should also 
terminate the polypeptide prematurely, preventing expression of NS-1. As predicted, 
there was no band for NS-1 in the cell lysate sample from pKUN85AOF transfected 
cells (Fig. 4.9 B). Notably, there was a clear 39-41 kDa band in the cell lysate sample 
from pKUN85A transfected cells (Fig. 4.9 B). This demonstrates that ORF sequence 
downstream of the Ag85A insertion site was translated in pKUN85A transfected cells. 
Translation of the NS genes is essential for expression of the RNA replicase, which is 
essential for dsRNA production and the enhanced immunogenicity of the DNA 
replicon.  
Translation from NS-1 implies that Ag85A inserted upstream of NS-1 is also 
translated, as sequencing has shown Ag85A is in-frame with the same ORF that contains 
NS-1. Therefore, while the anti-Ag85A primary antibody proved unsuitable for Western 
transfer and immunodetection, expression of Ag85A protein by the pKUN85A construct 
was implied by expression of the NS-1 protein. 
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Figure 4.9: Protein expression from pKUN85A-transfected NIH-3T3 cells 
DNA plasmids including pKUN85A were assessed for their ability to express NS-1 in 
mammalian cells. Plasmids were transfected into NIH-3T3 cells and left in culture for 72 hours 
to allow protein expression. Cell lysates were prepared and immunoprecipitated for NS-1, 
before being used in SDS-PAGE, Western transfer and immunodetection with antibodies 
specific for NS-1. A) Ponceau-S stained blot for NS-1. The Ponceau-S stained membrane 
demonstrates even loading of cell lysates. B) Western blot for NS-1. The membrane from A) 
was immunoblotted with mouse anti-NS-1 primary antibody and anti-native mouse IgG HRP-
conjugated secondary antibody. A 39-41 kDa band, corresponding to the expected size for NS-
1, was observed in cell lysate from pKUNrep6 transfected cells and from pKUN85A transfected 
cells. No bands were observed in negative controls. Results represent one experiment. 
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4.3.6 Immunogenicity of pKUN85A 
 
Protein from the pKUN85A construct was expressed by transfected mammalian cells in 
in vitro culture. However, the mechanism mediating in vivo transfection with DNA 
plasmids is not well understood and whether cells could be transfected by pKUN85A 
and express protein to induce an immune response in vivo remained to be tested. 
Furthermore, the dose of plasmid DNA replicons required for vaccination is typically 
lower than the dose for conventional DNA plasmids. Therefore, a dose titration was 
performed to assess the immunogenicity of pKUN85A. 
Different groups of mice were vaccinated i.m. with doses of pKUN85A ranging 
from 5 µg to 100 µg. Mice were primed, then boosted two weeks later, with the same 
vaccine dose. Two weeks after boosting, tissues were harvested and processed for in 
vitro restimulation. Lymphocyte proliferation was assessed by a [3H] thymidine 
incorporation assay, total IFN-γ production was assessed by ELISA and cytokine 
production by CD4+ and CD8+ T cells was assessed by flow cytometry. 
Proliferation in response to purified Ag85A protein was highest in mice 
vaccinated with 25 µg of pKUN85A and was significantly higher compared to 
pKUNrep6 vaccinated control mice (Fig. 4.10 A). The average total IFN-γ production in 
supernatants from restimulated cultures was highest, although not significantly 
different, in mice vaccinated with 25 µg of pKUN85A (Fig. 4.10 B). Total IFN-γ 
production was significantly higher in mice vaccinated with 100 µg of pKUN85A 
compared to PBS treated and pKUNrep6 vaccinated control mice (Fig. 4.10 B). The 
average numbers of IFN-γ-producing CD4+ lymphocytes and IFN-γ- or IL-2-producing 
CD8+ T lymphocytes were highest in mice vaccinated with 25 µg of pKUN85A (Fig. 
4.11) and were significantly higher than PBS treated and pKUNrep6 vaccinated mice 
(Fig. 4.11). Notably, cytokine production and proliferation appeared to decrease with a 
100 µg dose of pKUN85A compared to a 25 µg dose. With plasmid DNA replicons, 
higher doses often decrease the immunogenicity of the vaccine [433]. Therefore, i.m. 
vaccination with pKUN85A induced an Ag85A-specific immune response, with 
cytokine production and proliferation. As a result of these experiments, a 25 µg dose 
was chosen for experiments using pKUN85A in chapter 5. 
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Figure 4.10: Lymphocyte proliferation and IFN-γ  production after pKUN85A vaccination 
Groups of mice were primed and then boosted two weeks later i.m. with the indicated dose of 
pKUN85A, 100 µg of pKUNrep6 or PBS alone. Mice were left two weeks before spleens were 
harvested and processed. Lymphocytes were plated and restimulated with Ag85A and anti-
CD28 mAb to assess either proliferation by [3H] thymidine incorporation or IFN-γ production 
by ELISA. A) Antigen-driven proliferation of lymphocytes from vaccinated animals. Dotted 
line indicates maximal background proliferation.  B) IFN-γ production by lymphocytes from 
vaccinated animals measured by ELISA. The dotted line indicates limit of detection of ELISA 
at 0.0315 ng/mL. Bars represent mean values ± SEM. Five mice were analysed per treatment 
group. Treatment groups were compared using the two-tailed Mann Whitney test; * indicates p 
≤ 0.05. Results represent one experiment, although proliferation data for the 25 µg dose of 
pKUN85A has been replicated. 
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Figure 4.11: Cytokine production by CD4+ and CD8+ T cells after pKUN85A vaccination 
Groups of mice were primed and then boosted two weeks later i.m. with the indicated dose of 
pKUN85A, 100 µg of pKUNrep6 or PBS alone. Mice were left two weeks before spleens were 
harvested and processed. Lymphocytes were plated and restimulated with Ag85A and anti-
CD28 mAb to assess cytokine production via intracellular cytokine staining. A) Percentage of 
CD4+ T cells producing IFN-γ. B) Percentage of CD8+ T cells producing IFN-γ. C) Percentage 
of CD4+ T cells producing IL-2. D) Percentage of CD8+ T cells producing IL-2. Bars represent 
mean values ± SEM. Five mice were analysed per treatment group. Treatment groups were 
compared using the two-tailed Mann Whitney test; * indicates p ≤ 0.05, ** indicates p ≤ 0.01. 
Results represent one experiment. 
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4.3.7 Short-term protection from infection afforded by pKUN85A 
 
Vaccination with pKUN85A induced an immune response directed against 
mycobacterial antigens, with antigen-driven IFN-γ production by CD4+ T cells. This is 
often used as an indicator of immunity against Tb. However, it is becoming increasingly 
obvious that IFN-γ production by CD4+ T cells is not a good correlate of Tb vaccine 
efficacy [167]. Therefore, protective efficacy of pKUN85A against a virulent challenge 
with M. tuberculosis at a range of doses needed to be assessed.  
To evaluate protection afforded by pKUN85A, different groups of mice were 
vaccinated i.m. with doses of pKUN85A ranging from 5 µg to 100 µg. Mice were 
primed, then boosted two weeks later with the same vaccine dose. As a positive control, 
one group of mice was vaccinated with BCG s.c. at the same time as DNA boosting. Six 
weeks after boosting, all groups of mice were challenged by aerosol with M. 
tuberculosis. Five weeks after infection, lung and spleen tissue was harvested; a lung 
sample was taken for histology and the spleen and remainder of the lung tissue were 
processed to evaluate tissue bacterial numbers.  
Upon collection of tissue bacterial numbers, some samples were observed that 
had undetectable CFUs for both plated lung and spleen tissue homogenates. The murine 
model of M. tuberculosis infection used in this study aims to mimic natural human 
infection by using a low infection dose of approximately 50 CFU of M. tuberculosis per 
mouse. Due to this low infection dose, there is the risk that infections can be too low, 
resulting in variation and uninfected mice. In this study, six mice in five of the eight 
treatment groups were uninfected and within groups for mice that were infected, there 
was more variation in tissue bacterial numbers than is usually seen. In subsequent 
experiments, the infection dose was increased but, for analysis of this study, data from 
uninfected mice were excluded from analyses of lung and spleen bacterial numbers.  
Lung bacterial numbers were evaluated to assess pathogen control at the primary 
site of infection, the lung. BCG vaccinated mice displayed a 0.88 log10 reduction in total 
lung bacterial numbers compared to the naïve PBS treated mice (Fig. 4.12 A), which 
was statistically significant but slightly less than the ~1 log10 reduction typically seen in 
the C57BL/6 murine model of Tb [171]. The pcDNA3-85A vaccination was included as 
another positive control and this resulted in a 0.48 log10 reduction in total lung bacterial 
numbers compared to naïve PBS treated mice (Fig. 4.12 A), which was also statistically 
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significant but less than the 0.70 log10 reduction seen in previous vaccination studies 
[433]. Mice vaccinated with the empty pKUNrep6 vector displayed a 0.30 log10 
reduction in lung bacterial numbers compared to the naïve PBS treated mice, which was 
not statistically significant (Fig 3.10 A). Non-coding DNA can enhance protection 
against Tb in a heterologous prime-boost setting, presumably due the inherent 
adjuvancy of the bacteria-derived DNA [436], but this decrease in bacterial numbers 
was not seen in other short- or long-term protection studies (data not shown) so is 
unlikely to be a real effect. Mice vaccinated with 100, 25 or 5 µg of pKUN85A did not 
display significant reductions in lung bacterial numbers. Mice that received 10 µg of 
pKUN85A displayed a 0.39 log10 reduction in lung bacterial numbers compared to 
naïve PBS treated mice (Fig. 4.12 A), but this was not statistically significant 
(p=0.0635).  
Bacterial numbers in the spleen were evaluated to assess dissemination of Tb 
infection to tissues beyond the primary site of infection in the lung. BCG vaccinated 
mice displayed a 1.74 log10 reduction in average spleen bacterial numbers compared to 
naïve PBS treated mice, but this difference was not significant (p=0.0571) due to large 
variation within treatment groups and small sample size (Fig. 4.12 B). Mice vaccinated 
with all other constructs did not display significant reductions in total spleen bacterial 
numbers compared to naïve PBS treated mice (Fig. 4.12 B). 
Overall in this study, the infection dose was relatively low and there was more 
variation than usual in bacterial numbers in the tissues for each treatment group. The 
low infection dose resulted in mice with undetectable lung bacterial numbers and these 
mice were not included in data analysis. In spite of this, significant reductions in 
bacterial numbers in the lung were observed for mice vaccinated with BCG or 
pcDNA3-85A compared to naïve PBS control mice.  Mice vaccinated with pKUN85A 
did not display significant reductions in bacterial numbers in the lung or spleen 
compared to naïve PBS control mice in this study, but short-term protection against an 
M. tuberculosis challenge will be re-assessed in the future with a higher infection dose.  
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Figure 4.12: Short-term protection from M. tuberculosis infection after pKUN85A 
vaccination 
Mice were primed and then boosted two weeks later i.m. with the indicated dose of pKUN85A, 
100 µg of pKUNrep6 or 100 µg of pcDNA3-85A. Control groups of mice were also vaccinated 
with PBS alone or 106 CFU BCG s.c. at the time of DNA boosting in experimental groups of 
mice.  Mice were left 6 weeks before being challenged by aerosol with M. tuberculosis. Five 
weeks after infection, lungs and spleens were harvested, homogenised and plated to evaluate 
tissue bacterial numbers. A) Bacterial numbers in the lung after M. tuberculosis challenge. B) 
Bacterial numbers in the spleen after M. tuberculosis challenge. Bars represent geometric mean 
values ± GEM. Three to five mice were analysed per treatment group. Treatment groups were 
compared using the two-tailed Mann Whitney test; NS indicates p > 0.05, * indicates p ≤ 0.05. 
Results represent one experiment, although data for the 25 µg dose of pKUN85A has been 
replicated. 
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4.3.8 Long-term protection from infection afforded by pKUN85A 
 
A candidate Tb vaccine should confer protection that is long-lived; otherwise subjects 
may need to be periodically revaccinated. Therefore, a long-term protection study was 
undertaken using the same experimental design as the short-term protection study, 
except that mice were left for sixteen weeks after boosting before challenge with M. 
tuberculosis.  
The infection dose for this study was higher and all mice had detectable lung 
bacterial numbers. Therefore, differences in vaccine efficacy could be accurately 
evaluated. BCG vaccinated mice displayed a statistically significant 0.86 log10 reduction 
in lung bacterial numbers compared to naïve PBS treated mice (Fig. 4.13). The 
pcDNA3-85A vaccinated mice did not display a significant reduction in lung bacterial 
numbers compared to naïve PBS treated mice (Fig. 4.13), as expected since protection 
has been seen to wane over time in other studies with pcDNA3-85A [433]. Finally, 
significant reductions in lung bacterial numbers were not observed for mice vaccinated 
with either 100 µg or 10 µg of pKUN85A (Fig. 4.13). 
Overall, the long-term protection afforded by pKUN85A was difficult to 
compare to short-term protection due to the low infection dose and large amount of 
variation of bacterial numbers in the short-term study. However, only BCG vaccination, 
and not pKUN85A or pcDNA3-85A vaccination, resulted in a statistically significant 
reduction in lung bacterial numbers compared to naïve PBS treated mice after a long-
term challenge with M. tuberculosis. 
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Figure 4.13: Long-term protection from M. tuberculosis infection after pKUN85A 
vaccination 
Mice were primed and then boosted two weeks later i.m. with the indicated dose of pKUN85A, 
100 µg of pKUNrep6 or 100 µg of pcDNA3-85A. Control groups of mice were also vaccinated 
with PBS alone or 106 CFU BCG s.c. at the time of DNA boosting in experimental groups of 
mice. Mice were left 15 weeks before being challenged by aerosol with M. tuberculosis. Five 
weeks after infection, lungs were harvested, homogenised and plated to evaluate tissue bacterial 
numbers. Bars represent geometric mean values ± GEM. Five mice were analysed per treatment 
group. Treatment groups were compared using the two-tailed Mann Whitney test; * indicates p 
≤ 0.05. Results represent one experiment. 
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4.3.9 Pulmonary inflammation after pKUN85A vaccination followed 
by Tb challenge 
 
Inflammation in the lung tissue causes the pathology associated with Tb disease 
resulting in morbidity and death (outlined in chapter 1). A candidate Tb vaccine must 
control the infection in the tissues, as well as minimise immunopathology in the lung, to 
reduce morbidity associated with Tb disease. Therefore, pulmonary inflammation after 
virulent challenge is another important measure of the protective efficacy of a vaccine. 
 Lung samples were taken in parallel to the studies assessing short-term and 
long-term protection in Fig. 4.12 and 4.13. Samples were prepared for histological 
analysis and graded for the degree of pulmonary inflammation. Samples were harvested 
5 weeks after infection with M. tuberculosis and the degree of inflammation overall was 
low. As a result, differences in inflammation between treatment groups were 
statistically insignificant (Fig. 4.14 A/B) and, for better assessment of pathological 
changes in the lung tissue, future experiments should harvest tissue later after infection.  
Mild, localised granulomatous inflammation, with epithelioid histiocytes and 
lymphocytes present within the pulmonary interstitium and alveolar spaces, was 
observed in all groups after M. tuberculosis challenges either short- or long-term after 
vaccination (Fig. 4.14 A/B). The degree of inflammation appeared reduced in BCG 
vaccinated mice, although the median score did not differ significantly from naïve PBS 
treated mice (Fig. 4.14 A/B). In mice challenged long-term after vaccination, 
inflammation also appeared reduced to a level comparable to BCG vaccinated groups in 
groups vaccinated with 100µg of pKUN85A or 100µg of pcDNA3-85A, although 
scores did not differ significantly from PBS treated control mice (Fig. 4.14 B).  
Therefore, pKUN85A vaccination does not significantly decrease pulmonary 
inflammation induced 5 weeks after M. tuberculosis challenge compared to PBS treated 
controls, although differences between treatment groups may become more apparent 
later after infection. 
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Figure 4.14: Lung pathology after pKUN85A vaccination 
Mice were primed and then boosted two weeks later i.m. with the indicated dose of pKUN85A, 
100 µg of pKUNrep6 or 100 µg of pcDNA3-85A. Control groups of mice were also vaccinated 
with PBS alone or 106 CFU BCG s.c. at the time of DNA boosting in experimental groups of 
mice. Mice were left 6 or 15 weeks before being challenged by aerosol with M. tuberculosis. 
Five weeks after infection, lung samples were harvested, inflated and fixed. Samples were 
paraffin-embedded, sectioned and stained with haematoxylin and eosin. Sections were analysed 
by light microscopy and graded for inflammation. A) Composite lung pathology scores for M. 
tuberculosis challenge 6 weeks after vaccination. B) Composite lung pathology scores for M. 
tuberculosis challenge 15 weeks after vaccination. Pathology scores ranged from 0 (least 
severe) to 5 (most severe). Symbols represent individual values. Lung samples from five mice 
were analysed for each treatment group. Results in A represent one experiment, although data 
for the 25 µg dose of pKUN85A has been replicated. Results in B represent one experiment. 
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4.4 Discussion 
 
This chapter outlines the creation of pKUN85A, a novel plasmid DNA replicon vaccine 
for protection against Tb infection, and initial testing of vaccine efficacy. The Ag85A 
gene was cloned into the pKUNrep6 vector and a suitable transformant was selected for 
propagation and preparation of the pKUN85A vaccine (Figs. 4.3-4.8). The pKUN85A 
construct expressed protein from the ORF containing the Ag85A and the Kunjin RNA 
replicase genes in a mammalian cell-line (Fig. 4.9). Vaccination with pKUN85A 
induced an immune response directed against Ag85A, as assessed by antigen-driven 
proliferation and IFN-γ and IL-2 production by CD4+ and CD8+ lymphocytes (Figs. 
4.10/4.11). Studies assessing short-term and long-term protection (Figs. 4.12/4.13) 
remain to be repeated before firm conclusions can be drawn regarding vaccine efficacy. 
Vaccination with pKUN85A did not induce protection comparable to the BCG vaccine 
in either study (Figs. 4.12/4.13), indicating that homologous prime-boost vaccination 
with pKUN85A is not as effective as BCG vaccination in the murine model of Tb. 
However, refinements are can be made in order to improve the protective efficacy of the 
pKUN85A plasmid DNA replicon against Tb, as addressed in section 4.4.4. 
Tb vaccine efficacy studies conducted in PC-3 facilities can be complicated and 
must be carefully designed. Studies are lengthy and expensive in terms of reagents and 
space, as large numbers of mice must be vaccinated, boosted and challenged with 
virulent mycobacteria in specialised PC-3 facilities over several months and physical 
space in facilities is limited. For the short-term protection study, the infection dose was 
low to mimic low-dose natural human infection, but this resulted in some mice being 
uninfected (Fig. 4.12). Those that were infected had variable bacterial numbers in the 
tissues within treatment groups and the degree of inflammation in the lung was low 
(Fig. 4.14). This meant that while trends over treatment groups were apparent, 
differences between treatment groups were not statistically significant. There is 
variation inherent in the process of aerosol infection and the kinetics of mycobacterial 
infection. Factors such as vaccine batch and infection inoculum batch can also lead to 
variation in bacterial numbers. Therefore, for more accurate assessment of the 
protection afforded by pKUN85A against M. tuberculosis infection, these results will be 
repeated with a larger number of mice and higher infection dose, and lung pathology 
will be assessed later after virulent infection. 
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4.4.1 Titration of the optimal pKUN85A dose 
 
This study demonstrates a current issue for development of Tb vaccines; there is no 
reliable immunological correlate of protection that can be used to assess vaccine 
efficacy after vaccination or before infection [167]. The optimal dose of pKUN85A for 
immunogenicity at two weeks after boost vaccination was determined to be 25 µg. The 
25 µg dose of pKUN85A consistently induced increased markers of immunogenicity 
compared to the lower 10 and 5 µg doses of pKUN85A, such as proliferation and 
cytokine production in response to Ag85A stimulation (Fig. 4.10/4.11). However, the 
25 µg dose of pKUN85A did not confer measurable protection in a short-term challenge 
protocol (Fig. 4.12). Bacterial numbers for the short-term protection study were variable 
within treatment groups and some mice were uninfected, but the 25 µg dose of 
pKUN85A also did not provide a measurable degree of protection when used in 
experiments in chapter 5 (Fig. 5.15). Furthermore, proliferation and cytokine production 
was analysed only at 2 weeks after vaccination. While the 25 µg dose induced the 
highest average proliferative and cytokine responses at two weeks after vaccination, the 
other doses of pKUN85A may have had different kinetics and maximal responses for 
antigen-driven proliferation or cytokine production may have occurred at different times 
after vaccination. These results illustrate that while it is important to demonstrate an 
immune response against the target mycobacterial antigen has been elicited after 
vaccination, that response does not predict whether the Tb vaccine will confer 
protection against infectious challenge. 
This study also illustrates the importance of dose for plasmid DNA replicon 
vaccines. It has been shown that plasmid DNA replicons have a defined window for the 
optimal dose, rather than increased doses of vaccine resulting in better protection [433]. 
As the exact mechanism and target cells for plasmid DNA replicons is unknown, the 
basis for the optimal dose effect is yet to be defined. However, it is clear that the dose of 
plasmid DNA replicons must be titrated with respect to protection, as a given dose of a 
plasmid DNA replicon can induce a strong immune response but slight increases or 
decreases in dose may affect vaccine immunogenicity dramatically.  
As there is no reliable immune correlate for protection against Tb, plasmid DNA 
replicon dose may need to be titrated with respect to protection from Tb for clinical 
implementation of a Tb vaccine. While dose titrations can easily be performed for 
agricultural vaccines, this could be an inherent problem for translating plasmid DNA 
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replicon Tb vaccines into humans. Tb protection studies in humans are conducted over 
long periods of time, as Tb infection rarely progresses directly to an active infection but 
usually persists for years in a latent form, which is difficult to diagnose. The 
combination of the length of human protection studies and the complexity of 
characterising a dosing window for plasmid DNA replicons may prove prohibitive for 
the implementation of plasmid DNA replicons as Tb vaccines in humans. 
 
4.4.2 Longevity of protection after vaccination 
 
After vaccination, protection afforded by a vaccine can wane over time. Protection 
afforded by vaccination with the conventional pcDNA3-85A plasmid wanes over time 
(Figs. 4.12/4.13) [433], and protection afforded by BCG vaccination can also eventually 
wane in murine models and human studies [247, 257]. As pKUN85A uses a non-
cytopathic construct, it is conjectured to result in long-lived antigen expression in vivo 
relative to cytopathic plasmid DNA replicon systems. However, antigen persistence was 
not assessed in this study and it is not known how long-lived antigen expression would 
affect longevity of protection.  
It is difficult to evaluate antigen expression in vivo unless a reporter gene, such 
as β-galactosidase or GFP, is included in the pKUN85A construct [397, 409]. While 
persistence of protein expression is difficult to define accurately, persistence of the 
DNA plasmid or mRNA transcription from the plasmid is more easily assessed. 
Persistence of the pKUN85A DNA plasmid can be evaluated by PCR amplification of 
plasmid from total DNA preparations of tissue from, around or draining the vaccination 
site [437]. Persistence of mRNA transcription from the pKUN85A DNA plasmid can be 
evaluated by reverse transcriptase PCR of genes encoded by the plasmid from 
preparations of complimentary DNA from vaccinated tissue [437].  
Once persistence of either DNA plasmid or mRNA is assessed, this could be 
related to longevity of protection after pKUN85A vaccination. It is contentious whether 
persistent antigen is needed to maintain either CD4+ [438-440] or CD8+ [441, 442] 
memory T cells. Currently, long-lived protection against chronic intracellular pathogens 
like L. major and M. tuberculosis is mediated by live vaccines that persist in the host 
[305, 443].  
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The relationship between persistence of the vaccine and the longevity of 
protection afforded by the vaccine would be interesting to evaluate, particularly 
comparing non-cytopathic and cytopathic plasmid DNA replicons. CD8+ T cell 
responses, antibody responses and protection have been compared between a non-
cytopathic Kunjin virus-based plasmid DNA replicon and a cytopathic Semliki forest 
virus-based plasmid DNA replicon, both expressing a β-galactosidase reporter gene 
[444]. CD8+ T cell responses and protection from infection with vaccinia virus 
producing β-galactosidase were similar for both plasmid DNA replicon platforms, but 
protection was only evaluated 14 days after vaccination and the longevity of protection 
was not compared. The pSINCP-85A vaccine is a cytopathic DNA replicon, which uses 
the Sindbis RNA replicase and contains the Ag85A gene [433]. Comparison of the 
persistence of protection mediated by pKUN85A and pSINCP-85A could have 
implications for the whether prolonged or persistent antigen expression enhances the 
longevity of protection against Tb. 
 
4.4.3 The CD8+ T cell response to pKUN85A vaccination 
 
While the pKUN85A construct has been shown to induce a Th1 immune response in 
this study, the particular advantage of Kunjin-based plasmid DNA replicons is that they 
are very effective at inducing CD8+ T cell activation [411, 414]. CD8+ T cells are 
important in the control of primary Tb infection, most likely for their cytotoxic function 
that can control bacterial numbers and contain infection within the granuloma (sections 
1.2.3.4 and 1.2.4). CD8+ T cells also provide a measure of protection during secondary 
responses in BCG vaccinated animals, particularly for prevention of infection 
dissemination to tissues outside the lung (section 1.2.6). 
Despite Kunjin-based plasmid DNA replicons being effective at inducing CD8+ 
T cell activation, dissemination to other tissues was not reduced as bacterial numbers in 
the spleen were not significantly reduced in pKUN85A vaccinated mice compared to 
PBS treated control mice, although there was large variation in bacterial numbers (Fig. 
4.12). However, Ag85A-specific CD8+ T cell activation in response to pKUN85A 
vaccination is yet to be assessed and the dose for maximal CD8+ T cell activation 
remains to be determined.  
Chapter 4 – Construction of pKUN85A 
 
178 
The number of IFN-γ- or IL-2-producing CD8+ T cells from pKUN85A 
vaccinated mice was increased upon restimulation with Ag85A protein (Fig. 4.11 B/D) 
but cytokine production by CD8+ T cells after 20 hours of restimulation with whole 
protein is unlikely to represent antigen-specific cytokine production. The Ag85A 
protein would have to be processed and cross-presented on MHC I to induce true 
antigen-specific cytokine production. Cytokine production by CD8+ T cells after 
overnight restimulation with whole protein and anti-CD28 mAb is more likely to 
represent bystander activation of previously activated CD8+ T cells in response to CD28 
signalling [445] or cytokine production by CD4+ T cells. Therefore, the restimulation 
conditions used in the experiments described above are likely to underestimate the total 
CD8+ T cell response and not account for the antigen-specific CD8+ T cell response. 
The antigen-specific CD8+ T cell response has not been assessed for pKUN85A 
due to the complexity of assessing the CD8+ T cell responses for Ag85A epitopes. 
Using the C57BL/6 murine model of Tb, peptide library screening has not identified an 
immunogenic MHC I restricted epitope for Ag85A [430, 446], although antigen-
specific in vitro cytotoxic activity against Ag85A whole protein-loaded target cells is 
observed after DNA plasmid vaccination using Ag85A [432]. In contrast to C57BL/6 
mice, there are several immunogenic CD8+ T cell MHC I epitopes defined for BALB/c 
mice [430, 447, 448], which can potentially be used as peptides loaded onto target cells 
for in vitro and in vivo cytotoxicity assays. Therefore, future experiments to assess the 
CD8+ T cell function after vaccination with pKUN85A are planned. These will be 
performed in a BALB/c model of Tb infection and correlated with protection studies 
also performed in BALB/c mice.  
 
4.4.4 Future directions for pKUN85A vaccination 
 
While the mechanism of action of pKUN85A and its ability to activate antigen-specific 
CD8+ T cells will be explored in the future, the pKUN85A vaccine and its 
administration regimen could also be further improved. Vaccination with pKUN85A 
could be optimised on several levels, which are outlined below:  
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1. Cloning into the pKUNrep6 vector an antigen containing a CD8+ T cell 
epitope that is stronger than the epitopes found in Ag85A could enhance 
CD8+ T cell responses. The mycobacterial antigen, PstS-3, has been shown 
in murine models to induce strong CD8+ T cell responses, has a well-
defined CD8+ T cell epitope and is a strong vaccine candidate [449].  
 
2. Expression of antigens encoded in the pKUNrep6 vector could also be 
enhanced. Mycobacterial genes are optimised for the prokaryotic 
translational machinery with slightly different codon usage to the eukaryotic 
host. Therefore, optimising codons in Ag85A or PstS-3 could promote 
efficient translation of the antigen using host cellular machinery. Optimal 
expression of antigen genes also relies on efficient transfection of target 
cells. A basic anti-viral mechanism is the secretion of nucleases and rapid 
degradation of extracellular DNA [450]. The challenge for DNA 
vaccination is to protect the integrity of the DNA and transfect it efficiently 
into target cells. Pathogen-like particles (reviewed in [451]), chemical 
transfection agents [452, 453] [454] or electroporation [455, 456] can all be 
used to enhance transfection in vivo, and may also enhance vaccine 
immunogenicity. Electroporation in particular is becoming an increasingly 
viable option for DNA vaccination in humans as technology is developed to 
permit electroporation in the clinic and field. Eletroporation runs an electric 
current through tissue immediately after immunisation with naked DNA 
plasmid [455, 456]. This can be used to force DNA into the cells but it also 
causes local tissue damage and inflammation, which may enhance 
recruitment of APCs and enhance vaccine immunogenicity. 
 
3. The immunogenicity of pKUN85A could be optimised using a number of 
techniques. Cytokines, chemokines and co-stimulatory molecules can be 
included, either as a gene encoded by the same or co-administered plasmids 
or the protein can be administered to the vaccination site, to create a local 
inflammatory milieu essential for maximal priming [457-459]. Furthermore, 
unmethylated CpG motifs found in genetic material from bacteria interact 
with TLR 9 in the early endosome and activate type I interferon production 
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[460], contributing to local inflammatory signals. The pKUN85A plasmid 
sequence could be optimised for the murine model to include more of these 
motifs. 
 
4. The route of administration for pKUN85A could also be optimised. 
Administration of DNA vaccines to different tissues could lead to 
transfection of different cell types, altering mechanisms of APC activation 
and antigen presentation. Gene-gun bombardment, which delivers plasmid-
coated microbeads to the epidermis, and i.m. injection of DNA plasmids are 
the most common routes of administration used for DNA vaccination. For 
Tb DNA vaccines, i.m. injection has been shown to induce better protection, 
presumably as gene-gun bombardment favours the development of robust 
humoral immunity rather than cell-mediated immunity, which is important 
for Tb protective memory [389]. Other routes of administration have also 
been used for DNA vaccines. Mucosal administration of DNA vaccines can 
result in tolergenic responses to the antigen encoded in the construct, so may 
diminish rather than enhance immunogenicity [461]. Subsutaneous 
vaccination has also been used for DNA vaccines and s.c. vaccination with 
the pcDNA3-85A vaccine confers short-term protection against M. 
tuberculosis challenge [433]. Other promising routes of administration 
include epicutaneous vaccination, which involves tape-stripping the upper 
layers of the skin and painting the stripped area with a vaccine [462], and 
intradermal vaccination [463]. These methods of administration are thought 
to deliver antigen to the potent APCs that are resident in the skin, such as 
Langerhans cells in the epidermis and dermal DCs in the dermis, as well as 
activating these cells and triggering their migration. Targeting DNA 
vaccines to these potent APCs could enhance their efficacy.  
 
5. While the choice of antigen, its expression and immunogenicity can be 
optimised for the pKUN85A construct, it is difficult to generate long-lived 
immunity, particularly cell-mediated immunity. Boosting has been used to 
prolong immunity but repeated administration of the same vaccine, or 
homologous boosting, is not always beneficial due to interactions with pre-
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existing immunity to the vaccine. The other option is to use a heterologous 
prime-boost, whereby the immune response is primed against a target 
antigen using one vector and boosted against the target antigen using 
another vector (reviewed in [464]). The heterologous prime-boost approach 
can use a combination of live vaccines, adjuvanted protein, viral vectors or 
DNA vaccines and promotes cell-mediated immunity.  
The immunological principle that heterologous prime-boost 
approaches exploit is the concept of “original antigenic sin”. This states that 
repeated administration of a dominant antigen amplifies a response directed 
against that antigen during subsequent challenge, even using a challenge 
vector that shares only partial homology with the priming vector. In this 
way the size of the target antigen-specific T cell pool is expanded in 
preference to other antigens that may be included in either vector, and the 
avidity of the expanded antigen-specific T cell population is increased 
[465]. These factors combined can increase the number and functionality of 
the antigen-specific T cells over the thresholds required for protection 
against infection and result in not just additive but synergistic increases in 
measures of protection [466]. The effect of vaccinating with BCG or 
adenoviral or MVA vectors encoding Ag85A, which would enhance CD8+ 
T cell activation, in combination with pKUN85A in a prime-boost approach 
could be explored in the future in an effort to provide robust and long-lived 
immunity against Tb. 
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4.5 Summary 
 
In summary, a novel plasmid DNA replicon vaccine against Tb, pKUN85A, was 
created. The Ag85A gene from M. tuberculosis was cloned into the ORF of the non-
cytopathic pKUNrep6 construct and in-frame with NS genes derived from the Kunjin 
virus. The pKUN85A construct was administered in vivo in a C57BL/6 murine model, 
and the 25 µg dose was immunogenic two weeks after boosting; however preliminary 
protection studies did not indicate that homologous prime-boost vaccination with 
pKUN85A provides protection against M. tuberculosis challenge equivalent to the BCG 
vaccine.  
As with all plasmid DNA replicons, the dose of pKUN85A must be optimised 
for maximal protection against Tb and, as can occur with Tb vaccines, protection may 
wane over time. Further development of the pKUN84A vaccine will be undertaken to 
enhance immunogenicity and protection mediated by pKUN85A, particularly the 
longevity of protection. In the future, the CD8+ T cell responses induced by the 
pKUN85A vaccine will be assessed and correlated with protection data to explore the 
role of CD8+ T cells during vaccination and this could provide a more useful correlate 
of protection from Tb infection.
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Chapter 5: Natural Treg-Mediated Suppression of 
Protective Immunity Against Tb 
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5.1 Introduction 
 
The current Tb vaccine, BCG, is highly variable in its effectiveness (section 1.3.4). This 
variability gives rise to two key questions: 
 What can diminish the efficacy of the BCG vaccine? 
 How can the efficacy of BCG and other Tb vaccines be enhanced? 
The primary immune response to mycobacterial infection has been well characterised 
(section 1.2.3); however, less is known about the development of protective memory 
against Tb and which aspects of the BCG vaccine-induced immune response result in 
protective memory (section 1.2.6). To develop a more effective Tb vaccine, the memory 
cell subsets that mediate protection from Tb infection and how they are regulated need 
to be better understood.  
A cellular subset that may play a role in suppressing the BCG vaccine-induced 
immune response is the Treg population. Results presented in chapter 3 illustrate that 
Treg inactivation prior to mycobacterial infection increases the number of antigen 
responsive cells producing cytokines such as IL-2. Proliferation and signalling by the γc 
chain family of cytokines, including IL-2, are vital for optimal T cell memory 
development (sections 1.3.2.2 and 1.3.2.3). Thus, it has been suggested that 
immunosuppression mediated by Tregs during a BCG vaccine-induced immune 
response would diminish the protective immunity that BCG vaccination confers against 
Tb [339]. Treg inactivation prior to vaccination against several other diseases can 
enhance protective immunity, but it can also diminish resulting protective immunity, as 
discussed below. 
 
5.1.1 Tregs can suppress protective memory 
 
Antibody-mediated inactivation of natural CD25+ Tregs prior to or concurrently with 
vaccination has been shown to increase vaccine-induced immune responses and 
enhance the protective efficacy of vaccines [336, 338, 339]. 
  A recent study by Moore, et al. [339] assessed the effect of antibody-mediated 
inactivation of CD4+CD25+ natural Tregs prior to or concurrently with vaccine 
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administration. The types of vaccine that were assessed included viral vector and 
protein subunit vaccines, using a variety of bacterial, protozoal and tumour antigens. 
Treg inactivation enhanced vaccine-induced immune responses, as assessed by numbers 
of IFN-γ-producing lymphocytes measured by enzyme-linked immunospot assay 
(ELISpot) 10-14 days after vaccination. The effect of Treg inactivation prior to or 
concurrently with priming was also assessed for both homologous and heterologous 
prime/boost vaccines. Treg inactivation enhanced vaccine-induced immune responses 
after boosting for both prime/boost approaches. Therefore, it is well established that 
Treg inactivation can enhance vaccine-induced immune responses to a variety of 
formulations.  
Moore, et al. then focussed on a malarial vaccine in greater depth, assessing 
whether the primary immune response as well as the secondary immune response and 
protection against infectious challenge were enhanced by Treg inactivation during 
priming [339]. They used a fowlpox vector prime followed by a MVA vector boost and 
both vectors encoded the malarial Plasmodium berghei circumsporozoite protein. 
Moore, et al. demonstrated that, if Tregs were inactivated concurrently with priming, 
the primary immune response persisted longer and the response to sub-dominant 
epitopes within the target antigen was significantly enhanced as measured by IFN-γ 
ELISpot. Furthermore, when Tregs were inactivated, 100 % of vaccinated mice were 
protected upon challenge with malarial sporozoites compared to 40-60 % protection in 
vaccinated control mice.  
Collectively, the study by Moore, et al. illustrates that inactivating Tregs prior to 
or concurrently with a number of different vaccines enhances the vaccine-induced 
immune responses and, at least for the malarial vaccine that was studied, prolongs the 
vaccine-induced immune response and enhances protection from pathogen challenge. 
 In support of these results, studies in which Tregs were inactivated prior to 
HSV-1 vaccination or infection, or prior to hepatitis B virus vaccination, have shown 
amplified vaccine-induced primary immune responses and increased numbers of 
antigen-specific T lymphocytes after resolution of the primary response [336, 338, 375]. 
In the HSV-1 studies, when Tregs were inactivated prior to infection or vaccination, an 
earlier decline in viral plaque forming units in the tissues was observed following 
infectious challenge [338, 375]. Enhanced protection was observed after infectious 
challenge when Tregs were inactivated prior to priming with a live HSV-1 infection, an 
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HSV-derived peptide vaccine or a plasmid DNA vaccine encoding an HSV-1 
immunodominant protein [338, 375]. 
These studies illustrate that inactivation of Tregs prior to or concurrently with 
vaccination can result in enhanced primary immune responses, increased pools of 
antigen responsive lymphocytes after vaccination and, importantly, can enhance the 
efficacy of different types of vaccines, including live, subunit and DNA plasmid 
vaccines. 
 
5.1.2 Tregs can facilitate protective memory 
 
In contrast to the studies described above, while Tregs can suppress primary immune 
responses and negatively impact on the resulting protective immunity, in some 
circumstances Tregs are required to facilitate the development of protective immunity. 
In the L. major C57BL/6 murine model, maintenance of protective immunity in 
a mouse that has been previously exposed or vaccinated with live L. major is dependent 
on the persistence of low numbers of the protozoa in skin lesions [305]. If L. major 
infected or vaccinated animals lose these persistent protozoa, protective immunity is 
lost and mice are vulnerable to re-infection and disease. Protective immunity can also 
be lost when natural Tregs are depleted [305] or IL-10 signalling is blocked [358] 
during infection. Both of these scenarios result in enhanced infection-induced primary 
immune responses and enhanced clearance of the primary infection. It is proposed that 
the lack of persisting organisms then leads to a loss of memory maintenance and a lack 
of protection from subsequent infectious challenge [305]. Therefore, suppression of the 
primary immune response, mediated by Tregs, is essential for development of protective 
immunity in situations where antigen persistence is essential for ongoing maintenance 
of immunological memory. 
 
5.1.3 Tregs and development of anti-mycobacterial immunity 
 
As described above, the inactivation of CD25+ Tregs in several infection and 
vaccination models can enhance the primary immune response and thereby modulate 
the development and maintenance of protective immunity. The effect of Treg activity in 
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the models described above has implications for the effect of Tregs on BCG, other 
vaccines against Tb and overall protective immunity against Tb. 
The effect of Treg inactivation or depletion on antigen persistence after primary 
mycobacterial infection has been addressed. Following publication of my results 
(outlined in chapter 3) [374], two other groups have published their investigations, 
using alternative approaches, evaluating the role of Tregs during primary mycobacterial 
infection [383, 384] (discussed in section 3.4.5). The results presented in chapter 3 
illustrate that antibody-mediated Treg inactivation prior to BCG, M. tuberculosis and M. 
bovis infections did not result in clearance or even reductions in lung bacterial numbers 
(Figs. 3.11/3.13). Kursar, et al. [383] used an adoptive transfer model to show that Rag1 
-/- mice that received CD4+CD25−  donor T cells had reduced bacterial numbers in the 
lung and spleen after M. tuberculosis challenge compared to mice that received a 
mixture of CD4+CD25− and CD4+CD25+ donor T cells. Scott-Browne, et al. [384] used 
a mixed chimera model where irradiated recipient mice were reconstituted with Foxp3 -
/- and +/+ bone marrow. Foxp3 -/- bone marrow was derived from Thy 1.2+ donor mice 
and Foxp3 +/+ bone marrow from Thy 1.1+ donor mice, and administration of Thy 1.1 
depleting mAb to recipient mice resulted in depletion of all Foxp3+ Tregs [384]. When 
these mice were infected with M. tuberculosis, bacterial numbers in the lung were 
reduced compared to chimeras reconstituted with Foxp3 +/+ Thy 1.1+ and Foxp3 +/+ 
Thy 1.2+ bone marrow, which retained Foxp3+ Tregs [384]. From these studies the 
effect of Tregs in WT mice on tissue bacterial numbers in vivo is not clear; however, it 
is important to note that mice were not completely cured of mycobacterial infection in 
any study. Therefore, if antigen persistence is required for maintenance of anti-
mycobacterial immunity, antibody-mediated inactivation of Tregs is unlikely to affect 
BCG persistence. As a result, and in contrast to L. major infection and live vaccination, 
I hypothesised that Treg inactivation prior to BCG vaccination would be unlikely to 
inhibit the development and maintenance of protective immunity. 
As described in chapter 3, inactivation of Tregs during primary mycobacterial 
infection increased numbers of cytokine-producing lymphocytes at two weeks after 
infection (Fig. 3.7/3.8). In support of this data, the study by Moore, et al. inactivated 
Tregs concurrently with priming using a BCG / MVA-85A prime-boost vaccine against 
Tb. This resulted in increased numbers of IFN-γ+ lymphocytes measured by ELISpot in 
response to stimulation with a MHC II-restricted epitope two weeks after boosting 
[339]. Therefore, inactivation of Tregs during primary exposure to mycobacteria can 
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enhance the immune response. Given the impact of Tregs in these other vaccination 
settings, I hypothesised along with others [339]  that Treg inactivation during a primary 
immune response to mycobacterial antigen could enhance both the secondary immune 
response and development of protective immunity against Tb. 
Prior to this study, it had not been assessed whether Treg activity during priming 
with BCG or other Tb vaccines suppressed secondary immune responses or the 
protective efficacy of vaccines against a virulent mycobacterial challenge. If 
inactivation of CD25+ Tregs did enhance the protective efficacy of the BCG vaccine or 
other Tb vaccines, vaccination strategies could be developed to modulate Treg activity 
at the time vaccination and thereby optimise vaccine efficacy. Therefore, in this chapter, 
I evaluated the effect of Treg inactivation on the development of protective Tb 
immunity in a murine model. This was achieved by antibody-mediated inactivation of 
CD25+ Tregs prior to vaccination with BCG or plasmid DNA vaccines encoding Tb 
antigen, and assessment of the primary and secondary immune responses. Most 
importantly, functional protection from virulent M. tuberculosis or M. bovis aerosol 
challenge was evaluated. 
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5.2 Aims 
 
This chapter builds upon findings from chapter 3 and utilises the plasmid DNA replicon 
vaccine developed in chapter 4, to examine whether Treg inactivation prior to Tb 
vaccination enhances primary and secondary immune responses and enhances the 
development of protective Tb immunity.  
Inactivation of Tregs prior to vaccination can enhance vaccine efficacy [338, 
339, 375], if it does not interfere with mechanisms of memory maintenance, such as 
antigen persistence [305]. As inactivation of Tregs prior to BCG infection increases the 
primary immune response but does not decrease antigen persistence (Figs. 3.8-3.11), it 
was hypothesised that inactivation of Tregs prior to BCG vaccination would amplify 
primary and secondary immune responses and enhance protective efficacy. In addition, 
inactivation of Tregs prior to DNA vaccination can enhance vaccine efficacy [338]. 
Therefore, it was hypothesised that inactivation of Tregs prior to Tb DNA vaccination 
would enhance primary and secondary immune responses, as well as protective 
efficacy. 
To explore these hypotheses, CD4+CD25+ Tregs were inactivated in the 
C57BL/6 murine model prior to vaccination with one of three different Tb vaccines and 
subsequently challenged with M. tuberculosis or M. bovis by aerosol. The vaccines used 
were BCG as a live vaccine, pcDNA3-85A as a conventional plasmid DNA vaccine or 
pKUN85A, which was developed in chapter 4 and is a non-cytopathic plasmid DNA 
replicon vaccine. My main objectives were to: 
• Assess the effect of Treg inactivation on primary immune responses to BCG, 
pKUN85A or pcDNA3-85A vaccination. 
• Assess the effect of Treg inactivation on secondary immune responses to the 
vaccines listed above. 
• Characterise the protective efficacy of the vaccines listed above after 
inactivation of CD4+CD25+ Tregs by evaluating tissue bacterial numbers and 
lung pathology. 
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5.3 Results 
 
5.3.1 Experimental design 
 
In order to evaluate whether natural CD4+CD25+Tregs act during the primary immune 
response to inhibit Tb vaccine efficacy, the experimental protocol used in chapter 3 was 
modified to inactivate Tregs prior to either BCG or DNA vaccination (Fig. 5.1).  
Mice were administered anti-CD25 mAb (PC61) or control rat IgG i.p. and two 
days later peripheral blood samples were taken to confirm inactivation of Tregs. Surface 
staining for CD25 expression in these samples used the anti-CD25 mAb clone 7D4 to 
avoid epitope masking after PC61 treatment. Treg inactivation as assessed by flow 
cytometry was consistent in all mice that received PC61 across all experiments (data not 
shown). Three days after antibody treatment, mice were vaccinated with one of three 
vaccines: BCG, pcDNA3-85A or pKUN85A. Groups vaccinated with pcDNA3-85A or 
pKUN85A received a homologous boost vaccination two weeks later. Results from 
chapter 3 demonstrate that PC61 treatment inactivates CD4+CD25+ Tregs up to day 23 
after treatment and therefore Tregs were inactivated during the acute vaccine-induced 
immune response.  
After vaccination, mice were rested for either 6 or 15 weeks, to assess protection 
against an infectious challenge early or late after vaccination respectively, before 
receiving either an aerosol challenge with M. tuberculosis or M. bovis (Fig. 5.1 D), or 
an i.n. challenge with BCG (Fig. 5.1 C). Aerosol M. tuberculosis or M. bovis challenges 
were used to evaluate tissue bacterial load and lung pathology as measures of the 
protective efficacy of BCG or DNA vaccination. BCG i.n. challenge was used as a PC2 
model of mycobacterial infection to permit analysis of infected tissues in a PC2 flow 
cytometry facility and assessment of the secondary immune response after vaccination. 
Results from chapter 3 illustrate that, in terms of the acute immune response (Fig. 3.8) 
and tissue bacterial numbers (Fig. 3.11), primary BCG infection is a suitable PC-2 
model for virulent mycobacterial infections, such as M. tuberculosis and M. bovis. In 
addition, BCG infection has been used as an infectious challenge to assess secondary 
immune responses in other Tb vaccine pre-clinical studies [467]. Therefore, BCG 
infection is a relevant PC2 model of virulent mycobacterial infection and can be used 
for assessment of immune responses to vaccination.
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Figure 5.1: Experimental outline for testing whether natural Tregs inhibit the efficacy of 
BCG and DNA vaccination 
A) Mice were treated with 100 µg of rat IgG or 100 µg of PC61 i.p. and two days later a 
peripheral blood sample was taken and assessed by flow cytometry for the presence of 
CD4+CD25+ lymphocytes. The following day, mice were vaccinated with BCG or vaccinated 
with one of 2 DNA vaccines: pKUN85A or pcDNA3-85A. Mice receiving DNA vaccines were 
boosted with the same vaccine two weeks later. B) Two weeks after BCG vaccination or the 
boost DNA vaccinations, one group of mice was culled and the primary immune response 
assessed. C) Six weeks after BCG vaccination or the boost DNA vaccination, a second group of 
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mice were infected i.n. with BCG and the secondary immune response was assessed 
immediately prior to infection and at days 3, 8 and 15 after the infection. D) Six or fifteen 
weeks after BCG vaccination or the boost DNA vaccination, the final groups of mice were 
infected by aerosol with M. bovis or M. tuberculosis and lung bacterial numbers and pathology 
were evaluated five weeks later. Black mice indicate when Tregs were present, grey mice 
indicate when mice were being tested for the presence of Tregs and white mice indicate when 
Tregs were significantly reduced compared to control mice. 
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Therefore, the protocol outlined in Fig. 5.1 was used to test the hypothesis that 
inactivation of natural CD25+ Tregs during vaccination enhances primary and 
secondary immune responses and protective efficacies of Tb vaccines, initially 
focussing on BCG vaccination and later on pcDNA3-85A and pKUN85A vaccination. 
 
5.3.2 The vaccine-induced immune response to BCG vaccination 
 
To test the hypothesis that Treg inactivation prior to BCG vaccination would enhance 
the primary immune response, the vaccine-induced immune response was assessed two 
weeks after BCG vaccination. Mice were treated with either PC61 or control rat IgG, 
followed 3 days later by vaccination with BCG or a PBS vehicle control. Two weeks 
later, lymphocytes were isolated from the spleen and from the inguinal lymph nodes 
draining the site of vaccination (Fig. 5.1 B). Isolated lymphocytes were restimulated 
with either CFP or Ag85A and analysed by flow cytometry for IFN-γ or IL-2 
production. Of note, at two weeks after BCG vaccination, IL-2 and IFN-γ producing 
antigen-specific CD4+ lymphocytes fell into distinct populations after either Ag85A 
restimulation (Fig. 5.2) or CFP restimulation (data not shown), with no significant co-
production of the cytokines.  
After CFP restimulation, pooled lymphocytes from the draining inguinal lymph 
nodes of PC61 treated/BCG vaccinated mice had a higher percentage (data not shown) 
and average number (Fig. 5.3 A) of IFN-γ+CD4+ lymphocytes compared to rat IgG 
treated/BCG vaccinated mice. A similar trend was observed in CFP-restimulated 
splenocytes, although differences were not statistically significant (data not shown and 
Fig. 5.3 B).  
After Ag85A restimulation, the average number of IL-2+CD4+ T lymphocytes in 
the spleen was significantly increased in PC61 treated/BCG vaccinated compared to rat 
IgG-treated/BCG vaccinated mice (Fig. 5.3 C), although the average number of IFN-γ 
producing CD4+ T lymphocytes remained unchanged (data not shown).  
Overall, in agreement with previous studies, inactivation of Tregs during BCG 
vaccination led to enhanced cytokine production and a modest increase in the primary 
immune response.
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Figure 5.2: IFN-γ  and IL-2 production by CD4+ lymphocytes 2 weeks after BCG 
vaccination 
Mice were administered either rat IgG or PC61 antibody i.p and vaccinated 3 days later with 
BCG or mock vaccinated with PBS. At two weeks after vaccination, spleens were harvested and 
isolated splenocytes were stimulated with Ag85A overnight before being assessed for cytokine 
production.  Displayed are representative flow cytometry plots of lymphocyte gating, CD4 
gating and IFN-γ/IL-2 staining for restimulated splenocytes from rat IgG treated and PC61 
treated mice treated with PBS or vaccinated with BCG. Numbers in the gates on flow cytometry 
plots represent the percent of lymphocytes within that gate from the total parent population. 
Four to five animals were analysed per treatment group. Results represent two replicate 
experiments. 
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Figure 5.3: Cytokine production by CD4+ lymphocytes 2 weeks after BCG vaccination 
Mice were administered either rat IgG or PC61 antibody i.p and vaccinated 3 days later with 
BCG or mock vaccinated with PBS. At two weeks after vaccination, lymphocytes were isolated 
from tissues and restimulated with A/B) CFP or C) Ag85A overnight before being assessed for 
cytokine production.  A) Average number of CD4+IFN-γ+ lymphocytes in the inguinal lymph 
node after CFP restimulation. Lymph nodes were pooled to enable sufficient numbers of cells 
for restimulation and flow cytometric analysis.  B) Average number of CD4+IFN-γ+ 
lymphocytes in the spleen after CFP restimulation. C) Average number of CD4+IL-2+ 
lymphocytes in the spleen after Ag85A restimulation. Results in A) and B) are representative of 
two replicate experiments. Bars represent mean values ± SEM. Four to five animals were 
analysed per treatment group. Treatment groups were compared using the two-tailed Mann 
Whitney test; NS indicates p > 0.05, * indicates p ≤ 0.05. Results represent two replicate 
experiments. 
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5.3.3 Antigen-responsive lymphocytes after BCG vaccination 
 
PC61 treatment prior to BCG vaccination increased the numbers of antigen-responsive 
CD4+ T lymphocytes 2 weeks after BCG vaccination. However, the effector 
lymphocyte population goes through a contraction phase after activation [182, 183] and 
factors regulating this contraction phase in the context of mycobacterial infection and 
vaccination are not understood. Therefore, while there are more antigen-responsive 
lymphocytes 2 weeks after BCG vaccination in PC61 treated mice, it does not 
necessarily mean that more cells will be retained at later times to respond to an 
infectious challenge. In other vaccination models, primary immune responses have been 
shown to be prolonged and larger pools of antigen-responsive cells were present after 
contraction if Tregs were inactivated prior to or concurrently with vaccination [336, 
338, 339]. After primary exposure to BCG, the T cell mediated immune response peaks 
around weeks 3-4 and begins to subside by about week 6 [182, 183]. Therefore, 
numbers of cytokine-producing lymphocytes were quantified at 6 weeks after BCG 
vaccination to assess whether Treg inactivation resulted in a larger pool of antigen-
responsive lymphocytes after contraction of the BCG vaccine-induced immune 
response. 
 Lymphocytes from the spleen and pooled inguinal lymph nodes were isolated 
from mice 6 weeks after vaccination with either BCG, or PBS as a negative control. 
Lymphocytes were restimulated with CFP, processed for intracellular cytokine staining 
and analysed by flow cytometry for the production of IFN-γ and IL-2. In the spleen, the 
average number of CD4+IFN-γ+ lymphocytes was increased significantly in PC61 
treated/BCG vaccinated mice compared to rat IgG treated/BCG vaccinated mice (Fig. 
5.4 A). This trend was also observed in the lung, although differences were not 
statistically significant (Fig. 5.4 B). The average number of CD4+IFN-γ+ lymphocytes in 
BCG vaccinated mice 6 weeks after vaccination (Fig. 5.4 A) was similar to that 
observed 2 weeks after vaccination (Fig. 5.3 B). This is consistent with further 
expansion and then subsequent contraction occurring between 2 and 6 weeks after 
primary exposure to BCG [182, 183]. The average number of CD8+IFN-γ+ lymphocytes 
was also significantly increased in lung, but not the spleen, of PC61 treated/BCG 
vaccinated mice compared to rat IgG treated/BCG vaccinated mice (Fig. 5.4 C/D). 
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Figure 5.4: IFN-γ  production by CD4+ and CD8+ lymphocytes 6 weeks after BCG 
vaccination 
Mice were administered either rat IgG or PC61 antibody i.p and vaccinated 3 days later with 
BCG or mock vaccinated with PBS. At six weeks after vaccination, lymphocytes were isolated 
from spleens and lungs and restimulated with CFP overnight before being assessed for cytokine 
production by flow cytometry.  A) Average number of CD4+IFN-γ+ lymphocytes in the spleen. 
B) Average number of CD4+IFN-γ+ lymphocytes in the lung. C) Average number of CD8+IFN-
γ+ lymphocytes in the spleen. D) Average number of CD8+IFN-γ+ lymphocytes in the lung. Bars 
represent mean values ± SEM. Five animals were analysed per treatment group. Treatment 
groups were compared using the two-tailed Mann Whitney test; * indicates p ≤ 0.05. Results 
represent one experiment. 
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Interestingly, when CD4+ lymphocytes from BCG vaccinated animals were assessed for 
cytokine production 6 weeks after vaccination, a small population of lymphocytes was 
observed that produced both IFN-γ and IL-2 (Fig. 5.5). In both the spleen and lung, the 
numbers of IFN-γ+IL-2+CD4+ lymphocytes were significantly increased in PC61 treated 
compared to rat IgG treated BCG vaccinated mice (Fig. 5.6 A/B). However, when the 
proportion of IFN-γ+IL-2+CD4+ lymphocytes within the total IFN-γ or IL-2 producing 
CD4+ lymphocyte population was assessed in BCG vaccinated mice, this proportion 
was unchanged by PC61 treatment (Fig. 5.6 C/D).  
Although there were more lymphocytes capable of producing cytokine 
immediately prior to challenge in PC61 treated/BCG vaccinated mice, the quality of 
these cells may have been compromised during their development. To explore this 
possibility, the mean fluorescence intensity (MFI) of CD4+ and CD8+ lymphocytes 
staining positive for IFN-γ or IL-2 in the lung and the spleen was assessed. There were 
no significant differences in MFI between BCG vaccinated groups for either cytokine 
by CD4+ or CD8+ lymphocytes in the spleen of the lung (data not shown).  
Therefore, inactivation of Tregs during BCG vaccination led to a larger pool of 
antigen-responsive CD4+ and CD8+ lymphocytes in the spleen and lung 6 weeks after 
vaccination and immediately prior to infectious challenge. Furthermore, it appears that 
the increase in the number of antigen-responsive lymphocytes did not correlate with a 
decrease in their quality, as assessed by comparison of cytokine stain MFI.  
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Figure 5.5: IFN-γ  and IL-2 production by CD4+ lymphocytes 6 weeks after BCG 
vaccination 
Mice were administered either rat IgG or PC61 antibody i.p and vaccinated 3 days later with 
BCG or mock vaccinated with PBS At six weeks after vaccination, spleens were harvested and 
isolated splenocytes were stimulated with CFP overnight before being assessed for cytokine 
production.  Displayed are representative flow cytometry plots of lymphocyte gating, CD4 
gating and IFN-γ/IL-2 staining for restimulated splenocytes from rat IgG treated and PC61 
treated mice treated with PBS or vaccinated with BCG. Numbers in the gates on flow cytometry 
plots represent the percent of lymphocytes within that gate from the total parent population. 
Five animals were analysed per treatment group. Results represent one experiment. 
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Figure 5.6: IFN-γ  and IL-2 co-production by CD4+ lymphocytes 6 weeks after BCG 
vaccination 
Mice were administered either rat IgG or PC61 antibody i.p and vaccinated 3 days later with 
BCG or mock vaccinated with PBS. At six weeks after vaccination, lymphocytes were isolated 
from spleens and lungs and restimulated with CFP overnight before being assessed for cytokine 
production by flow cytometry.  A) Average number of CD4+IFN-γ+IL-2+ lymphocytes in the 
spleen. B) Average number of CD4+IFN-γ+IL-2+ lymphocytes in the lung. C) Percentage of 
cytokine producing CD4+ lymphocytes that co-produce IFN-γ and IL-2 in the spleen. D) 
Percentage of cytokine producing CD4+ lymphocytes that co-produce IFN-γ and IL-2 in the 
lung. Bars represent mean values ± SEM. Five animals were analysed per treatment group. 
Treatment groups were compared using the two-tailed Mann Whitney test; NS indicates p > 
0.05, * indicates p ≤ 0.05, ** indicates p ≤ 0.01. Results represent one experiment. 
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5.3.4 The secondary immune response for BCG vaccination 
 
Increased numbers of antigen-responsive cells prior to infectious challenge have been 
observed in other models of Treg inactivation prior to vaccination and this has 
correlated with an amplified immune response to infectious challenge [338, 339]. 
However, increased numbers of antigen-responsive cells present in the host prior to 
secondary antigen exposure do not guarantee that the cells will respond efficiently to the 
infectious challenge. To assess the response of lymphocytes to an infectious challenge, 
numbers of cytokine producing lymphocytes were quantified over the course of a BCG 
infection and responses were compared between treatment groups. 
 Vaccinated mice were challenged with BCG i.n. and lymphocytes were isolated 
immediately prior to challenge and at days 3, 8 and 15 after challenge (Fig 5.1 C). 
Lymphocytes were isolated from the mediastinal lymph nodes draining the site of 
infection and from the lung. These lymphocytes were restimulated with CFP, processed 
for intracellular cytokine staining and analysed by flow cytometry for the production of 
IFN-γ and IL-2. Some lymph nodes isolated from BCG vaccinated mice at day 15 after 
BCG infection were fibrotic and therefore the day 15 time point for mediastinal lymph 
nodes was not included. 
In the mediastinal lymph node, numbers of both IFN-γ+CD4+ and IFN-γ+CD8+ 
lymphocytes increased markedly in BCG vaccinated mice over the early course of the 
infection (Fig. 5.7 A/B). However, in PC61 treated/BCG vaccinated mice the increase 
in cytokine producing lymphocytes was accelerated compared to rat IgG treated/BCG 
vaccinated mice, where there were more IFN-γ producing lymphocytes at day 3 after 
challenge in these mice (Fig. 5.7 A/B). At the times analysed, the maximum numbers of 
antigen-responsive lymphocytes for both PC61 treated/BCG vaccinated mice and rat 
IgG treated/BCG vaccinated mice were similar (Fig. 5.7 A/B). However, statistical 
significance for differences observed between treatments groups could not be assessed 
for mediastinal lymph nodes as these had been pooled for each treatment group to 
provide enough cells for restimulation and flow cytometric analysis. 
In the lung immediately prior to challenge, the average number of IFN-γ+CD4+ 
and IFN-γ+CD8+ lymphocytes was already elevated in PC61 treated/BCG vaccinated 
mice compared to rat IgG treated/BCG vaccinated mice (Figs. 5.4 B/D and 5.7 C/D). By 
day 3 after infection, there were still significantly more IFN-γ+CD4+ lymphocytes in 
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PC61 treated/BCG vaccinated mice compared to rat IgG treated/BCG vaccinated mice 
(Fig. 5.7 C). A similar trend at day 3 was also observed for IFN-γ+CD8+ lymphocytes 
(Fig. 5.7 D), although differences were not statistically significant. Furthermore, at the 
times analysed, the maximum numbers of IFN-γ+CD4+ lymphocytes in the lung were 
similar across PC61 treated and rat IgG treated groups for BCG vaccinated mice (Fig. 
5.7 A/B/C). 
Therefore, when Tregs were inactivated during BCG vaccination, the secondary 
response to a mycobacterial challenge was accelerated compared to BCG control 
vaccinated animals in both the draining lymph node and the lung but, at the times 
assessed in this study, the response magnitude was not significantly amplified. 
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Figure 5.7: The secondary immune response after i.n. BCG challenge 
Mice were administered either rat IgG (filled symbols) or PC61 antibody (empty symbols) i.p., 
3 days before vaccination with BCG (circles) or mock vaccination with PBS (squares). At six 
weeks after vaccination mice were infected i.n. with BCG. Lymphocytes were harvested 
immediately prior to infection and at days 3, 8 and 15 after infection from the mediastinal 
lymph node and the lung. Lymphocytes were restimulated overnight with CFP before being 
assessed for cytokine production by flow cytometry. A) Number of CD4+IFN-γ+ lymphocytes in 
the mediastinal lymph node. B) Number of CD8+IFN-γ+ lymphocytes in the mediastinal lymph 
node. C) Average number of CD4+IFN-γ+ lymphocytes in the lung. D) Average number of 
CD8+IFN-γ+ lymphocytes in the lung. Symbols for the lung represent mean values ± SEM. Four 
to five animals were analysed per treatment group at each time point. Treatment groups were 
compared using the two-tailed Mann Whitney test; * indicates p ≤ 0.05. The day three time 
point was repeated twice with similar results. 
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5.3.5 Short-term protection for BCG vaccination 
 
An accelerated but not amplified secondary immune response after Treg inactivation 
prior to vaccination has not been observed in other vaccination models. However, 
accelerating the influx of cytokine-producing cells to the infected lung tissue could 
conceivably result in earlier control of pulmonary mycobacterial infection and reduce 
dissemination from the lung to other tissues [84, 171]. Therefore, bacterial burden in the 
lung and spleen were assessed after a virulent mycobacterial aerosol challenge. 
 Vaccinated animals were challenged by aerosol with M. tuberculosis or M. bovis 
6 weeks after vaccination and bacterial numbers in the tissues were assessed 5 weeks 
after infection (Fig. 5.1 D). BCG vaccination, compared to PBS control vaccination, 
afforded on average a 0.79-0.87 log10 reduction in bacterial numbers in the lung after M. 
tuberculosis infection (Fig. 5.8 A), a 1.32-1.54 log10 reduction in bacterial numbers in 
the spleen after M. tuberculosis infection (Fig. 5.8 B) and a 1.33-1.39 log10 reduction in 
bacterial numbers in the lung after M. bovis infection (Fig. 5.8 C). However, despite 
significant differences in both the primary immune response and the kinetics of the 
secondary immune response, there was no difference in bacterial numbers in the lung 
after M. tuberculosis or M. bovis infection between PC61 treated and control treated 
BCG vaccinated mice (Fig. 5.8 A/C). This demonstrates that control of mycobacterial 
infection in the lung by BCG vaccination was not affected by antibody-mediated Treg 
inactivation. Furthermore, there was no difference in bacterial numbers in the spleen 
after M. tuberculosis infection between PC61 treated and control treated BCG 
vaccinated mice (Fig. 5.8 B), suggesting that dissemination of mycobacterial infection 
to the spleen was not affected by Treg inactivation prior to BCG vaccination. 
 Therefore, after an infectious challenge early (6 weeks) after vaccination, 
protection afforded by the BCG vaccine was not affected by PC61 treatment prior to 
vaccination. 
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Figure 5.8: Tissue bacterial numbers after early virulent mycobacterial challenge 
Mice were treated with rat IgG (filled bars) or PC61 (empty bars) 3 days before vaccination 
with BCG or mock vaccination with PBS. At 6 weeks after vaccination mice were infected by 
aerosol with M. tuberculosis or M. bovis. Bacterial numbers in the lung were determined 5 
weeks after infection. A) Bacterial numbers in the lung after M. tuberculosis infection. B) 
Bacterial numbers in the spleen after M. tuberculosis infection. C) Bacterial numbers in the lung 
after M. bovis infection. Symbols represent geometric means ± GEM. Five animals were 
analysed per treatment group. Treatment groups were compared using the two-tailed Mann 
Whitney test; NS indicates p > 0.05, ** indicates p ≤ 0.01.Results in A represent two replicate 
experiments, while B or C represent single experiments. 
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5.3.6 Long-term protection for BCG vaccination 
 
Treg inactivation significantly increased the number of lymphocytes producing 
cytokines, including IFN-γ, during and after the primary immune response to BCG 
vaccination (Figs. 5.2/5.3). Currently, it is thought that the BCG vaccine protects 
against Tb infection through induction of Th1 immunity [170]. The current model of 
Th1 memory development proposes that increased numbers of IFN-γ-producing cells 
during and after vaccination do not correlate with enhanced protective memory, as cells 
that produce IFN-γ do not survive long-term [221]. If the model described above applies 
to BCG-mediated immunity, then using Treg inactivation prior to vaccination to 
generate more IFN-γ producing lymphocytes during the primary immune response 
could be detrimental to the longevity of protection afforded by BCG. To determine if 
this was indeed the case, long-term protection afforded by BCG vaccination after Treg 
inactivation was evaluated. 
Vaccinated animals were challenged by aerosol with M. tuberculosis or M. bovis 
15 weeks after vaccination and bacterial numbers in the tissues were assessed 5 weeks 
after infection (Fig. 5.1 D). Similar to results shown in Fig. 5.7, BCG vaccination 
afforded on average a 0.52-0.82 log10 reduction in bacterial numbers in the lung after M. 
tuberculosis infection (Fig. 5.9 A) and a 1.51-1.63 log10 reduction in bacterial numbers 
in the lung after M. bovis infection (Fig. 5.9 B) compared to PBS control vaccinated 
animals. However, there was again no significant difference in bacterial numbers in the 
lung caused by PC61 treatment with either M. tuberculosis or M. bovis infection (Fig. 
5.9 A/B).  
This illustrated that the inactivation of Tregs prior to BCG vaccination and the 
expansion of IFN-γ-producing lymphocytes during the primary immune response did 
not decrease protection after BCG vaccination against a late (15 week) infectious 
challenge. However, it also reinforced that control of M. tuberculosis or M. bovis 
infection in the lung by BCG vaccination is not affected by Treg inactivation.  
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Figure 5.9: Lung bacterial numbers after late M. tuberculosis or M. bovis challenge 
Mice were treated with rat IgG (filled bars) or PC61 (empty bars) 3 days before vaccination 
with BCG or mock vaccination with PBS. At 15 weeks after vaccination mice were infected by 
aerosol with M. tuberculosis or M. bovis. Bacterial numbers in the lung were determined 5 
weeks after infection. A) Bacterial numbers in the lung after M. tuberculosis infection. B) 
Bacterial numbers in the lung after M. bovis infection. Symbols represent geometric mean 
values ± GEM. Five animals were analysed per treatment group. Treatment groups were 
compared using the two-tailed Mann Whitney test; NS indicates p > 0.05, * indicates p ≤ 0.05, 
** indicates p ≤ 0.01. Results represent single experiments. 
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5.3.7 Lung pathology for BCG vaccination 
 
The pulmonary inflammation induced in the lung following M. tuberculosis or M. bovis 
infection was assessed after early and late challenges. Lung tissue was collected 
concurrently with bacterial burden studies (Figs. 5.8 and 5.9), prepared for histological 
analysis and scored for the degree of inflammation. When M. tuberculosis infected 
samples were harvested, the degree of inflammation was low and differences between 
treatment groups were insignificant (data not shown). However, M. bovis infection 
causes more extensive inflammation in mice than M. tuberculosis infection [382], and 
the degree of pulmonary inflammation in M. bovis infected mice yielded significant 
differences between groups.  
Mild, localised granulomatous inflammation, with epithelioid histiocytes and 
lymphocytes present within the pulmonary interstitium and alveolar spaces, was 
observed in PBS treated groups after either early (Fig. 5.10 A) or late (data not shown) 
M. bovis challenge. This inflammation was reduced in BCG vaccinated mice after either 
early (Fig. 5.10 A) or late (data not shown) M. bovis challenge. BCG vaccinated mice 
exhibited a trend for lower lung pathology composite scores (Fig. 5.10 B) and had 
significantly lower numbers of lung lesions (Fig. 5.10 C) than PBS treated groups after 
early M. bovis challenge. These patterns were also observed after late M. bovis 
challenge (data not shown). However, the degree and composition of pulmonary 
inflammation between PC61 and control treated mice that were BCG vaccinated was 
similar (Fig 5.10 A/B/C).  
These results show that inactivation of Tregs during vaccination did not affect 
the ability of BCG to mitigate the extent of pathological damage in the lung associated 
with mycobacterial infection. 
 
 
 
 
 
 
Chapter 5 – Tregs and Protective Immunity Against Tb 
 
209 
 
Figure 5.10: Pulmonary inflammation after M. bovis infection 
Mice were treated with rat IgG (filled bars) or PC61 (empty bars) 3 days before vaccination 
with BCG or mock vaccination with PBS. At 6 weeks after vaccination mice were infected by 
aerosol with M. bovis. Lung tissue samples were fixed, sectioned and stained with haematoxylin 
and eosin before being graded for pulmonary inflammation. A) Sections from lungs taken week 
5 after M. bovis infection. One micrograph, representative of sections from five animals, is 
shown for each treatment group. Micrographs for PBS vaccinated mice were taken at 40x 
magnification, whereas micrographs for BCG vaccinated mice were taken at 110x 
magnification. B) Composite pathology score (ranging from 0 (least severe) to 5 (most severe)) 
for lungs after M. bovis infection. Symbols represent individual values and median values are 
indicated by the horizontal black line (although some symbols obscure this line). C) Numbers of 
lesions per lung sample. Bars represent mean values ± SEM. Five animals were analysed per 
treatment. Statistical significance was determined by the two-tailed Mann Whitney test; NS 
indicates p > 0.05,  * indicates p ≤ 0.05. Results represent one experiment and similar results 
were found for mice infected with M. bovis 15 weeks after vaccination. 
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5.3.8 Vaccine-induced immune responses to Tb DNA vaccines 
 
My studies have shown that inactivation of Tregs during BCG vaccination did not affect 
protective outcomes of BCG vaccination, such as bacterial numbers in tissues or 
pulmonary inflammation. These findings contrast with studies where inactivation of 
Tregs has been shown to enhance the protective efficacy of vaccines against other 
pathogens, such as P. berghei and HSV-1 [338, 339]. The BCG vaccine is the only 
currently available vaccine for Tb, but other vaccines against Tb, including DNA 
vaccines, have been developed and methods for enhancing DNA vaccine 
immunogenicity are of significant interest. If inactivation of Tregs prior to Tb DNA 
vaccination resulted in enhanced vaccine efficacy, then more effective Tb vaccine 
strategies could be designed that minimise Treg activation. Therefore, I hypothesised 
that Treg inactivation prior to Tb DNA vaccination would enhance primary and 
secondary immune responses, as well as protection afforded against virulent M. 
tuberculosis infection. Two Tb DNA vaccines were used to assess this; pcDNA3-85A 
[433] and pKUN85A (chapter 4). 
 To examine this hypothesis, groups of mice were treated with either PC61 or 
control rat IgG followed by homologous prime-boost vaccination with one of the 
vaccines (Fig. 5.1 A). DNA vaccines were administered i.m., with 2 weeks rest between 
the prime and boost vaccinations. For pcDNA3-85A, a standard dose of 100 µg was 
administered [433]. For pKUN85A, a 25 µg dose was chosen as this dose induced 
maximal cytokine production and lymphocyte proliferation at two weeks after 
vaccination during assessment of vaccine immunogenicity (Figs. 4.10/4.11). As a 
positive control, other groups of PC61 or rat IgG treated mice were vaccinated with 
BCG at the same time as the DNA vaccine boosts (Fig. 5.1 A).  Two weeks after the 
DNA vaccine boost, lymphocytes were harvested from the spleen and restimulated with 
Ag85A, the mycobacterial antigen encoded by both of the DNA vaccines (Fig. 5.1 B). 
Restimulated lymphocytes were either assessed for IFN-γ or IL-2 production by flow 
cytometry or for proliferation by [3H] thymidine incorporation.  
PC61 treatment alone induced a small but significant increases in basal IFN-γ 
production by CD8+ lymphocytes (Fig. 5.11 A) and proliferation (Fig. 5.11 E) in PBS 
vaccinated mice. PC61 treatment did not significantly alter the number of CD8+IFN-γ+ 
or CD4+IFN-γ+ T lymphocytes in BCG, pKUN85A or pcDNA3-85A vaccinated mice 
(Fig. 5.11 A/C). PC61 treatment also did not affect the number of CD8+IL-2+ or 
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CD4+IL-2+ T lymphocytes in pKUN85A or pcDNA3-85A vaccinated mice (Fig. 5.11 
B/D), although both cell populations were significantly increased in PC61 treated 
compared to control treated BCG vaccinated mice (Fig. 5.11 B/D).  Finally, lymphocyte 
proliferation was significantly increased in PC61 treated compared to control treated 
pKUN85A vaccinated mice, but PC61 treatment did not alter proliferation in either 
BCG or pcDNA3-85A vaccinated mice (Fig. 5.11 E).  
Therefore, inactivation of Tregs prior to pKUN85A vaccination led to modest 
increase in the proliferative response to Ag85A at two weeks after vaccination. In 
contrast, inactivation of Tregs prior to pcDNA3-85A vaccination did not affect 
lymphocyte proliferation or the numbers of cytokine producing lymphocytes two weeks 
after vaccination. 
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Figure 5.11: Vaccine-induced immune responses after DNA vaccination 
Mice were treated with rat IgG or PC61 then vaccinated with BCG, pKUN85A or pcDNA3-85A 
3 days later. Mice vaccinated with pKUN85A or pcDNA3-85A received a boost vaccination 
two weeks later. Two weeks after BCG vaccination and two weeks after the boost pKUN85A or 
pcDNA3-85A vaccinations, splenocytes were isolated and restimulated with Ag85A before 
being assessed for cytokine production by flow cytometry and for lymphocyte proliferation by 
[3H] thymidine incorporation assay. A) Average number of CD8+IFN-γ+ lymphocytes. B) 
Average number of CD8+IL-2+ lymphocytes. C) Average number of CD4+IFN-γ+ lymphocytes. 
D) Average number of CD4+IL-2+ lymphocytes.  E) Lymphocyte proliferation as measured by 
[3H] thymidine incorporation. Bars represent mean values per spleen ± SEM. Five animals were 
analysed per treatment group. Treatment groups were compared using the two-tailed Mann 
Whitney test; NS indicates p > 0.05, * indicates p ≤ 0.05, ** indicates p ≤ 0.01. Results 
represent one experiment. 
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5.3.9 Secondary immune responses for Tb DNA vaccines 
 
Inactivation of Tregs caused a modest enhancement of the primary immune response 
after pKUN85A vaccination but the effect of Treg inactivation prior to DNA 
vaccination on the secondary immune response remained to be tested.  
To evaluate the secondary immune responses of DNA vaccinated mice to 
infectious challenge, vaccinated mice were infected i.n. with BCG 6 weeks after 
boosting and lymphocytes were isolated at day 3 after infection (Fig. 5.1 C). 
Lymphocytes were isolated from the spleen and lung and restimulated with Ag85A. 
Restimulated lymphocytes were processed for intracellular cytokine staining and 
analysed by flow cytometry for the production of IFN-γ and IL-2. Cytokine production 
was assessed at day 3 after infection, as the most striking differences between PC61 and 
control treated BCG vaccinated mice were observed at day 3 after infection (Fig. 5.7). 
At day 3 after challenge in the spleen, for BCG vaccination, numbers of 
CD4+IFN-γ+ lymphocytes were significantly increased in PC61 treated compared to rat 
IgG treated mice (Fig. 5.12 C). CD8+IFN-γ+ lymphocytes were also increased but the 
difference was not statistically significant (Fig. 5.12 A). For pcDNA3-85A vaccination, 
the same trends were observed for CD4+IFN-γ+ and CD8+IFN-γ+ lymphocytes (Fig. 5.12 
A/C) and, in addition, numbers of CD8+IL-2+ and CD4+IL-2+ lymphocytes were 
significantly increased in PC61 treated compared to rat IgG treated mice (Fig. 5.12 
B/D). For pKUN85A vaccination, numbers of cytokine producing lymphocytes in the 
spleen in PC61 treated mice did not differ significantly from rat IgG treated mice and 
were largely comparable to PBS vaccinated control mice (Fig. 5.12 A-D). 
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Figure 5.12: Secondary immune responses in the spleen after DNA vaccination 
Mice were treated with rat IgG or PC61 then vaccinated with BCG, pKUN85A or pcDNA3-85A 
3 days later. Mice vaccinated with pKUN85A or pcDNA3-85A received a boost vaccination 
two weeks later. Six weeks after BCG vaccination and six weeks after the boost pKUN85A or 
pcDNA3-85A vaccinations, mice were challenged i.n. with BCG. Three days after challenge, 
splenocytes were isolated and restimulated with Ag85A before being assessed for cytokine 
production by flow cytometry. A) Average number of CD8+IFN-γ+ lymphocytes. B) Average 
number of CD8+IL-2+ lymphocytes. C) Average number of CD4+IFN-γ+ lymphocytes. D) 
Average number of CD4+IL-2+ lymphocytes. Bars represent mean values per spleen ± SEM. 
Four to five animals were analysed per treatment group. Treatment groups were compared using 
the two-tailed Mann Whitney test; NS indicates p > 0.05, * indicates p ≤ 0.05. Results represent 
one experiment. 
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At day 3 after challenge in the lung, there were no significant differences between PC61 
treated and rat IgG treated mice in the numbers of IFN-γ+CD8+, IL-2+CD8+, IFN-
γ+CD4+ or IL-2+CD4+ lymphocytes for any of the DNA vaccinated groups (Fig. 5.13 
A/B/C/D). A small but significant increase in numbers of IFN-γ+CD8+ lymphocytes was 
observed with PC61 treatment in the PBS treated control groups, which may indicate an 
increase in basal cytokine production (Fig. 5.13 A). 
The numbers and proportions of IFN-γ+IL-2+CD4+ lymphocytes were also 
assessed in both the spleen and lung for each treatment group. In the spleens, pcDNA3-
85A vaccinated mice exhibited a trend for increased numbers of IFN-γ+IL-2+CD4+ 
lymphocytes in PC61 treated compared to rat IgG treated mice, although the difference 
was not statistically significant (Fig. 5.14 A). In the lung, there were very low numbers 
of IFN-γ+IL-2+CD4+ lymphocytes in pKUN85A or pcDNA3-85A vaccinated mice and 
these numbers did not differ significantly between PC61 treated and rat IgG treated 
groups (Fig. 5.14 B). When proportions of IFN-γ+IL-2+CD4+ lymphocytes within the 
total IFN-γ or IL-2 producing CD4+ lymphocyte population were assessed, the 
proportions were unchanged by PC61 treatment for all vaccination groups in both the 
spleen and lung (Fig. 5.14 C/D), although there was large variation in the proportions of 
IFN-γ+IL-2+CD4+ lymphocytes in the lung due to low total numbers of cytokine-
producing cells. 
In summary, at 3 days after infectious challenge, PC61 treated/pcDNA3-85A 
vaccinated mice had increased numbers of cytokine producing CD8+ and CD4+ 
lymphocytes in the spleen compared to rat IgG treated/pcDNA3-85A vaccinated mice. 
Significant differences between PC61 treated and rat IgG treated groups for each DNA 
vaccine were not observed in the lung. Numbers of cytokine producing CD8+ and CD4+ 
lymphocytes in pKUN85A vaccinated mice were low in both the spleen and lung and 
comparable in many cases to PBS vaccinated control mice, and did not exhibit 
significant differences between PC61 treated and rat IgG treated groups. 
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Figure 5.13: Secondary immune response in the lung after DNA vaccination 
Mice were treated with rat IgG or PC61 then vaccinated with BCG, pKUN85A or pcDNA3-85A 
3 days later. Mice vaccinated with pKUN85A or pcDNA3-85A received a boost vaccination 
two weeks later. Six weeks after BCG vaccination and six weeks after the boost pKUN85A or 
pcDNA3-85A vaccinations, mice were challenged i.n. with BCG. Three days after challenge, 
lungs were harvested and isolated lymphocytes were restimulated with Ag85A before being 
assessed for cytokine production by flow cytometry. A) Average number of CD8+IFN-γ+ 
lymphocytes. B) Average number of CD8+IL-2+ lymphocytes. C) Average number of 
CD4+IFN-γ+ lymphocytes. D) Average number of CD4+IL-2+ lymphocytes. Bars represent mean 
values per lung ± SEM. Four to five animals were analysed per treatment group. Treatment 
groups were compared using the two-tailed Mann Whitney test; NS indicates p > 0.05, * 
indicates p ≤ 0.05. Results represent one experiment. 
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Figure 5.14: IFN-γ  and IL-2 co-production by CD4+ lymphocytes after DNA vaccination 
Mice were treated with rat IgG or PC61 then vaccinated with BCG, pKUN85A or pcDNA3-85A 
3 days later. Mice vaccinated with pKUN85A or pcDNA3-85A received a boost vaccination 
two weeks later. Six weeks after BCG vaccination and six weeks after the boost pKUN85A or 
pcDNA3-85A vaccinations, mice were challenged i.n. with BCG. Three days after challenge, 
spleens and lungs were harvested and isolated lymphocytes were restimulated with Ag85A 
before being assessed for cytokine production by flow cytometry. A) Average number of 
CD4+IFN-γ+IL-2+ lymphocytes in the spleen. B) Average number of CD4+IFN-γ+IL-2+ 
lymphocytes in the lung. C) Percentage of cytokine producing CD4+ lymphocytes that co-
produce IFN-γ and IL-2 in the spleen. D) Percentage of cytokine producing CD4+ lymphocytes 
that co-produce IFN-γ and IL-2 in the lung. Bars represent mean values per tissue ± SEM. Four 
to five animals were analysed per treatment group. Treatment groups were compared using the 
two-tailed Mann Whitney test; NS indicates p > 0.05. Results represent one experiment. 
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5.3.10 Protection from infectious challenge for Tb DNA vaccines 
 
PC61 treatment prior to vaccination significantly increased numbers of cytokine 
producing lymphocytes in the spleen but not the lung after infectious challenge in 
pcDNA3-85A vaccinated mice. Although the effects of Treg inactivation on vaccine-
induced and secondary immune responses after DNA vaccination were relatively minor 
compared to those seen following BCG vaccination, the effect of Treg inactivation on 
the protective efficacy of pKUN85A and pcDNA3-85A remained to be assessed. 
Vaccinated animals were challenged by aerosol with M. tuberculosis 6 weeks 
after vaccination (Fig. 5.1 D). Bacterial numbers in the lung and spleen were assessed 5 
weeks after infection. Lung samples were collected concurrently and prepared for 
histological analysis but the degree of inflammation in the lung at the time was too low 
for differences between groups to be significant (data not shown).  
When bacterial numbers in the lung were assessed, BCG vaccination afforded a 
significant ~1 log10 reduction in the lung and spleen after M. tuberculosis infection 
compared to control treated PBS vaccinated animals and PC61 treatment did not affect 
bacterial numbers either tissue (Fig. 5.15 A/B). Control treated mice vaccinated with 
pKUN85A, using a 25 µg dose, did not exhibit reduced bacterial numbers in either the 
lung or the spleen compared to control treated PBS vaccinated mice and PC61 treatment 
prior to pKUN85A vaccination did not alter bacterial numbers (Fig. 5.15 A/B). Control 
treated mice vaccinated with pcDNA3-85A exhibited a trend for reduced bacterial 
numbers in the lung and spleen compared to control treated PBS vaccinated mice, but 
the differences were not statistically significant (p = 0.1508 for lung, p = 0.0714 for 
spleen) (Fig. 5.15 A/B).  However, PC61 treatment prior to pcDNA3-85A vaccination 
led to a significant increase in bacterial numbers in the spleen (Fig. 5.15 A/B), 
suggesting protection from dissemination to the spleen afforded by pcDNA3-85A 
vaccination may be abrogated in this group. 
 These results suggest that, while Treg inactivation prior to vaccination did not 
affect the BCG vaccine, it may diminish protection against dissemination afforded by 
the pcDNA3-85A DNA vaccine. In addition, the 25 µg dose chosen for pKUN85A 
vaccination did not confer measurable protection in terms of reduced bacterial numbers 
in the lung or spleen, and Treg inactivation prior to vaccination does not affect this. 
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Figure 5.15: Protection afforded by DNA vaccination 
Mice were treated with rat IgG or PC61 then vaccinated with BCG, pKUN85A or pcDNA3-85A 
3 days later. Mice vaccinated with pKUN85A or pcDNA3-85A received a boost vaccination 
two weeks later. Six weeks after BCG vaccination and six weeks after the boost pKUN85A or 
pcDNA3-85A vaccinations, mice were challenged by aerosol with M. tuberculosis. Bacterial 
numbers in the lung were determined 5 weeks after infection. A) Bacterial numbers in the lung 
and B) bacterial numbers in the spleen after M. tuberculosis infection. Symbols represent 
geometric mean values ± GEM. Five animals were analysed per treatment group. Treatment 
groups were compared using the two-tailed Mann Whitney test; NS indicates p > 0.05, ** 
indicates p ≤ 0.01. Results represent one experiment. 
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5.4 Discussion 
 
I hypothesised that Treg inactivation through PC61 treatment prior to BCG or plasmid 
DNA vaccination would enhance the primary and secondary immune responses and 
would also enhance the protective efficacy of the vaccines against Tb. 
In keeping with my hypothesis, for BCG vaccination, an increase in the number 
of cytokine producing antigen-specific CD4+ lymphocytes in the spleen and lymph 
nodes was observed during the primary immune response (Fig. 5.3) and the secondary 
immune response in the lung upon infectious challenge was accelerated (Fig. 5.7). 
Contrary to my hypothesis, the enhancement or acceleration of primary and secondary 
immune responses by Treg inactivation did not enhance protection afforded by BCG 
vaccination (Figs. 5.8-5.10).  
 The outcomes from Treg inactivation prior to Tb DNA vaccination also differed 
from my original hypothesis. For pcDNA3-85A vaccination, inactivation of Tregs prior 
to priming did not significantly affect the primary immune response to vaccination (Fig. 
5.11) but did increase numbers of cytokine producing CD8+ and CD4+ lymphocytes in 
the spleen 3 days after infectious challenge (Fig. 5.12). Interestingly, Treg inactivation 
prior to pcDNA3-85A vaccination resulted in a significant increase in bacterial numbers 
in the spleen after M. tuberculosis infection (Fig. 5.15). The study evaluating the effect 
of Treg inactivation on pcDNA3-85A vaccination requires confirmation and will be 
investigated further. 
Inactivation of Tregs prior to pKUN85A vaccination modestly increased 
lymphocyte proliferation two weeks after boosting. However, vaccination with the 25 
µg dose of pKUN85A did not reduce bacterial numbers in the lung or spleen after M. 
tuberculosis challenge. The 25 µg dose was chosen on the basis that it resulted in 
maximal mean cytokine production and proliferation after in vitro restimulation of 
lymphocytes isolated from vaccinated mice (Figs. 4.10/4.11), rather protection data 
(Figs. 4.12/4.13). Protection data was not available at the time that these experiments 
were initiated, as protection studies for Tb vaccines can take 4-6 months to allow for 
vaccination, infection and processing of tissues for assessment of bacterial numbers. 
Given the decrease in protection that has been observed with high doses of plasmid 
DNA replicon vaccines [433], it is possible that the 25 µg dose of pKUN85A was too 
high to mediate protection against mycobacterial challenge. In future studies, a dose of 
pKUN85A titrated to confer significant protection against M. tuberculosis challenge 
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will be used to assess whether Treg inactivation prior to pKUN85A vaccination 
enhances vaccine efficacy. 
Overall, the protective efficacy of the BCG vaccine is not affected, whereas the 
protective efficacy of the pcDNA3-85A vaccine may be diminished by Treg 
inactivation prior to vaccination. Both of these results contrast with results obtained in 
other studies assessing the impact of Treg inactivation on vaccines against other 
infectious diseases. 
 
5.4.1 Comparison to other studies 
 
Inactivation of Tregs prior to vaccination against HSV-1 [338], hepatitis B virus [336] 
or concurrently with malarial vaccination [339], has been shown to result in increased 
primary immune responses and secondary immune responses, similar to the enhanced 
immune responses observed in this chapter. However, in contrast to our findings, 
inactivation of Tregs prior to or concurrently with vaccination against HSV-1 or malaria 
resulted in enhanced protection from challenge [338, 339].  
When comparing these studies to my own, there are several points of difference 
between the vaccines that may account for the distinct outcomes observed after Treg 
inactivation. The malarial and HSV-1 vaccines utilised a single protein antigen and 
induced protection predominantly mediated by CD8+ T cells [338, 339]. BCG is a live 
vaccine with a large number of different antigenic targets and CD4+ more so than CD8+ 
T cells are thought to mediate protection against Tb [61, 468]. The different outcomes 
caused by Treg inactivation prior to vaccination for each vaccine could be due to Tregs 
affecting the development of the discrete lymphocyte populations, which mediate 
protection for the different vaccines in distinct ways.  
Tregs can inhibit production of γc family cytokines, such as IL-2, by responder 
T cells [289, 291] and signalling from these cytokines is vital for optimal memory 
development (section 1.3.4.3).   For example, IL-2 signalling during CD8+ T cell 
activation has been shown to promote expansion of the effector population and CD8+ 
memory T cells that receive IL-2 signalling during priming accumulate in vastly larger 
numbers after secondary stimulation [202]. In addition, IL-2 signalling during CD4+ T 
cell activation has been shown to promote re-expression of IL-7Rα on the resulting 
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population [201]. Signalling from IL-7 is important for maintenance of CD4+ memory T 
cells [201] and therefore early IL-2 signalling facilitates the later survival of CD4+ 
memory T cells.  
Studies of the effect of IL-2 signalling on CD4+ memory T cell development 
have not differentiated between memory subsets within the CD4+ T cell population. 
Although CD8+ and CD4+ T cells have subtly different requirements for cytokine 
signalling for memory induction and maintenance, it is possible that different subsets of 
CD4+ T cells, such as Th1, Th2, Th17, Treg and other yet to be identified subsets, also 
have different cytokine requirements. Therefore, if the development of protective 
memory were reliant on signalling from cytokines such as IL-2, Treg inactivation prior 
to vaccination would be anticipated to enhance the protective efficacy of vaccination. 
On the contrary, if development of protective memory was not reliant on such 
signalling, Treg inactivation prior to vaccination might not affect the protective 
efficacy. 
Both CD4+ T cells and CD8+ T cells potentially contribute to protection 
mediated by vaccination with the live BCG vaccine, although CD4+ T cells are regarded 
as the major protective population [170]. The protective CD4+ T cell subset for the BCG 
vaccine is not definitively known, but results presented in this thesis have suggested 
some refinements. Inactivation of Tregs prior to BCG vaccination resulted in increased 
numbers of IFN-γ+ and IL-2+ CD4+ T cells in the draining lymph node and spleen two 
weeks after vaccination (Fig. 5.3), and increased numbers of IFN-γ+ and IL-2+IFN-γ+ 
CD4+ T cells in the spleen and lung six weeks after vaccination (Figs. 5.4/5.6). Treg 
inactivation prior to BCG vaccination did not affect the protective efficacy of the BCG 
vaccine (Figs. 5.8/5.9). This suggests that IFN-γ+, IL-2+ or IL-2+IFN-γ+ CD4+ T cell 
subsets do not define the protective subset arising from BCG vaccination. As a result, 
one might speculate that the quality and/or quantity of the memory T cell subset 
responsible for protection after BCG vaccination is unaffected by Treg inactivation 
prior to vaccination (Fig. 5.16) 
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Figure 5.16: Schematic for hypothesised effect of Treg inactivation on lymphocyte subsets 
and protection after BCG vaccination 
For the live BCG vaccine, 1) if Tregs are active, a robust cell-mediated response develops and a 
protective lymphocyte subset develops and confers protection against Tb infection. 2) If Tregs 
are inactive, enhanced activation signals, such as increased IL-2 signalling, could enhance the 
development of IFN-γ, IL-2 or IFN-γ/IL-2 producing CD4+ T cell subsets. I hypothesise that 
these cellular subsets do not define the protective subset for the BCG vaccine. I also hypothesise 
that enhanced activation signals when Tregs have been inactivated do not affect the 
development of the lymphocyte subset that mediates protection. Therefore, Treg inactivation 
does not alter protection from infection for the BCG vaccine.
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By contrast, preliminary data suggests that inactivation of Tregs may diminish 
protection afforded by pcDNA3-85A (Fig. 5.15). The only published experimental 
model where protective memory is lost after Treg inhibition is during L. major murine 
infection [305]. It was hypothesised that protection was abrogated as the immune 
response is increased to the point that low-grade infection was resolved and the source 
of persistent antigen for maintenance of memory was removed. It has been reported that 
CD4+CD25+ Tregs can expand after DNA vaccination and suppress immune responses 
[469], although the degree of Treg expansion is enhanced with certain routes of 
vaccination, such as mucosal vaccination. The effect of Tregs on the persistence of cells 
transfected with a DNA vaccine construct has not been assessed and if inactivation of 
Tregs prior to DNA vaccination results in increased clearance of transfected cells, it 
could negatively impact on vaccine protective efficacy. 
Therefore, the differing effects of Treg inactivation on the various vaccines 
tested could reflect the diversity of protective mechanisms elicited by the vaccines.  
 
5.4.2 CD4+CD25−Foxp3+ and induced Tregs 
 
It is important to note that similar to the discussion presented in chapter 3, there are 
other subsets of functional Tregs that may suppress immune responses to BCG and 
DNA vaccination, as the anti-CD25 mAb PC61 inactivated only CD4+CD25+ natural 
Tregs.  
CD4+CD25− T cells that express Foxp3 are unaffected by PC61 treatment [374]. 
Since expression of Foxp3 correlates highly with suppressive Treg activity [282], these 
lymphocytes represent a major Treg population that persists after PC61 treatment and 
may affect memory development and protective efficacy of the vaccines.  
Furthermore, vaccination may induce the development of Tregs that affect the 
primary and secondary immune responses and the resulting protective efficacy. There is 
evidence that BCG vaccination can induce Treg development from naïve CD4+CD25− T 
cells. DCs stimulated with BCG produce IL-10 and, when incubated with naïve T cells, 
can induce a subset of cells that produce IL-10, which is consistent with the Tr1 subset 
of induced Tregs [470]. In addition, BCG vaccinated infants have increased expression 
of Foxp3 mRNA in mycobacteria-stimulated peripheral blood samples, which may be 
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indicative of either Foxp3+ Treg expansion or induction of Tregs [471]. While it is 
interesting to note that Foxp3 expression isw induced in BCG vaccinated infants despite 
this group being effectively protected from Tb infection, it would be informative to 
compare this to induction of Foxp3 expression in BCG vaccinated adults in whom the 
vaccine is less effective. Increased Foxp3 expression in adults compared to infants after 
vaccination could indicate that Foxp3+ Treg expansion or induction of Tregs contribute 
to the diminshed efficacy of BCG in adults compared to children. 
Induction of Tregs or expansion of natural Tregs may also occur after DNA 
vaccination. Increased numbers of T cells with a suppressive phenotype are found after 
vaccination but this may be more pronounced with certain routes of vaccination, such as 
mucosal vaccination. For example, intranasal vaccination with DNA encoding 
proinsulin was able to inhibit the development of autoimmune diabetes in non-obese 
diabetic mice [461]. Through adoptive transfer experiments, it was determined that both 
CD25+ and CD25− CD4+ T cells could mediate this inhibition [461]. However, this 
inhibition was completely abrogated by pre-incubation of transferred T cells with the 
anti-GITR mAb DTA-1, which is thought to inhibit suppression by Tregs through 
modulation of GITR/GITRL signaling [461]. Whether Tregs are induced with other 
routes of DNA vaccination and whether Tregs induced by DNA vaccination migrate to 
the vaccination site have not been assessed.  
 
5.4.3 Implications for models of Th1 immunity 
 
A key aspect of this chapter is that the results allow us to further define the appropriate 
secondary response that enables protection from Tb infection. Current dogma suggests 
an effective Tb vaccine should induce a strong Th1 primary immune response 
characterised by CD4+ T cells producing IFN-γ (reviewed in [472-474]). Following a 
linear model of memory development [475], such a vaccine would thereby result in a 
larger pool of Th1 memory lymphocytes and a secondary immune response with an 
increased magnitude or speed of onset.  The results presented in this chapter showed 
that inactivation of Tregs during BCG vaccination induced a larger vaccine-induced 
immune response (Fig. 5.3) and larger subsequent pool of CD4+ and CD8+ lymphocytes 
that could express IFN-γ in response to mycobacterial antigen (Fig. 5.4), as well as an 
accelerated secondary immune response (Fig. 5.7). However, these factors were not 
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sufficient to reduce bacterial burden (Figs. 5.8/5.9). Therefore, this study lends weight 
to mounting evidence against the current dogma of Tb protective immunity in two 
areas.  
Firstly, it illustrates that after vaccination, increased numbers of IFN-γ 
producing lymphocytes locally in the lung and systemically in the spleen after 
vaccination and before infection does not correlate with increased protection from 
infectious challenge. This finding is consistent with other studies [167, 476].  
Secondly, it suggests that accelerating the existing BCG-induced secondary 
immune response in the lung is insufficient to enhance protection against Tb infection. 
It has been suggested that BCG vaccination results in lower bacterial burden in the lung 
because it accelerates the arrival of the IFN-γ expressing CD4+ lymphocytes in the lung 
[47, 84, 171]. The earlier exposure of infected alveolar macrophages to IFN-γ could 
arrest the growth of mycobacteria residing in macrophages earlier after infection, 
resulting in the ~1 log10 reduction in lung bacterial numbers in the lung and spleen that 
is typically observed in BCG vaccinated compared to naïve animals. However, 
inactivation of Tregs prior to BCG vaccination accelerated the secondary immune 
response compared to BCG vaccination alone (Fig. 5.7), with no corresponding 
decrease in bacterial numbers in the lung or spleen (Figs. 5.8/5.9). 
Recently, the protective efficacy of vaccines targeting Th1 immunity has been 
shown to correlate with their ability to induce an increased proportion of multi-
functional CD4+ Th1 cells that are capable of producing multiple cytokines rather then 
just IFN-γ [477]. This study used a L. major model of Th1 immunity and the multi-
functional CD4+ Th1 cells produced a combination of IL-2, TNF-α and IFN-γ [477]. It 
has been proposed that T cells that produce solely IFN-γ represent a terminal 
differentiation state [221] and they do not contribute to long-term Th1 immunity. 
However, multifunctional CD4+ Th1 cells are long-lived and capable of producing high 
amounts of all three cytokines upon in vitro restimulation [477]. As a result, it has been 
proposed that multi-cytokine producing CD4+ T cells are the mediators of Th1 
immunity. 
TNF-α production was not assessed in these studies, as the number of cellular 
markers that could be simultaneously assessed was limited by 4-colour flow cytometry. 
However, co-production of IL-2 and IFN-γ was evaluated. Co-production of IL-2 and 
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IFN-γ was not observed 2 weeks after BCG vaccination (Fig. 5.2) but by week 6 after 
vaccination, a small population of IL-2+IFN-γ+CD4+ lymphocytes was observed (Fig. 
5.5/5.6). Co-production of IL-2 and IFN-γ by CD4+ lymphocytes was also observed 3 
days after infectious challenge for BCG, pcDNA3-85A and pKUN85A vaccinated 
groups (Fig. 5.14). The numbers of IFN-γ+IL-2+CD4+ lymphocytes were significantly 
increased in PC61 treated compared to control treated BCG vaccinated mice in both the 
spleen and lung immediately prior to infectious challenge (Fig. 5.6). This significant 
increase did not correlate with a decrease in bacterial numbers in the lung or spleen after 
virulent mycobacterial challenge (Figs. 5.8/5.9).  
When IFN-γ+IL-2+CD4+ lymphocytes were evaluated as a proportion of the total 
IFN-γ or IL-2 producing CD4+ lymphocyte population, PC61 treatment did not alter the 
proportion of these cells 6 weeks after BCG vaccination (Fig. 5.6 C/D) or 3 days after 
infectious challenge in BCG vaccinated animals (Fig. 5.14 C/D). This correlates with 
the fact that PC61 treatment did not cause a difference in the protective efficacy of the 
BCG vaccine (Figs. 5.8/5.9). Therefore, the proportion rather than absolute numbers of 
CD4+ lymphocytes producing multiple cytokines may prove to be a useful correlate of 
protective efficacy for the BCG vaccine. 
Interestingly, preliminary results for pcDNA3-85A vaccination suggest that 
proportions of IFN-γ+IL-2+CD4+ lymphocytes might not consistently correlate with the 
protective efficacy of all Tb vaccines. Proportions of IFN-γ+IL-2+CD4+ lymphocytes 
were comparable between PC61 treated and control treated pcDNA3-85A vaccinated 
mice in the spleen 3 days after infectious challenge (Fig. 5.14 C/D); however, bacterial 
numbers in the spleen were significantly higher in PC61 treated compared to control 
treated pcDNA3-85A vaccinated mice after M. tuberculosis challenge (Fig. 5.15). It 
might not be appropriate to look for an immune correlate of protection against Tb 
shared between BCG and pcDNA3-85A vaccination and this issue will be discussed in 
greater depth in section 6.3.4. 
Overall, these results illustrate that several proposed immune correlates of 
protection for Tb do not consistently correlate with vaccine protective efficacy after 
Treg inactivation. In future studies, it would be interesting to assess IL-2, IFN-γ and 
TNF-α co-production, to more accurately assess the proportions of multi-functional 
CD4+ Th1 cells after vaccination and test this as an immune correlate of protection for 
Tb. 
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5.5 Summary 
 
Two key outcomes emerge from this study. Firstly, inactivation of natural Tregs may 
diminish the protective efficacy of pcDNA385A, resulting in slight increases in the 
secondary immune response but diminished protection from infectious challenge in the 
spleen. Secondly and in contrast, natural CD4+CD25+ Tregs did not have a significant 
effect during vaccination on protective outcome of the BCG vaccine.  
These outcomes also had implications for the validity of several proposed 
immune correlates of protection for Tb. They lend weight to mounting evidence that 
increased numbers of IFN-γ producing CD4+ lymphocytes [476] do not correlate with 
enhanced protection. The data also suggests that accelerating the appearance of IFN-γ 
producing T cells in the lung following infection [47, 84, 171] does not correlate with 
enhanced protection. Finally, the assessment of whether the proportion of multi-
functional CD4+ Th1 cells [477] is a correlate of Tb vaccine efficacy requires evaluation 
of TNF-α as well as IFN-γ and IL-2 production by CD4+ T cells. This data illustrated 
that, while the number of IFN-γ+IL-2+CD4+ T cells did not consistently correlate with 
protection against Tb infection, the proportion of IFN-γ+IL-2+CD4+ T cells may be a 
correlate of BCG vaccine efficacy. Thus, while Treg inactivation during vaccination 
does not enhance the protective efficacy of the BCG vaccine, it has provided insights 
into aspects of the immune response that do not limit the efficacy of BCG and assists in 
narrowing the search for more effective immune correlates of protection against Tb.
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At the time this study was initiated, Treg immunology was a relatively new field and 
natural Tregs had been shown to suppress immune responses and protection in some 
infection and vaccination models. However, the influence of Tregs during primary and 
memory responses to mycobacterial infection had not been assessed using an in vivo 
model. Given the effects of natural Tregs on other models, there was much speculation 
that natural Tregs would similarly suppress immune responses and protection during Tb 
infection and vaccination. It is interesting that, in this study, inactivation of natural 
Tregs enhanced primary and secondary immune responses but did not enhance control 
of a primary Tb infection or protection from a secondary infectious challenge. 
This discussion firstly summarises the results presented in this thesis. Secondly, 
it outlines ways of refining and optimising the DNA vaccine, pKUN85A, which was 
developed during this thesis. Thirdly, it explores other avenues through which Treg 
subsets may affect mycobacterial infection or vaccination and which were not addressed 
in this thesis. Finally, the broader implications of this study are examined for proposed 
immunological correlates of protection from Tb infection. 
 
6.1 Summary of experiments 
 
The main question addressed in this thesis was whether natural CD4+CD25+ Tregs 
suppressed the protective primary and memory immune responses against 
mycobacterial infection.  
I had initially hypothesised that Tregs would suppress both the immune response 
to mycobacterial infection and the immune response elicited by vaccination. To 
evaluate this, Tregs were inactivated in vivo using antibody-mediated inactivation prior 
to infection or vaccination, including pKUN85A vaccination, and resulting immune 
responses were followed. By inactivating Tregs, I hypothesised that immunosuppression 
mediated by Tregs would be relieved and thereby control of infection or vaccine-
mediated protection respectively would be enhanced. Several different mycobacterial 
infections were used in this study, including i.n. BCG infection and aerosol M. bovis or 
M. tuberculosis infection. The effect of Treg inactivation on three different Tb vaccines 
was also assessed: BCG, pcDNA3-85A and the pKUN85A plasmid DNA replicon 
vaccine, which was developed during the course of this thesis (chapter 4). 
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Initial studies revealed that natural Tregs suppressed the acute immune response 
to mycobacterial infections (Figs. 3.8-3.10). However, inactivation of Tregs did not 
affect bacterial numbers in the tissues during early stages of disease (Figs. 3.11-3.13) 
and only transiently reduced lung pathology in M. bovis infected mice (Fig. 3.14). 
Natural Tregs also suppressed immune responses to BCG vaccination, since inactivation 
of Tregs prior to BCG vaccination led to an enhanced vaccine-induced immune 
response (Fig. 5.3) and accelerated the immune response to secondary challenge (Fig. 
5.7). However, this accelerated secondary immune response did not affect the protective 
efficacy of the BCG (Figs. 5.8/5.9). Preliminary studies with the pcDNA3-85A plasmid 
DNA vaccine suggest that inactivation of Tregs prior to vaccination may diminish 
vaccine-mediated protection from infectious challenge (Fig. 5.15). 
Overall, this body of work suggests that natural Tregs suppress immune 
responses after mycobacterial infection or vaccination against Tb but this does not 
significantly inhibit control of a primary mycobacterial infection or protection from 
infection after Tb vaccination. This work also has implications for the validity of 
different immunological correlates of protection for Tb and for models of protective 
memory development after vaccination, which will be discussed in sections 6.3. 
 
6.2 Optimisation of the pKUN85A DNA replicon vaccine 
 
6.2.1 Techniques for optimising pKUN85A efficacy 
 
The novel pKUN85A Tb vaccine was developed, as outlined in chapter 4, with the aim 
of creating the first non-cytopathic plasmid DNA replicon vaccine against Tb. 
Vaccination with a non-cytopathic plasmid DNA replicon was anticipated to result in 
prolonged antigen expression in vivo and efficient activation of CD8+ T cells.  
The pKUN85A construct was created by cloning the Ag85A gene from the 
pcDNA3-85A plasmid DNA vaccine into the pKUNrep6 vector (Fig. 4.5). Orientation 
PCRs (Fig. 4.7) and digests (Fig. 4.8) followed by sequencing around the cloning site of 
this construct (Appendix 8.2) revealed that the Ag85A gene inserted in the correct 
orientation and in the correct frame with the surrounding ORF. Transfection of 
pKUN85A into the NIH-3T3 murine fibroblast cell-line demonstrated that NS-1 protein 
was produced from the ORF that also contained the Ag85A gene (Fig. 4.9). When 
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pKUN85A was administered i.m. to mice, it induced an Ag85A-directed immune 
response (Figs. 4.10/4.11). These data suggest that pKUN85A facilitates production of 
Ag85A protein in vivo and initiates an Ag85A-specific immune response. The dose 
titration of pKUN85A with respect to protection was complicated by high variation 
within treatment groups (Fig. 4.12) and further dose titrations of pKUN85A will be 
performed to determine the dose that confers maximal protection from Tb. 
 Once an appropriate dose of pKUN85A has been determined, it would be 
informative to characterise the type of immune response induced by the vaccine. Tb 
vaccines are often designed to activate CD4+ T cells and induce Th1 immunity but 
plasmid DNA replicon vaccines are known to induce cell-mediated immunity and 
robust CD8+ T cell activation. Restimulation of lymphocytes from pKUN85A 
vaccinated mice with whole Ag85A protein resulted in cytokine production by CD8+ T 
cells (Fig. 4.11 B/D), but this is likely to be a result of bystander activation of CD8+ T 
cells mediated by CD28 signalling rather than true antigen-driven cytokine production 
[445]. To assess antigen-driven cytokine production by CD8+ T cells, lymphocytes 
should be restimulated with APCs loaded with an MHC I restricted peptide from 
Ag85A. Currently, there have not been any MHC I restricted peptides from Ag85A 
identified for C57BL/6 mice, but an MHC I restricted peptide from Ag85A has been 
identified for BALB/c mice [430, 446, 447, 478]. Therefore, induction of CD8+ T cell 
responses will be assessed after vaccination of BALB/c mice with pKUN85A and, 
thereafter, the contribution of CD8+ T cells to protection from mycobacterial infection 
afforded by pKUN85A vaccination will be assessed. 
Additionally, vaccination with pKUN85A could be optimised in a number of 
ways, including choice of antigen, optimisation of antigen expression, optimisation of 
vaccine delivery or enhancement of vaccine adjuvancy (section 4.4.4). However, the 
most promising way to enhance the efficacy of the pKUN85A vaccine is to incorporate 
it into a heterologous prime-boost vaccination approach. DNA vaccines have been used 
in human clinical trials as part of a heterologous prime-boost approach to enhance 
vaccine efficacy (reviewed in [232, 479, 480]). It is possible that pKUN85A would be 
more effective as a component of a heterologous prime-boost vaccine in combination 
with adjuvanted protein subunit Tb vaccines, BCG or viral vectors containing Ag85A. 
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6.2.2 Progressing towards clinical trials 
 
There are several major hurdles for efficacy testing and study design before a DNA 
vaccine, such as pKUN85A, could be considered for Tb vaccine clinical trials.  
Firstly, the safety and efficacy of a vaccine needs to be validated in a number of 
animal models. For Tb vaccines, pre-clinical studies are usually performed in murine 
models followed by the guinea pig model. The guinea pig model exhibits lung 
pathology that that more closely models the human granuloma, with central necrosis, 
and displays progressive disease not only in the lung but also the spleen, which only 
occurs in highly susceptible humans [22, 186]. Due to their high susceptibility, guinea 
pigs are often used as a final pre-clinical model to test novel Tb vaccine efficacy. 
During testing in animal models, vaccines are compared to the BCG vaccine, which is 
used as the gold standard for Tb vaccines. Vaccine efficacy for a Tb vaccine would 
need to be at least equivalent if not better than BCG to progress into clinical trials.  
Preclinical safety testing for DNA vaccines also carries a particular set of 
considerations. DNA vaccine plasmids could theoretically insert into the genome of the 
transfected host cell or DNA vaccination could result in the development of anti-DNA 
antibodies and autoimmunity, but so far neither of these outcomes has been observed in 
practice (reviewed in [481]). In fact, plasmid DNA vaccines have been used in 
numerous preclinical safety trials and phase I human clinical trials and they have a 
consistently high safety record. However, evaluating vaccine efficacy in humans for Tb 
vaccines can be a complicated and prolonged process.  
Clinical trials to assess Tb vaccine efficacy are complicated by two issues. 
Firstly, Tb does not often progress rapidly to symptomatic disease and may persist in its 
latent form. Secondly, the latent form of Tb infection can be difficult to diagnose. 
Therefore, vaccinated individuals must be followed for a long period, using relatively 
labour-intensive methods to diagnose disease, to accurately assess vaccine efficacy. The 
prolonged and involved nature of these studies could be minimised for Tb if an accurate 
immune correlate of protection could be identified and efficacy could be assessed 
earlier after vaccination. 
 Despite potential issues associated with human clinical trials of Tb vaccines, 
there have been a number of recent trials [254]. One recent study recruited individuals 
already vaccinated with BCG and boosted them with a viral vector expressing Ag85A 
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[480]. This viral vector boost resulted in strong induction of IFN-γ production by T cells 
assessed by ELISpot after boosting and these responses were assessed as an indicator of 
vaccine immunogenicity [480].  
Unfortunately, while parameters such as IFN-γ production and antigen-specific 
proliferation are used to assess Tb vaccine immunogenicity, these parameters do not 
consistently correlate with maximal protection from infection [167]. Additionally, small 
changes in the dose of plasmid DNA replicons can have a major effect on the efficacy 
of the vaccine in a homologous prime-boost setting [433]. Given the sensitivity of 
plasmid DNA replicons to dose and the lack of an immune correlate of protection, an 
efficacy trial for pKUN85A would need to test different doses of pKUN85A and relate 
this to protection from Tb infection rather than immunogenicity. Therefore, a clinical 
trial to assess efficacy of a plasmid DNA replicon vaccine, such as pKUN85A, against 
Tb would be relatively large, prolonged and difficult to perform compared to a clinical 
trial for vaccines against other infections. 
Overall, vaccination with pKUN85A requires a number of refinements to 
enhance vaccine efficacy (discussed in section 4.4.4) and these refinements need to be 
tested in small animal models, such as the C57BL/6 and BALB/c murine models of Tb. 
If the vaccine is able to improve upon the efficacy seen with BCG, pre-clinical efficacy 
trials could be considered using other animal models, such as the highly susceptible 
guinea pig model. Depending on the success of pre-clinical trials, human clinical trials 
could be considered. However, human clinical trials of vaccine efficacy would be 
complex to undertake, considering the lack of an immune correlate of protection for Tb 
and the need for plasmid DNA replicon vaccine dose to be carefully titrated with 
respect to protection. 
 
6.3 Tregs and anti-mycobacterial immunity 
 
The experiments in this thesis were driven by the hypothesis that inactivating natural 
CD4+CD25+ Tregs prior to mycobacterial infection or vaccination would enhance acute 
immune responses and thereby enhance control of primary infection or enhance 
development of protective memory.  
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This thesis focussed on natural Tregs and the acute immune response to 
mycobacterial infection, primarily because of tools available to manipulate Tregs in 
vivo. At the outset of these studies, these tools were limited to anti-CD25 antibodies, 
such as PC61, and antibodies blocking or signalling through the GITR/GITRL pathway, 
such as DTA-1 and 5F-1. In vivo administration of PC61 was used to inactivate Tregs 
but results contained in this thesis outlined several limitations of this method:  
• PC61 treatment inactivated CD4+CD25+Foxp3+ lymphocytes efficiently but did 
not target CD4+CD25−Foxp3+ lymphocytes (Fig. 3.2). Foxp3 is a better correlate 
of Treg suppressive phenotype than CD25 and CD4+CD25−Foxp3+ lymphocytes 
possess significant suppressive function [282]. As a result, PC61 treatment 
inactivated natural CD4+CD25+Foxp3+ lymphocytes effectively but suppressive 
CD4+CD25−Foxp3+ lymphocytes were retained and comprised up to 50% of the 
total Foxp3+ Treg population in tissues like the lung and spleen of naïve mice 
[282]. 
• After a single treatment with PC61, CD25+ Tregs were inactivated for up to 23 
days but eventually repopulated the periphery (Fig. 3.3). The onset of 
repopulation may coincide with the clearance of the PC61 antibody from the 
periphery (Fig. 3.5). Therefore, PC61 treatment prior to infection or vaccination 
inactivated Tregs during the acute immune response but inactivation did not 
persist during later stages of infection or vaccination. 
• While PC61 treatment inactivated natural CD25+ Treg subsets in a naïve mouse, 
induced subsets of Tregs may arise upon infection or vaccination. This study did 
not address the role of induced Treg subsets during mycobacterial infection and 
vaccination.  
Therefore, my thesis illustrates that CD25+ Tregs do not suppress protection in 
mycobacterial infection and vaccination models to the degree that has been observed for 
other infection and vaccination models, but this does not rule out a role for Tregs 
altogether. Induced Tregs or memory Tregs may affect anti-mycobacterial immunity 
and Treg activity may be induced in certain immunological settings, such as co-
infection, chronic mycobacterial infection or virulent mycobacterial infection, as will be 
discussed below. Recently, several tools have been developed that will enable deeper 
exploration of Treg involvement for anti-mycobacterial immunity and potential 
applications of these tools will be outlined.  
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6.3.1 Induced Tregs and anti-mycobacterial immunity 
 
 
Induced Tregs can arise under a number of different conditions, including low-dose 
antigen presentation and antigen presentation during conditions in which TGF-β or IL-
10 is present (section 1.4.3). Currently, there have not been any studies directly 
assessing the role of induced Tregs during mycobacterial infection or vaccination. 
However, it is possible that during mycobacterial infection or vaccination against Tb, 
antigen presentation occurs in conditions of low-dose antigen or elevated TGF-β or IL-
10, as described below. 
 Although substantial amounts of antigen may be available during mycobacterial 
infection and vaccination, it is possible that mycobacterial antigen presentation is not 
optimal, resulting in the induction of Tregs. MHC II presentation is down-regulated in 
mycobacteria infected macrophages and DCs by suppression of H-2DM gene 
expression [166] and inhibition of release of MHC II molecules into physiologically 
relevant cellular compartments [165]. Therefore, although antigen is phagocytosed 
during mycobacterial infection and vaccination, the amount of antigen presented by 
APCs containing mycobacteria may be low, resulting in the differentiation of induced 
Tregs. 
IL-10 or TGF-β may also be produced during presentation of mycobacterial 
antigen. APCs can be stimulated to produce IL-10 upon exposure to mycobacterial 
products. For example, an LPS-free preparation of M. tuberculosis heat shock protein 
70 inhibited maturation of murine DC precursors in vitro and in vivo [482]. DCs 
cultured in these conditions produced IL-10 and inhibited T cell proliferation in vitro 
[482]. These results illustrate that mycobacterial proteins can suppress APC maturation 
and activation, and can induce IL-10 production in a context that would promote 
induction of Tregs, resulting in immunosuppression.  
Furthermore, IL-10 and TGF-β producing CD4+CD25+ T cells have been 
detected in the lungs of M. tuberculosis infected mice. [483]. Co-expression of IL-10 
and TGF-β by CD4+CD25+ T cells was not assessed but neutralisation of either IL-10 or 
TGF-β enhanced in vitro IFN-γ production by lung lymphocytes [483]. Therefore, 
CD4+CD25+ Tregs producing IL-10 or TGF-β can access the lung and suppress local 
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responses. These Tregs could have been natural CD25+ Tregs or induced Tregs, as 
induced Tregs can upregulate CD25 upon TCR stimulation. 
Production of IL-10 by APCs not only occurs after exposure of APCs to M. 
tuberculosis proteins but also after exposure of APCs to BCG. DCs matured in the 
presence of BCG decreased the amount of IL-12 they produced but increased IL-10 
production upon stimulation with CD40L compared to LPS-matured DCs [484]. When 
BCG-matured DCs were used to prime naïve T cells, the T cells produced IL-10 but had 
no bias for IFN-γ or IL-4 production compared to LPS-matured DCs [484]. Therefore, 
APCs stimulated with BCG in vitro induce conditions conducive for Treg induction 
during antigen presentation to naïve T cells, and these naïve T cells acquire an induced 
Treg-like phenotype. 
Finally, the ability of DNA vaccination to induce Tregs or even expand natural 
Tregs has not been widely explored. It is known that delivery of DNA vaccines to 
mucosal surfaces can result in tolerogenic responses against antigens encoded in the 
construct. Vaccination with DNA encoding proinsulin by an i.n. route resulted in 
suppression of autoimmune diabetes in non-obese diabetic mice [461]. When 
mechanisms responsible for suppression were explored, it was found to be mediated by 
both CD25+ and CD25− CD4+ T cells in a GITR-dependent mechanism [461]. These 
results support the hypothesis that DNA vaccination via mucosal surfaces can result in 
natural Treg activation or induction of Tregs. Natural Treg activation or induction of 
Tregs following i.m. DNA vaccination has not been directly assessed but inactivation of 
Tregs prior to pcDNA3-85A did not significantly enhance the primary immune response 
(Fig. 5.11), although it did enhance the secondary response (Fig. 5.12).  These results 
illustrate that CD4+CD25+ Tregs can suppress the development of secondary immune 
responses after i.m. DNA vaccination and suggest that Tregs are activated or induced 
upon vaccination. 
Considering the conditions, such as sub-optimal antigen presentation or antigen 
presentation in the presence of IL-10 and TGF-β, which occur during mycobacterial 
infection or vaccination, Treg populations may be induced. As a result, I hypothesise 
that an induced Treg population could mediate immunosuppression during primary 
mycobacterial infection and during Tb vaccination. This would introduce a degree of 
redundancy into the system. Immunosuppressive responses detected during 
mycobacterial infection and vaccination could be as a result of suppression mediated by 
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natural Tregs or by induced Tregs. During inactivation of CD4+CD25+ Tregs, the 
suppressive activity of induced Tregs unaffected by PC61 treatment could mask any 
effect of inactivation of natural Tregs. Therefore, significant questions remain, 
including whether induced Tregs suppress bacterial clearance after mycobacterial 
infection or suppress the protective efficacy of Tb vaccines, and whether there is 
redundancy between the immunosuppressive mechanisms of natural and induced Tregs. 
 
6.3.2 Tregs during chronic mycobacterial infection 
 
Tregs suppress immune responses predominantly during chronic infections [305, 330, 
333, 349, 375], and mycobacterial infections are well known for their chronicity. 
Therefore, Tregs could be more important for immunosuppression in the granuloma 
during the chronic phase of mycobacterial infection, a point also briefly explored in this 
thesis. 
Tregs have been shown to accumulate in mycobacterial lesions. Results 
presented in this thesis demonstrated that CD4+CD25+Foxp3+ Tregs accumulate in the 
lung during the acute phase of mycobacterial infection (Figs. 3.5/3.6). Another recent 
study by Scott-Browne, et al. demonstrated that Foxp3+ Tregs accumulate along with 
other lymphocytic infiltrate in the lung in granulomatous lesions [384] and thus are 
likely an integral part of the granuloma. It remains to be seen whether these Tregs 
suppress immune responses in the granuloma and, to date, no studies evaluating co-
localisation of Foxp3 and Treg mediator molecules such as IL-10 and TGF-β have been 
published. While it is possible that the Tregs themselves secrete these molecules, it is 
also possible that Tregs direct other effector cells within the granuloma to secrete 
suppressive cytokines, such as is the case with L. major infection in both Th1- and Th2-
biased murine models [360, 361]. It is also not known which Treg subsets, whether 
natural or induced Tregs, make up the majority of infiltrate to the lung. 
Tregs contribute to the cellular composition of the granuloma but whether Tregs 
suppress bacterial clearance during chronic mycobacterial infection has not been 
extensively examined. In this thesis, Treg activity was modulated during the chronic 
phase of mycobacterial infection to address this point. Neither enhancing Treg activity 
through administration of 5F-1 (anti-GITRL mAb) nor inhibiting Treg activity through 
administration of PC61 (anti-CD25 mAb) and/or DTA-1 (anti-GITR mAb) altered the 
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bacterial numbers present in the lung (Fig. 3.15). Inhibition of Treg activity through 
administration of PC61 and DTA-1 during chronic infection with L. sigmodontis has 
been shown to reduce pathogen load [330] and it is interesting that a similar effect was 
not apparent for M. tuberculosis infection.  
There are potential limitations associated with using these mAbs to assess the 
effect of Tregs during chronic M. tuberculosis infection. Administration of PC61 during 
an active immune response has been controversial, since recently activated effector T 
cells upregulate CD25 and, thereby, PC61 may inhibit the activity of both Tregs and T 
effector cells. While this could occur theoretically, enhanced effector responses were 
observed in mice that had PC61 persisting in their circulation during the first week of 
mycobacterial infection (Figs. 3.5/ 3.8-3.10), suggesting that the presence of PC61 does 
not inhibit the development of effector immune responses.  
Anti-GITR or anti-GITRL mAbs can be used to modulate the activity of Tregs 
through the GITR/GITRL signalling pathway. The use of these antibodies in vivo 
presupposes that the activity of Tregs present during chronic mycobacterial infection is 
affected by GITR/GITRL signalling. During L. sigmodontis infection, there is 
substantial expression of GITR on lymphocytes associated with lesions [330] and some 
GITR expression has been observed by lymphocytes in PBMCs from M. tuberculosis 
infected patients [370, 371]. However, the exact mechanism of GITR/GITRL signalling 
is not well characterised and whether it interferes with mechanisms of suppression 
utilised by Tregs present during chronic mycobacterial infection is uncertain. Finally, as 
noted in the previous section, induced Tregs may develop over time and play a role 
during chronic stages of mycobacterial infection. The effect of PC61, DTA-1 and 5F-1 
mAbs on the activity of induced Tregs has not been characterised.  
Thus, it remains to be fully explored whether Tregs suppress clearance of 
bacteria during the chronic stages of mycobacterial infection. Specifically, it remains to 
be seen whether targeted inhibition of natural and/or induced Treg function during the 
chronic phase of mycobacterial infection will enhance tissue pathology or decrease 
tissue bacterial numbers. It is apparent from results presented in this thesis (Figs. 
3.5/3.6) and other recently published studies [384] that Tregs infiltrate the lung and 
granuloma during mycobacterial infection, which supports the hypothesis that Treg 
activity can modulate the granuloma environment during chronic infection. 
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6.3.3 Tregs during virulent mycobacterial disease 
 
Treg inactivation did not affect bacterial numbers in the lung after pulmonary BCG, M. 
tuberculosis or M. bovis infection (Fig. 3.11/3.13), but may result in transiently 
diminished pulmonary inflammation after M. bovis infection (Fig. 3.14). The 
preliminary finding that Treg inactivation could diminish pulmonary pathology after M. 
bovis infection requires further testing; however, if this proves to be the case, there are 
interesting implications for the role of Tregs in the pathology of virulent mycobacterial 
infection. In chapter 3, it was speculated that, since M. bovis infection is more virulent 
in mice compared to BCG or M. tuberculosis infection [382], Tregs might somehow 
contribute to this virulence.  
 It has recently been found that Tregs can have altered kinetics in more virulent 
mycobacterial infections. After infection of mice with a hypervirulent strain of M. 
tuberculosis, bacterial numbers in the tissue increased rapidly and pathology rapidly 
progressed [485]. This correlated with a very rapid Th1 immune response but also with 
a rapid emergence of CD4+CD25+Foxp3+ Tregs [485]. This paper suggested that the 
rapid emergence of Tregs suppressed the Th1 immune response before it was able to 
control the infection, resulting in hypervirulence. However, it would be interesting to 
inactivate Tregs prior to infection with the more virulent M. tuberculosis infection. If 
Treg inactivation resulted in a reduction of inflammation similar to the reduction 
observed with Treg inactivation prior to M. bovis infection, it would suggest that Tregs 
contributed to a mechanism of virulence. 
 
6.3.4 Cross-reactivity or bystander Treg suppression 
 
The methodology in this thesis was used to assess whether natural Tregs suppress 
protective immune responses to mycobacterial infection in animals that were not known 
to have encountered any pathogens previously. However, human subjects are not naïve 
prior to mycobacterial infection or BCG vaccination. They may be exposed to 
environmental mycobacteria that possess cross-reactive antigens or may be infected 
with other pathogens at the time of infection or vaccination. Co-infections or cross-
reactivity with tolergenic antigens could result in scenarios in which Tregs can 
modulate the outcome of infection or vaccination. These scenarios have not been 
explored in these studies but there is evidence in the literature that Tregs induced during 
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co-infection or induced to cross-reactive antigen could suppress immune responses or 
protection to mycobacterial infection and vaccination, as described below. 
Tregs are activated or induced in an antigen-specific manner, as they require 
TCR stimulation with their cognate antigen to initiate their suppressive capabilities. 
Once activated or induced, Tregs can suppress other responses in a non-antigen specific 
manner [290], particularly through soluble mediators such as cytokines. Thus, Tregs 
activated during co-infection or during a previous infection that possesses shared 
antigens could confer generalised bystander suppression on responses to mycobacterial 
infection or vaccination (reviewed in [486]).  
Environmental mycobacteria may induce or activate Tregs specific for antigens 
cross-reactive with BCG or M. tuberculosis antigens. For example, the environmental 
mycobacterium M. vaccae can promote Treg-mediated suppression for co-administered 
antigens. When a suspension of heat-killed M. vaccae was administered with a 
sensitising antigen for airway hypersensitivity assays, the eosinophilic response during 
challenge was greatly suppressed [487]. The cellular population responsible for 
suppression was CD4+CD45RBlo, which is a classic Treg phenotype [488], and the 
suppression was dependent on the presence of IL-10 and TGF-β [487]. Therefore, after 
exposure to environmental mycobacteria such as M. vaccae, Tregs specific for co-
delivered and cross-reactive mycobacterial antigens may be induced.  
In addition, co-infection with helminths or other pathogens that effectively 
induce Tregs could result in bystander suppression of immune responses to 
mycobacterial infection or vaccination. Helminth co-infections correlate with 
diminished responses to both mycobacterial infection and BCG vaccination in human 
studies. Human Tb patients that had concomitant helminth infections had decreased 
IFN-γ production but increased IL-10 production by PBMCs in response to 
mycobacterial antigen compared to helminth-free Tb patients [489]. For BCG 
vaccination it has been found that de-worming treatment prior to vaccination leads to 
increased proliferation and IFN-γ production by PBMCs after in vitro restimulation with 
mycobacterial antigen [490]. These results suggest that helminth co-infection results in 
immunosuppression of mycobacterial immune responses and Treg activity could 
contribute to this suppression. 
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Therefore, Tregs may be activated during co-infection or during a previous 
cross-reactive infection. The effects of Treg cross-reactivity or bystander suppression on 
anti-mycobacterial immunity remain intriguing possibilities for future study. 
 
6.3.5 Treg memory 
 
For the experiments described in thesis, Tregs were inactivated prior to vaccination and 
primary and secondary immune responses were then assessed. It was hypothesised that 
the enhanced effector responses observed after secondary challenge were due to 
alterations in Th1 memory cell populations caused by the lack of suppression by Tregs 
during priming. However, an alternative explanation is that inactivation of Tregs during 
priming resulted in failure to induce a Treg memory population. This hypothetical 
previously activated Treg memory population may be essential for suppression of the 
secondary immune response. 
Treg memory is difficult to define. A Treg memory subset could arise from 
natural or induced Treg populations, and Treg memory has not been widely studied. The 
conventional definition of a memory cell is a long-lived cell that has experienced 
antigen and responds quantitatively or qualitatively better than naïve cells to secondary 
stimulation. It is widely thought that natural Tregs are selected in the thymus based on 
intermediate affinity TCR interactions with self-peptide leading to a semi-activated cell 
surface marker phenotype [491]. Due to their phenotype, natural Tregs are never truly 
naïve, even upon egress from the thymus. However, Tregs that then encounter antigen 
in the lymphoid tissues reach a heightened state of activation and can exhibit additional 
markers of activation, such as loss of CCR7 and CD62L expression and increased 
CD103 expression [492, 493]. By virtue of this altered expression of chemokine 
receptors and cell surface adhesion molecules, these activated Tregs migrate into 
tissues. Presumably both natural and induced Tregs migrate into tissues and tissue 
resident Tregs are referred to as having an effector/memory phenotype [492, 493]. 
Lymphoid tissue resident Tregs with a more naïve phenotype are efficient at inhibiting 
proliferation of naïve T cells and tissue resident Tregs with an effector/memory 
phenotype are efficient at inhibiting ongoing inflammatory responses [492]. However, it 
has not been assessed whether naïve or effector/memory Tregs are long-lived or 
whether the response of effector/memory Tregs to secondary stimulation is enhanced 
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compared to a primary response. As these aspects are central tenets of the definition of a 
memory cell, it is premature to call tissue resident Tregs true memory cells. 
Thus, it is not known to what degree antigen-experienced Tregs from a primary 
immune response affect the secondary immune response. In mice vaccinated against L. 
monocytogenes, antibody-mediated Treg inactivation immediately prior to secondary 
challenge releases suppression on CD8+ T cell effector mechanisms [337]. Whether 
Treg suppression during secondary challenge was a result of de novo Treg activation or 
activation of antigen-experienced, tissue-resident Tregs residual after the initial 
vaccination was not assessed. To ascertain whether suppression of secondary immune 
responses is due to long-lived memory Tregs or de novo activation of Tregs, the kinetics 
of accumulation and persistence of Tregs in the tissues would need to be observed 
during primary and secondary immune responses. 
 
6.3.6 Recent progress and remaining questions 
 
As alluded to above, a number of avenues remain to be explored to test whether Tregs 
suppress anti-mycobacterial immunity, and the recent development of several 
experimental tools will assist these studies. Mice that express GFP as a fusion protein 
with Foxp3 [282] enable better tracking of Tregs in general as Foxp3 is a tighter 
correlate of the Treg suppressive phenotype than markers like CD25, GITR and CD154. 
Furthermore, mice that express GFP and a diphtheria toxin receptor under the control of 
the Foxp3 promoter [494] will permit targeted depletion of Foxp3 expressing cells at 
discrete stages during an active immune response. These tools could be used to resolve 
a number of outstanding issues for the role of Tregs in anti-mycobacterial immunity, 
including: 
• Are Tregs induced during mycobacterial infection or vaccination? To address 
this issue, a CD4+CD25−Foxp3−GFP− population could be sorted from naïve 
GFP-Foxp3 transgenic mice and adoptively transferred into congenic mice 
before infection or vaccination. The transferred CD4+CD25−Foxp3−GFP− 
population should contain naïve T cells but no Tregs. If a significant 
CD4+Foxp3+GFP+ population develops after infection or vaccination, then that 
would suggest that Tregs are induced after exposure to mycobacterial antigen.  
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• Are the Tregs that migrate to the granuloma during mycobacterial infection 
natural or induced Tregs? To address this issue, CD4+CD25+Foxp3+GFP+ Tregs 
and CD4+CD25−Foxp3−GFP− naïve T cells could be sorted from naïve GFP-
Foxp3 transgenic mice. CD4+CD25−Foxp3−GFP− naïve T cells could be 
stimulated in vitro with mycobacterial antigen under conditions that result in 
Treg induction. These populations could be adoptively transferred into separate 
congenic mice early or late during mycobacterial infection. Localisation of the 
transferred populations in non-lymphoid and lymphoid tissues could be 
observed. The cellular composition of the granuloma could be examined to 
determine which cell type predominates in the granuloma.  
• Do natural or induced Foxp3+ Tregs facilitate pathogen persistence and prevent 
pathology during chronic mycobacterial infection? To examine this, mice 
expressing the diphtheria toxin receptor under the control of the Foxp3 promoter 
could be infected with mycobacteria. Once the infection reaches a chronic phase, 
treatment of the mice with diphtheria toxin would deplete all Foxp3+ Tregs, 
including both natural and induced Tregs. The integrity of the granuloma and 
bacterial numbers in tissues could be assessed. Increased pathology after Treg 
depletion would indicate that Tregs act during chronic mycobacterial infection 
to suppress tissue pathology, as has been observed in other infections. However, 
decreased bacterial numbers in tissues would indicate that Tregs act at later 
stages of mycobacterial infection to facilitate pathogen persistence. 
• Do long-lived Treg cells develop during mycobacterial infection or vaccination? 
Are these Treg cells derived from natural or induced populations? 
CD4+CD25+Foxp3+GFP+ Tregs and CD4+CD25−Foxp3−GFP− naïve T cells 
could be sorted from naïve GFP-Foxp3 transgenic mice. These populations 
could be adoptively transferred into congenic mice prior to mycobacterial 
infection or vaccination. The expansion and persistence of congenic 
Foxp3+GFP+ Tregs after priming could be followed. The tissue distribution of 
effector/memory phenotype Tregs could also be assessed as other studies have 
shown that effector/memory Tregs localise in peripheral tissue due to altered 
chemokine receptor and adhesion molecule expression [492].  
• If long-lived Treg cells develop during mycobacterial infection or vaccination, it 
raises the question of whether these are memory cells in the sense that their 
suppressive function is enhanced upon secondary challenge. To assess this, 
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Foxp3+ Tregs could be sorted from previously infected or vaccinated mice, and 
the cells adoptively transferred into naïve congenic mice. As a control, Foxp3+ 
Tregs could be sorted from naïve mice and transferred into naïve congenic mice, 
and all recipient mice would then be subsequently infected with mycobacteria. If 
expansion of Foxp3+GFP+ Tregs and suppression of the immune response to 
infectious challenge was enhanced in mice that receive Foxp3+GFP+ Tregs from 
infected or vaccinated donors compared to naïve donors, that would suggest that 
long-lived Treg cells possess an enhanced ability to respond to secondary 
antigen stimulus. This would fit the definition of a memory cell as a cell that 
responds quantitatively or qualitatively better than naïve cells to secondary 
stimulation. 
 
6.3.7 Summary: Tregs and anti-mycobacterial immunity 
 
Results presented in this thesis demonstrated that inactivating natural Tregs prior to 
mycobacterial infection or vaccination enhanced the acute primary immune response to 
infection and enhanced primary and memory immune responses to BCG vaccination. 
Despite these enhanced immune responses, and in contrast to other infection and 
vaccination models, inactivating natural Tregs did not have any effect on protection 
from primary mycobacterial infection or the protective efficacy of the BCG vaccine.   
Overall, this study illustrates that under naïve WT conditions, CD4+CD25+ 
Tregs modestly suppress immune responses to mycobacterial infection and vaccination 
in the murine model but do not affect protection from infection. However, it is possible 
that Tregs can be induced, expanded or their activity enhanced under certain conditions 
as outlined above. In a heterogeneous outbred human population, exposed to a diverse 
array of environmental conditions, there may be more variation in Treg numbers or 
activity upon mycobacterial infection or vaccination compared to an inbred murine 
population, such as was used in this thesis. A study by Kursar, et al. indicated that 
extremely high proportions of natural Tregs could suppress bacterial clearance after M. 
tuberculosis infection [383]. Therefore, in scenarios in which Tregs represent a high 
proportion of CD4+ T cells, then inhibition of Treg-mediated suppression or avoidance 
of Treg activation could be employed as strategies to enhance immunotherapy or 
vaccination against Tb.  
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6.4 Lessons for the immunological basis of mycobacterial 
protection 
 
Contrary to the broad hypothesis of this thesis, inactivation of natural Tregs prior to 
mycobacterial infection and vaccination did not enhance control of infection or 
protective efficacy of the vaccines. Although this suggests that modulation of natural 
Treg activity would not be useful as a general immunotherapeutic approach to enhance 
bacterial clearance after Tb infection, the effects of Treg inactivation prior to 
vaccination against Tb on primary and secondary immune responses can contribute to 
the search for more effective correlates of protection for mycobacteria. 
 
6.4.1 IFN-γ+CD4+ T lymphocytes 
 
The production of IFN-γ by CD4+ lymphocytes is widely regarded as vital for anti-
mycobacterial immunity (section 1.2.3.3). Humans with mutations in the IFN-γ receptor 
gene are highly vulnerable to mycobacterial infection [67, 68] and mice deficient in 
IFN-γ or the IFN-γ receptor are exquisitely sensitive to M. tuberculosis infection, as the 
infection rapidly progresses until death with very high bacterial numbers in the lung 
[49, 64-66]. Control of bacterial growth in the lung after mycobacterial infection in 
murine models coincides with the influx of IFN-γ producing CD4+ T cells [171]. 
Furthermore, treatment of infected macrophages with IFN-γ can enhance functions of 
those macrophages that can eliminate mycobacteria, or at least inhibit their growth, such 
as autophagy [97] and production of ROI [99] or RNI [100, 102, 105, 106]. Therefore, 
the current model of the protective primary immune response against mycobacteria is 
that IFN-γ produced by activated CD4+ T cells activates mycobacteriocidal activities of 
infected macrophages, which degrade or inhibit the growth of the mycobacteria that 
they have phagocytosed.  
Control of bacterial growth in the lung after mycobacterial infection in BCG-
vaccinated mice also coincides with the earlier influx of IFN-γ producing CD4+ T cells 
compared to naïve mice [171]. Given the importance of IFN-γ during the primary 
immune response to mycobacteria, it has been presumed that IFN-γ production by CD4+ 
T cells is also the key mediator of protective immunity after vaccination (section 1.2.6). 
To that end, IFN-γ production by CD4+ lymphocytes was assessed in this thesis, and 
this measure was used to test the hypothesis that inactivating Tregs prior to 
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mycobacterial infection or vaccination against Tb would enhance anti-mycobacterial 
immune responses. 
The presumption that IFN-γ is the key mediator of both primary and secondary 
immunity has been held for many years. However, it is becoming increasingly obvious 
that, while production of IFN-γ mediates protection against a primary Tb infection, the 
amount of IFN- γ induced during mycobacterial infection does not correlate with the 
degree of protection from infection. For example, IL-4 -/- mice infected with M. 
tuberculosis displayed increased IFN-γ production by splenocytes and increased IFN-γ 
mRNA expression in the lung up to 4 weeks after infection compared to WT mice [85]. 
Despite enhanced IFN-γ production, IL-4 -/- mice did not exhibit any difference in 
tissue bacterial numbers compared to WT mice [85]. Similarly the number of IFN-
γ+CD4+ T cells induced during vaccination against Tb does not correlate with the 
protective efficacy of the vaccine. For example, in a comparison of mucosal and 
subcutaneous BCG vaccination, numbers of IFN-γ+CD4+ T cells induced by mucosal 
BCG were much lower in the draining lymph node, spleen and lung tissue compared to 
subcutaneous BCG vaccination, when assessed two weeks after vaccination [167]. 
Despite profound differences in numbers of IFN-γ+CD4+ T cells two weeks after 
vaccination, both mucosal and subcutaneous BCG vaccination conferred a similar 
degree of protection from challenge with M. tuberculosis [167].  
Results presented in this thesis corroborate the hypothesis that numbers of IFN-
γ+CD4+ T cells do not correlate with the degree of protection either for primary or 
secondary immune responses.  Inactivation of Tregs prior to mycobacterial infection led 
to increased numbers of IFN-γ+CD4+ T cells in the spleen (Figs. 3.9/3.10) but did not 
affect bacterial numbers in the lung (Figs. 3.11/3.13). Inactivation of Tregs prior to 
BCG vaccination led to increased numbers of IFN-γ+CD4+ T cells in the lung and 
spleen after vaccination (Fig. 5.4) but did not affect bacterial numbers in the lung or 
spleen after infectious challenge (Figs. 5.8/5.9). 
Since numbers of IFN-γ+CD4+ T cells after vaccination do not correlate with 
protection from infectious challenge, vaccinologists desperately need an immunological 
correlate of protection from Tb. Several alternatives have been suggested, including the 
timing of CD4+ T cell influx to the lung in vaccinated mice after challenge [84, 171, 
495] and the presence of high proportions of multifunctional Th1 CD4+ T cells [477], 
which are each discussed in detail below. 
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6.4.2 Timing of IFN-γ+CD4+ T cell influx to the lung 
 
In BCG vaccinated mice, the influx of IFN-γ+CD4+ T cells to the lung is earlier and 
correlates with bacterial numbers stabilising earlier in the lung and lower bacterial 
numbers compared to naïve mice [171]. Earlier expression of type I cytokines after 
mycobacterial challenge, including IFN-γ, was shown to occur in mice vaccinated with 
either BCG or a DNA vaccine cocktail encoding several mycobacterial antigens, when 
compared to naïve mice [495]. 
Recently, this concept has been extended by a study in which mice were 
vaccinated with mycobacterial peptide in adjuvant then challenged with M. 
tuberculosis. The influx of IFN-γ+CD4+ lymphocytes to the lung was earlier and 
correlated with lower bacterial numbers in peptide vaccinated mice compared to naïve 
mice [84]. Importantly, the influx of IFN-γ+CD4+ lymphocytes to the lung was preceded 
by an influx of IL-17+CD4+ lymphocytes. Blocking IL-17 production diminished the 
influx of IFN-γ+CD4+ lymphocytes. Therefore, this model of mycobacterial protective 
immunity after vaccination suggests that vaccination induces IL-17+CD4+ T cells that 
infiltrate the lung earlier after challenge than in naïve animals. The IL-17+CD4+ T cells 
recruit IFN-γ+CD4+ T cells, which mediate control of bacterial numbers. 
In this thesis, inactivation of Tregs prior to BCG vaccination accelerated the 
influx of IFN-γ+CD4+ lymphocytes to the lung after challenge compared to control 
treated BCG vaccinated mice (Fig. 5.7). Despite acceleration of IFN-γ+CD4+ 
lymphocyte influx, Treg inactivation prior to BCG vaccination did not alter bacterial 
numbers in the lung compared to control treated BCG vaccinated mice (Figs. 5.8/5.9). 
IL-17 production was not assessed in this thesis but it would be interesting to see 
whether the influx of IL-17+CD4+ lymphocytes to the lung was also accelerated when 
Tregs were inactivated prior to BCG vaccination compared to control treated BCG 
vaccinated mice. A similar acceleration would be consistent with the proposed role of 
IL-17 producers mediating the influx of IFN-γ+CD4+ lymphocytes. 
Two issues arise concerning the results presented in this thesis. The first and 
most obvious issue is that these results call into question whether the timing of IFN-
γ+CD4+ lymphocyte influx to the lung is an appropriate correlate of protection for Tb. 
Since accelerating IFN-γ+CD4+ lymphocyte influx by inactivating Tregs prior to 
vaccination did not correlate with changes in bacterial numbers, the timing of IFN-
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γ+CD4+ lymphocyte influx does not appear to be a consistent correlate of protection for 
Tb. It also suggests for therapeutic settings that ensuring an accelerated influx of IFN-
γ+CD4+ lymphocytes to the lung upon secondary challenge will not guarantee that the 
resulting Tb vaccine is more effective.  
The second issue that arises is whether IFN-γ+CD4+ lymphocytes are actually 
the lymphocytes that mediate the reduction in bacterial numbers in the lung in 
vaccinated animals. Since the accelerated arrival of IFN-γ+CD4+ lymphocytes did not 
affect bacterial numbers, it suggests that IFN-γ+CD4+ lymphocytes are not responsible 
for control of bacterial numbers after infectious challenge and the kinetics or quality of 
another cell population that is responsible for control of bacterial numbers is unaffected 
by Treg inactivation. While IFN-γ production by CD4+ T cells undoubtedly contributes 
to control of primary mycobacterial infection, cellular subsets producing other related 
cytokines may be responsible for protection in a vaccination setting. Early expression of 
type I cytokines and chemokines at the level of mRNA and protein has been 
demonstrated to correlate with the protective efficacies of BCG vaccination and a DNA 
Tb vaccine cocktail [495]. The type I cytokines and chemokines that were expressed 
earlier in vaccinated mice included IFN-γ but also included IL-12 and the chemokine 
RANTES. In addition, earlier expression of IFN-γ occurred not only in CD4+ T cells but 
also CD8+ T cells, as assessed by flow cytometry. This thesis focussed on the kinetics of 
IFN-γ+CD4+ lymphocytes in the lung and draining lymph node upon infectious 
challenge and changes in the numbers or kinetics of this population did not always 
correlate with changes in protection.  A fuller assessment of the kinetics of CD4+ T cells 
and CD8+ T cells producing chemokines or cytokines, such as IFN-γ, IL-2, TNF-α, and 
IL-17, upon challenge in vaccinated mice, could be compared to protective efficacies of 
the vaccines. Correlations between the appearance of cellular subsets and protection 
may give important insights as to which cell type is responsible for protection from Tb.  
 
6.4.3 Multifunctional Th1 lymphocytes 
 
In a L. major vaccination model, an increased proportion of CD4+ T cells producing 
IFN-γ, IL-2 and TNF-α amongst the total cytokine (IFN-γ, IL-2 or TNF-α) producing 
CD4+ T population has been shown to correlate with protection [477]. These IFN-γ, IL-
2 and TNF-α producing CD4+ T cells have been termed multi-functional Th1 
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lymphocytes. L. major is an intracellular protozoal pathogen, which is reliant on a 
robust Th1 immune response for control of the infection, and this provides a model for 
Th1 immunity. Based on results gained in the L. major model, it has been proposed that 
successful vaccines relying on Th1 immunity will induce a higher proportion of multi-
functional Th1 lymphocytes [477].  
Multi-functional CD4+ Th1 lymphocytes produce increased amounts of each 
cytokine upon restimulation, as determined by flow cytometric analysis [477]. It has 
also been proposed that CD4+ T cells that do not exclusively produce IFN-γ are longer-
lived than CD4+ T cells committed to exclusive IFN-γ production [221]. Therefore, it is 
reasoned that multi-functional CD4+ Th1 lymphocytes are more effective at mediating 
protection than CD4+ T cells committed to only IFN-γ production as they persist longer 
after vaccination and respond with increased amounts of these cytokines upon 
secondary challenge. Furthermore, it has been shown that BCG-vaccinated human 
subjects possess multifunctional cells that can produce all three cytokines after in vitro 
restimulation with mycobacterial proteins [477]. Consequently, it is proposed that 
successful Tb vaccines should promote the development of increased proportions of 
multi-functional Th1 lymphocytes to promote long-lived, robust Th1 immunity. 
In this thesis, IFN-γ, IL-2 and TNF-α production by CD4+ T cells were not 
assessed simultaneously, but IL-2/IFN-γ co-production by CD4+ T cells was assessed. 
At two weeks after either BCG i.n. infection or BCG s.c. vaccination, IL-2 and IFN-γ 
production resolved to distinct populations within the CD4+ lymphocyte compartment 
and IL-2/IFN-γ co-producers were not observed (Figs. 3.8/3.9 and 5.2). By six weeks 
after BCG vaccination, a small population of IL-2/IFN-γ co-producing CD4+ 
lymphocytes was observed in both the spleen and the lung (Figs. 5.5/5.6). After DNA 
vaccination, an IL-2/IFN-γ co-producing population of CD4+ lymphocytes was also 
observed when secondary immune responses were observed three days after infectious 
challenge (Fig. 5.14). Therefore, in the murine model, a population of IL-2/IFN-γ co-
producing CD4+ lymphocytes could be observed in BCG or DNA vaccinated mice after 
vaccination or after secondary challenge. 
Numbers of IL-2/IFN-γ co-producing CD4+ lymphocytes were assessed for the 
different vaccination groups and compared to protection data. Treg inactivation prior to 
BCG vaccination significantly increased the number of IL-2/IFN-γ co-producing CD4+ 
lymphocytes at six weeks after vaccination in both the lungs and spleen (Fig. 5.6). This 
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did not correlate with any change in bacterial numbers in the lung or spleen after 
mycobacterial challenge (Figs. 5.8/5.9).  
However, the proportions of IFN-γ/IL-2 co-producing CD4+ lymphocytes within 
the total IFN-γ or IL-2 producing CD4+ lymphocyte population were also assessed. At 6 
weeks after BCG vaccination, the proportion of IFN-γ/IL-2 co-producing CD4+ 
lymphocytes was unchanged by PC61 treatment (Fig. 5.6.). This data correlated with 
protection, since bacterial numbers in the lung and spleen after virulent infectious 
challenge were unchanged in BCG vaccinated mice, regardless of PC61 treatment (Figs. 
5.8/5.9).  
Preliminary data suggests that the proportions of IFN-γ/IL-2 co-producing CD4+ 
lymphocytes after Tb vaccination might not always correlate with differences in 
protection against virulent challenge. Three days after infectious challenge, the 
proportions of IFN-γ/IL-2 co-producing CD4+ lymphocytes in the spleens and lungs of 
pcDNA3-85A vaccinated mice appeared unchanged, regardless of PC61 treatment (Fig. 
5.14). When bacterial numbers in tissues were assessed after virulent infectious, 
bacterial numbers in the spleen were significantly increased in PC61 treated compared 
to rat IgG treated pcDNA3-85A vaccinated mice (Fig. 5.15). However, it may not be 
appropriate to compare the BCG vaccine and the pcDNA3-85A vaccine in the search 
for a broad immune correlate of protection for Tb, as will be discussed in section 6.4.4. 
Taken as a whole, these data indicate that, although numbers of IL-2/IFN-γ co-
producing CD4+ lymphocytes do not consistently correlate with protection, proportions 
of IL-2/IFN-γ co-producing CD4+ lymphocytes may correlate with the protective 
efficacy of the BCG vaccine. The study that identified multifunctional Th1 cells 
assessed TNF-α production, as well as IL-2 and IFN-γ production, and the frequency of 
multifunctional Th1 cells amongst total cytokine producing CD4+ T cells correlated 
with the protective efficacy of the L. major vaccines [477]. As a result, it would be 
interesting to assess TNF-α production, as well as IL-2 and IFN-γ production, for the 
BCG, pcDNA3-85A and pKUN85A vaccines.  
It would also be informative to assess the kinetics of the development of the 
TNF-α/IL-2/IFN-γ co-producing CD4+ lymphocyte population for the BCG, pcDNA3-
85A and pKUN85A vaccines. The kinetics could differ for different Tb vaccines and 
the relative numbers and proportions of this population could differ depending on the 
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time after vaccination that these parameters are assessed. The proportion of TNF-α/IL-
2/IFN-γ producing CD4+ T cells amongst total cytokine producing CD4+ T cells may 
prove to be a valuable immune correlate of protection for Tb vaccines. 
 
6.4.4 Summary: Immune correlates of protection for Tb 
 
Overall, the findings in this thesis were used to assess the applicability of several 
proposed correlates of protection for Tb vaccination strategies. The results illustrated 
that the number of IFN-γ+CD4+ lymphocytes, the timing of IFN-γ+CD4+ lymphocyte 
influx to the lung and the number of IFN-γ/IL-2 co-producing CD4+ lymphocytes did 
not consistently correlate with the protective efficacy of Tb vaccines. However, the 
proportion of IFN-γ/IL-2 co-producing CD4+ lymphocytes may correlate with the 
protective efficacy of the BCG vaccine. This study did not assess TNF-α, IFN-γ and IL-
2 co-production, and therefore the applicability of the proportion of multifunctional Th1 
cells as a correlate of protection against Tb remains an intriguing possibility. The results 
presented in this thesis have illustrated scenarios in which several proposed immune 
correlates of protection for Tb do not apply and hence narrowed the search for a broad 
immune correlate for protection against Tb. 
The search for a broad immune correlate of protection for all Tb vaccines 
assumes that there is only one protective mechanism and one protective cell subset that 
all Tb vaccines induce. An ideal correlate of protection is a parameter that is measurable 
early after vaccination that goes on to contribute to the mechanism of protection during 
infectious challenge. If there are multiple different memory cell subsets that can mediate 
protection and different Tb vaccines can induce different protective subsets, then a 
broad immune correlate for all Tb vaccines might not exist. For example, it might not be 
appropriate to look for a correlate shared by a live vaccine such as BCG, which is 
thought to rely on Th1 immunity, with a DNA vaccine, where CD8+ T cell-dependent 
mechanisms might contribute more to protection from infection. This highlights the 
importance of understanding protective mechanisms induced by vaccines before using 
them to search for broad immune correlates of protection encompassing all vaccines 
targeting a single pathogen. 
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6.5 Conclusions 
 
Using a murine C57BL/6 model of mycobacterial infection and vaccination and in vivo 
administration of anti-CD25 (clone PC61) mAb to inactivate CD25+ natural Tregs, this 
thesis has offered several conclusions relating to anti-mycobacterial immunity and the 
role of Tregs: 
• The plasmid DNA replicon vaccine, pKUN85A, was created and i.m. 
vaccination with pKUN85A induced an Ag85A-driven immune response, as 
assessed by IFN-γ and IL-2 production from CD4+ T cells and bystander 
cytokine production from CD8+ T cells. Preliminary data suggests homologous 
prime-boost vaccination with pKUN85A is not as protective as BCG vaccination 
against virulent mycobacterial challenge, although further refinements will be 
made to enhance pKUN85A vaccine efficacy. 
• Enhanced immune responses were observed when natural Tregs were 
inactivated prior to mycobacterial infection. 
• Inactivation of natural Tregs prior to mycobacterial infection did not affect 
bacterial numbers in the lung during acute mycobacterial infections, although 
inactivation of natural Tregs prior to M. bovis infection may cause transient 
reductions in lung pathology. 
• Enhanced primary immune responses, increased numbers of antigen-responsive 
cells in the spleen and lung prior to secondary challenge and an accelerated 
secondary immune response upon secondary challenge were observed when 
natural Tregs were inactivated prior to BCG vaccination. 
• Inactivation of Tregs prior to BCG vaccination did not affect the protective 
efficacy of the BCG vaccine.  
• Preliminary data suggests that inactivation of Tregs prior to pcDNA3-85A 
vaccination modestly enhanced secondary immune responses but may have led 
to reduced protection in the spleen. 
In summary, this thesis illustrates that BCG, M. tuberculosis and M. bovis contrast with 
other infection and vaccination models, as inactivation of natural CD25+ Tregs by in 
vivo treatment with PC61 does not affect protection in terms of pathogen load. 
However, this thesis also highlights a general concern for Tb vaccine design. Using the 
current dogma for protective immunity against Tb, several hypotheses were proposed 
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during the course of this thesis that were later found to be incorrect. These assumptions 
based on the current dogma were logical but the outcomes reflect the fact that there are 
fundamental flaws in the current model and therefore Tb vaccine research lacks a 
robust, consistent model of protection against Tb. As a result, researchers also currently 
lack an accurate immune correlate of protection for the development of a more effective 
Tb vaccine. Identification of the cellular subset responsible for protection against 
mycobacterial infection would facilitate rational vaccine design for Tb, but due to this 
gap in our understanding, truly rational vaccine design for Tb is at an impasse at 
present. However, through empirical experimentation supported by rational hypotheses, 
vaccine design can progress. Lessons learned from failed and successful vaccine 
designs can be used as clues to build knowledge about protective cellular subsets and 
correlates of protection. Eventually, this knowledge will narrow the gap between 
immunology and vaccinology, permitting truly targeted design of Tb vaccines.
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Appendix 
 
8.1: Primer designs and properties 
 
Molecular weight, projected melting temperature, secondary structure and primer dimer 
projections were calculated using the Sigma Genosys primer design website, 
http://www.sigma-genosys.com/calc/DNACalc.asp. Projected annealing temperatures 
were calculated using TA = TM – 5 to 10 ˚C.  
 
Table 8.1: Primers for amplification of the Ag85A insert 
 
5’ Ag85A primer GCGACGCGTTGCAGCTTGTTGACAGGGTTCG 
Number of bases 31 
Molecular weight (Da) 9598.97 
TM: projected melting temperature (˚C) 85.22 
TA: projected annealing temperature (˚C) 80.22 to 75.22 
GC content (%) 61.29 
Projected secondary structure Weak 
Projected primer dimer None 
 
3’ Ag85A primer GATACGCGTGACCCAGTGCCCGTTGCAGG 
Number of bases 29 
Molecular weight (Da) 8919.6 
TM: projected melting temperature (˚C) 83.89 
TA: projected annealing temperature (˚C) 78.89 to 73.89 
GC content (%) 65.52 
Projected secondary structure Weak 
Projected primer dimer None 
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Table 8.2: Primers for orientation PCR and sequencing of the Ag85A insert 
 
5’ CS primer CAGTGCGAGCTGTTTCTTAGC 
Number of bases 21 
Molecular weight (Da) 6428.0 
TM: projected melting temperature (˚C) 64 
TA: projected annealing temperature (˚C) 59 to 54 
GC content (%) 52.38 
Projected secondary structure Weak 
Projected primer dimer None 
 
3’ CS primer CAGTATCAGCATGCACGTTC 
Number of bases 20 
Molecular weight (Da) 6076.9 
TM: projected melting temperature (˚C) 61.9 
TA: projected annealing temperature (˚C) 56.9 to 51.9 
GC content (%) 50 
Projected secondary structure Weak 
Projected primer dimer None 
 
5’ Mid primer CGGTCTTTCGATGGCTGCTTC 
Number of bases 21 
Molecular weight (Da) 6395.0 
TM: projected melting temperature (˚C) 70 
TA: projected annealing temperature (˚C) 65 to 60 
GC content (%) 57.14 
Projected secondary structure None 
Projected primer dimer None 
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3’ Mid primer CATGTCGGAGGCCTTGTAGC 
Number of bases 20 
Molecular weight (Da) 6148.9 
TM: projected melting temperature (˚C) 66.8 
TA: projected annealing temperature (˚C) 61.8 to 56.8 
GC content (%) 60 
Projected secondary structure None 
Projected primer dimer None 
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8.2: Sequencing of pKUN85A 
 
 
Figure 8.1: Primer design for sequencing of transformant plasmids 
Primers were designed to sequence the length of the Ag85A insert and into vector DNA at the 5’ 
and 3’ ends of the insert. Total bp size of the plasmids is indicated and the first bp is designated 
by the black notch at the top of the plasmid. MluI restriction sites either end of the Ag85A insert 
are indicated at 4239 bp and 5223 bp. Primer binding sites for sequencing are indicated. 5’ CS 
binds at 4057-4077 bp and 5’ Mid binds at 4740-4760 bp and both result in sequence running 
from 5’ to 3’. 3’ CS binds at 5376-5395 bp and 3’ Mid binds at 4889-4908 bp and both result in 
sequence running from 3’ to 5’. 
 
For the following page: 
Figure 8.2: Sequencing alignment for transformant 37 
The sequences acquired for transformant 37, using the 3’ Mid, 5’ Mid, 3’ CS and 5’ CS primers 
described above, were compiled to provide the subject sequence. This subject sequence was 
aligned with the query sequence, which was the projected sequence of pKUN85A after insertion 
of the Ag85A insert. The MluI restriction sites either side of the Ag85A insert are underlined. For 
some bases highlighted in red, sequencing analysis software did not define the nucleotide. 
However, these bases were verified as being the correct projected nucleotide after analysis of 
the corresponding electropherogram (data not shown).  M 511 =A, Y836 = C. 
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8.3: Solutions and media 
 
Freezing Media 
 9 mL Fetal Bovine Serum (FBS) (PAA Laboratories GmbH, Pasching, Austria) 
 1 mL Dimethyl Sulfoxide (Sigma) 
Mix together under sterile conditions and resuspend cells to be frozen in this at 2 x 106 
cells/mL, Freeze aliquots immediately but slowly in ethanol at -80 ˚C.  
 
Incomplete Iscove’s Modified Dulbecco’s Medium 
 3.024 g NaHCO3 (BDH) 
 1 sachet of powdered IMDM (Gibco BRL) 
 1000 mL of MilliQ H20 
Add water to powders. Filter sterilise using a VacuCap60 filter (Pall Life Sciences). 
Store at 4 ˚C until use. 
 
Complete Iscove’s Modified Dulbecco’s Medium- 20, 10, 5, 1 or 0 % 
 10 mL of Gibco Penicillin-Streptomycin liquid (Invitrogen) 
 10 mL of Gibco GlutaMAXTM-1 (Invitrogen) 
 1 mL of Gibco 2-Mercaptoethanol liquid (1000x) (Invitrogen) 
 200 mL (20 %), 100 mL (10 %), 50 mL (5 %), 10 mL (1 %) or 0 mL (0 %) of 
FBS (PAA Laboratories GmbH) 
 Top up to 1000 mL with iIMDM (as above) 
Store at 4˚C for up to 4 weeks. 
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Purification Wash Buffer 
 2.84 g Na2HPO4 (BDH) 
 1000 mL of dH20 
Adjust pH to 8.0. Store at 4 ˚C but warm to room temperature and filter to degas and 
remove particulates prior to use.  
 
Purification Elution Buffer 
 3.75 g of Glycine (BDH) 
 500 mL of dH20 
Use HCl to adjust pH to 2.7. Store at 4 ˚C but warm to room temperature and filter to 
degas and remove particulates prior to use.  
 
Neutralisation/Stabilisation Buffer 
 6.06 g of Tris (BDH) 
 50 mL of dH20 
Use HCl to adjust pH to 9.0. Filter to remove particulates prior to use.  
 
Phosphate Buffered Saline 
 8 g NaCl 
 0.2 g KH2PO4  
 1.15 g Na2HPO4 (anhydrous)  
 0.2 g KCl 
 1000 mL MilliQ water 
All components are contained in 1 sachet of Dulbecco’s Phosphate Buffered Saline mix 
(Gibco). Add water to components and adjust pH to 7.4. Filter sterilise using a 
VacuCap60 filter (Pall Life Sciences). Store at 4 ˚C until use. 
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Tween Albumin Broth 
 1.3 g of Dubos Broth Base (Difco, BD Diagnostic Systems, Sparks, MD, USA) 
 180 mL of dH20 
Autoclave at 121 ˚C for 15 minutes, cool to 45 ˚C and add 20 mL of sterile oleic acid-
albumin-dextrose (OADC) supplement (Difco). Filter if desired. 
 
PBS/Tween 80- 0.5 or 0.05 % 
 1000 mL of PBS (as described above) 
 5 mL (0.5%) or 0.5 mL (0.05 %) of Tween80 (Sigma) 
Dissolve Tween80 into PBS, some heating may be required. Filter sterilise using a 
VacuCap60 filter (Pall Life Sciences). Store at 4 ˚C until use. 
 
Middlebrooks 7H11 agar plates 
 10.5 g of 7H11 agar (Difco) 
 450 mL of dH20 
 5 ml of Glycerol BP 100% (for growing M. tuberculosis or M. bovis BCG) or 
2.01 g of Sodium Pyruvate (for growing M. bovis) (both from Sigma) 
Boil to dissolve the agar and then autoclave the solution at 121˚C for 10 minutes. Cool 
to 56˚C in a waterbath then add 0.5 mL of polymyxin B (200K U/mL) (Gibco BRL), 0.5 
mL of carbenicillin (50 mg/mL) (Gibco BRL) and 50 ml of sterile OADC supplement 
(Difco) and mix thoroughly. Pour ~20 mL of agar into sterile plates (Biolab, Auckland, 
New Zealand) and cool and dry plates in a Class II cabinet overnight. Store at 4˚C for 
up to 2 months and keep plates protected from light. 
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10x Anaesthetic 
 10 mL of Ketamine at 100 mg/mL (Phoenix, Auckland, New Zealand) 
 1.5 mL of Xylazine at 20 mg/mL (Phoenix) 
Store 10x anaesthetic stock at room temperature. Dilute 1:10 immediately prior to use. 
Use at 100 µL (26 µg of xylazine and 870 µg of ketamine) per 10g body weight for 
anaesthesia or 400 µL (104 µg of xylazine and 3480 µg of ketamine) per 10g body 
weight for lethal anaesthesia. 
 
Alsevers Solution 
 20.5 g of Dextrose (BDH) 
 4.2 g of NaCl (BDH) 
 8.0 g of Na citrate (BDH) 
 Top up to 1000 mL of dH20 
Autoclave at 121 ˚C for 15 minutes, cool and aliquot into sterile containers. Store at 
room temperature until use. 
 
ACT Lysis Buffer 
 Solution 1: 
o 8.3 g of NH4Cl (BDH) 
o 1000 mL of MilliQ H20 
 Solution 2: 
o 20.6 g Tris (BDH) 
o 900 mL of MilliQ H20 
Adjust the pH of solution 2 to 7.65 and top it up to a total volume of 1000 mL. Take 
900 mL of solution 1 and mix with 100 mL of solution 2. Adjust the pH of the mixed 
solutions to 7.2. Filter sterilise using a VacuCap60 filter (Pall Life Sciences). Store at 4 
˚C until use but allow solution to warm to room temperature before use. 
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Flow Cytometry Buffer 
 1000 mL of PBS (as described above) 
 10 mL FBS (PAA Laboratories GmbH) or 10g Bovine Serum Albumin (Gibco) 
Prepare under sterile conditions. Store at 4˚C for up to 4 weeks 
 
Lung Digestion Media (per lung) 
 5 mL of 0 % cIMDM (as described above) 
 12 mg of Collagenase Type I (Gibco) 
 5 mg of DNAase Type I (Roche) 
Mix components immediately before use under sterile conditions. Use 5 mL of lung 
digestion media per lung. 
 
Percoll Diluent 
 45 mL of 10 x PBS 
 3 mL of 0.6M HCl 
 132 mL of dH20 
Filter sterilise using a VacuCap60 filter (Pall Life Sciences). Store at 4 ˚C until use. 
 
70 % Percoll 
 63 mL of Percoll Diluent (as described above) 
 37 mL of Percoll (GE Healthcare) 
Mix liquids and adjust pH to 7.2. Filter sterilise using a VacuCap60 filter (Pall Life 
Sciences). Store at 4 ˚C until use. 
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4% Paraformaldehyde Solution 
 6 g of anhydrous Na2H2PO4 (BDH) 
 17.9 g of Na2HPO4.12 H2O (BDH) 
 900 mL of MilliQ H2O 
Mix together and warm on a hot plate. Carefully add 40 g of paraformaldehyde (Sigma) 
so as to not disperse into the air. Stir with heating on the hot plate for 30-45 min until 
dissolved. Add small amounts of NaOH if needed to help dissolving. Cool the solution 
and top up with MilliQ H2O to a volume of 950 mL. Adjust the pH to 7.0 and bring the 
final volume to 1000 mL with more MilliQ H2O. Aliquot and store immediately at –
20˚C in 50ml tubes for up to 1 year. Minimise exposure to light and defrost several 
hours prior to use.  If cloudy it may require warming to re-dissolve. Store thawed 
aliquots at 4 ˚C and use within 3 days. 
 
Saponin Buffer 
 1000 mL of PBS (as described above) 
 5 g of Bovine Serum Albumin (Gibco) 
 1 g of Saponin (Sigma) 
Dissolve BSA in PBS, then add saponin and mix gently for 15 min. Filter sterilise, 
aliquot and keep at 4 ˚C for short-term storage or – 20˚C for long-term storage. 
 
ELISA Coating Buffer 
 3.56 g of Na2CO3 (or 4.23 g of Na2C03.10H20) (BDH) 
 8.40 g of NaHCO3 (BDH) 
 1000 mL of dH20 
Store at 4 ˚C for no longer than 3 weeks 
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10x ELISA Wash Buffer 
 1000 mL of 10x PBS 
 5 mL of Tween20 (Sigma) 
Dissolve Tween20 in 10x PBS and adjust pH to 7.4. Store at 4˚C for several months. 
Dilute to make 1x ELISA Wash Buffer immediately prior to use. 
 
ELISA Assay Diluent 
 500 mL of PBS (as described above) 
 50 mL FBS (PAA Laboratories GmbH) 
Freshly prepare under sterile conditions and use within 3 days of preparation with 
storage at 4 ˚C. 
 
ELISA Stop Solution 
 2 N H2SO4 
Store at 4˚C for several months. 
 
LB Amp+ agar plates 
 500 mL of dH20 
 6.25 g of Bacto-Agar (BD Biosciences) 
 12.5 g of LB Broth Base (Invitrogen) 
Autoclave at 121 ˚C for 15 minutes, cool to 45 ˚C and add 0.5 mL ampicillin (100 
µg/mL) (Sigma). Pour ~20 mL of agar into sterile agar plates (Biolab) and cool for 20 
minutes store at 4˚C for up to 4 weeks. 
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LB Amp+ liquid broth 
 500 mL of dH20 
 12.5 g of LB Broth Base (Invitrogen) 
Autoclave at 121 ˚C for 15 minutes to sterilise and store at room temperature until 
needed. Just before use, add a 0.5 mL freshly thawed aliquot of ampicillin (100 µg/mL) 
(Sigma). Store at 4˚C for up to 7 days. 
 
Glycerol Stocks 
 850 µL of E. coli grown in LB Amp+ liquid broth 
 150 µL of Glycerol BP (Sigma) 
Vortex thoroughly and freeze immediately at – 80 ˚C.  
 
Lysis Buffer 
 6.71 mL MilliQ H20 
 0.5 mL of Tris-HCl (1 M, pH 8.0) (BDH) 
 1.5 mL of NaCl (1M) (BDH) 
 0.1 mL of Sodium Dodecyl Sulphate (10%) (Sigma) 
 1 mL of NP-40 (10%) (Sigma) 
 0.09 mL of Triton X-100 (100%) (Sigma) 
 0.1 mL of Phenylmethanesulfonyl Fluoride (PMSF) (100mM) (Sigma) 
Mix it all of the above and freeze in 1 mL aliquots immediately. Thaw aliquots just 
before use. PMSF is a protease inhibitor that only has a half-life of 30 min at room 
temp, so keep lysis buffer and cell lysates at 4 ˚C. 
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50x TAE buffer 
 121 g of Tris (BDH) 
 28.55 mL of Glacial Acetic Acid (BDH) 
 2 mL of 0.5 M EDTA (ph 8.0) 
 500 mL of MilliQ H20 
Autoclave in a 1 L Schott bottle at 121 ˚C for 15 minutes to sterilise and store at room 
temperature until needed. Before use dilute 50x. 
 
Agarose gel- 2, 1.5 or 0.8 % 
 100 mL TAE buffer 
 2 g (2 %), 1.5 g (1.5 %) or 0.8 g (0.8 %) of UltraPureTM Agarose (Invitrogen) 
Melt the agarose by putting on for initially 3 min at high in the microwave, swirling and 
continuing to melt 1 min at a time until the solution boils and is clear. Store at 40 ˚C for 
up to 6 weeks. Once poured, leave for 30 min to cool. 
 
PCR Loading Buffer 
 19.5 g of Sucrose (BDH) 
 3 mL of 0.1M EDTA (Sigma) 
 3 mL of 0.1M Tris-HCl (pH 7.5) (BDH) 
 90mg of Bromophenol Blue (Sigma) 
 Up to 30 mL with MilliQ H20 
Initially dissolve sucrose in a minimum volume of water as it has substantial mass itself. 
Heat to dissolve. Mix components, aliquot into 1 mL batches and freeze at -20 ˚C until 
needed. Store thawed aliquots at 4 ˚C. 
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10x Western Transfer buffer 
 3.03 g of Tris (BDH) 
 144 g of Glycine (BDH) 
 1000 mL of MilliQ H20 
Store at 4˚C for several months. Before use dilute 10x and add methanol to 20% v/v 
final. 
 
10x Tris Buffered Saline 
 48.5 g of Tris (BDH) 
 88.7 g of NaCl (BDH) 
 5 mL of Tween20 (Sigma) 
 950 mL of MilliQ H20 
Adjust pH to 8.6 with HCl and top up to a final volume of 1000 mL. Store at 4˚C for 
several months. Before use dilute 10x. 
 
Western Blocking Solution 
 100 mL 1x TBS (as described above) 
 4 g of Anchor Low-Fat Milk Powder (Fonterra Brands NZ Ltd., Auckland New 
Zealand) 
Mix well to ensure that the milk powder is resuspended. Store at 4˚C for up to 3 days 
then discard.  
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